U.S. patent application number 10/937758 was filed with the patent office on 2005-05-26 for compositions and methods for treatment of neoplastic disease.
Invention is credited to Terman, David S..
Application Number | 20050112141 10/937758 |
Document ID | / |
Family ID | 34590594 |
Filed Date | 2005-05-26 |
United States Patent
Application |
20050112141 |
Kind Code |
A1 |
Terman, David S. |
May 26, 2005 |
Compositions and methods for treatment of neoplastic disease
Abstract
The present invention comprises compositions and methods for
treating a tumor or neoplastic disease in a host, The methods
employ conjugates comprising superantigen polypeptides or nucleic
acids with other structures that preferentially bind to tumor cells
and are capable of inducing apoptosis. Also provided are
superantigen-glycolipid conjugates and vesicles that are loaded
onto antigen presenting cells to activate both T cells and NKT
cells. Cell-based vaccines comprise tumor cells engineered to
express a superantigen along with glycolipids products which, when
expressed, render the cells capable of eliciting an effective
anti-tumor immune response in a mammal into which these cells are
introduced. Included among these compositions are tumor cells,
hybrid cells of tumor cells and accessory cells, preferably
dendritic cells. Also provided are T cells and NKT cells activated
by the above compositions that can be administered for adoptive
immunotherapy.
Inventors: |
Terman, David S.; (Pebble
Beach, CA) |
Correspondence
Address: |
CENTRAL COAST PATENT AGENCY
PO BOX 187
AROMAS
CA
95004
US
|
Family ID: |
34590594 |
Appl. No.: |
10/937758 |
Filed: |
September 8, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10937758 |
Sep 8, 2004 |
|
|
|
09650884 |
Aug 30, 2000 |
|
|
|
Current U.S.
Class: |
424/192.1 ;
435/366; 514/44R; 530/395; 536/23.2 |
Current CPC
Class: |
A61P 35/00 20180101;
A61K 2039/5156 20130101; C07K 2319/33 20130101; C07K 14/31
20130101; A61K 48/005 20130101; C07K 14/70503 20130101; C07K
14/7156 20130101; A61K 2039/55544 20130101; C07K 14/3156 20130101;
A61K 39/0011 20130101 |
Class at
Publication: |
424/192.1 ;
514/044; 530/395; 536/023.2; 435/366 |
International
Class: |
A61K 048/00; A61K
039/00; C12N 005/08; C12P 021/04; C07K 014/47 |
Claims
What is claimed is:
1. A mammalian cell comprising an exogenous nucleic acid encoding a
superantigen which is expressed in said cell which cell also
produces or expresses all .alpha.-anomers of monoglycosylceramide
or diglycosylceramide, wherein expression of said superantigen and
said mono- or di-glycosylceramide is capable of eliciting an
effective anti-tumor immune response in a mammal into which said
cell is introduced.
2. The cell of claim 1 which is selected from a group consisting of
(a) a tumor cell (b) an accessory cell (c) a tumor cell/accessory
cell hybrid
3. The cell of claim 1 wherein said mammal bears a tumor, against
which the antitumor response is directed, said tumor being selected
from the group consisting of a carcinoma, a melanoma, a sarcoma, a
neuroblastoma, an astrocytoma, a lymphoma and a leukemia.
4. The cell of claim 1 wherein the superantigen is selected from
the group consisting of a Staphylococcal enterotoxin and a
Streptococcal pyrogenic exotoxin.
5. A method of treating a tumor or neoplastic disease in a subject,
comprising administering to said subject an effective amount of the
cells of any of claims 1-4, wherein said nucleic acid is introduced
in vivo into a cell that produces or expresses said mono- or
diglycosylceramide.
6. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of the cells of any of
claims 1-4 wherein said superantigen exogenous nucleic acids is
introduced ex vivo or in vitro into a cell which produces or
expresses said mono- or di-glycosylceramide.
7. A composition useful for treating a tumor or neoplastic disease
in a subject comprising a conjugate or complex of (a) a
superantigen; and (b) a glycosylceramide.
8. The composition of claim 7 wherein the glycosylceramide is
selected from a group consisting of (a) an
.alpha.-1-4-galabiosylceramide, (b) an
.alpha.-1-4-globotriosylceramide, (c) an
.alpha.-1-4-globoteterasylcerami- de or (d) a
glycosylphosphatidylinositol-anchored .alpha.-1-4-galabiosylce-
ramide, (e) a glycosylphosphatidylinositol-anchored
.alpha.-1-4-globotriosylceramide, and (f) a
glycosylphosphatidylinositol-- anchored
.alpha.-1-4-globoteterasylceramide.
9. The composition of claim 7, wherein the glycosylceramide
comprises a phytosphingosine chain having unsubstituted hydroxyl
groups at its C3- and C4 position.
10. The composition of claim 7, wherein the length of the ceramide
fatty acyl chain is from about 12 to about 24 carbons.
11. The composition of claim 7, wherein the sphingosine portion of
the ceramide has a chain length of about 10 to about 13
carbons.
12. The composition of claim 7, wherein the conjugate or complex
further comprises CD1 receptors, MHC class I molecules, MHC class
II molecules or superantigen receptors.
13. The composition of claim 7-12 wherein the
superantigen-glycosylceramid- e is in or on a vesicle, exosome,
liposome, phage display, prokaryotic cell surface or eukaryotic
cell surface.
14. The composition of claims 7-12 wherein said complex or
conjugate is obtained by shedding from cells expressing said
complexes or conjugates.
15. The composition of claim 7-12 wherein the
superantigen-glycosylceramid- e conjugate, or, if present, said
superantigen-GPI-glycosylceramide conjugate, is chemically linked
by a crosslinking agent
16. The compositions of claims 13 wherein the
superantigen-glycosylceramid- e is loaded onto a prokaryotic or
eukaryotic cell surface.
17. A method of treating a tumor or neoplastic disease in a subject
comprising administering to the subject an effective amount of
cells loaded with the compositions of any of claims 7-12, so that
the cells present the composition to the immune system, thereby
inducing an anti-tumor immune response.
18. A method of treating a tumor or neoplastic disease in a subject
comprising administering to the subject an effective amount of
compositions of claim 13, thereby inducing an anti-tumor immune
response.
19. A method of treating a tumor or neoplastic disease in a subject
comprising administering to the subject an effective amount of the
composition of claim 15, thereby inducing an anti-tumor immune
response.
20. The method of claim 17 wherein the composition is a
superantigen-glycosylceramide-CD1 conjugate or complex wherein the
glycosylceramide is selected from a group consisting of (a) an
.alpha.1-4-galabiosylceramide, (b) an
.alpha.-1-4-globotriosylceramide, (c) an
.alpha.-1-4-globoteterasylceramide or (d) a
glycosylphosphatidylinositol-anchored
.alpha.-1-4-galabiosylceramide, (e) a
glycosylphosphatidylinositol-anchored
.alpha.-1-4-globotriosylceramide, and (f) a
glycosylphosphatidylinositol-anchored .alpha.-1-4-globoteterasy-
lceramide.
21. The method of claim 18 wherein the composition is a
superantigen-glycosylceramide-CD1 conjugate or complex wherein the
glycosylceramide is selected from a group consisting of (a) an
.alpha.1-4-galabiosylceramide, (b) an
.alpha.-1-4-globotriosylceramide, (c) an
.alpha.-1-4-globoteterasylceramide or (d) a
glycosylphosphatidylinositol-anchored
.alpha.-1-4-galabiosylceramide, (e) a
glycosylphosphatidylinositol-anchored
.alpha.-1-4-globotriosylceramide, and (f) a
glycosylphosphatidylinositol-anchored .alpha.-1-4-globoteterasy-
lceramide.
22. The method of claim 17 wherein the cells are selected from the
group consisting of: (a) dendritic cells; (b) macrophages or
monocytes; (c) fibroblasts; (d) keratinocytes; (e) stromal cells;
(f) antigen presenting cell; (g) tumor cells; (h) lymphocytes; and
(i) a combination of any two or more of (a)-(h).
23. The method of claim 18 wherein the cells are selected from the
group consisting of: (a) dendritic cells; (b) macrophages or
monocytes; (c) fibroblasts; (d) keratinocytes; (e) stromal cells;
(f) antigen presenting cell; (g) tumor cells; (h) lymphocytes; and
(i) a combination of any two or more of (a)-(h).
24. The method of claim 19 wherein the cells are selected from the
group consisting of: (a) dendritic cells; (b) macrophages or
monocytes; (c) fibroblasts; (d) keratinocytes; (e) stromal cells;
(f) antigen presenting cell; (g) tumor cells; (h) lymphocytes; and
(i) a combination of any two or more of (a)-(h).
25. The method of claim 20 wherein the cells are selected from the
group consisting of: (a) dendritic cells; (b) macrophages or
monocytes; (c) fibroblasts; (d) keratinocytes; (e) stromal cells;
(f) antigen presenting cell; (g) tumor cells; (h) lymphocytes; and
(i) a combination of any two or more of (a)-(h).
26. The compositions of claim 7-12, wherein the superantigen is
selected from the group consisting of a Staphylococcal enterotoxin
and a Streptococcal pyrogenic exotoxin.
27. A method of treating a tumor or neoplastic disease in a subject
comprising administering to said subject an effective amount of the
composition of any of claims.
28. A method of preparing a population of immunotherapeutically
active T or NKT cells useful to treat a tumor or neoplastic disease
in a subject, comprising: (a) providing to (i) a subject in vivo or
(ii) a population of T and/or NKT cells ex vivo or in vitro the
cells of any of claims 1-4 or a composition of any of claims 7-12
to prime or stimulate the production of a population of
tumor-specific T cells and/or NKT cells, (b) obtaining said primed
or stimulated T or NKT cells; (c) optionally, further contacting
said primed or stimulated T or NKT cells with any of said cells or
compositions ex vivo to expand and further stimulate said T or NKT
cells. thereby preparing said of immunotherapeutically active
cells.
29. A method of treating a tumor or neoplastic disease in a
subject, comprising administering an effective amount of T and/or
NKT cells prepared in accordance with claim 24 to said subject to
treat said tumor or neoplastic disease.
30. A composition useful for treating a tumor or neoplastic disease
in a subject comprising naked DNA encoding a superantigen
conjugated to a protein which induces apoptosis of tumor cells in
said subject.
31. The composition of claim 25 wherein the protein is selected
from a group consisting of (a) Fas; (b) Perforin; (c) Granzyme B;
(d) Tumor Necrosis Factor .alpha. or .quadrature.; (e) Verotoxin;
and (f) a Verotoxin A chain, B chain or hybrid AB chain.
32. A composition useful for treating a tumor or neoplastic disease
in a subject comprising naked DNA encoding a superantigen
conjugated to a verotoxin.
33. A composition useful for treating a tumor or neoplastic disease
in a subject comprising naked DNA encoding a superantigen
conjugated to a protein or peptide that has at least about 30%
sequence identity to the Gal(.alpha.1-4)Gal-binding region of a
verotoxin.
34. A composition useful for treating a tumor or neoplastic disease
in a subject comprising naked DNA encoding a superantigen
conjugated to a protein or peptide that has at least about 45%
sequence identity to the Gal(.alpha.1-4)Gal-binding region of a
verotoxin.
35. The composition of claim 33 or 34 wherein the peptide or
protein has the amino acid sequence of all or part of any
Gal(.alpha.1-4)Gal-binding portion of: (a) the 63 kDa extracellular
peptide of the interferon .alpha. receptor; or (b) the N terminal
extracellular domain of CD19.
36. An apoptotic cell preparation or lysate useful for treating a
tumor or neoplastic disease in a subject, comprising a cell
population that has been (a) transfected with naked DNA encoding a
superantigen; and (b) treated to undergo apoptosis or lysis.
37. A cell which has ingested or been transfected with the
apoptotic preparation or lysate of claim 36, thereby rendering the
cell effective in presenting material expressed from transfecting
nucleic acid or material ingested to the immune system of a mammal
to elicit an anti-tumor immune response.
38. A method for treating a tumor or neoplastic disease in a
subject, comprising (a) providing to a population of cells selected
from the group consisting of: (i) tumor cells; (ii) accessory
cells; (iii) tumor cell/accessory cell hybrids; (iv) cells with an
inherent or acquired -galactosidase deficiency; and (v) a
combination of any two or more of (i)-(iv), said apoptotic cell
preparation or said lysate of claim 36, to produce an
immunostimulatory cell population; (b) administering to said
subjected an amount of said immunostimulatory cell population
effective to treat said tumor or neoplastic disease.
39. The method of claim 38 wherein said accessory cells are
dendritic cells and said hybrid cells (iii) are dendritic
cell/tumor cell hybrids.
40. The method of claim 38 wherein the providing step (a) is in
vivo.
41. The method of claim 38 wherein the providing step (a) is in
vitro.
42. A method of treating a tumor or neoplastic disease in a subject
comprising administering to said subject an effective amount of
cells according to claim 36, wherein said ingested lysate,
transfecting nucleic acid or other apoptotic matter is presented to
the immune system to elicit a tumoricidal response.
43. A composition useful for treating a tumor or neoplastic disease
in a subject comprising a lipoprotein which is capable of binding
to receptors in tumor microvasculature and eliciting apoptosis of
tumor endothelial cells and eliciting an effective anti-tumor
response in a mammal into which said lipoprotein is introduced.
44. The composition of claim 43 wherein the lipoprotein is selected
from the group consisting of: (a) low density lipoproteins (a)
chylomicrons (b) very low density lipoproteins (c) apolipoproteins
(d) oxidized low density lipoproteins (e) oxidized low density
lipoprotein byproducts (f) oxidized low density lipoproteins mimics
(g) low density lipoprotein complexed with compounds which enhance
or promote the uptake by cells expressing LDL or oxidized LDL
receptors.
45. The composition of claim 44 wherein the compounds which enhance
or promote the uptake by cells expressing LDL or oxidized LDL
receptors are selected from a group consisting of: (a) fibronectin
(b) collagen (c) heparan
46. A composition useful for treating a tumor or neoplastic disease
in a subject comprising a conjugate or complex of: (a) a
superantigen; and (b) a lipoprotein
47. The composition of claim 46 wherein the lipoprotein is selected
from the group consisting of: (a) low density lipoproteins (a)
chylomicrons (b) very low density lipoproteins (c) apolipoproteins
(d) oxidized low density lipoproteins (e) oxidized low density
lipoprotein byproducts (f) oxidized low density lipoproteins mimics
(g) low density lipoprotein complexed with compounds which enhance
or promote the uptake by cells expressing LDL or oxidized LDL
receptors.
48. the composition of claim 47 wherein the compounds which enhance
or promote the uptake by cells expressing LDL or oxidized LDL
receptors are selected from a group consisting of: (a) fibronectin
(b) collagen (c) heparan
49. The compositions of claims 46-48 wherein the
superantigen-lipoprotein conjugate is in or on a vesicle, exosome,
liposome, phage display, prokaryotic cell surface or eukaryotic
cell surface.
50. The compositions of claim 49 which are are derived from a group
consisting of: (a) a mammalian cell transfected with superantigen
genes (b) a sickle cell or sickle cell precursor transfected with
superantigen genes (c) a yeast cell or mutant transfected with
superantigen genes (d) a Staphylococcus carnosus transfected with
superantigen genes. (e) a Sphingomonas paucimobilis transfected
with superantigen genes
51 The compositions of claims 46-50 wherein the superantigen is
selected from the group consisting of a Staphylococcal enterotoxin
and a Streptococcal pyrogenic exotoxin.
52. The method of treating a tumor or neoplastic disease in a
subject comprising administering to the subject an effective amount
of the compositions of claims 46-50 so that the composition
localizes in tumor microvasuclature and is presented to the immune
system, thereby inducing an anti-tumor response
53. A mammalian cell useful for treating a tumor or neoplastic
disease in a subject comprising a nucleic acid encoding a receptor
for LDL or oxidized LDL which renders the said cell capable of
binding LDL or oxyLDL and undergoing apoptosis and eliciting an
effective anti-tumor response.
54. The mammalian cell of claim 53 comprising a second exogenous
nucleic acid encoding a superantigen such that the expression of
said superantigen and products of the first nucleic acid alone or
in combination are capable of eliciting an effective anti-tumor
immune response.
55. The cell of claim 53 is selected from a group consisting of:
(a) tumor cells (b) endothelial cells (c) stromal cells
56. The cell of claim 53 wherein the LDL or oxidized LDL receptor
is selected for the group consisting of: (a) scavenger receptors
expresssed on endothelial cells and macrophages (b) LOX-1 receptor
(c) oxidized low density lipoprotein receptor (d) CD36 receptor (e)
Acetyl low density lipoprotein receptor (f) low density lipoprotein
receptor (g) low density lipoprotein receptor-related protein
(LRP)
57. The cell of claim 55 wherein the superantigen is selected from
the group consisting of a Staphylococcal enterotoxin and a
Streptococcal pyrogenic exotoxin.
58. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of exogenous LDL
receptor, oxyLDL receptor nucleic acid or superantigen nucleic acid
wherein they are introduced into the cell in vivo.
59. A composition useful for treating a tumor or neoplastic disease
in a subject comprising a conjugate or complex of: (a) a
superantigen; and (b) a LDL or oxidized low density lipoprotein
receptor
60. The composition of claim 59 wherein the LDL or oxidized LDL
receptor is selected for the group consisting of: (a) scavenger
receptors expresssed on endothelial cells and macrophages (b) LOX-1
receptor (c) oxidized low density lipoprotein receptor (d) CD36
receptor (e) Acetyl low density lipoprotein receptor (f) low
density lipoprotein receptor (g) low density lipoprotein
receptor-related protein (LRP) (h) apolipoprotein receptors
61. The compositions of claims 58-59 wherein the LDL and oxidized
LDL receptors are in the form of naked DNA.
62. The compositions of claims 59-60 wherein the LDL receptor or
superantigen or LDL receptor is a polypeptide or nucleic acid in or
on a vesicle, exosome, liposome, phage display, plasmid, expression
vector, prokaryotic cell surface or eukaryotic cell surface.
63. The vesicles, exosomes prokaryotic and eukaryotic cell surfaces
of claim 61 which are derived from a group consisting of: (a) a
mammalian cell transfected with superantigen genes (b) a sickle
cell or sickle cell precursor transfected with superantigen genes
(c) a yeast cell or mutant yeast cell transfected with superantigen
genes (d) a Staphylococcus carnosus transfected with superantigen
genes. (e) a Sphingomonas paucimobilis transfected with
superantigen genes
64. The compositions of claims 58-63 wherein the superantigen is
selected from the group comprising a Staphylococcal enterotoxin and
Streptococcal pyrogenic exotoxin
65. A mammalian cell comprising an exogenous nucleic acid encoding
a superantigen which is expressed in said cell which cell also
produces or expresses low density lipoproteins, wherein expression
of said superantigen and said native LDL or oxidized LDL or
biologically active LDL mimics and byproducts is capable of
eliciting an effective anti-tumor immune response in a mammal into
which said cell is introduced.
66. The cell of claim 65 which is selected from a group consisting
of (a) a tumor cell (b) a endothelial cell (b) a sickled cell or
sickled cell precursor
67. The cell of claim 65 wherein the the low density lipoproteins
are selected from the group consisting of: (a) native low density
lipoprotein (a) oxidized low density lipoprotein (b) low density
lipoprotein mimics (c) low density lipoprotein byproducts
68. The cell of claim 65 wherein said mammal bears a tumor, against
which the antitumor response is directed, said tumor being selected
from the group consisting of a carcinoma, a melanoma, a sarcoma, a
neuroblastoma, an astrocytoma, a lymphoma and a leukemia.
69. A method of treating a tumor or neoplastic disease in a
subject, comprising administering to said subject an effective
amount of the cells of any of claims.
70. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of the cells of any of
claims 65-67 wherein said superantigen exogenous nucleic acids is
introduced ex vivo or in vitro into a cell which produces or
expresses low density lipoproteins
71. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of the cells of any of
claims 65-67 wherein said superantigen exogenous nucleic acids and
apolipoprotein nucleic acid is introduced ex vivo or in vitro into
a cell which thereby expresses superantigen and apolipoprotein.
72. The method of claim 70-71 wherin the low density lipoproteins
are selected from a group consisting of: (a) native low density
lipoprotein (a) oxidized low density lipoprotein (b) low density
lipoprotein mimics (c) low density lipoprotein byproducts
73. A mammalian cell comprising expressing a
.alpha.-monogalactosylceramid- e or .alpha.-digalactosylceramide or
oxidized low density lipoprotein individually or in any combination
which is (are) capable of binding to tumor microvasculature,
inducing apoptosis and eliciting an effective anti-tumor immune
response in a mammal into which said cell is introduced.
74. The cell of claim 73 which also expresses a superantigen
75. The cell of claims 73-74 which is selected from a group
consisting of: (a) a tumor cell (b) a sickled cell or sickled cell
precursor
76. A mammalian tumor cell/accessory cell hybrid cell comprising an
exogenous nucleic acid encoding a superantigen which is expressed
in said cell such that expression of said superantigen renders the
said cell capable of elicting an effective anti-tumor immune
response in a mammal into which said cell is introduced.
77. The cell of claim 76 wherein said hybrid cell is a dendritic
cell/tumor cell hybrid.
78. The cells of claims 73-77 wherein said mammal bears a tumor,
against which the antitumor response is directed, selected from the
group consisting of a carcinoma, a melanoma, a sarcoma, a
neuroblastoma, a lymphoma and a leukemia.
79. The cell of claim 73-77 wherein the superantigen is selected
from the group consisting of a Staphylococcal enterotoxin and a
Streptococcal pyrogenic exotoxin.
80. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of nucleic acids in
vivo to the tumor/accessory tumor/accessory cell hybrid cells of
claims 76-77.
81. A method of treating a tumor or neoplastic disease in a subject
comprising administering an effective amount of the cells of claim
76-77 wherein said exogenous nucleic acids are introduced into the
cell ex vivo or in vitro.
Description
CROSS-REFERENCE TO RELATED DOCUMENTS
[0001] The Instant application is a continuation application of
U.S. application Ser. No. 09/650,884 filed on Aug. 30, 2000 which
claims priority to provisional applicaton 60/151,470 filed on Aug.
30, 1999. Both of the above referenced applications are
incorporated herein in their entirety by reference.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The invention relates generally to immunotherapeutic
compositions and methods for treating tumors and cancer. The
methods are based on the expression of superantigen ("SAg") alone
or in combination with other molecules in transfected host cells
(tumor cells, accessory cells or lymphocytes). Other therapeutic
methods are based on administering T cells which are activated by
cells engineered to express SAg and other immunostimulatory
molecules and structures.
[0004] 2. Description of the Background Art
[0005] Therapy of the neoplastic diseases has largely involved the
use of chemotherapeutic agents, radiation, and surgery. However,
results with these measures, while beneficial in some tumors, has
had only marginal effects in many patients and little or no effect
in many others, while demonstrating unacceptable toxicity. Hence,
there has been a quest for newer modalities to treat neoplastic
diseases.
[0006] In 1980, tumoricidal effects were demonstrated in four of
five patients with advanced breast cancer treated with autologous
plasma that had been perfused over columns in which Staphylococcal
Protein A was chemically attached to a solid surface (Terman et
al., New Eng. J. Med., 305:1195 (1981)). While the initial
observations of tumor killing effects with the immobilized Protein
A perfusion system have been confirmed, some have obtained
inconsistent results.
[0007] The explanation of these inconsistencies appears to be as
follows. First, commercial Protein A is an impure preparation, as
evident from polyacrylamide gel electrophoresis and
radioimmunoassays that detected Staphylococcal enterotoxins in the
preparations. Second, various methods of immobilizing Protein A to
solid supports have been used, sometimes resulting in loss of
biological activity of the perfusion system. Third, the plasma used
for perfusion over immobilized Protein A has often been stored and
treated in different ways, also resulting in occasional
inactivation of the system. Moreover, the substance(s) or factors
responsible for the anti-tumor effect of this extremely complex
perfusion system have not been previously defined. The system
contained an enormous number of biologically active materials,
including the Protein A itself, Staphylococcal proteases,
nucleases, exotoxins, enterotoxins and leukocidin, as well as the
solid support and coating materials. In addition, several
anaphylatoxins were generated in plasma after contact with
immobilized Protein A. Finally, it was speculated that the
biological activity of the system was due to the removal from the
plasma by the Protein A of immunosuppressive immune complexes that
otherwise inhibit the patient's antitumor immune response.
[0008] The Staphylococcal enterotoxins that contaminate the Protein
A columns are a family of extracellular products of Staphylococcal
aureus that belong to a well recognized group of proteins that have
common physical and chemical properties. The enterotoxins produce a
number of characteristic effects in humans and animals, such as
emesis, hypotension, fever, chills, and shock in primates and
enhancement of gram negative endotoxic lethality in rabbits. At
least some of these effects are due to the ability of these
proteins to act as extremely potent T cell mitogens.
[0009] Staphylococcal enterotoxins are representative of a family
of molecules known as SAgs which are the most powerful T cell
mitogens known. They are capable of activating 5 to 30% or the
total T cell population compared to 0.01% for conventional
antigens. Moreover, the enterotoxins elicit strong polyclonal
proliferation at concentrations 10.sup.3-fold lower than
conventional T cell mitogens. The most potent enterotoxin,
Staphylococcal enterotoxin A (SEA), has been shown to stimulate DNA
synthesis in human T cells at concentrations of as low as
10.sup.-13 to 10.sup.-16M. Enterotoxin-activated T cells produce a
variety of cytokines, including IFN, various interleukins and TNF.
Enterotoxins stimulate several other cell populations involved in
innate and adaptive immunity which also play a major role in
anti-tumor immunity, For example, enterotoxins engage the variable
region of the TCR chain on exposed face of the pleated sheet and
the sides of the MHC class II molecule.
[0010] The SAg is capable of augmenting the TH-1 cytokine response
by CD4+ cells r while also activating NKT and NK cells. NK cell
cytotoxicity is augmented by IFN produced by SAg activated T cells.
NKT cells are known to be activated by SAgs, peptides,
-galactosylceramides and lipoarabinomannans presented on CD1
receptors. Evidence points to an invariant lectin like recognition
unit on the NKT cell chain as a specific ligand for
galactosylceramide determinants on tumor cells. SAgs induce tumor
killing in vivo when given alone or conjugated to tumor associated
antibodies. They are also effective when employed ex vivo to
produce tumor sensitized T cells for the adoptive therapy of MCA
205/207 tumors. SAg transfected tumor cells have shown a capacity
to reduce metastatic disease in a murine mammary carcinoma
model.
[0011] In addition to these common biological activities, the
Staphylococcal enterotoxins share common physicochemical
properties. They are heat stable, trypsin resistant, and soluble in
water and salt solutions. Furthermore, the Staphylococcal
enterotoxins have similar sedimentation coefficients, diffusion
constants, partial specific volumes, isoelectric points, and
extinction coefficients. The Staphylococcal enterotoxins have been
divided into five serological types designated SEA, Staphylococcal
enterotoxin B (SEB), Staphylococcal enterotoxin C (SEC),
Staphylococcal enterotoxin D (SED), and Staphylococcal enterotoxin
E (SEE), which exhibit striking structural similarities. The
enterotoxins are composed of a single polypeptide chain of about 30
kilodaltons (kD). All staphylococcal enterotoxins have a
characteristic disulfide loop near the middle of the molecule. SEA
is a flat monomer consisting or 233 amino acid residues divided
into two domains. Domain I comprises residues 31-116 and domain II
of residues 117-233 together with the amino tail 1-30. In addition,
the biologically active regions of the proteins are conserved and
show a high degree of homology. One region of striking amino acid
sequence homology between SEA, SEB, SEC, SED, and SEE is located
immediately downstream (toward the carboxy terminus) from the
cysteine located at residue 106 in SEA. This region is thought to
be responsible for T cell activation. A second homologous region
that begins at residue 147 and extends downstream is highly
conserved. This region is believed to mediate emetic activity. The
region related to emetic activity can be omitted from enterotoxins
used as therapeutics.
[0012] A sequence analysis of the Staphylococcal enterotoxins with
other toxins has revealed SEA, SEB, SEC, SED, Staphylococcal toxic
shock-associated toxin (TSST-1 also known as SEF), and the
Streptococcal exotoxins share considerable nucleic acid and amino
acid sequence homology. The enterotoxins belong to a common generic
group of proteins thought to be evolutionarily related.
[0013] Enterotoxins bind to MHC Class II molecules and the T cell
receptor ("TCR") in a manner quite distinct from conventional
antigens. Enterotoxins engage the variable region of the TCR
.quadrature. chain on an exposed face of the .quadrature. pleated
sheet and the sides of the MHC Class II molecule, rather than
engaging the groove of the Class II molecule like conventional
antigens. In contrast to SEB and the SEC, which have only the
capacity to bind to the MHC class II .alpha. chain, SEA, as well as
SEE and SED, in a zinc dependent manner, also interacts with the
MHC class II .quadrature. chain. T cell recognition is based on the
presence of the .quadrature. chain and is therefore independent of
other TCR components and diversity elements. Single amino acid
positions and regions important for SAg-TCR interactions have been
defined. These residues are located in the vicinity of the shallow
cavity formed between the two domains. The alanine substitution of
amino acid residue Asn23 in SEB has demonstrated the importance of
this residue in SEB/TCR interaction. This particular residue is
conserved among all of the Staphylococcal enterotoxins and may
constitute a common anchor position for enterotoxin interaction
with TCR V.quadrature. chains. Amino acid residues in positions
60-64 have also been shown to contribute to the TCR interaction as
do the cysteine residues forming the intermolecular disulfide
bridge of SEA. For SEC2 and SEC3, the key points of interaction in
the V.quadrature. chain are located in the CDR1, CDR2 and HRV4 TCR
V.quadrature.-3 chain. Hence, multiple and highly variable parts of
the V.quadrature. chain contribute to the formation of the
enterotoxin binding site on the TCR. Thus far, a single and linear
consensus motif in the TCR V.quadrature. displaying a high affinity
interaction with particular enterotoxins has not been identified. A
significant contribution of the TCR .alpha. chain in
enterotoxin-TCR recognition is acknowledged as well as MHC class II
isotypes. This distinctive binding mechanism of enterotoxins which
bypasses the highly variable parts of the MHC class II and TCR
molecules allows them to activate a high frequency or T cells with
massive lymphoproliferation, cytokine induction and cytotoxic T
cell generation. These properties are shared by other proteins made
by infectious agents. Together, these proteins form a well
recognized group known as SAgs.
[0014] There are two general classes of SAgs. The first includes
minor lymphocyte stimulating (MLS) antigens. The second class of
SAgs includes mycoplasmal, viral, and bacterial proteins such as
the Staphylococcal enterotoxins. Streptococcal exotoxins. All SAgs
have the following properties. T cell activation does not require
antigen processing. There is no MHC restriction of responding T
cells. SAgs bind to and evoke responses from all T cells expressing
V receptors, without requiring other TCR or diversity elements.
CD4-CD8-.alpha./.quadrature. T cells and .gamma./.delta. T cells
are also capable of responding to SAgs. The SAgs induce a
biochemically distinct T cell activation pathway. Thus, SAgs
interact with and activate a much larger proportion of T cells than
conventional antigens, causing massive lymphoproliferation,
cytotoxic T cell generation, and cytokine secretion. A given SAg
can activate up to 30% of resting T cells compared to 0.01% for
conventional antigens. As highly representative members of this
family of SAgs, the enterotoxins share these characteristics.
[0015] The present invention features the use of SAgs in
association with molecules to produce tumor killing effects. The
SAgs are useful in peptide form and may combine with another
peptide or nucleic acid to form a conjugate. The effect of the
combined molecules is synergistic. These conjugates are useful when
administered as a preventative or therapeutic antitumor vaccine in
tumor bearing patients. Alternatively, they may be used ex vivo to
load an antigen presenting cell as a means of immunizing a T or NKT
cell population for use in adoptive therapy of cancer. Examples of
such conjugates are complexes between: SAg and glycosylceramide;
SAg and apolipoproteins (Lp(a)), SAg and oxyLDL, SAg and
verotoxins, SAg and GPI-ceramide (with phytosphingosine backbone),
SAg and lipopolysaccharide (LPS), SAg and peptidoglycan, SAg and
mannan proteoglycan, SAg and muramic acid, SAg and tumor peptides.
Also intended are SAg and Gal conjugates and glycosylated SAgs.
[0016] The present invention features the use of SAg in association
or conjugated to oxidized low density lipoproteins (oxyLDL) and
apolipoproteins (e.g., lipoprotein (a) (Lp(a)). OxyLDL and its
byproducts bind to receptors on sinusoidal endothelial cells in the
tumor microcirculation where they induce apoptosis, increase levels
of tissue factor and activated thrombin, upregulate achesion
molecules and produce a prothrombotic state. Lp(a) is densely
deposited in tumor microcirculation and as a competitive inhibitor
of plasminogen is prothrombotic. Hence, both apolipoproteins and
oxyLDL not only home to receptors on the tumor microcirculation but
they also induce endothelial cell or macrophage apoptosis as well
as a prothrombotic state. These local effects are amplified by the
presence of the conjugated superantigen which induce a localized T
cell immune and inflammatory response collectively resulting in a
potent anti-tumor response.
[0017] The present invention also features the use of the SAg in
association or conjugated to verotoxins. The latter molecules have
the capacity to bind to galactosylceramide receptors on tumor cells
and induce apoptosis. Hence, the tumor targeting and apoptosis
inducing functions of the verotoxin are coupled with the T cell
immune and inflammatory response induced by the SAgs to produce a
potent and well localized anti-tumor response.
[0018] The present invention features the use of SAgs in
association or conjugated to mono or digalactosylceramides. The
latter have been isolated from marine sponge Aegelus mauritanius
and is expressed in certain bacteria such as Sphingomonas
paucimobilis. They have been shown to activate NKT cells and to
induce anti-tumor effects in vivo against several types of tumors.
The activation of NKT cells in the presence of the mono and
digalactosylceramides appears to be IL-12 dependent. The biological
activity of the -galactosylceramides is observed in both mono and
digalactosylceramide forms and is dependent upon the presence of an
anomeric configuration on the terminal galactose. The lengths of
the sphingosine base and fatty acyl chains of 23 and 15
respectively also appear to be optimal for production of the
anti-tumor effects.
[0019] SAgs are known to be the most powerful T cell mitogens known
and have been shown to produce anti-tumor effects in several animal
models. The -galactosylceramides are known to be potent inducers of
NKT cell activation which have been shown to produce an anti-tumor
effect in an IL-12 dependent manner. In the present invention SAgs
are combined with -galactosylceramides biochemically as conjugates
and genetically within a cell which expresses the newly synthesized
protein-bound galactosylceramide on the cell surface. The newly
synthesized conjugates in native form or expressed in or on the
cell produce a synergistic anti-tumor effect due to the activation
of T cells and NKT cell populations.
[0020] Furthermore, in the present invention the
SAg--galactosylceramides are expressed in tumor cells, dendritic
cells ("DC") or a hybrid cell made by fusing a tumor cell and a DC.
The use of DCs or DC/tumor cell hybrids (DC/tc) to present the
SAg-galactosylceramides fusion constructs or conjugates provides
the optimal costimulation for activation of a tumor specific T cell
population. The use of a tumor cell or a DC/tc provides in addition
to costimulation, expression of the tumor antigen itself to
activate anti-tumor T and NKT cell clones which are tumor specific.
Hence, an optimal cell is a DC/tc which expresses SAg and
SAg-anomeric galactosylceramides.
[0021] The SAg--galactosylceramide conjugates are useful in the
present invention. However, there are distinct differences and
advantages to producing and expressing the SAg-galactosylceramide
conjugates within a cell. First, final products are quite
different. One involves the enterotoxin--galactosylceramide in free
form whereas the other involves cell
associatedenterotoxin-galactosylceramide which includes enterotoxin
nucleic acids and peptides. In the cell both enterotoxins and
-galactosylceramides are associated with numerous intracellular and
membrane structures such as MHC, costimulatory and adhesion
molecules, heat shock proteins, membrane glycolipids and
glycosphingolipids. which may improve immunogenicity and antigen
presentation. They may also be transported in various vesicles and
exosomes which may provide additional immunogenicity. With the
addition of appropriate signals sequences and association with
molecules involved in the antigen presenting pathways such as the
invariant chain, TAP and LAMP molecules the conjugates may be
routed in the cell to the MHC class I, class II or CD1 receptor.
Therefore, enterotoxin and -galactosylceramides produced within a
cell is presented to the host's immune system in an entirely
different form compared to the purified enterotoxin
polypeptide.
[0022] Unlike free enterotoxin polypeptide or -galactosylceramide,
SAg transfected tumor cells, DCs or DC/tc present enterotoxins to
the T cell system in association and or conjugated to tumor
associated antigens including mutated normal structures or fusion
structures, costimulatory and adhesion molecules. Indeed, the
coadministration of SAg with tumor antigen would be expected to
produce a heightened response to the tumor antigens while
preventing the clonal deletion which occurs with SAg alone. Liu et
al., Proc. Natl. Acad. Sci., 88: 8705-8709, (1991); McCormack et
al., Proc. Natl. Acad. Sci., 91: 2086-2090, (1994); Coppola et al.,
Int. Immunol., 9: 1393-403, (1997). Hence, the coadministration of
SAg-galactosylceramide and tumor associated antigens would induce a
predictably heightened tumor specific response by the host. This
prediction was borne out by the Applicant's work showing that SAg
transfection of tumor cells abolished the tumorigenicity of 4T1
mammary carcinoma cells, significantly reduced the number of
established metastases and prolonged survival compared to untreated
controls. (Pulaski, Terman, et al., American Association of Cancer
Research, April 1999 and submitted to Proc. Natl. Acad. Sci,
1999).
[0023] SAg transfected tumor cells in vivo are effective in an
additional manner which does not apply to SAg polypeptide.
Ingestion of apoptotic cells by DCs augments the immunogenicity of
tumor cells. Fields et al., Proc. Natl. Acad. Sci., 95: 9882-9887,
(1998); Albert et al., Nature, 392: 86-89, (1998). DCs are
acknowledged as the premier accessory cell for antigen
presentation. They have been shown to ingest apoptotic cells and
nucleic acids and process them for presentation to host T cells in
the context of costimulation, adhesion and MHC molecules. Akbari et
al., J. Exp. Med., 189: 169-177, (1999). Therefore, following
apoptosis of SAg transfected tumor cells and ingestion by DCs,
SAg-encoding nucleic acid as well as tumor associated nucleic acids
in the transfected cells would produce additional anti-tumor
responses. Purified polypeptide enterotoxins do not share with the
SAg transfectants this property of enhanced immunogenicity
following ingestion and processing by DCs.
[0024] There are enormous structural and functional differences
between the polypeptide enterotoxin and SAg-transfected tumor
cells. The starting materials are different i.e. peptides vs
nucleic acids and the product is different i.e. polypeptide vs
enterotoxin transfected cell in which the SAg is may exist in
nucleic acid and peptide form associated with a vast number of
intracellular and membrane structures. Some of these structures may
actually improve the T cell activating function of SAgs such as
deoxyribonucleic acids, ribonucleic acids, tumor associated
antigens, heat shock proteins, costimulatory molecules and adhesion
molecules and endosomes. Cellular SAg peptides or nucleotides exist
in association with tumor associated antigens, costimulants,
adhesion molecules, heat shock proteins and MHC molecules,
GPI-ceramides or SAg receptors (digalactosylceramides) which
improve the immunogenicity of the tumor antigens. Therefore, these
structural and functional differences between the polypeptide SAg
and the enterotoxin transfected tumor cells clearly show that SAg
transfected tumor cells have a far greater potential than the
polypeptide to induce a tumor specific response.
[0025] Moreover, SAg transfected tumor cells possess an additional
unique property not shared by the polypeptide SAg. SAg-transfected
tumor cells display the metastatic phenotype of the tumor cells
which enables them to colonize and traffic to metastatic sites in
vivo. Once localized to micrometastatic sites the transfectants
expressing SAg induce a potent tumor specific T cell response. In
contrast, the purified polypeptide SAg unassociated with a tumor
cell would have no capacity whatsoever to colonize metastatic
sites.
[0026] The present invention also provides SAg-encoding nucleic
acid, preferably DNA, fused with (or cotransfected with ) a nucleic
acid encoding another molecule. The transfected cells include tumor
cells, accessory cells e.g., DCs, tumor cell/accessory cell (e.g.,
DC) hybrids. The expression of molecules in addition to
enterotoxins by these cells serves the following functions:
[0027] 1) enhance the immunogenicity of the SAg transfected cell by
providing nucleic acids encoding an additional potent immunogen.
Examples would include tumor associated antigens or mutated normal
antigen or fusion peptides in tumor cells, an immunogenic bacterial
product such as Staphylococcal adhesin protein A, LPS,
.quadrature.-glucans, and peptidoglycans, costimulatory and
adhesion molecules, heat shock protein, growth factor receptors
such as Her/neu and tumor markers such as PSA.
[0028] 2) assist in tumor killing activity by the SAg transfected
cell when localized to tumor sites. by providing nucleic acids
encoding the following: angiogenesis antagonists, chemoattractants
such as C5a, chemokines such as RANTES, hyaluronidase and coagulase
and CD44 isoforms.
[0029] 3) increase the binding of immunogenic substances to the
surface of the SAg transfected cell by providing nucleic acids
encoding the following: CD1 receptors, CD14 receptors, SAg
receptors
[0030] 4) increase the production of SAg in the SAg transfected
cell by providing nucleic acids encoding the following: cell cycle
proteins, amplified oncogenes, and signal transduction
molecules.
[0031] 5) assist in trafficking of SAg to class I or class II
pathway in the SAg transfected cell by providing nucleic acid
encoding the following: the invariant chain, the LAMP1 proteins and
TAP proteins.
[0032] 6) induction of a local tumoricidal response by intratumoral
injection of nucleic acids encoding the following: oxyLDL receptor
and SAg receptor, chemoattractants, chemokines.
SUMMARY OF THE INVENTION
[0033] The present invention comprises a method for treating cancer
in a host comprising providing conjugates, fusion proteins or naked
nucleic acids of superantigen and additonal molecule(s) which
produce an tumoricidal response. The addtional molecule serves the
following functions: 1) to target a receptor (digalactosylceramide)
expressed on tumor cells in vivo and induce tumor cell apoptosis
e.g., SAg-verotoxin conjugates. 2) to target receptors expressed on
tumor sinusoidal endothelium, induce apoptosis and a prothrombotic
state e.g. SAg-oxyLDL conjugates and SAg-Lp(a) conjugates 3) to
activate a dormant population of tumoricidal NKT cells e.g.
SAg-digalactosylceramides, SAg-GPI-digalactosylceramide
(phytosphingosine) complexes. 4) target receptors for integrins
expressed on tumor microvasculature e.g., SAg-RGD conjugates. 5)
naked DNA administered intratumorally induces tumor cell expresson
in vivo of receptors for ligands which produce apoptosis and
inflammation e.g, naked DNA SAg-oxyLDL receptor, SAg-LOX-1
receptor, SAg-SREC receptor..
[0034] Sickled erythrocytes are useful in the present invention
since they have natural ligands for integrins expressed on tumor
neovasculature which facilitates their targeting to the tumor
endothelium. Sickled erythrocyte membranes acquire oxyLDL using
fusigenic techniques with oxyLDL containing liposomes and
apoproteins via gene transfection in the nucleated pre-reticulocyte
phase. The oxyLDL and apoproteins expressed by the sickled cells
facilitates targeting to oxyLDL, LOX-1 and SREC receptors present
on the tumor microvasculature. These erythrocytes are also useful
for carrying nucleic acids for transfection of the tumor
endothelial cells in vivo. Vesicles derived from sickled
erythrocytes are more rigid, prothrombotic and target the tumor
microvascularture more effectively than the parent cell. They also
carry oxyLDL to receptors on tumor endothelium. Likewise, vesicles,
exosomes or SAg-GPI-digalctosylceramides shed from from SAg
transfected tumor cells are capable of inducing potent tumoricidal
responses and are useful in the present invention.
[0035] In addition, bacterial expression systems are useful for the
expression of SAg in association with other anti-tumor molecules.
The yeast sec mutant is used to produce a SAg-ceramide conjugate in
which the sphingosine portion of the ceramide is a
phytosphingosine. Sphingomonas paucimobilis which naturally
expresses .alpha.-galactosylceramide is transfected with SAg
nucleic acids which results in the shedding of
SAg-.alpha.-galactosylceramide complexes.
[0036] The present invention comprises a method for treating cancer
in a host comprising providing cells transfected with a gene that
express and/or secretes a SAg or T cells activated by the
transfected cells to the host. The cells are transfected in vivo or
in vitro. SAgs may activate T cells or NKT cells in the host. These
same transfectants may be used to stimulate a population of T cells
or NKT cells ex vivo which are provided to the host as tumor
specific effector cells in adoptive immunotherapy. The transfected
cells may be, for example, tumor cells accessory cells, DCs muscle
cells, immunocytes, fibroblasts. When transfected in vitro the
cells can be xenogeneic to the host, from the same species as the
host or host cells.
[0037] For in vivo immunization, tumor cells are transfected with
nucleic acids encoding SAgs together with a carbohydrate modifying
enzyme such as galactosyl transferase to produce the Gal epitope,
Staphylococcal hyaluronidase, Streptococcal capsular
polysaccharide, Staphylococcal erythrogenic toxin, Staphylococcal
Protein A, Staphylococcal .quadrature. hemolysin, Staphylococcal
coagulase, costimulants such as B7-1 and B7.2, chemoattractants and
chemokines. SAgs are also cotransfected into tumor cells with gene
clusters encoding the biosynthesis of highly immunogenic microbial
Lipid A, membrane or capsular polysaccharides, lipoproteins and
peptidoglycans. Nucleic acids are useful when transfected alone.
However combinations are preferred. The cotransfection into tumor
cells of the SAg-encoding nucleic acid together with the nucleic
acids encoding Gal or GalCer biosynthesis is particularly useful.
The cotransfection into tumor cells of the nucleic acid encoding
SAg with nucleic acids encoding Staphylococcal erythrogenic toxins
and hyaluronidase allows the transfected tumor cells to simulate
the in vivo inflammatory activity of a Staphylococcus or leukocyte
or macrophage by secreting enzymes and toxins which induce a
sterile cellulitis in tumor sites.
[0038] Further provided are tumor cells transfected with nucleic
acid encoding structures such as the erb/Neu gene which upon
administration to the host promotes tumor cell trafficking and
colonization of micrometastatic sites. Amplified oncogenes linked
to SAg nucleic acids provide the locus and energy for expression or
overexpression of both gene products. Thus, provided herein are
tumor cells transfected with SAg-encoding nucleic acid together
with nucleic acid encoding other oncogenes, amplified oncogenes and
transcription factors, angiogenic factors such as angiostatin,
angiogenesis receptors such as VEGF, tumor growth factors, tumor
suppressors, cell cycle proteins and key proteins engaged in the
antigen routing and processing pathway. In one example, the
microbial SAg and erb/Neu nucleic acids are cotransfected into
tumor cells. These nucleic acids may also linked to an inducible
gene such as that encoding metallothionein or corticosteroid
receptors. In this way, the cells are activated by exogenous
delivery of corticosteroids or a heavy metal only after a suitable
period of time has lapsed to allow them to localize in metastatic
sites in vivo
[0039] Tumor cell transfectants are also useful ex vivo to immunize
a T cell or NKT cell population producing tumor specific effector
cell population for adoptive immunotherapy of cancer. These
immunizing tumor cells are transfected with nucleic acids encoding
SAgs and the SAg receptor. The latter transfectants are capable of
binding exogenous SAg for presentation to a T cell population. In
addition, tumor cells are transfected with nucleic acids encoding
CD1 receptors which are capable of binding exogenous
glycosylceramides and lipoarabinans free or bound to SAgs for
presentations to T or NKT cells. Similarly, tumor cells are
transfected with nucleic acids encoding the CD14 receptor which
bind exogenous peptidoglycans and LPS's, free or bound to SAgs for
presentation to T cells.
[0040] Likewise, the nucleic acids encoding the mannose receptor
are transfected into tumor cells which are capable of binding a
broad range of glycosylated SAgs for presentation to T cells. The
present invention provides detailed methods for preparation of the
SAg-glycosylceramide, SAg-LPS, SAg-peptidoglycan complexes as well
as glycosylated SAgs which are loaded onto their respective
receptors expressed on tumor cells, accessory cells and, in some
instances, immunocytes. For ex vivo use, any prokaryotic or
eukaryotic cell may be used which is transfectable with nucleic
acid encoding SAgs to provide surface expression of the SAg or
constructs expressed on tumor, accessory cell or immunocyte
transfectants. When the transfected cells are not host tumor cells,
the cells additionally express a tumor associated antigen expected
to be present on the host's cancer cells.
[0041] Also provided is a tumor specific T cell or NKT cell
population which is activated by SAgs or the tumor cell
transfectants above to produce a population of tumor specific
effector cells useful in adoptive immunotherapy. After ex vivo
stimulation, the T cells or NKT cells used for adoptive
immunotherapy should preferentially express CD44 which indicates
that they are capable of trafficking and homing to tumor sites.
Additionally, the T cell population used for ex vivo immunization
is engineered to overexpress the TCR variable V.quadrature. and
invariant V.alpha. sites specific for SAg and glycosylceramide
binding respectively and to produce IFN by exogenous delivery of
corticosteroids or a heavy metal. A particularly useful population
of therapeutic tumor specific effector T cells or NKT cells which
demonstrates overexpressed CD44 together with V.quadrature.
variable and V.alpha. invariant regions and high IFN production.
Also provided are methods for reactivating anergic T cells in
cancer patients by transfecting nucleic acids encoding the SAg
receptors to produce a T cell population which may now be
stimulated with exogenous SAgs.
[0042] Compositions which mimic SAgs are used in place of native
SAgs for in vivo administration in order to circumvent the problem
of naturally occurring SAg-specific antibodies. The SAg mimics are
largely comprised of nucleotides or oligonucleotide-peptide
chimeric constructs which are specific for tumor cells expressing
SAg receptors (via the nucleotide) while retaining their SAg
specificity for the TCR (via the peptide). The class II binding
site of the SAg may optionally be eliminated or mutated to minimize
SAg peptide binding to MHC class II receptors in vivo. The molecule
may be composed entirely of nucleotides for which there are no
naturally occurring antibodies. In addition, carriers are provided
for in vivo transfection of tumors by nucleic acids encoding SAgs
or other nucleic acid constructs given in Table I. Phage displayed
tumor neovasculature ligands may also carry nucleic acids encoding
SAgs or other constructs.
[0043] The constructs and method are used to treat any solid tumor
such as carcinoma, melanoma and sarcoma or cancer of hemopoietic
origin, such as lymphomas and leukemias which may or may not form
solid tumors.
[0044] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art of this invention. Although methods and
materials similar or equivalent to those described herein can be
used in the practice or testing of the present invention, suitable
methods and materials are described below. All publications, patent
applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including definitions, will control. In
addition, the materials, methods, and examples are illustrative
only and not intended to be limiting. Other features and advantages
of the invention will be apparent from the following detailed
description and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0045] FIG. 1. Schematic diagram of the cloning of the SEB gene
into the pH.beta.=Apr1-neo vector. The coding region of the SEB
gene was amplified with PCR primers. The upstream primer (SEB 1)
has a SalI site at its 5'end and the downstream primer (SEB2), a
BamHI site. Both the pHb Apr1-neo vector and the amplified SEB
insert were digested with SalI and BamHI, ligated and transformed
into XL1-Blue competent cells. The final construct was verified by
restriction enzyme and sequence analyses.
[0046] FIG. 2. Cloning of the SEB gene into the neo vector. Clones
1-5 contained the SEB insert (coding region 801 bp) and the neo
vector (10 kb). All DNA was digested with SalI and BamHI and
electrophoresed on a 1% agarose gel in 1.times.TAE buffer.
[0047] FIG. 3. Alignment of the published SEB coding sequence (SEQ
ID NO:1) and the newly constructed SEB gene (SEQ ID NO:2) in neo
vector (Clone #2). Clone #2 was sequenced with 4 primers: SEB1, 2,
3, and 4. SEB1 and 2 (SEQ ID NOS:3-4) are the PCR primers that were
used for the amplification of the SEB gene. SEB 3
(TATGAAAGTTTTGTATGATGAT) (SEQ ID NO:5) and SEB 4 (SEQ ID NO:6)
(AGTGACGAGTTAGGTAATCT) are internal primers. The final sequence was
confirmed by the multiple overlapping of sequences and aligned with
the published SEB sequence. It is a perfect match. The start codon
(ATG) and the stop codon (TGA) are underlined. The upstream and the
downstream sequences are the human .quadrature.-actin promoter and
the SV40 polyA sequences in the pH.beta..sup.a-Apr1 neo vector with
the addition of SalI and BamHI restriction enzyme sites.
1TABLE I Therapeutic Constructs And Preferred Conditions Of Use I.
CELLS: Tumor Cells, DCs or DC/Tumor Cell Hybrids (DC/tc) USE: In
vivo and Ex vivo PURPOSE A. In Vivo Preventative or Therapeutic
Vaccine (Established Tumor) Accomplish by transfecting or
co-transfecting with nucleic acid encoding superantigen plus one or
more of the following: 1. Superantigens 2. Enzyme that modifies
carbohydrate to induce Gal or GalCer epitope expression 3.
Functional hyaluronidase from microbial or human sources 4.
Staphylococcal or streptococcal erythrogenic toxin 5.
Staphylococcal protein a or a domain thereof 6. Staphylococcal
hemolysin and functional microbial toxins 7. Functional microbial
or human coagulase 8. Costimulatory protein 9. Chemoattractants 10.
Chemokines 11. Nucleic acids encoding biosynthesis of
lipopolysaccharides 12. Nucleic acids encoding biosynthesis of
glycosylceramides 13. Nucleic acids encoding biosynthesis of
microbial membrane or capsular lipoproteins and polysaccharides 14.
Oncogenes, amplified oncogenes and transcription factors 15.
Angiogenic factors and receptors 16. Tumor growth factor receptors
17. Tumor suppressor receptors 18. Cell cycle proteins 19.
Heat-shock proteins, ATPases and G proteins 20. Proteins engaged in
antigen processing, sorting and intracellular trafficking 21.
Inducible nitric oxide synthase (iNOS) 22. apolipoproteins (e,g,.
Lp(a)) transfected into tumor cells & sickled erythrocytes used
for targeting tumor microvasculature 23. LDL and oxyLDL receptors
(e.g., SCEP receptor) transfected into tumor cells and sickled
erythrocytes & used for targeting to tumor microvasculature B.
Ex Vivo Immunization of T and/or NKT cells to Produce Tumor
Specific Effector Cells (for Adoptive Immunotherapy)* Accomplish by
(i) transfecting or co-transfecting tumor or accessory cells with
nucleic acid encoding the following, or (ii) providing immobilized
molecules or receptors that present the following: 1. Superantigen
2. Superantigen receptor and transcription factor with bound
superantigen 3. CD1 receptor binding and/or expressing
superantigen-glycosyl ceramide complex 4. CD14 receptor binding or
expressing superantigen- lipopolysaccharide or
superantigen-peptidoglycan complex 5. Mannose receptor binding
glycosylated superantigen 6. Glycophorin receptor 7.
Superantigen-tumor peptide(s) complex on MHC or CD1-bearing APC in
soluble or immobilized form C. Therapeutic Molecules or Complex
Applied to Transfected or Untransfected Tumor cells or Accessory
Cells; or MHC class I, class II, CD1, Superantigen receptor or CD14
receptor: 1. Superantigen (wherein cell may express Gal) 2.
Glycosylated superantigen 3. Superantigen complex with a. glycosyl
ceramide b. lipopolysaccharide c. peptidoglycan d. mannan
proteoglycan e. muramic acid f. tumor peptide g. glycosylceramides
with terminal Gal(.alpha.1-4)Gal e.g. globotriosylceramide and
galabiosylceramide h. Conjugates of SAg-(Gb2 or Gb3 or Gb4) i.
Conjugates of SAg-(Gb2 or Gb3 or Gb4)-CD1 j. GPI anchored
conjugates: SAg-GPI-(Gb2 or Gb3 or Gb4) l. GPI anchored conjugates:
SAg-GPI-(Gb2 or Gb3 or Gb4)- CD1 m. Conjugates of SAg polypeptide
or nucleic acid with Verotoxin n. Conjugates of SAg Polypeptide or
nucleic acid with Verotoxin A or B subunit o. Conjugates of SAg
polypeptide or nucleic acid with IFN.alpha. receptor peptides
homologous to verotoxin p. Conjugates of SAg polypeptide or nucleic
acid with CD19 peptides homologous to verotoxin q. Conjugates of
SAg polypeptide or nucleic acid with Arg-Gly- Asp or Asn-Gly-Arg r.
Conjugates of SAg polypeptide or nucleic acid with LDL, VLDL, HDL
s. Conjugates of SAg polypeptide or nucleic acid with
Apolipoproteins (e.g., Lp(a), apoB-100, apoB-48, apoE) t.
Conjugates of SAg polypeptide or nucleic acid with oxyLDL, oxyLDL
mimics, (e.g., 7.quadrature.-hydroperoxycholesterol,
7.quadrature.-hydroxycholesterol, 7-ketocholesterol,
5.alpha.-6.alpha.-epoxycholesterol, 7.quadrature.-hydroperoxy-ch-
oles-5-en-3b-ol, 4-hydroxynonenal (4- HNE), 9-HODE, 13-HODE and
cholesterol-9-HODE) u. Conjugates of SAg polypeptide or nucleic
acid with oxyLDL by products (e.g. lysolecithin,
lysophosphatidylcholine, malondialdehyde, 4-hydroxynonenal) v. LDL
& oxyLDL receptors (e.g., LDL oxyLDL, acetyl-LDL, VLDL, LRP,
CD36, SREC, LOX-1, macrophage scavenger receptors) as polypeptide
or nucleic acid alone or with SAg polypeptide or nucleic acid
intratumorally II. CELLS: Specialized Tumor Specific Effector Cells
(T and/or NKT Cells) USE: Adoptive Immunotherapy In Vivo PURPOSE:
A. CD44 Expression on T cells or NKT Accomplished by: (i)
Superantigen stimulation; and/or (ii) transfection with nucleic
acid encoding CD44 and/or (iii) transfection with nucleic acid
encoding glycosyltransferase B. Chimeric TCR with: Invariant a
chain site for binding GalCer and V.beta.uchain site for binding
superantigen C. Dual TCR V.quadrature. chains with sites for
superantigen binding D. T cells or NKT cells with overexpressed
V.beta.Nregion specific for a given superantigen E. T cells or NKT
cells with lowered signal transduction threshold III. MOLECULES:
Superantigen mimics USE: In Vivo Administration A. Superantigen
receptor-binding oligonucleotides B. Superantigen
oligonucleotide-peptide conjugate Oligo nucleotide is specific for
superantigen receptor on tumor cells Peptide has deleted class II
binding site and intact TCR binding site C. Phage displayed
integrin ligand on tumor neovasculature - carrier for
superantigen-encoding nucleic acid. IV. CARRIERS: for nucleic acid
encoding superantigen USE Transfection of Tumors In vivo A. Sickled
erythrocytes that target tumor neovasculature B. Phage displayed
tumor neovascular integrin and superantigen receptor carrying
superantigen nucleic acids V. CARRIERS: constructed to co-express
superantigen conjugates or complexes with: Glycosylceramide
.alpha.Gal Lipopolysaccharides Peptidoglycans USE Transfection of
Tumor Cells and/or DCs and/or DC/tc's - in vivo or ex vivo. A.
Liposomes B. Proteosomes
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0048] The present invention provides methods and materials for
treating cancer related to the polypepide or nucleic acid
conjugates or fusions comprising SAg with other molecules that
synergize or cooperate with SAg in the induction of an anti-tumor
response. The present invention also provides materials and methods
for treating cancer related to transfection of cells with nucleic
acid that encode a SAg and/or another polypeptide. The cells can be
transfected in vivo or in vitro. The expression of the SAg
polypeptide activates host immunocytes, such as T or NKT cells.
[0049] As used in this application, T cells are defined as any
class of lymphocytes that undergo maturation and differentiation in
the thymus. They include, but are not limited to NK cells, NKT
cells and/T cells and may be known as cytotoxic, helper or
suppressor T cells or they may be defined by the expression or type
of CD or TCR present. The same transfected nucleic acid molecule,
or a separate nucleic acid molecule, can also encode another
polypeptide such as an adhesion molecule, glycosyltransferase,
glycosidase, CD44, cytokine, tumor associated antigen,
costimulatory molecule, and the like. In addition, cells
transfected in vitro or ex vivo with any of these nucleic acids as
well as T cells activated by these transfected cells are
administered directly to a cancer-bearing host. Cells transfected
in vitro or ex vivo as well as cells activated ex vivo may
additionally express a tumor associated antigen expected to be
present on host cancer cells. Further, cells transfected with
nucleic acid that encodes a SAg polypeptide is also be used as a
vaccine to immunize a host against a cancer previously present in
the host or a cancer that is likely to develop in the host. For
example, a host can be vaccinated against a particular cancer by
administering tumor cells transfected with nucleic acid encoding a
SAg. Alternatively, a SAg transfected cell is used to activate a
host T cell population in vitro. This activated T cell population
is then administered to a host as a cancer treatment
(immunotherapeutic agent). Once activated ex vivo or in vivo, these
T cells are expanded with cytokine treatment such as IL-2
treatment.
[0050] Cells to be "transfected" include accessory cells,
immunocytes, fibroblasts, or tumor cells. Accessory cells may
include, without limitation, endothelial cells, DCs, monocytes,
macrophages as well as B and T lymphocytes which can play an
"accessory" as well as direct effector role in an immune response.
When transfected in vitro, the cells can be xenogeneic, allogeneic
to the host to provide, among other things, additional
immunogenicity. Preferably, the transfected cells that are
administered to a host, preferably a human, are syngeneic or
autologous (or autochthonous).
[0051] Cells transfected with nucleic acid encoding a SAg may also
express a tumor associated antigen that is potentially present on
host cancer cells. For example, nucleic acid encoding a known tumor
antigen are transfected into the SAg-containing cell, or a tumor
cell that endogenously contains many different tumor antigens are
transfected with SAg-encoding nucleic acid. In the latter case,
additional nucleic acids encoding other polypeptides are
transfected into the tumor cell. For example, nucleic acid encoding
a carbohydrate modifying enzyme such as
.alpha.1,3-galactosyltransferase, adhesion molecule, costimulatory
molecule such as B7-1 and B7-2, MHC class I molecule and/or MHC
class II molecule are cotransfected into tumor cells together with
nucleic acid encoding a SAg.
[0052] SAg-encoding nucleic acid can encode a mutant, variant,
and/or modified form of a SAg. These forms can be used to transfect
T cells, alone or in combination with wild-type SAg-encoding acid.
In addition, tumor cells are provided with the capacity to colonize
sites of metastases and the ability to locally hydrolyze
surrounding tumor ground substance and neovasculature by
transfection of key bacterial Staphylococcal and Streptococcal
enzymes, toxins and capsular polysaccharides which confer upon the
tumor cell additional tumor killing properties and immunogenicity.
The transfected genes include staphylococcal hyaluronidase (tissue
spreading factor), Staphylococcal erythrogenic toxin and
Streptococcal capsular polysaccharide. The tumor cell may thus be
capable of mimicking the tissue invasive and destructive properties
of the Streptococcus and Staphylococcus as they produce a sterile
cellulitis localized to tumor sites.
[0053] These methods are used to treat any solid tumor such as
carcinoma, melanoma, and sarcoma, or cancers of hematopoietic
origin such as leukemia and lymphomas. This invention also provides
for T cells or NKT cells including .gamma./.delta.T cells which
after activation by SAgs in native or mutant form or transfected
into tumor cells express surface phenotypes which enhance their
ability to traffic efficiently to tumor sites in vivo. Such
phenotypes include CD44 and/or selective V.quadrature. expression.
In response to these SAg stimulants, the T cells produce TH1
cytokines and, in particular, IFN.gamma. and IL-2.
[0054] Further, provided are methods of overcoming the T cell
unresponsiveness of cancer patients by transfection of T cells from
tumor bearing host with the nucleic acids encoding the SAg receptor
thus enabling these cells to be reactivated by exogenous SAg and
used for adoptive immunotherapy in the same cancer patient.
Provided herein are SAg oligonucleotide and oligonucleotide-peptide
compositions capable of targeting and delivering SAgs to tumor
sites in vivo without elimination by circulating naturally
occurring SAg specific antibodies prevalent in the human cancer
patients. Provided also are compositions and methods for delivery
of therapeutic nucleic acid constructs to tumor sites in vivo using
therapeutic genes carried by erythrocytes from patients with sickle
cell anemia which have the unique capability of adhering to sites
on tumor neovasculature.
[0055] 1. Cancer
[0056] This invention is used to treat any type of cancer in a host
at any stage of the disease. More particularly, the cancer is a
solid tumor such as a carcinoma, melanoma, or sarcoma. This
invention is used to treat cancers of hemopoietic origin such as
leukemia or lymphoma, that involve solid tumors. A host is any
animal that develops cancer and has an immune system such as
mammals. Thus, humans are considered hosts within the scope of the
invention. Since the invention provides SAg-transfected cells as a
vaccine, a cancer is one that a host is likely to develop based on
family history or other criteria. In this case, the host is one
that is susceptible to cancer.
[0057] 2. Nucleic Acid
[0058] The term nucleic acid as used herein encompasses both RNA
and DNA, including cDNA, genomic DNA, and synthetic (e.g.,
chemically synthesized) DNA. The nucleic acid can be
double-stranded or single-stranded. Where single-stranded, the
nucleic acid can be the sense strand or the antisense strand. The
term isolated nucleic acid means that the nucleic acid is not
immediately contiguous with both of the sequences with which it is
immediately contiguous (one on the 5' end and one on the 3' end) in
the naturally occurring genome of the organism from which it is
derived. For example, an isolated nucleic acid molecule can be,
without limitation, a recombinant DNA molecule of any length,
provided nucleic acid sequences normally found immediately flanking
that recombinant DNA molecule in a naturally occurring genome are
removed or absent. Thus, an isolated nucleic acid molecule
includes, without limitation, a recombinant DNA that exists as a
separate molecule (e.g., a cDNA or a genomic DNA fragment produced
by PCR or restriction endonuclease treatment) independent of other
sequences as well as recombinant DNA that is incorporated into a
vector, an autonomously replicating plasmid, a virus (e.g., a
retrovirus, adenovirus, or herpes virus), or into the genomic DNA
of a prokaryote or eukaryote. In addition, an isolated nucleic acid
can include a recombinant DNA molecule that is part of a hybrid or
fusion nucleic acid sequence.
[0059] Typically, regulatory elements are nucleic acid sequences
that regulate the expression of other nucleic acid sequences at the
level of transcription and/or translation. Thus, regulatory
elements include, without limitation, promoters, operators,
enhancers, ribosome binding sites, transcription termination
sequences (i.e., a polyadenylation signal), and the like. In
addition, regulatory elements can be, without limitation, synthetic
DNA, genomic DNA, intron DNA, exon DNA, and naturally-occurring DNA
as well as non-naturally-occurring DNA. It is noted that isolated
nucleic acid molecules containing a regulatory element are not
required to be DNA even though regulatory elements are typically
DNA sequences. For example, nucleic acid molecules other than DNA,
such as RNA or RNA/DNA hybrids, that produce or contain a DNA
regulatory element are considered regulatory elements. Thus,
recombinant retroviruses having an RNA sequence that produces a
regulatory element upon synthesis into DNA by reverse transcriptase
are isolated nucleic acid molecules containing a regulatory element
even though the recombinant retrovirus does not contain any
DNA.
[0060] 3. Transfection
[0061] The term "transfection," of a nucleic acid into a cell, as
used herein is intended to include "transformation,"
"transduction," "gene transfer" and the like, as they are commonly
used in the art. "Transfection" is not intended to be limited to
transfer of nucleic acid into a cell by means of an infectious
particle such as a retrovirus, as the term may have been used
originally. Rather any form of delivery and introduction of a
nucleic acid molecule, preferably DNA, into a cell, whether in the
form of a plasmid, a virus, a liposome-based vector, or any other
vector, so that the nucleic acid is expressed in the cell and its
protein product(s) made, is included within the definition of
"transfection."
[0062] When a nucleic acid is said to "encode" a product other than
a protein, this language is intended to mean that it encodes the
necessary proteins/enzymes that are involved in, or required for,
the synthesis of that product. For example, if a DNA molecule is
said to encode LPS, it clearly encodes one or more proteins
(enzymes) that are involved in the biosynthesis of LPS. If a
nucleic acid is said to "encode the biosynthesis" of a structure,
it means that the nucleic acid encodes the enzymes that participate
in the creation of that structure. In particular for the
carbohydrate structures referred to herein, the nucleic acids used
in the invention are introduced into a cell that normally does not
make, or makes little of, the carbohydrate structure so as to
provide to that cell the genetic material for an enzyme or enzymes
that generate the carbohydrate structure or modify a different
carbohydrate structure to that one indicated. As a further example,
DNA encoding a tumor antigen may directly encode a protein/peptide
tumor antigen, or alternatively, may encode proteins or peptides
that either contribute structurally to, or catalyze the synthesis
of, a tumor antigen which is partly protein (e.g., lipoprotein or
proteoglycan) or totally non-protein (e.g., a glycolipid). The
invention provides methods of treating cancer in a host by
transfecting cells with SAg-encoding nucleic acid. Suitable host or
non-host cells for transfection include, without limitation,
endothelial cells, DCs, monocytes, macrophages, B cells, T cells,
immunocytes, muscle cells, fibroblasts, NK cells, NKT cells (TCR
.alpha..quadrature..sup.+ CD4.sup.neg and CD8.sup.neg),
.gamma./.delta. T cells and tumor cells. The terms accessory cell
and antigen presenting cell (APC) can be used interchangeably and
include cells having the ability to process and present antigens to
T cells as well as to provide both defined and less well defined
growth and differentiation factors (costimulatory signals) during
an ongoing immune response.
[0063] Cells are transfected in vivo or in vitro. When transfected
in vivo, the cells are of host origin. When transfected in vitro,
the cells are autologous, allogeneic, or xenogeneic to the host to
provide additional immunogenicity. In addition to being transfected
with nucleic acid encoding a SAg, the cells are transfected with
nucleic acid encoding any other polypeptide including, without
limitation, a galactosyltransferase, staphylococcal hyaluronidase
and/or erythrogenic toxin, streptococcal capsular polysaccharide,
CD44, tumor antigen, costimulatory molecule such as B7-1 and B7-2,
adhesion molecules, MHC class I molecule and/or MHC class II
molecule. Nucleic acids encoding the molecules are cotransfected
with the SAgs. But for others, including but not limited to
Staphylococcal hyaluronidase, erythrogenic toxin, Streptococcal
capsular polysaccharide and CD44 genes, the nucleic acids encoding
the SAgs are fused to other nucleic acids resulting in expression
of a fusion protein.
[0064] Methods for in vivo and in vitro transfection of cells are
well known. For example, two books in the series Methods in
Molecular Medicine published by Humana Press, Totowa, N.J.,
describe in vivo and in vitro transfection protocols that are
adaptable to the present invention (Vaccine Protocols edited by
Robinson et al., (1996) in Gene Therapy Protocols edited by Robbins
et al., Humana Press, Totowa, N.J. (1997)). Transfection protocols
are also discussed elsewhere ((Sambrook, J. et al., Molecular
Cloning, Second Edition, Cold Springs Harbor Laboratory Press,
Plainview, N.Y., (1989)). In addition, use of various vectors to
target epithelial cells, use of liposomal constructs, methods of
transferring nucleic acid directly into T cells, hematopoietic stem
cells, and fibroblasts, methods of particle-mediated nucleic acid
transfer to skin cells, and methods of liposome-mediated nucleic
acid transfer to tumor cells have been described elsewhere.
(Felgner, P L et al., Cationic Lipids for Intracellular Delivery of
Biologically Active Molecules, U.S. Pat. No. 5,459,127, issued Oct.
17, 1995; Felgner, P L, Cationic Lipids for Intracellular Delivery
of Biologically Active Molecules, U.S. Pat. No. 5,264,618, issued
Nov. 23, 1993; Felgner, P L, Exogenous DNA Sequences in a Mammal,
U.S. Pat. No. 5,580,859 issued Dec. 3, 1996; Felgner, P L, A
Protective Immune Response in a Mammal by Injecting a DNA Sequence,
U.S. Pat. No. 5,589,466 issued Dec. 31, 1996).
[0065] Further, use of ligand-based nucleic acid carriers to effect
transfection of mammalian cells in vivo has been described
elsewhere (Wu et al., J. Biol. Chem., 262:4429-4432 (1987); Wu et
al., J. Biol. Chem., 263:14621-14624 (1988); Wu et al., J. Biol.
Chem., 264:16 985-16987 (1989); Wu et al., J. Biol. Chem.,
266:14338-14342 (1991); and Garrigues J et al., Am. J. Path.
142:607-622 (1993)). Briefly, plasmid DNA is conjugated to a
desialylated branched carbohydrates such as orosomucoid by
carbodiimide crosslinking to polylysine and targeted to
asialoprotein receptors expressed on cells in the liver. In
addition, enhanced nucleic acid delivery and expression can be
achieved using a ligand-polylysine conjugate coupled to
carbohydrate moieties on viruses that is then combined with DNA.
These preparations are suitable for parenteral injection and are
readily taken up by cells expressing asialoprotein receptors in the
liver after which the DNA is internalized and integrated into the
host genome. In addition, nucleic acid can be administered
intravenously, intramuscularly, or subcutaneously to induce a
response in a host.
[0066] Thus, targeting nucleic acid to the surface of particular
cells is accomplished by conjugating nucleic acid to molecules that
bind to a cell surface structure such as a receptor. Examples of
cell surface structures that can be targeted include, without
limitation, the transferrin receptor, and asialoglycoprotein
receptor. The molecules that bind cell surface structures and are
conjugated to nucleic acid for targeting can be, without
limitation, natural ligands for the surface structure, synthetic
compositions that exhibit specific binding, and antibodies directed
against the surface structure. For example, a monoclonal antibody
specific for a cell surface epitope such as the BR96 antibody that
recognizes Lex carbohydrate epitope abundantly expressed by colon,
breast, ovary, and lung carcinomas can be used. Other monoclonal
antibodies can include, without limitation, those that recognize
growth factor receptors, transferrin receptors, IL-2 receptors,
epidermal growth factor receptors, the hev oncogene, and TAPA-1 as
well as any other antibody having specificity for a surface
structure that can be internalized.
[0067] Liposomes containing nucleic acid are also targeted to
specific cell types such that the nucleic acid is expressed. For
example, nucleic acid is loaded into or attached to cationic DOTMA:
doleoylphosphatidylethanolamine (DOPE) liposomes that contain
exposed molecules that bind to a cell surface structure such as
tumor cells or tumor microvasculature (Example 5). The molecules
that bind cell surface structures and are attached to liposomes can
be, without limitation, natural ligands for the surface structure,
synthetic compositions that exhibit specific binding, and
antibodies directed against the surface structure. Maximal transfer
of nucleic acids encoding SAgs is attained by synthesizing the
liposomes with an appropriate ratio of nucleic acid to lipid. In
addition, these nucleic acid- containing liposomes are administered
intravenously, intramuscularly, or subcutaneously to induce a
response in a host.
[0068] Naked nucleic acid is also administered to a host. For
example, naked pharmaceutical-grade plasmid DNA are injected into a
host intramuscularly such that it is expressed by host cells (U.S.
Pat. Nos. 5,589,466; 5,580,599; 5,264,618; 5,459,127; and
5,561,064). In addition, cationic lipids are used to deliver
biologically active molecules, such as oligonucleotides to host
cells in vivo (U.S. Pat. Nos. 5,264,618, 5,459,127, and 5,561,064).
Thus, nucleic acid encoding a SAg is administered to a host in
naked or cationic lipid form such that the SAg is expressed. It is
noted that any nucleic acid described herein can be administered in
vivo as naked DNA. Further, other methods of administering naked
DNA to a host can be used such as those related to the direct
injection of naked DNA for use in vaccines (Cohen et al., Science
259:1691-1692 (1993); Corr et al., J. Exp. Med. 184:1555-1560
(1996); Varmus et al., Proc. Natl. Acad. Sci. USA 81:5849-5852
(1984); and Benveniste et al., Proc. Natl. Acad. Sci. USA
83:9551-9555 (1986)). Our previous patent applications which are
hereby incorporated by reference include U.S. patent application
Ser. No. 07/416,530, filed Oct. 3, 1989, U.S. patent application
Ser. No. 07/466,577, filed Jan. 17, 1990, U.S. patent application
Ser. No. 07/891,718, filed Jun. 1, 1992, U.S. patent application
Ser. No. 08/025,144, filed Mar. 2, 1993, U.S. patent application
Ser. No. 08/189,424, filed Jan. 31, 1994, U.S. patent application
Ser. No. 08/491,746, filed Jun. 19, 1995, PCT applications
PCT/US91/00342, and PCT/US94/02339. These applications have given
comprehensive description of the SAg genes, the creation of high
enterotoxin producing mutant strains as well as recombinant methods
of production of SAgs. In addition, methods of treating cancer by
transfecting tumor cells in vivo and in vitro with SAg nucleotides
using well defined recombinant technology have been described in
these applications. Subsequently, Dow et al., (J. Clin. Invest. 99:
2616-2624 (1997)) described in vitro and in vivo transfection of
eukaryotic cells with SAg DNA which was capable of inducing
inflammatory responses in vivo. It is noted that the SAg genes have
been cloned and their sequences delineated before 1988 and methods
used to transfect cells in vivo or in vitro with nucleic acids
encoding polypeptides are also well known in the art.
[0069] 4. Constructs
[0070] Tumor cells are transfected with various nucleic acids which
are designed to increase their immunogenicity and to provide them
with capacity to traffic to metastatic sites where they may
initiate a potent inflammatory and immune response. Such constructs
of this invention can be linear or circular nucleic acids obtained
from mammals or bacteria that encode a polypeptide such as a SAg,
mutant SAg, erythrogenic toxin, enzymes involved in the
biosynthesis of glycosyltransferases, bacterial glycosylceramides,
LPS's, lipoproteins, capsular or membrane polysaccharides,
microbial toxins and enzymes such as hyaluronidase, collagenase,
elastase, coagulase, protease, kinase, lipase. Constructs may also
contain tumor associated antigens, costimulatory molecules such as
B7-1 and B7-2, adhesion molecules, receptor molecules such as SAg
receptors, CD1, CD14, MHC class I molecules and/or MHC class II
receptors. Such constructs may also contain amplified nucleic acids
associated with tumors such as oncogenes, transcription factors,
angiogenesis factors and receptors, tumor growth factor receptors,
chimeric receptors. The latter nucleic acids may be linked to
SAg-encoding nucleic acid to produce heightened expression of the
SAg. The amplified nucleic acids may include tumor tissue specific
promoters and nucleic acids that direct the colonization or
metastasis of tumors to selected sites in vivo. Constructs can also
contain elements that regulate and/or promote the expression of an
encoded polypeptide. For example, a construct containing nucleic
acid that encodes enterotoxin B (SEB) can have a strong promoter
element upstream of the SEB encoding sequence. In addition,
constructs can contain nucleic acid that anchors an encoded
polypeptide to the cell surface after expression. For example, a
construct containing nucleic acid that encodes SEB can contain a
membrane-anchoring sequence such as nucleic acid that encodes a
hydrophobic stretch of amino acids or a
glycosylphosphatidylinositol (GPI)-anchoring motif Thus, the SAg,
or other polypeptides as well, can be anchored in the plasma
membrane by coupling to membrane lipids or glycolipids. These
anchors can be attached to the C terminus of the polypeptide in the
endoplasmic reticulum. Alternatively, a SAg known to be associated
with the cell surface after expression can be used such as the
mammary tumor viral (MMTV) SAg that is GPI-linked. In one
embodiment, SAgs as well as SAg receptors are engineered to remain
anchored to the surface of transfected cells when the cell is to be
used for immunization. Likewise, when a SAg receptor gene is
transfected into anergized T cells from cancer patients, it is
desirable to express the receptor on the cell surface so that they
are readily recognized and activated by exogenous receptor bound
SAg. In contrast, when it is desirable to use SAg transfected cells
to activate T cells in vivo or ex vivo or to promote trafficking of
transfected tumor cells to metastatic sites in vivo, it is suitable
for the SAg to be secreted from the transfected cells.
[0071] In additional embodiments, potent tumor specific effector T
or NKT cell clones are produced with overexpressed V.quadrature.
regions of their TCRs making them highly receptive to activation by
exogenous SAg. Likewise CD44 genes are transfected into T cells or
NKT cells making them more susceptible to expression of this
epitope after SAg stimulation.
[0072] Constructs also contain a selectable marker or reporter such
that transfected cells can be isolated. For example, a construct
containing nucleic acid that encodes a SAg can also contain nucleic
acid that encodes a polypeptide that confers resistance to a
selection agent such as neomycin (also called G418), puromycin, or
kanamycin.
[0073] Nucleic acid and nucleic acid constructs of the present
invention are incorporated into a vector, an autonomously
replicating plasmid, or a virus (e.g., a retrovirus, adenovirus, or
herpes virus). Typically, these vectors, plasmids, and viruses can
replicate and function independently of the cell genome or
integrate into the genome. Vector, plasmid, and virus design
depends on, for example, the intended use as well as the type of
cell transfected. Appropriate design of a vector, plasmid, or virus
for a particular use and cell type is within the level of skill in
the art. In addition, a single vector, plasmid, or virus can be
used to express either a single polypeptide or multiple
polypeptides. It follows that a vector, plasmid, or virus that is
intended to express multiple polypeptides will contain one or more
operably linked regulatory elements capable of effecting and/or
enhancing the expression of each encoded polypeptide.
[0074] The term "operably linked" means that two nucleic acid
sequences are in a functional relationship with one another. For
example, a promoter (or enhancer) is operably linked to a coding
sequence if it effects (or enhances) the transcription of the
coding sequence. A ribosome binding site is operably linked to a
coding sequence if it is positioned to facilitate translation.
Operably linked nucleic acid sequences are often contiguous, but
this is not a requirement. For example, enhancers need not be
contiguous with a coding sequence to enhance transcription of the
coding sequence.
[0075] A vector, plasmid, or virus that directs the expression of a
polypeptide such as a SAg can include other nucleic acid sequences
such as, for example, nucleic acid sequences that encode a signal
sequence or an amplifiable gene. Signal sequences are well known in
the art and can be selected and operatively linked to a polypeptide
encoding sequence such that the signal sequence directs the
secretion of the polypeptide from a cell. An amplifiable gene
(e.g., the dihydrofolate reductase [DHFR] gene) in an expression
vector can allow for selection of host cells containing multiple
copies of the transfected nucleic acid.
[0076] Standard molecular biology techniques are used to construct,
propagate, and express the nucleic acid, nucleic acid constructs,
vectors, plasmids, and viruses of the invention ((Sambrook, J. et
al., supra; Maniatis et al., Molecular Cloning (1988); and U.S.
Pat. No. 5,364,934. For example, prokaryotic cells (e.g., E. coli,
Bacillus, Pseudomonas, and other bacteria), yeast, fungal cells,
insect cells, plant cells, phage, and higher eukaryotic cells such
as Chinese hamster ovary cells, COS cells, and other mammalian
cells can be used.
[0077] Constructs are used in vivo or ex vivo or in combination as
in Example 5-7, 16-23. They are used to immunize a host by direct
in vivo administration or they are used ex vivo to activate T cells
or NKT cells to become tumor specific effector cells which are
employed for adoptive immunotherapy of cancer by methods and models
(Examples 7, 16, 19-23).
[0078] To test the anti-tumor-inducing ability of a particular
construct as well as the transfected cell itself, the following
general assay is performed. B16 melanoma, A20 lymphoma, host tumor
cells, or any other tumor cell lines appropriate to the host (i.e.,
having tumor antigens expected to be present on the host tumor
cells) are transfected with a given construct. Appropriate numbers
of transfected cells (e.g., 10.sup.5-10.sup.7 cells) are then
implanted subcutaneously into animals such as mice, rats, rabbits,
or the like and 1-6 months later untransfected tumor cells are
implanted. Tumor outgrowth from the untransfected tumor cells is
measured and compared to control animals not given the transfected
tumor cells. If tumor outgrowth is reduced or prevented, then the
transfected cells are effective anti-tumor agents useful as tumor
vaccines. Alternatively, 10.sup.5-10.sup.7 transfected tumor cells
can be given 3-10 days after the appearance of established tumors
from untransfected tumor cells. If tumor outgrowth is reduced or
arrested, then the transfected cells are effective anti-tumor
agents useful in treating established tumors.
[0079] To test the anti-tumor effect of SAg activated T cells, NKT
cells or T cells clones overexpressing V.quadrature. or CD44, the
following general protocol is used. Lymph node cells from C57/B1
mice bearing MCA 205 or 207 sarcomas which were implanted in the
adjacent inguinal region three to ten days before are extracted and
placed in tissue culture. The cells are incubated with various
enterotoxins for two days and then with IL-2 for an additional two
to three days. The cells are then harvested and injected into
syngeneic mice with established pulmonary metastases (six to twelve
days after tumor injection). Three weeks later the animals are
evaluated for pulmonary metastases compared to controls which
receive no cells or cells that were stimulated without
enterotoxins. The adoptively transferred cells may be enriched for
NKT cells or T cells alone (to include/T cells) which are
selectively injected into tumor bearing hosts. Likewise, they are
selected for predominant expression of the CD44 phenotype during
the SAg activation phase at which time the CD44 enriched population
is harvested and used for adoptive immunotherapy. The dose of
injected T cells, NKT cells or .gamma./.delta. T cells and/or CD44
enriched cells (which are produced by any of these T cell, NKT cell
or .gamma./.delta. T cell populations) range from 10.sup.6 to
.sup.7 and are be given on a schedule of once weekly for one to
four weeks.
[0080] 5. Superantigens (SAgs)
[0081] SAgs are polypeptides that have the ability to stimulate
large subsets of T cells. SAgs include Staphylococcal enterotoxins,
Streptococcal pyrogenic exotoxins, Mycoplasma antigens, rabies
antigens, mycobacteria antigens, EB viral antigens, minor
lymphocyte stimulating antigen, mammary tumor virus antigen, heat
shock proteins, stress peptides, and the like. Any SAg can be used
as described herein, although, Staphylococcal enterotoxins such as
SEA, SEB, SEC, and SED and streptococcal pyrogenic exotoxins such
as toxic shock-associated toxin (TSST-1 also called SEF) are
preferred.
[0082] When using enterotoxins, the region related to emetic
activity can be omitted to minimize toxicity. In addition, SAgs can
be derivatized to minimize toxicity. The level of toxicity may not
be a concern when using SAg transfected cells to activate
lymphocytes ex vivo since the lymphocytes can be rinsed of SAg
polypeptide prior to administration to a host.
[0083] The nucleic acid sequences that encode SAgs are known and
readily available. For example, Staphylococcal enterotoxin A (SEA)
(SEQ ID NOS:7-8), SEB (SEQ ID NOS:9-10), SEC (SEQ ID NOS:11-12),
SED (SEQ ID NOS:13-14), SEE (SEQ ID NOS:15-16), TSST-1 (SEQ ID
NOS:17-18), and Streptococcal pyrogenic exotoxin (SPEA) (SEQ ID
NOS:19-20) have been cloned and can be expressed in E. coli (Betley
M J and J J Mekalonos, J. Bacteriol. 170:34 (1987); Huang I Y et
al., J. Biol. Chem., 262:7006 (1987); Betley M et al., Proc. Natl.
Acad. Sci. U.S.A, 81:5179 (1984); Gaskill M E and S A Khan, J.
Biol. Chem., 263:6276 (1988); Jones C L and S A Khan, J.
Bacteriol., 166:29 (1986); Huang I Y and M S Bergdoll, J. Biol.
Chem., 245:3518 (1970); Ranelli D M et al., Proc. Nat. Acad. Sci.
U.S.A 82:5850 (1985); Bohach G A, Infect Immun., 55:428 (1987);
Bohach G A, Mol. Gen. Genet. 209:15 (1987); Couch J L et al., J.
Bacteriol. 170:2954 (1988); Kreiswierth B N et al., Nature, 305:709
(1983); Cooney J et al., J. Gen. Microbiol., 134:2179 (1988);
Iandolo J J, Annu. Rev. Microbiol., 43:375 (1989); and U.S. Pat.
No. 5,705,151)). Additional nucleic acid sequences encoding SAgs
are described elsewhere (Bohach et al., Crit. Rev. in Microbiology
17:251-272 (1990); (Kotzin, B L et al., Advances Immunology 54:
99-165 (1993)) PCR can be used to isolate SAg-encoding acid. For
example, the nucleic acid encoding SEA, SEB, and TSST-1 can be
isolated as described elsewhere (Dow et al., J. Clin. Invest.
99:2616-2624 (1997)). Briefly, the following primers can be used to
amplify the SAg-encoding nucleic acid:
2 SEA forward: GGGAATTCCATGGAGAGTCAACCAG, (SEQ ID NO:21) SEA
backward: GCAAGCTTAACTTGTTAATAG; (SEQ ID NO:22) SEB forward:
GGGAATTCCATGG-AGAAAAGCG, (SEQ ID NO:23) SEB backward:
GCGGATCCTCACTTTTTCTTTG; (SEQ ID NO:24) and TSST-1 forward:
GGGGTACCCCGAAGGAGGAAAAAAAAATGTCTACAAACGATAATATAAAG, (SEQ ID NO:25)
TSST-1 backward: TGCTCTAGAGCATTAATTAATTTCT- GCTTCTATAGTTTTTAT. (SEQ
ID NO:26)
[0084] The full-length TSST-1 nucleic acid sequence is cloned into
a eukaryotic expression vector (pCR3; InVitrogen Corp., San Diego,
Calif.), whereas only the sequence corresponding to the mature SEB
and SEA (sequences minus the putative bacterial signal sequences)
is cloned into pCR3. Removal ofthe SEB and SEA signal sequences
increases the level of expression in transfected cells. The
plasmids are grown in Escherichia coli and plasmid DNA extracted by
the modified alkaline lysis method and purified on a CsCl
gradient.
[0085] Nucleic acids encoding mutant or variant SAgs are also
considered nucleic acid sequences encoding SAgs within the scope of
the invention. For example, a mutant SAg-encoding acid sequence is
engineered such that the resulting SAg is devoid of amino acid
residues, e.g., histidine, known to produce toxicity. Likewise,
SAg-encoding nucleic acid is engineered to contain or lack
sequences that facilitate the selective binding of SAgs to certain
V.quadrature. regions of the TCR present on T cells or to
ganglioside, mannose (or other carbohydrate) receptor, certain
regions of MHC class II, and/or enterotoxin receptors present on
tumor cells, antigen presenting cells (APCs), and/or
lymphocytes.
[0086] Nucleic acid sequences that encode a SAg are also fused, in
frame, with nucleic acid that encodes another polypeptide. This
larger nucleic acid is termed herein a SAg fusion gene and the
resulting polypeptide product is a SAg fusion product. Nucleic acid
sequences that are fused to SAg-encoding nucleic acid include,
without limitation, nucleic acid sequences that encode tumor
antigens, costimulatory molecules, adhesion molecules and MHC class
II molecules. The superantigen fusion product is secreted by a
transfected cell, expressed on the cell surface or it may remain
intracellular in nucleic acid or partly processed form.
[0087] SAgs are also isolated and purified from their natural
source as well as from a heterologous expression system such as E.
coli. Likewise, SAg-containing polypeptides (e.g., SAg fusion
products) are isolated and purified from a heterologous expression
system. In addition, Staphylococcus strains producing high levels
of enterotoxin have been identified and are available. For example,
exposing enterotoxin-producing Staphylococcus aureus to mutagenic
agents such as N-methyl-N-nitro-N-nitr- osoguanidine results in a
20 fold increase in enterotoxin production over the amounts
produced by the parent wild-type Staphylococcus aureus strain
(Freedman M A and Howard M B J. Bacteriol., 106:289(1971)).
[0088] 6. Glycosylated SAgs and SAgs Conjugated to
Glycosylceramides. Lipopolysaccharides. Glycans and
Lipoarabinomannans: Presentation on CD1 Receptors for Activation of
T or NKT Cells and Differentiation to Tumor Specific Effector
Cells.
[0089] In a tumor cell or accessory cell, nucleic acid signal
sequences are integrated into nucleic acids encoding the SAg
molecules in order to route them to the Golgi apparatus and
endoplasmic reticulum of tumor cells where they are glycosylated
via appropriate glycosyltransferases (precedents from the selective
transferases used to produce monogalactosylceramide in the
Sphingomonas paucimobilis) to produce a proteoglycan with
structural similarity to LPS, lipoteichoic acid, GalCer, a Gal,
Streptococcus capsular polysaccharide. This construct is then
secreted as an immunogenic "ground substance." Alternatively, the
resulting SAg glycolipid is anchored to the membrane, expressed on
the cell surface and routed specifically to CD1 receptors.
[0090] SAgs which are glycosylated by the above intracellular
processes have improved capacity to bind surface structures such as
mannose receptors, ganglioside receptors and CD1 receptors.
Generally, the nucleic acids encoding a SAg are modified to include
a signal sequence for routing to the Golgi apparatus and a core
sequence which initiates glycosylation. It is important that the
V.quadrature. TCR binding region is not blocked by the added
carbohydrate modifications. For example, an N-linked glycosylation
site (in the sequence Asn X Ser/Thr where X is any residue except
Pro) is engineered into SAg-encoding acid sequences which do not
functionally interfere with TCR binding and activation. The nucleic
acid encoding these signal sequences and core binding glycosylation
sites of SAgs are fused to nucleic acids encoding SAg and the
fusion gene used to transfect tumor cells of a host. In addition,
glycosylated forms of SAgs are expressed in a heterologous
eukaryotic expression system such as yeast cells or
baculovirus-infected insect cells. In gram negative bacteria (such
as E. coli), nucleic acids encoding SAgs are fused to nucleic acids
encoding LPS's, in gram positive bacteria (such as Staphylococcus
or Streptococcus), to nucleic acids encoding capsular
polysaccharides and teichoic acids and in mycobacterial species to
nucleic acids encoding lipoarabinan.
[0091] The gram negative bacterium Sphingomonas paucimobilis
produces the monogalactosylceramide. In this bacterium, nucleic
acids encoding SAgs (containing serine) are fused to nucleic acids
encoding and directing the synthesis of glycosylceramides and
monogalactosylceramide in particular. The resulting
galactosylceramide-SAgs are powerful T cell stimulants. The same
procedure is followed in bacteria which naturally produce LPS's
such as E. coli, Salmonella or Klebsiella or for bacteria which
naturally produce lipoarabinomannans glycans or polysaccharides
containing cell walls such as Mycobacterium and Streptococcus
respectively. The SAg-polysaccharide constructs bind to CD1
receptors of antigen presenting cells. They are then capable of
activating NKT cells either in vivo or ex vivo to become tumor
specific effector cells in response to IL-12. SAgs are also
conjugated genetically or biochemically as in Example 5 to LPS's
via a natural high affinity binding site for LPS binding protein
(LPB). Once bound, the SAg catalyzes the binding of LPS monomers to
CD14 and CD1 receptors in a fashion similar to that of LPB. In this
way, the conjugates are capable of activating T cells for use in
vivo or ex vivo for adoptive immunotherapy while preserving the
anti-apoptotic effect of LPS on SAg activated T cells. Examples of
their preparation and use in vivo and in vitro are given in
Examples 4, 7, 15, 16, 18-23.
[0092] In addition, SAgs similarly conjugated to lipoarabinomannans
and glycans are integrated into lymphomonocytic cell membranes via
glycosylphosphatidylinositol anchors. These SAg-lipoarabinomannan
complexes are expressed or secreted by antigen presenting cells or
tumor cells. They are also bound to CD1, mannose or class II
receptors in which form they are used to activate T or NKT cells.
These constructs are administered in vivo or they are used ex vivo
to produce tumor specific effector cell populations (T cell or NKT
cells) which are employed for adoptive immunotherapy of cancer
(Examples 5, 15-16, 18-23).
[0093] Mannose receptor expression is upregulated by cytokines. For
example, accessory cells including DCs, and tumor cells express
mannose receptors on their surfaces after GM-CSF treatment. SAgs
are bound to mannose receptors by transfecting cells with nucleic
acids encoding SAg which also consist of nucleic acids encoding
signal sequences and glycosylation sites which, in the presence of
appropriate glycosyltransferases, produce mannosylated SAgs. These
preferentially bind to mannose receptors. In addition, glycosylated
SAgs bind to amphipathic cell surface gangliosides and glycolipids
via hydrophobic interactions. These glycosylated SAgs presented in
a form bound to mannose receptors are capable of activating T cells
and NKT cell populations. They are used either in vivo by direct
administration or ex vivo to produce a tumor specific effector cell
population (T cell or NKT cells) for use in adoptive immunotherapy
of cancer (Examples 4, 5, 15, 16, 18-23).
[0094] 7. SAgs Conjugated to Glycosylceramides, Gangliosides and
Verotoxins (VT)
[0095] Amphipathic ganglio sides bound to tumor cell surfaces such
as GD1, GD2, GD3, GM1, GM2, GM3, GQ1 and GT1 are capable of binding
exogenous SAgs. The binding of a SAg to the surface of a tumor cell
creates an immunogen on the tumor cell surface. Tumor cells
transfected with nucleic acids encoding glycosyltransferases
overexpress gangliosides, producing a greater surface density of
ganglioside moieties available to bind exogenous SAgs. Enterotoxins
bind to cell surface amphipathic gangliosides and/or glycophorins
via their hydrophobic residues while preserving their T cell
binding properties. SAgs are also glycosylated intracellularly by
addition of a glycosylation site or by chemical conjugation of a
carbohydrate moiety using methods well described in the art. In
glycosylated or native form, the SAgs bind to surface ganglioside
while retaining their T cell activating properties. Overexpression
of the hydrophobic regions of the molecule promotes binding to the
surface gangliosides (Example 5). Examples from nature of exogenous
proteins that bind to cell surface gangliosides include falciparum
malarial merozoite which combines with gangliosides associated with
the Duffy blood group and induce long standing and durable
protection and tetanus toxin which binds to surface gangliosides
with highest affinity for the disialyl groups linked to inner
galactosyl residues.
[0096] Enterotoxin B contains a T cell activating sequence which is
chemically cross-linked or polymerized using bifunctional agents
such as carbodiimide, glutaraldehyde or formaldehyde by established
methods well known in the art. These polymers are then bound to
gangliosides expressed on tumor cells such as GD1, GD2, GQ1, GD3 or
GM1, GM2, GM3, GT1. In monomeric or polymerized form, SAgs also
bind to monogalactosylceramides which are free or bound to CD1
receptors on tumor cells or antigen presenting cells via
hydrophobic interactions. The monogalactosylceramide binds to
hydrophobic sequences on the SAg which are expressed at multiple
sites on the molecule. In one embodiment, the lauroyl group
[CH.sub.3(CH).sub.10CO] or the group [CH.sub.3(CH).sub.13CO] is
covalently added to each of the peptide's amino terminus to serve
as a of the CD1 receptor. The key SAg peptide sequence such as of
SEB (amino acids 225-234) which confers T cell activating
properties is tandemly repeated to various lengths prior to lipid
conjugation.
[0097] Hydrophobic SAg peptides(such as Trp, Tyr, Phe, Leu, and
Ile) are screened for binding to glycosylceramides immobilized on
CD1 receptors or via adsorption chromatography with immobilized
glycosylceramide. The SAg sequences with the greatest affinity for
the CD1 receptor are selected for conjugation to the
glycosylceramides and LPS's. Alternatively, the SAg sequence is
screened for affinity for the CD1 or MHC class II receptor using a
peptide phage display library as described in Examples 4. Likewise,
pre-formed SAg-glycosylceramide or LPS complexes are also screened
for affinity for the CD1 or MHC class II receptor (Example 4).
These lipopeptide complexes are then screened for T cell
proliferative activity and IL-12 production. The monomeric or
polymerized SAg in native or glycosylated form binds to the
monoglycosylceramides or gangliosides expressed on CD1 receptors on
the tumor cell surface.
[0098] Therapeutic Construct: SAg-Glycosylceramide Conjugates
[0099] SAgs have an affinity for glycosphingolipids especially
those with terminal or subterminal Gal(.alpha.1-4)Gal residues.
Such residues are expressed on tumor cells as
Gal(.alpha.1-4)Gal(.quadrature.1-4)GlcCeramid- e
(globotriaosylceramide or Gb3) and Gal(.alpha.1-4)GalCeramide
(galabiosylceramide or Gb2). Gb3 and Gb2 also known as CD77,
Burkitt's lymphoma antigen, and the human blood group p.sup.k
antigen are the natural receptors for Shiga toxins and VT's . Shiga
toxin, a 69-kDa complex of proteins comprised of five
.quadrature.-subunits (7 kDa each) and one a-subunit (30 kDa) has
high affinity for the terminal digalactose of Gb3 or Gb2. Methods
for their preparation and isolation are described in Example 41.
Once bound to the tumor cell, these toxins are internalized and
induce apoptosis.
[0100] The synthetic pathway for neutral glycosphingolipids in
eukaryotic cells is known. Glucosylceramide (GlcCer) is the
precursor of lactosylceramide (LacCer), which leads, in order, to
Gb3 and globotetraosylceramide (Gb4). Different Golgi enzymes are
responsible for addition of monosaccharides from nucleotide-sugar
donors in each step of the pathway. Globotriaosylceramide synthase
(UDP-galactose:lactosylcerami- de .alpha.1-4-galactosyltransferase)
has been purified. In the cytoplasm, the .alpha.-subunit of the
Shiga toxin or VT is processed by a trypsin-like cleavage. The
"activated" 27-kDa .alpha.-subunit inactivates 60S ribosomes by
depurination of a single nucleotide in 28S rRNA, rendering
ribosomes incapable of carrying out peptide elongation.
[0101] The present invention provides therapeutically active
soluble complexes comprising SAg and glycosphingolipids which have
terminal or subterminal Gal(.alpha.1-4)Gal residues and Shiga toxin
receptors Gb3 and Gb2, (collectively referred to as "GTSG1-4").
These complexes include but are not limited to SAg-GPI-GTSG1-4
complexes, and synthetic and functional derivatives thereof. Such
structures appear naturally on surfaces of certain tumor cells such
as astrocytoma, Burkitt's lymphoma and ovarian carcinoma. Methods
of preparing and isolating glycosylceramides and VTs are given in
Example 41.
[0102] SAgs also have a demonstrable affinity for
galactosylceramides containing Gal(.alpha.1-4)Gal residues. Methods
of assessing SAg binding to GTSG1-4 are provided given in Example
43. These conjugates are also shed from SAg-transfected tumor cells
as binary complexes of SAg-GTSG1-4 or ternary complexes of
SAg-GPI-GTSG1-4, in free form, as vesicles or as exosomes(see
Sections 38 and Example 38). Methods of isolating and
characterizing these shed complexes appear in Section 38 and
Example 42. The complexes may also be prepared by chemical or
genetic methods (Example 5). SAg-GTSG1-4 or SAg-GPI-GTSG1-4
complexes or exosomes are useful as a preventative vaccine or
against established tumor. They are also useful in vivo by direct
administration or ex vivo where they are loaded onto antigen
presenting cells comprising CD1 or MHC receptors to activate NKT
and T cells to produce tumor specific effector T or NKT cells for
adoptive therapy of cancer (Examples 5, 7, 14, 15, 16, 18-23,
38).
[0103] Therapeutic Construct: Tumor Cells Expressing SAgs and
Galactosylsylceramides
[0104] Additional immunogenic complexes comprising SAgs bound to
tumor cells, DCs DC/tc constructs expressing surface Gb2 and Gb3 or
other glycosphingolipids containing terminal Gal(.alpha.1-4)Gal are
prepared by transfecting these cells with nucleic acids encoding a
SAg. The transfected cell expresses the SAg in the context of the
glycosphingolipid comprising the terminal or subterminal
Gal(.alpha.1-4)Gal moiety. Alternatively, free or GPI linked
glycolipids containing SAg peptides or polypeptides bind to tumor
cells or accessory cells in tissue culture (Section 38). The
expression of Gb3 and Gb2 on tumor cells is optionally upregulated
by various cytokines, including IFN.alpha. and TNF .alpha., before
contacting the SAg
[0105] Tumor cells, accessory cells or fused tumor/accessory cells
transfected with SAg which are not naturally endowed with the
GalCer (optionally coupled to SAg) acquire these molecules in free
or GPI-linked form from surrounding media or by transfer from
liposomes or vesicles (exosomes) which express them (Section 38 and
Example 5). The resulting cells, coexpress SAgs and
glycosylceramides or other glycosylceramides capable of stimulating
an effective T or NKT cell immune response. Multidrug resistant
(MDR) tumor cells or cell lines which naturally accumulate and
express intracellular glycosylceramides are useful in this
invention. MDR agonists such as SDA PSC 833, a cyclosporin
analogue, and fumonisin B1, a ceramide synthase inhibitor, are
employed to induce ceramide accumulation in MDR cells (Example 45).
Tumor cells or accessory cells which overexpress key
glycosylceramides due to transfection with .alpha..quadrature.-2,
.alpha.1-4, .alpha.1-6 glycosyltransferases (Example 38) or a
natural or induced deficiency of .alpha.-galactosidase are also
useful. In addition, tumor cells with high concentrations of GalCer
expressed on their surface or that of accessory cells are generated
by incubation with ceramides containing a 2-hydroxy fatty acid
C.sub.6OH. Tumor cells selectively convert them to GalCer,
galabiosylceramide and sulfatide in the trans-Golgi network where
they are sorted and transported selectively to the cell surface.
Methods for this selective biosynthesis of GalCer with hydroxy
fatty acids are in Example 46.
[0106] These fused SAg-tumor cell/accessory cell constructs are
used to activate a T or NKT cell population. They are used in vivo
by direct administration or ex vivo to produce a population of
tumor specific effector cells (T cells or NKT cells ) for adoptive
therapy of cancer (Examples 5, 7, 14, 15, 16, 18-23, 38).
[0107] SAg-VT Conjugates to Induce Tumor Cell Apoptosis
[0108] The present invention contemplates the induction of
apoptosis in tumor cells expressing Gb2 and Gb3 (or other
glycosphingolipids containing terminal Gal(.alpha.1-4)Gal) by using
free SAgs, conjugates and fused DNA that comprises SAg, SAg peptide
or SAg-encoding DNA fused to intact VT or to VT A or B chains.
Preparation of these conjugates and fusion proteins from their
corresponding DNA, polypeptides or functional derivatives is
provided in Examples 1 and 5. These conjugates induce apoptosis by
binding to tumor cell glycosphingolipid receptors having terminal
Gal(.alpha.1-4)Gal. Methods of assessing tumor cell apoptosis are
in Example 44. CD19 or IFN.alpha. peptide sequences and generic
carbohydrate recognition domains which bind Gal(.alpha.1-4)Gal
structures are also useful. CD19, a B-cell restricted
differentiation antigen, naturally binds to Gb3 and Gb2 on the cell
surface which incudes apoptosis. CD19 has VT-like sequences in the
N-terminal extracellular domain (NBRF protein data bank) that have
41%, 34% and 37% sequence identity to VT1, VT2, and VT2e B
subunits, respectively. When compared to a consensus VT B sequence,
the CD19 sequences show 49% identity. Binding of these peptide
sequences to membrane Gal(.alpha.1-4)Gal-containing glycolipids
facilitates receptor mediated induction of apoptosis.
[0109] The IFN.alpha. receptor has a 63-kDa extracellular peptide
with regions of amino acid identity to domains in the VT B subunit
implicated as Gb2/Gb3 binding sites. The preferred targets of the
above conjugates on tumor cells are the naturally expressed Shiga
toxin receptors Gb3 and Gb2 with a terminal Gal(.alpha.1-4)Gal.
Astrocytomas and Burkitt's lymphomas are the preferred tumors as
they naturally express glycosphingolipid receptors. However, any
tumor expressing the appropriate receptor is appropriate. Tumor
cells which express either engineered or natural functional
derivatives, or mutants of these glycosphingolipid receptors, are
also useful. Receptor expression on the target cells is optionally
upregulated by cytokines such as IFN.gamma. and TNF.alpha.. Tumor
cell sensitivity to the cytotoxic effects of a VT is enhanced by
administration of interleukin-1.quadrature. before the addition of
the conjugates. Tumor cells which do not naturally display Gb3 or
Gb2 acquire these structures by transfer from free, soluble
structures or liposomes which express the missing glycosphingo
lipid receptor (Section 38, Example 5). The reconstituted tumor
cells bearing the appropriate glycolipid receptors are thus
targeted for apoptosis by the above constructs and conjugates.
[0110] SAg Nucleic Acid-Verotoxin Conjugate
[0111] A preferred construct is the SAg-VT conjugate wherein the
SAg is preferably in nucleic acid form (prepared according to
Example 3). The VT portion of the complex binds to the tumor cell
and initiates apoptosis. The VT also acts as a "vector" for
transfer of the SAg nucleic acid into the cell. SAg-VT conjugates
bind to the terminal Gal(.alpha.1-4)Gal receptors on tumor cell
surfaces and are internalized via endocytosis. The SAg nucleic acid
is internalized together with the VT. The VT A chain is an RNA
N-glycosidase acting on the 60S ribosomal subunit. It induces
apoptosis in the tumor cell by removing an adenine base on amino
acyl-transfer RNA so that peptide chain elongation is blocked. The
resulting apoptotic tumor cells contain the internalized SAg
nucleic acid and are then ingested by dendritic cells. The DCs are
cross primed to induce an effective anti-tumor response by
presenting the tumor associated antigens in the class I pathway to
T cells while the SAg nucleic acid expresses SAg polypeptide. These
activated DCs or DC/tc hybrids can be prepared by the methods of
Examples 28-29. They are used to activate a T or NKT cell
population in vivo as a preventative vaccine or by direct
administration against established tumor. They are also used ex
vivo to produce a population of tumor specific effector cells (T
cells or NKT cells ) for adoptive therapy of cancer (Examples 5, 7,
14, 15, 16, 18-23, 28-29).
[0112] Glycosylation or lipid binding of the enterotoxin does not
interfere with T cell binding and activating properties. The SAg is
glycosylated by chemical or recombinant techniques described in the
Examples 4. The SAg glycoprotein is the further conjugated to
gangliosides in the ganglioside synthetic pathway via the presence
of key signal peptides on the glyco-SAg (Example 4). The SAg is
also rerouted to the LAMP pathway, glycosylated in the Golgi
apparatus and the endoplasmic reticulum and then translocated to
the membrane class II receptor as a glycosylated ganglioside.
Gangliosides are glycosylated to form glycosylceramides by
recombinant techniques as described in the Example 4. They are also
glycosylated by glycosyltransferases to form homologues which bind
to hydrophobic regions of the SAg peptide. The final products
namely SAg-glycosylceramides or SAg-LPS's then bind to CD1
receptors and are used to activate T cells or NKT cells. These
construct are administered directly vivo or they are useful ex vivo
to produce a population of tumor specific effector T cells or NKT
cells for adoptive immunotherapy of cancer by protocols given in
Examples 7, 15, 16, 18-23).
[0113] The present invention contemplates the fusion or
coexpression within the same cell of SAg polypeptides with anomeric
mono and digalactosylceramides which are expressed within a tumor
cell or on the tumor cell surface. These construct could also be
effectively expressed on the surface of accessory cells defmed in
Oxford Dictionary of Biochemistry and Molecular Biology 1997
edition as any one of various types of cell which assist in the
immune response cell and includes but is not limited to DCs,
fibroblasts, synoviocytes, astrocytes antigen presenting cells,
neutrophils, macrophages, basophils, eosinophils, mast cells,
keratinocytes and platelets, as well as fusion cells comprising
accessory cells and tumor cells.
[0114] The anomeric mono and digalactosylceramides have been shown
to activate NKT cells and to produce an anti-tumor response in the
context of IL-12. The galactosyl ceramides have several structural
requirements in order to produce anti-tumor effects. 12. Mono and
digalactosylceramides require an anomeric galactose or glucose as
the terminal sugar or inner sugar as for example anomeric
1,6-digalactosylceramide, -anomeric 1,2-digalactosylceramide,
anomeric 1,4-digalactosylceramide, a diglycosylceramide wherein the
inner sugar is an anomeric galactose or an anomeric glucose and
anomeric galactosyl or anomeric glucosyl ceramide. In addition, the
3- and 4-hydoxyl groups on the phytosphingosine portion of the
ceramides are preferably unsubstituted, the sphingosine base length
is preferably from about 10 to about 13 carbon units and the fatty
acyl chain length is preferably in the range of about 12 to about
24 for optimal anti-tumor effectiveness of the molecule.
[0115] The expression of anomeric mono- and digalactosylceramides
in a cell is achieved by several methods. The first involves the
transfection and amplification of nucleic acid encoding the enzymes
which synthesize the anomeric 1,4-, the anomeric 1,6- or the
anomeric 1,2.- mono- and digalactosylceramides such that these
glycolipids are overproduced. The genes for these transferase
enzymes have been cloned. Transfection of nucleic acid encoding
these terminal transferases into the above cells is carried out in
vivo by the methods described in Example 1.
[0116] A second method for creating cells that overexpress the
foregoing glycolipids uses monensin or brefeldin which block
additional glycosylation and sialylation of the
-galactosylceramides, so that the mono- and digalactosylceramides
accumulate in the cell.
[0117] A third approach employs cells from patients with Fabry's
disease. These cells are genetically deficient in the
-galactosidase so they naturally accumulate
-galactosylceramides.
[0118] In a forth technique, an -galactosidase deficiency is
induced in the target cell so that -galactosylceramides
accumulate.
[0119] In a fifth approach, the -galactosyltransferase is
transfected Fabry's disease cells, thereby adding to the usual
accumulation due to the catabolic enzyme deficiency. Such cells
should have massive accumulations of -galactosylceramides.
[0120] In a sixth approach, the desired mono- or diglycosylceramide
expressed on liposome surfaces are transferred to tumor cells
lacking these structures by co-culture and employment of fusion
techniques given in example 5.
[0121] Nucleic acids encoding SAgs are transfected into the above
cells which are overexpressing, overproducing or otherwise
accumulating mono and digalactosylceramides. The Golgi apparatus
(or Golgi complex) is a major site of synthesis of the foregoing
glycolipids. In the present context, the SAg combines with it the
mono and digalactosylceramides. From the Golgi the
SAg-galactosylceramide conjugates or complexes, with the
appropriate sorting signals, are dispatched in transport vesicles
to other destinations. For a SAg peptide to combine effectively
with an -galactosylceramide, the peptide must first have the
appropriate sorting signal which directs it to the Golgi and from
there, after complexing with the glycolipid, to the cell surface.
The trafficking pathway of SAg polypeptide from the ER to the Golgi
does not require special signals. SAg polypeptides that enter the
ER (and fold and assembles properly) will automatically be
transported through the Golgi apparatus to the cell surface unless
they carry signals that either detain them in an earlier
compartment en route or divert them (via the Golgi apparatus) to
lysosomes or secretory vesicles. The SAg-glucosylceramide
conjugates are routed from the Golgi to the cell surface after
acquiring a structure like a cytoplasmic tail such as
phosphoinositol which assures that these molecules will be bound in
the cell membrane. The conjugates may also be routed to CD1 or MHC
class I receptors, or via, the class II pathway, to MHC class II
receptors by associating with invariant chain or LAMP-1 signals as
described in Section 8.
[0122] The mono- and digalactosylceramides are capable of
stimulating NKT cells (via an invariant chain) in the presence of
IL-12 to produce an anti-tumor response. SAgs are capable of
stimulating a T cell-dependent anti-tumor response. The present
invention utilizes tumor cells, accessory cells or hybrid cells
such as DC/tc, engineered to express SAg--galactosylceramide for
anti-tumor therapy. These cells may be administered as a
preventative or therapeutic vaccine (Example 29). Alternatively,
they may be useful ex vivo to activate an NKT or T cell population
for use in adoptive immunotherapy of cancer (Example 29).
[0123] 8. SAg Targeting to Lysosomes
[0124] LAMP-1 is a transmembrane protein localized predominantly to
lysosomes and late endosomes. The cytoplasmic domain of LAMP-1
contains the amino acid sequence (SEQ ID NO:29) Tyr-Gln-Thr-Ile
whose structure conforms to the Tyr-Xaa-Xaa hydrophobic amino acid
motif that mediates cell membrane internalization and possibly
lysosomal targeting of several surface receptors. The intracellular
targeting of LAMP-1 is controlled by the Tyr-Gln-Thr-Ile motif
located at the C terminus of its cytoplasmic tail.
[0125] In the present invention, nucleic acid encoding a SAg is
fused with nucleic acids encoding the transmembrane and cytoplasmic
tail of LAMP-1. Nucleic acids encoding the signal peptide (N
terminal) of LAMP-1 are integrated into this chimeric construct.
These chimeric SAg/LAMP-1 polypeptides are targeted to endosomal
and lysosomal compartments, thereby rerouting transfected SAg
polypeptides into the MHC class II processing pathway. Thus, cells
such as tumor cells transfected with nucleic acid encoding this
modified SAg preferentially target the SAg to lysosomal
compartments and are presented to T cells in the context of MHC
class II. MHC class II negative tumor cells are also transfected
with nucleic acid encoding MHC class II molecules. The association
of SAgs with MHC class II molecules, their natural ligands on APCs,
produce optimal T cell activation to the tumor. Antigen presenting
cells transfected with these constructs are capable of inducing
potent activation of T cells. Tumor cells, in particular,
transfected with this construct are administered directly in vivo
or used ex vivo to sensitize a T cell population which is useful in
adoptive immunotherapy of cancer by protocols described in Example
16, 18-23).
[0126] 10. SAg Receptors
[0127] It is clear that certain tissues express receptors for
enterotoxins that are not MHC class II and that binding is reserved
for selected enterotoxins and not others. Non MHC cell II binding
has been reported for colon carcinoma, mast cells epithelial cells
and B cells. In a tumor bearing patient, it is desirable for
administered SAgs to target tumor cells in vivo. which naturally
express enterotoxin binding sites or receptors. Natural ligands for
these receptors are native enterotoxins. However, because of the
existence of naturally occurring enterotoxin specific antibodies in
the circulation, native enterotoxins are incapable of binding
target tumor cell or T cells. The isolated receptor is used to
screen and identify SAg proteins and/or nucleic acids which bind to
the native or chimeric receptor. SAg constructs are produced which
target the tumor via its SAg receptor while also retaining T cell
activating properties. In addition, T cells or NKT cells from tumor
bearing patients are anergized in the course of tumor growth and
are incapable of being used as a source of T cells for ex vivo
stimulation and adoptive immunotherapy. After transfecting these
cells with nucleic acids encoding enterotoxin receptors, they are
capable of responding to exogenous enterotoxins and are once again
a source of T cells useful in adoptive immunotherapy of cancer by
protocols given in Examples 8, 9, 12, 16, 18-23.
[0128] Methods for receptor isolation purification and retrieval of
cDNA are given in Example 12. The nucleic acids encoding SAg
receptors are transfected into cells by methods given in Example 1
Tumor cells have a natural binding site for exogenously
administered SAg polypeptides. In addition, nucleic acid encoding
the SAg receptors are transfected into T cells, NKT cells, or
.gamma./.delta. T cells of cancer patients which have been
anergized in the course of tumor growth. The expression of the SAg
receptor permits these cells to proliferate and produce TH1
cytokines in response to exogenous native SAg, Hence, these
autologous T cell populations are useful in adoptive immunotherapy.
Likewise, accessory cells are transfected with SAg receptor genes
and used ex vivo to present SAg to T cells. Further, the nucleic
acid encoding the SAg receptor is transfected into T cells and
fused, in frame, to the nucleic acid encoding the TCR-associated
.zeta. chain or the IL-2 .gamma. to produce a chimeric receptor
capable of generating a signal for cell proliferation and the
release of TH1 cytokines after binding its natural ligand exogenous
SAg.
[0129] In one embodiment, the enterotoxin receptor is immobilized
as in Example 12 and used to screen oligonucleotide libraries for
binding (Gold L, J. Biol. Chem. 270:13581-13584 (1995)). Avidly
binding oligonucleotides are used to mimic the native enterotoxin
by targeting the receptor in vivo. They are coupled to the TCR
binding site of an enterotoxin peptide. In this way, the hybrid
molecule is administered to the patient in a form protected from
circulating enterotoxin-specific antibodies. Additionally, a
nucleic acid molecule is prepared which mimics the enterotoxin in
its ability to bind to the enterotoxin receptor on tumor cells and
to the TCR on T cells. This nucleic acid mimicking the native
enterotoxin is administered to the tumor bearing patients and is
capable of targeting the enterotoxin receptor sites on tumor cell
and the TCR without being eliminated by circulating enterotoxin
specific antibodies as in Example 13, 18, 20-23.
[0130] 11. Tumor Cells that Express SAgs and the .alpha.Gal
Epitope
[0131] Tumor cells are for the large part weakly antigenic and
poorly recognized by the immune system. various attempts to
increase the immunogenicity of tumor cells by transfection of
various cytokines or histocompatibility antigens have for the most
part been unsuccessful. Hyperacute rejection of xenografted organs
is a very rapid and dramatic immune event often occurring within
minutes of vascularization of the xenografted organs. Very
recently, a major antigenic system on xenografts which is the
target of this reaction has been identified as
.alpha.Gal.quadrature.1-3Gal.quadrature.1-4GlcNAc or .alpha.Gal.
This epitope is expressed in the tissues of pigs, guinea pigs,
rodents, dogs, and cows but has not been detected in human tissue.
The present invention improves the antigenicity of tumor cells and
their recognition by the immune system by providing the Gal epitope
on the cell surface either alone or together with SAg
expression.
[0132] The .alpha.Gal epitope is expressed by endothelial cells in
xenografts such as pig organs is a major antigenic target causing
hyperacute organ rejection in human transplant patients. This
hyperacute rejection appears to involve a complement dependent
mechanism that occurs within a few minutes. An
.alpha.1-3-galactosyltransferase, is an enzyme capable of producing
.alpha.1-3-galactose-.quadrature.1-4-N-acetylglucosa- mine moiety
by adding a terminal galactose residue to a subterminal galactose
residue via an .alpha.1-3 linkage. In addition, the
.alpha.1-3-galactosyltransferase is not expressed by human and
certain primate cells. Humans contain xenoreactive natural
antibodies that recognize Gal. For example, anti-Gal antibodies
bind to pig endothelial cells that express the Gal epitope. These
anti-Gal antibodies are naturally occurring IgM antibodies recently
found to be present in large amounts in human serum. Surface
expression of the .alpha.Gal epitope on tumor cells is achieved by
transfecting a cell with a cDNA clone encoding the
.alpha.1-3-galactosyltransferase. While tumor cells are the
preferred cells for transfection, other cells such as accessory
cells or immunocytes are also contemplated as being within the
scope of this invention.
[0133] Nucleic acids encoding .alpha.1-3-galactosyltransferase
polypeptides are known (Sandrin, M S et al., Proc. Natl. Acd. Sci.
U.S.A 90: 11391-11395 (1993)). A cDNA clone encoding murine
1-3-galactosyltransferase is prepared using the known sequence of
this protein and the polymerase chain reaction (PCR) technique
(Dabrowski, P L et al., Transplant. Proc. 26: 1335-1337 (1994).
Briefly, two oligonucleotide primers are synthesized: (SEQ ID
NO:30) 5'-GAATTCAAGCTTATGATCACTATGCTTCAAG-3', which is a sense
primer that encodes the first 6 amino acids of the mature
1-3-galactosyltransferase and contains an HindIII restriction site;
and (SEQ ID NO:31) 5'-GAATTCCTGCAGTCAGACATTATTCTAAC-3', which is an
anti-sense primer that encodes the last 5 amino acids of the
premature 1-3-galactosyltransferase and contains an in-frame
termination codon and PstI restriction site. These primers amplify
a 1185 bp fragment from a C57BL/6 spleen cell cDNA library that is
subsequently purified, digested with HindIII and PstI (Pharmacia
LKB) restriction endonucleases, and directionally cloned into
HindIII/Pst I-digested expression vector such as CDM8 vector. After
verifying the correct sequence, the
1-3-galactosyltransferase-containing expression vector is
transfected into heterologous cells such as COS cells to confirm
activity. Activity can be confirmed by testing transfected cells
for Gal expression using the IB4 lectin (Sigma) of Griffonia
simplicifolia that binds to Gal residues.
[0134] In the preferred mode, cells transfected with nucleic acids
encoding a SAg are co-transfected with nucleic acids that encode an
-galactosyltransferase. Alternatively, nucleic acids encoding the
transferase are transfected into a separate cell population which
is coadministered with the SAg transfected cell population.
[0135] The SAg-encoding nucleic acid can be transfected into cells
which already express Gal epitope. In addition, any cell can be
transfected with the -galactosyltransferase-encoding nucleic acid.
For example, Gal-negative human tumor cells or tumor cell lines
such as melanoma or adenocarcinoma are transfected with nucleic
acid encoding the -galactosyltransferase. Tumor cells transfected
with -galactosyltransferase-encoding nucleic acid express the Gal
on their surface and are rapidly rejected when administered to a
host with preexisting Gal specific antibodies. Methods of
transfection are given in Example 1. Human tumor cells expressing
the Gal epitope after transfection, become strongly reactive with
human serum containing preexisting antibodies to the Gal
epitope.
[0136] Thus, an Gal-expressing tumor cell is rejected after
implantation. The ability of Gal-transfected tumor cells to induce
rejection is demonstrated by implantation into severely compromised
immune deficient (SCID) mice that have been reconstituted with
human T and B cells and transfused with normal human plasma
containing the naturally occurring human antibodies specific for
the Gal epitope. In this case, tumor cells transfected with
-galactosyltransferase-encoding nucleic acid is rejected while
untransfected cells are not. Similarly, tumor cells transfected
with -galactosyltransferase-encoding nucleic acid is rejected when
implanted into species such as humans which synthesize antibodies
to the Gal epitope compared to untransfected control tumor cells
that are unaffected by the treatment.
[0137] For example, pretreatment with
10.sup.5-10.sup.7-galactosyltransfer- ase transfected tumor cells
subcutaneously followed by implantation of untransfected tumor
cells prevents the outgrowth of untransfected malignant tumor
cells. Hence, the -galactosyltransferase transfected tumor cells
function as a vaccine. Further, -galactosyltransferase transfected
cells implanted into animals after untransfected tumors are
established induce rejection of an established untransfected
tumor.
[0138] To test for the presence of Gal on a cell surface, 1-3
galactosyltransferase knockout mice that do not express the Gal
antigen are used. The 1-3 galactosyltransferase knockout mice are
described elsewhere (Tearle et al., Transplantation 61:13-19 (1996)
and Shinkel et al., Transplantation 64:197-204 (1997)). A syngeneic
tumor cell that is Gal negative such as B16 melanoma variants is
transfected with nucleic acids that encode a given carbohydrate
modifying enzyme. These transfected cells are then implanted into
the knockout mouse that received plasma containing Gal specific
antibodies. Tumors do not grow in animals containing Gal specific
antibodies if the Gal epitope is expressed. Thus, hosts implanted
with Gal positive tumor cells exhibit less growth than those
exhibited in hosts implanted with tumor cells that are Gal
negative.
[0139] Gal negative transgenic animals are prepared which are
useful for testing Gal expressing tumors. To produce these animals,
nucleic acids encoding Gal fucosyltransferase are transfected into
Gal positive mice. The fucosyltransferase dominates the usage of
substrate N-acetyllactosamine and precludes -galactosyltransferase
from utilizing this substrate. The transgenic mice do not express
-Gal on the cell surface. In this way, transgenic mice with the H
antigen rather than the Gal antigen develop. Transgenic guinea pigs
producing minimal Gal are also created in this way. These animals
are used as models for testing their capacity to reject syngeneic
Gal positive tumors. These systems also permit the testing of Gal
specific antibodies for anti-tumor effects after they are passively
infused into animals bearing Gal positive tumors.
[0140] Neuroblastoma and some melanoma cells overexpress several
disialogangliosides, for example, GD2 and GD3. In the present
invention, nucleic acid-encoding specific sialidases or
glucosidases or neuraminidases that cleave terminal sialic acid or
carbohydrate residues are transfected into cells that then express
or overexpress a ganglioside with an exposed Gal epitope.
[0141] Fucosylated glycolipids such as B group antigens, Lewis
blood group antigens, and L-selectin ligands are converted to the
a.sub.iGal epitope using the appropriate sialidases and
glycosyltransferase enzymes. For example, a desialylating enzyme is
introduced into B group antigen expressing cells such that the
-1,3-linked galactose is exposed and now recognized by Gal
antibodies. Mild acid treatment to remove the branching fucose
residues on the fucosylated B antigen is used to expose the ,3
galactose residues. Alternatively, cells expressing the B antigen
or selectin antigen are transfected with
a,-galactosyltransferase-encoding nucleic acid that competes
successfully with fucosyltransferases for N-acetyl-lactosamine
substrate and preferentially expresses the aGal epitope
[0142] Nucleic acid encoding other polypeptides are also used to
produce the surface expression of the Gal epitope such as nucleic
acid encoding glycosidases that specifically cleave carbohydrate
residues to expose the Gal epitope. Tumor cells transfected with
nucleic acids encoding N-acetyl-glucosaminyl transferase show an
increased tendency to metastasize and colonize new organs. These
same tumor cells are cotransfected with nucleic acids encoding
SAgs, Staphylococcal hyaluronidase and erythrogenic toxins as well
as Streptococcal capsular polysaccharide which enables them to
secrete enzymes and toxins locally inducing a potent inflammatory
and immune response at metastatic sites. Co-transfection of tumor
cells with nucleic acid encoding SAg and nucleic acid encoding a
galactosyltransferase, sialidase, and/or glycosyltransferase
results in expression of SAg, GalCer, Gal, or other glycolipids on
the cell surface. These tumor cells are used to stimulate T or NKT
cells ex vivo to produce a population of tumor specific effector
cells which are deployed for adoptive immunotherapy of cancer.
[0143] Mutation of the glycosyltransferase nucleic acid in tumor
cells produces a specific LPS containing the Gal/Cer or the Gal
which coordinated with genes for protein glycosylation produce the
desired integrated SAg LPS.
[0144] 13. Tumor Cells Expressing SAgs, Glycosylceramides and LPS's
and their Receptors
[0145] It appears that anti-tumor responses are produced by a
subpopulation of T cells known as NKT cells. These cells recognize
glycosylceramides with certain specifications which are presented
in the context of CD1 receptors on antigen presenting cells. They
produce IL-12 mediated anti-tumor responses. Peptides of certain
length with hydrophobic sequences have been shown to react with
various hydrophobic regions of the CD1 receptor and produce an
immune response. However, these peptides have not been implicated
in an anti-tumor response. In the present invention, lipoproteins
are contemplated which consist of SAg or their major bioreactive
domains fused to glycosylceramides in the context of the CD1
receptor.
[0146] To make this construct, CD1 positive cells are transfected
with nucleic acids encoding glycosyltransferases that result in
GalCer or GlcCer expression on the cell surface and preferably in
the context of the CD1 receptor. The appropriate
glycosyltransferase nucleic acid is obtained from Sphingomonas
paucimobilis or Agelas mauritianus which are known to express the
GalCer on their cell surface. The GalCer and GlcCer moieties are
recognized by NKT cell Va invariant chains in the context of CD1
receptors on antigen presenting cells. CD1 positive cells are
cotransfected with nucleic acids encoding SAgs The resulting CD1
positive cells coexpress both GalCer and SAg on the cell surface or
in the context of CD1. The GalCer and SAg presented simultaneously
as a complex and/or separate from each other on the cell surface,
in the context of CD1 produces potent activation of NKT cells due
to recognition of SAg by NKT cell V.quadrature. chain and GalCer by
the V.alpha. invariant chain. Such GalCer-SAg complexes are loaded
onto the CD1 receptor and presented to NKT cells in this fashion. A
SAg peptide capable of binding to the TCR and activating the T cell
is useful for coupling to the Gal-Cer before or after it is
positioned on the CD1 receptor. (See Examples 1-4, 5). CD1 positive
antigen presenting cells or tumor cells bearing the SAg
glycosylceramide are used to stimulate a population of NKT cells ex
vivo which is then useful in adoptive immunotherapy of cancer by
protocols given in Examples 7, 15, 16, 18-23). They are also useful
when administered directly in vivo to tumor bearing patients to
produce an anti-tumor response. (See Examples 18-23).
[0147] In the present invention, nucleic acids encoding the CD1
receptor are transfected into tumor cells in vivo or ex vivo.
Martin L H. et al. Proc. Natl. Acad. Sci. U.S.A 83: 9154-9158
(1986). Nucleic acids encoding the CD1 receptor are also
cotransfected into tumor cells with nucleic acids encoding the SAg
receptor. A tumor cell expressing a chimeric receptor comprising
sequences of CD1 and SAg receptors is also produced by transfection
of fusion nucleic acids encoding both receptors. The transfected
tumor cell expresses either dual or chimeric receptors which bind
SAg and GalCer independently or as fusion protein or conjugate.
Likewise, tumor cells are transfected with nucleic acids encoding
CD14, the LPS receptor, (Ferrero, E. et al., J. Immunol. 145:
331-336 (1990)) a leucine rich receptor glycoprotein found on
myeloid cells with a LPS binding site between amino acids 57-64.
Nucleic acids encoding CD14 are transfected into tumor cells
together with nucleic acids encoding SAgs and resulting tumor cell
expresses several receptors or a single chimeric receptor with
preserved consensus binding sequences common to each. These tumor
cell transfectants are capable of binding exogenous SAg and/or LPS
and or GalCer. The resulting tumor cells with bound SAg, and/or
Gal/Cer and/or LPS activate a population of T cells and/or NKT cell
to produce tumor specific effector cell which are useful in the
adoptive immunotherapy of cancer by methods in Example 1-7, 12, 15,
16, 18-23. The tumor cell transfectants are also administered as a
vaccine or to hosts with established tumors as in Example
19-23.
[0148] Alternative splicing and utilization of cryptic splice sites
generates alternative reading frames and secretory isoforms of CD1,
CD14 and SAg receptors. Woolfson A. et al., Proc. Natl. Acad. Sci.
U.S.A 91: 6683-6687 (1994). These soluble receptors are immobilized
on solid surfaces such as polystyrene plates or beads and bind
their respective ligands e.g. GalCer and SAg. In this form the
GalCer and SAgs activate T cell or NKT cell to produce a population
of tumor specific effector T cell or NKT cells useful in adoptive
immunotherapy of cancer by methods given in Examples 7, 15, 16,
18-23).
[0149] 14. SAg-Activated Tumor Specific T Cells, NKT Cells or
.gamma./.delta. T Cells Expressing CD44 for Adoptive
Immunotherapy
[0150] It is imperative that T cells, NKT which are stimulated in
vivo or ex vivo by the SAg constructs given herein are capable of
trafficking and homing effectively to tumor sites. CD44 expression
on T cells after SAg stimulation, is an indicator of upregulated
adhesive capacity which is requisite for the homing of SAgs to
tumor sites. T cells or NKT cells or cells transfected with nucleic
acids encoding SAg receptors i.e. tumor cells or accessory cells
are stimulated by SAgs in vivo or ex vivo to express CD44. These
CD44 expressing T cells are enriched and expanded and then
harvested for use in adoptive therapy of cancer by protocols given
in Examples 7, 15, 16, 18-23).
[0151] Transfection of cDNAs encoding soluble isoforms of CD44 into
tumor cells results in the local release of soluble CD44 which
inhibits the ability of endogenous cell surface CD44 to bind and
internalize hyaluronate and to mediate tumor cell invasion. Mice
injected with tumor cell transfected with the CD44 isoform showed
not tumor metastases. Such tumor cells were shown to undergo
apoptosis. These transfectants displayed a marked reduction in
their ability to internalize and degrade hyaluronate. Therefore,
CD44 function promotes tumor cell survival in invaded tissues
possible as a result of impairing their ability to penetrate the
host tissue hyaluronan barrier. In the present invention,
SAg-encoding nucleic acid is co-transfected or fused to nucleic
acids encoding CD44 isoforms. These transfected cells are capable
of migrating to sites of metastatic tumor in tumor bearing hosts
and eliciting a potent anti-tumor response. The combined apoptotic
effect to the CD44 isoform with the enhanced immunogenicity of the
SAg produces a powerful synergistic anti-tumor response. The
nucleic acids encoding the CD44 isoform and SAg are transfected
into accessory (DC)/tumor cell hybrids. In addition, to presenting
tumor antigen and SAg to the immune system and inhibiting
metastases, the CD44 isoform produces apoptosis of the fusion cell
which in turn is ingested by DCs resulting in enhanced
immunogenicity and a more potent tumoricidal response. These
combined transfectants are used preferably against established
tumor according to protocols in Example 19-23.
[0152] NKT cells or T cells that do not produce CD44 after SAg
stimulation do so after transfection with nucleic acids encoding
CD44 or transferases such as N-acetylglucosaminyl transferase III
or CD44 (Sheng, Y. et al., Int. J. Cancer 73, 850-858 (1997);
Nottenberg, C. et al., Proc. Natl. Acad. Sci. U.S.A 86: 8521-8525
(1992)).The latter enzyme synthesizes bisecting N-acetylglucosamine
structures on asparagine linked oligosaccharides. Glycosylation of
CD44 by these transferases produces enhanced CD44 mediated adhesion
to immobilized hyaluronate. SAgs are used to activate T cells which
have been transfected with nucleic acids encoding
N-acetylglucosaminyltransferase III. The SAg stimulated
transfectants display increased CD44-mediated adhesion. as well as
lymphocyte homing and trafficking. Certain T cell, NKT cell or/T
cell populations which are unable to express CD44 after SAg
stimulation are transfected with nucleic acids encoding CD44 before
sensitization with SAgs. These cells express CD44 after
immunization with SAgs in vivo or in vitro. These additional
populations of effector T cells are useful in adoptive
immunotherapy of cancer by methods given in Examples 5, 7, 15, 16,
18-23.
[0153] 15. Tumor Associated Antigens include
[0154] (1) Normal structures, e.g., differentiation or tissue
specific antigens,
[0155] (2) Mutated normal structures
[0156] (3) Products of alternate reading frame or fusion of several
genes
[0157] (4) Chimeric products resulting from cell or gene fusion
[0158] (5) Xenogeneic antigens ("xenoantigens")
[0159] A tumor antigen (also called "tumor associated antigen) is
any antigenic structure expressed by a tumor cell. For example,
tumor antigens include mutated products of various oncogenes and
p53 genes that are expressed in tumor cells generally. Many tumor
antigens associated with particular types of cancers are known. For
example, tumor antigens associated with breast, colon, and lung
cancer are known and have been cloned. Common melanoma antigens
recognized by T lymphocytes have been identified and are used as
immunotherapeutic antigens for treatment of melanoma. Five genes
encoding different melanoma antigens have been identified. For
example, MAGE1 and 3, expressed on melanoma and other tumor cells,
are recognized by cytotoxic T lymphocytes (CTL) in the context of
HLA-A1 (Van der Bruggen P et al., Science 254:1643 (1991) and
Gauler B et al., J. Exp. Med. 179:921 (1994)). MART-1 identical to
Melan-A (Kawakami et al., Proc. Natl. Acad. Sci. U.S.A 91:3515
(1994) and Coulie et al., J. Exp. Med. 180:35 (1994)); gp100
(Kawakami et al., Proc. Natl. Acad. Sci. U.S.A 91:6458 (1994)); and
tyrosinase (Brichard et al., J. Exp. Med. 178:48 (1993)) are
melanocyte lineage-related antigens expressed on both melanoma and
melanocytes. MART-1 and gp100 have been shown to be recognized by
MHC-class I-restricted CTL in the context of HLA-A2, and tyrosinase
in the context of HLA-A2 and HLA-A24 [Robbins et al., Cancer Res.
54:3126 (1995)]. An additional list of tumor antigens useful in
this invention is given in Rosenberg, S A. Principles and
Applications of Biologic Therapy in Cancer: Principles and Practice
of Oncology DeVita, V T., Hellman, S., Rosenberg, S. A., eds, J. B.
Lippincott Co. Philadelphia, Pa. 1993.
[0160] In addition tumor associated antigens are defined as
including normal structures expressed in tumor cells, mutated
normal structures, normal differentiation- or tissue-specific
structures, products of alternate reading frames of the same
genetic regions, chimeric products of several genes that originated
in a parental or in a fused, hybrid cell. This also includes gene
products expressed in association with MHC molecules or other
surface receptors, organelles or vesicles. Tumor cells expressing
tumor-associated antigens are transfected in vivo or ex vivo with
nucleic acids encoding a SAg alone or together with nucleic acids
encoding other products, such as those listed in Tables I and II.
These include surface antigens and receptors such as the Gal
epitope, GalCer, CD1, CD14 and SAg receptor. The transfected cells
may be of host origin, or syngeneic, allogeneic or xenogeneic; the
cells may be non-malignant. SAg-encoding nucleic acid may also be
inserted into a mutated normal gene in a tumor cell, e.g., LDL
receptor gene in a melanoma cell. The LDL receptor is expressed as
a fusion product of the LDL receptor gene (chromosome 19) and a
fructose transferase gene on the same chromosome. This combination
results from chromosome inversion which gives rise to the fusion
product probably due to recombination between the two ends of this
chromosome. The expressed peptide epitope is therefore a nonsense
sequence being read in the wrong direction. The three base pair
mutations in the third open reading frame results in the expression
of a mutant peptide. Site directed mutagenesis can be achieved by
insertion of SAg-encoding nucleic acid into the mutant gene at any
feasible site or by targeting insertion in place of the mutated
base pairs. The resultant LDL receptor displays the SAg alone or as
a chimera with the mutant sequence. Site directed mutagenesis by
SAg-encoding nucleic acid may also target the .quadrature.-catenin
gene which in melanoma shows a single C-T mutation which results in
a ser to phe substitution and the generation of the 9 amino acid
mutant peptide. The SAg-encoding acid may be inserted or may
substitute for any sequence in a normal non-mutated gene, a
tissue-specific or differentiation-associated gene in tumor cells,
or other genes expressing their products in a tumor cell.
Preferably, the. mutated gene product is immunogenic and recognized
as a dominant epitope by the host immune system, preferably by T
cells (including tumor infiltrating lymphocytes). The mutated
sequence may, in contrast, be a weak immunogen which is rendered
more immunogenic when presented in the context of a SAg.
[0161] In the preferred embodiment, the transfected cells are tumor
cells of host origin expressing a defined tumor associated antigen
such as MART-1. If the tumor antigen is not expressed or weakly
expressed on the transfected cells, then the tumor cell is
transfected with nucleic acids encoding an immunogenic tumor
antigen such as MART-1, tyrosinase or MAGE-1 in addition to SAg and
other constructs described herein.
[0162] The tumor cells may be transfected in vivo by administering
nucleic acids encoding SAgs and/or the other nucleic acid
constructs described above using a site directed mutagenesis
approach in vivo and methods such as described in Example 1, 3,
18-23. Tumor cells may also be transfected ex vivo by methods given
in Example 1-3. Ex vivo transfected tumor cells are used as vaccine
or to treat established tumor by methods and protocols in Example
18-23 They are also useful ex vivo to immunize T cells or NKT cells
to produce a population of tumor specific effector cells adoptive
immunotherapy of cancer by methods and protocols given in Examples
7, 15, 16, 18-23.
[0163] 16. Immunostimulatory Sequences
[0164] Several of constructs consist of nucleic acids encoding SAg
peptides which produce anti-tumor responses by activating host TH-1
CD4+ T cells to proliferate and produce tumoricidal cytokines such
as IL-1.alpha., IL-1.quadrature., IL-2, IL-6, TNF.alpha.,
TNF.quadrature. and IFN.gamma.. The incorporation of the
immunostimulatory sequence into the genetic construct of SAg DNA,
ensures that the T cell response is skewed to produces a
predominant proliferation of TH1 cells and production of a TH1
cytokine profile. Immunostimulatory sequences (ISS) consist of DNA
sequences that exhibit immunogenicity. Briefly, plasmid DNA (pDNA)
having short immunostimulatory DNA sequences containing a CpG
dinucleotide in a particular base context were shown to be
immunogenic (Tokunaga J et al., J. Natl. Cancer Inst. 72:955-962
(1984)). By synthesizing single stranded nucleotides corresponding
to different regions in the Mycobacterium bovis genome, specific
single stranded oligonucleotides that activate adherent splenocytes
and enhanced natural killer cell activity have been identified. In
addition, single stranded oligonucleotides with CpG motifs induce B
cell proliferation and secretion of IL-6 and IFN (Krieg et al.,
Nature, 374:546 (1995)). The activation capability generally has
the formula 5'-Pur-Pur-C-G-Pyr-Pyr-3'- . Further, human monocytes
transfected with pDNA or double stranded oligonucleotides
containing ISS transcribed large amounts of IFN.gamma. and IL-12
(Sato et al., Science 273:352-354 (1996); Zhu et al., Science 261,
209-211, (1993)) Direct gene transfer with plasmid-cationic
liposome complexes resulted in lasting, generalized or tissue
specific expression of the injected genetic phenotype.
[0165] In the present invention, the ISS is inserted into nucleic
acid sequences of SAgs and tumor associated antigens which are used
to transfect tumor cells, antigen presenting cells, accessory cells
including muscle cells in vitro or in vivo by methods given in
Example 1-3, 15, 16, 18-23. In all instances, the SAg stimulation
of the T cell response is critical to an effective anti-tumor
response of the host. The presence of the ISS ensures that the SAg
nucleic acids preferentially activate the TH1 after in vivo
administration of the nucleic acids encoding SAg. SAg DNA is useful
ex vivo in activating T cells by direct transfection or by
presentation via incubation with pretransfected antigen-presenting
cells or tumor cells. The tumor specific T effector cell are then
useful for adoptive therapy of cancer using protocols given in
Examples 7, 15, 16, 18-23). A particularly useful method involves
the intratumoral injection of nucleic acids encoding SAgs. The
latter is administered in naked, plasmid or liposomal form. Once
tumor inflammation is initiated (generally within 15 days after
injection), the host is given T cells or NKT cells which have been
immunized in vitro to the tumor by tumor cells transfected with
nucleic acids encoding SAg plus additional constructs given in
Tables 1 and II by methods given in Examples 7, 15 16 18-23.
[0166] 17. Liposomes
[0167] Liposomes containing repeating units of the Gal epitope,
GalCer, and/or SAgs are constructed and administered directly into
a tumor. These elements are combined before incorporation into
liposomes or they are added individually in the preparative
procedure. Methods for preparation of these liposomes are given in
Examples 5. These liposomes are preferentially delivered
parenterally or directly into the tumor. The administration of SAgs
in this manner provides a high local concentration of SAg to
stimulate an anti-tumor response. These liposomes are also useful
ex vivo by activating a T cell or NK T cell population which is
then harvested and used for adoptive immunotherapy as described in
protocols in Examples 5, 7, 15-17, 18-23).
[0168] 18. Tumor Cells that Induce Cellulitis
[0169] Transfection with microbial nucleic acids that encode tissue
spreading factor (hyaluronidase), erythrogenic toxins,
enterotoxins; capsular polysaccharides from S. aureus and
Streptococcus pyogenes, S. aureus and S. pyogenes have potent
tissue invasive properties. Specifically, Staphylococcus and
Streptococcus are capable of invading tissues by secreting several
enzymes which lyse ground substance such as mucopolysaccharide,
hyaluronic acid, or chondroitin sulfate, create local thrombosis,
and initiate inflammation and edema. These enzymes consist of
hyaluronidase, streptokinase, streptodornase, erythrogenic toxins
as well as various enterotoxins (Example 3). In the present
invention, the nucleic acid sequences encoding these potent enzymes
are transfected into tumor cells, either in vitro or in vivo
(Examples1-3, 6, 15, 16, 18-23). In vivo, the transfected tumor
cells migrate to sites of existing metastases. The transfected
tumor cells secrete the enzymes which hydrolyze the tumor ground
substance and neovasculature and toxins to induce inflammation and
an immune response in tumor tissue. Tumors which are encased in
nests of connective tissue are eliminated by this process. The
resulting increase in local vascular permeability induced by the
combined effect of enzymes and toxins produces intense inflammation
at tumor sites. If their administration is timed to the peak of
tumor inflammation, liposomes as described herein and chemotherapy
are sequestered and concentrated in the inflamed tumor bed
producing an augmentation of the tumoricidal response.
[0170] A relatively low number of transfected tumor cells with the
complete microbial enzymatic and toxin genetic construct would be
required to induce a tumoricidal effect. The population of
transfectants would then proceed to secrete these microbial enzymes
locally. In addition, nucleic acid encoding these enzymes are
derived from a strain of Staphylococcus or Streptococcus such as
Staphylococcus epidermidis or Streptococcus bovis of low or
intermediate virulence.
[0171] Tumor cells are cotransfected with glycosyltransferases or
treated with glycosyltransferase-inducing agents resulting in the
expression of the Gal epitope and reduction in the survival time of
tumor cells For example, the nucleic acids encoding the
glycosyltransferase from Sphingomonas paucimobilis or Agelas
mauritianus produce GalCer are transfected into tumor cells to
induce the surface expression of GalCer or Gal. The tumor cells
then express and/or secrete microbial agents such as SAgs,
hyaluronidase and erythrogenic toxins that hydrolyze the ground
substance of the tumor. By also displaying SAgs and -Gal or Gal/Cer
epitopes which activate NKT cells, T cells, and Gal specific
antibodies the transfected tumor cells induce profound tumoricidal
activity. These transfected tumor cells are used to activate a
population of T cells to become tumor specific effector cells which
are employed for the adoptive immunotherapy of cancer. See Examples
1, 2, 4-5, 7, 15, 16, 18-23.
[0172] For in vivo transfection of tumor cells, the microbial
genetic nucleic acids are targeted to tumor cells as described
herein (See p. 12 "Transfection", Examples 1-3, 6, 19). Once
localized in tumor sites in vivo, the tumor cell is capable of
hydrolyzing surrounding stroma and, initiating thrombosis,
inflammation, and increased tissue permeability. Additional
microbial nucleic acid encoding proteinases, lysoproteinases,
tissue spreading factors, .alpha. and .quadrature. hemolysins and
toxins are also transfected into tumor cells and used in accordance
with this invention.
[0173] Micrometastatic disease in cancer patients is of great
concern as it often goes undetected and is refractory to
chemotherapeutic agents. Documented metastases in breast cancer
patients is associated with a poor prognosis. The present invention
contemplates that the metastatic properties of tumor cells coupled
with the potent inflammatory properties of the microbial products
are useful in tracking and eliminating micrometastatic disease in
tumor bearing patients. Tumor cells are transfected with nucleic
acid encoding polypeptides involved in metastasis. These include
but are not limited to peptides that upregulate the adhesive
properties of CD44 (e.g., glycosyltransferases), the c-erbB-1
encoded EGF receptor which is associated with enhanced metastases
in breast carcinomas or c-erbB-2/neu encoding the p185 receptor
associated with poor prognosis in breast and ovarian carcinomas.
These cells with metastatic activity are programmed to traffic,
home and colonize specific sites of existing metastases the tumor
bearing host. Hence they have the unique property of charting the
micrometastatic sites of the tumor. These tumor cells are
cotransfected with microbial nucleic acids encoding the
hyaluronidase, erythrogenic toxin and enterotoxins as well as the
Gal. Hence, as they colonize metastatic sites, these transfectants
induce a potent inflammatory and immune response. This ensures
their own destruction together with the surrounding untransfected
micrometastatic tumor cell population and neovasculature and
stroma. Methods of preparation, administration and assessment of
these transfectants in tumor bearing hosts are in Example 1-3,
18-23.
[0174] The tumor cells are also transfected with the above
microbial genes on a DNA template with a tissue specific promoter
in order to target the activity of these transfected tumor cells to
the vital organs (and sites therein) affected by the existing
metastatic tumor. For breast cancer, this would be lung, liver or
brain. These organ-specific promoters ensure that the expression of
the microbial products would occur in the organ(s) targeted by the
tissue specific promoter The same tumor cells are also provided
with inducible promoter sequences which control the level of
receptor transcription and expression. Inducible promoters suitable
for use in mammalian cells include the MMTV-LTR under the control
of steroid hormones and the metallothionein promoter under the
control of heavy metal ions. In this case, the microbial nucleic
acids are linked to steroid inducible gene sequences. Transcription
is triggered when these cells are exposed to a threshold level of
steroids. Hence, two to three days after administration to the
host, when the above transfectants have colonized tumor metastatic
sites, a bolus of corticosteroid is administered which initiates
transcription of the microbial enzymes and toxins by the tumor cell
transfectants and their secretion. In this fashion, the transfected
tumor cells express and secrete their inflammatory products in
metastatic tumor sites resulting in the elimination of metastatic
disease.
[0175] 19. Tumor Cells as Mimics of Virulent Bacteria: Transfection
with Nucleic Acid Encoding Bacterial Invasins, Virulence Factors,
and Enzymes that Degrade Extracellular Matrix
[0176] Tumor cells with a metastatic phenotype are transfected with
nucleic acids encoding proteins with the capacity to invade and
adhere to inflammatory cells such as macrophages (adhesins and
virulence factors). These genes are inducible and controlled by
operons.
[0177] SAg-encoding nucleic acid is fused in frame to nucleic acid
encoding oncogenes involved in tumorigenesis and metastasis.
Examples of such genes, in addition to erb/neu, erb, erbB2 and EGF
(epidermal growth factor receptor) discussed above, include ras and
mutated ras, erk, and mtal, 182mts1, nm23 (See Table 9.5, p181 of
Franks L. M. et al., Cellular and Molecular Biology of Cancer,
Oxford University Press, Oxford UK, (1997) which is incorporated by
reference), as well as the laminin-integrin and the cadherin
family. These genes are particularly useful because they are
overexpressed in tumor cells displaying a metastatic phenotype.
[0178] Invasins
[0179] SAg-encoding nucleic acid is fused in frame or cotransfected
into tumor cells with nucleic acids encoding bacterial invasins and
hyaluronidases. The invasin imparts leukocyte like activity to
bacteria is transfected into tumor cells which allows the tumor
cells to penetrate tissues. These are exemplified by Yersinia
pseudotuberculosis invasin and hyaluronidase (including its various
isotypes) and also known as tissue spreading factors. The invasin
gene exemplified in Y. pseudotuberculosis encodes a protein located
in the outer membrane of the bacterium called invasin (Inv) and the
gene is known as inv. The DNA region of the inv gene contains a
open reading frame 2964 bases. This protein binds to the host cell
surface by means of the C-terminal 192 residue region. Mutation by
insertion of a transposon or elimination of the inv gene greatly
impairs the ability of the bacterium to penetrate tissues
(Schaecter M et al., Genetics of Bacteria edited by Baer G M et
al., in Mechanisms of Microbial Disease Williams and Wilkins
Baltimore (1993)).
[0180] The host membrane receptors for invasin belong to the
integrin superfamily with a particular affinity for VLA-3, 4, 5, 6.
Invasin also bind to T cell .alpha..sub.4.quadrature..sub.1 which
is involved in lymphocyte homing or traffic. Once bound to a
phagocyte, phagocytosis is triggered and the bacterium is taken up.
Nucleic acids encoding Inv are transfected into tumor cells which
confers upon the tumor cell a phagocytosis triggering signal for
host macrophages.
[0181] E. coli genes of the P pili or pap operon encoding adhesin
proteins have been isolated from chromosomes and plasmids. The gene
cluster is linked to genes for other virulence determinants such as
the KI capsular polysaccharide and hemolysin. The receptor for the
pili is the Gal(1-4)Gal moiety of the P blood group antigen.
Examples of host cell receptors for bacterial adhesins is given in
Table 7.2 of Patrick and Larkin. Pilin genes in N. meningitidis
encode proteins is which the fimbriae are the N-methylphenylalanine
pili. An extensive region of amino acid homology at the N-terminal
end is common to a wide range of bacterial genera including
Pseudomonas aeruginosa, N. gonorrhoeae, N. menigitidis, Moraxella
bovis and Bacteroides nodosus. This N-terminal region is highly
hydrophobic which is in contrast to the fimbriae of the
Enterobacteriaceae which either have a hydrophobic region at the
C-terminal end or lack a hydrophobic region altogether. Of interest
is the presence of a site on SAgs which resembles the third Ig-like
disulfide-bridged loop of VCAM-1 and a conserved sequence is
present within the same subregion of the fifth Ig-like VCAM-1 loop.
The only known receptor for the VCAM-1 is VLA-4, an adhesion
molecule expressed primarily by activated T and B cells. A survey
of target cell susceptibility to SEC dependent lysis shows a
correlation between VLA-4 expression and susceptibility to
lysis.
[0182] Hyaluronidases and Proteases
[0183] Bacteroides species produce hyaluronidase, heparanase, and
chondroitin sulfatase enzymes. C. perfringens m toxin is a
hyaluronidase enzyme and Bacteroides and C. perfringens produce
elastase and collagenase enzyme while Porphyromonas gingivalis has
a cell associated collagenase. Streptococcus pyogenes produces
hyaluronidase enzymes which depolymerize their own capsules.
Neuraminidases and endoglycosidases, lipases, nucleases and
proteases produced by a wide variety of bacteria are also useftil
in this invention as capable of promoting tissue necrosis in tumor
masses and/or tumor nests.
[0184] The staphylococcal invasive genome is predominantly
chromosomal and the nucleic acid segments encoding the major
invasive enzyme systems, permeability factors, and toxins have been
isolated, cloned, and sequenced. For example, the nucleic acid
sequence encoding a hyaluronidase from group A Streptococcus strain
10403 is described elsewhere (Hynes et al., Infect. Immun.
63:3015-3020 (1995)). Tumor cells transfected with nucleic acids
encoding microbial invasive and inflammatory substances are
preferentially used in vivo where they are programmed to traffic to
metastatic sites and/or organs primarily infiltrated by the tumor.
Once situated in tumor, they commence secretion of their
inflammatory enzymes and toxins. Protocols for their preparation,
use, and assessment are given in Examples 1-3, 18-23.
[0185] Consolidation of Bacterial Genes
[0186] The microbial nucleic acids encoding hyaluronidase,
erythrogenic toxins proteases, coagulases and enterotoxins are
consolidated into a chimeric construct or plasmid and transfected
into tumor cells which then commence secretion of the spreading
factors, pro-inflammatory and permeability inducing agents. For
example, a single construct or multiple constructs contains the
nucleic acid encoding polypeptides including, without limitation,
enterotoxin B, hyaluronidase, streptokinase, coagulase,
Staphylococcal protease and erythrogenic toxins.
[0187] Tumor cells transfected with the above microbial genes are
prepared as in Example 1-3 and are used in the treatment of
established and metastatic tumor or as a preventative vaccine as
described in Examples 15-23.
[0188] 20. Combined Expression of Different Stimulatory Molecules
by Co-Transfection of Tumor Cells or Fusion of Singly Transfected
Cells
[0189] Tumor cells that express two different types of exogenous
molecules are produced by either cotransfection of the same cells
with (a) SAg-encoding nucleic acid and (b) nucleic acid encoding a
toxins or autolysin, or by fusion of tumor cells that have been
singly transfected with (a) with tumor cells transfected by (b)
Tumor cells are provided which have the dual capacity to colonize
metastatic tumor sites in vivo and induce inflammation. Once
situated in sites of tumor metastasis, the tumor cells behave like
a necrotizing bacterium or leukocyte. For example, tumor cell are
transfected with nucleic acids encoding bacterial invasins to
promote adhesion, "tissue spreading factor" or hyaluronidase to
hydrolyze the ground substance, coagulase to induce local
thrombosis and streptokinase and streptodornase. In addition, tumor
cell are provided with nucleic acids encoding bacterial toxins
which bind and produce autolysis and cytotoxicity for surrounding
tissue and tumor cells. The tumor cells are also cotransfected with
additional nucleic acids encoding SAgs. The toxin genes useful
herein are amplified by providing two copies tandemly duplicated on
a chromosome and linked to an amplified oncogene. Situated in tumor
tissue, these transfected tumor cells release enterotoxins as well
as inflammatory enzymes, immunogenic capsular lipoproteins, cell
wall LPS's and cytolysins. This evokes a potent T cell and
inflammatory response in tumor tissue. These inflammatory genes are
inducible at the level of the operon or in some instances
bacteriophage which controls their activation. Transfected tumor
cells are transfected with microbial nucleic acids given above
either in vitro or in vivo at tumor sites as in Example 1-3, 5,
16-23 and p.11 under "transfection".
[0190] The S. aureus a toxin forms pores or transmembrane channels
in a wide range of host cells. It is released from the bacteria
during exponential growth and has a molecular mass of 33 kDa.
Expression of the gene encoding the a toxin, hly, is under the
control of the agr gene which coordinately controls the expression
of a number of extracellular proteins, including exfoliatin toxin,
toxic shock syndrome toxin, .alpha., .quadrature., and .delta.
toxins, enterotoxin B, lipases and nucleases. The .quadrature.
toxin is a phospholipase which attacks a sphingomyelin in the cell
membranes. The phage encoding the toxin is hlb. Exfoliatin toxin A
is encoded by a chromosomally located gene eta and the gene for
toxin B is etb. The eta gene is by the agr gene regulator which is
a member of the histidine-protein kinase response regulator
superfamily. (Patrick S et al., Immunological and Molecular Aspects
of Bacterial Virulence, John Wiley and Sons New York, N.Y.
1995)
[0191] SEB binds to glycosphingolipids on cell membranes. The
ganglioside binding site on SEB is overexpressed, or a
myristoylation site or GPI binding site is integrated into its
structure so that it is bound to the surface of the tumor cell
membrane and not secreted. The SEB will preferentially bind to
tumor cell expressing ganglioside tumor associated antigens and
will augment the immunogenicity of these antigens.
[0192] S. aureus produces a bifunctional protein autolysin of
110-kDa,(HlyA) via the atl gene that has an
N-acetylmuramoyl-L-alanine amidase domain and an
endo-.quadrature.-N-acetylglucosaminidase domain. It undergoes
proteolytic processing to generate two extracellular enzymes that
are secreted. The specific secretion proteins HlyB and HlyD are 80
kDa and 54kDa respectively. The process is directed by the hlyB and
hlyD genes which are contiguous and co-expressed with the hylC and
hylA genes that are required for the synthesis of protoxin and the
acyl carrier protein-dependent fatty acylation that matures it to
cytolytically active toxin. Hemolysin is secreted as the mature
acylated form of the hlyA gene product proHlyA following the
covalent attachment of a fatty acid moiety in a cytoplasmic
mechanism directed by the dimeric HlyC activator, a putative acyl
transferase and dependent upon the acyl carrier protein. This
specific and novel HlyC-directed fatty acylation is required to
target the hemolysin toxin to mammalian cell membranes prior to
forming cation-selective pores and disrupting the host cell.
[0193] Bacteria such as E. coli, Bordetella pertussis, Pasteurella
haemolytica, Proteus vulgaris and P. mirabilis produce genetically
related toxins. Their activity is dependent on the presence of
calcium ions. Characteristically, they have regions of 10 to 47
repeats within the amino acid sequence and termed repeats in toxin
or RTX gene family. The repeat sequence contains the following nine
amino acids (SEQ ID) NO:34);
leucine-X-glycine-glycine-X-glycine-asparagine-aspartic acid-X
where X is a variable amino acid. These repeats are required for
hemolytic activity. A large hydrophobic region of the hemolysin
separate from the repeats, is also essential for activity and may
be involved in the interaction with the host cell membrane. The
hemolysin A of E. coli apparently form pores on the target cell
membrane. This requires a 20 kDa product of another gene HlyC
before it becomes actively hemolytic. In E. coli, the operon for
the production of the hemolysin contains four genes hlyA which
codes for the structural hemolysin and hlyc which is required for
activation of the HlyA. The other two genes hlyB and hlyD are
involved in the transport of HlyA to the extracellular environment.
Pasteurella haemolytica leukotoxin and Bordetella pertussis
adenylate cyclase hemolysin have similar C-terminal sequence and
associated genes analogous to those in the hly operon. (Koronakis V
et al., Secretion of Hemolysin and other Proteins out of the
Gram-Negative Bacterial Cell, in Ghuysen J M et al., ed, Bacterial
Cell Wall, Elsevier, Amsterdam (1994)).
[0194] The Shiga toxin of Shigella dysenteriae and Shiga-like
toxins of E. coli (Verotoxins) are a family of related toxins which
have similar amino acid sequences and biological activities. The A
subunit of Shiga toxin has a molecular mass of 31 kDa which
associates with five to the 7 kDa B subunits. The A subunits is
proteolytically cleaved into A1 and A2. It is the A1 fragment which
is biologically active. The host cell receptor for Shiga toxin is
the glycolipid Gal(.alpha.1-4)Gal(.quadrature.1-4) GlcCeramide
(globotriosylceramide; Gb3) and for Shiga-like toxin I (SLTI) and
SLTII of E. coli is Gal(.alpha.1-3)GalCeramide
(Galabiosylceramide). The binding specificity is dependent on both
sugars residues and the lipid moiety. The Shiga toxin is known to
inhibit protein synthesis. It is a RNA N-glycosidase enzyme whose
site of action is the 60S ribosomal subunit. The toxins remove an
adenine base from position 4324 on the aminoacyl-transfer RNA
binding site of 28S ribosomal RNA hence preventing peptide length
elongation. The effect on protein synthesis is similar to that of
diphtheria toxin and Pseudomonas aeruginosa exotoxin A. The SLTI
and II toxins of E. coli and encoded by lysogenic phage. Its
expression is controlled by iron concentration in the growth medium
by way of the fur gene and iron box repressor protein binding site.
Clostridia difficile toxins A and B also bind to anomeric galactose
epitopes on cell membranes and induce membrane associated enzymes
and inhibit G protein activation which results in cell death. Tumor
cells transfected with a galactosyltransferase genes to produce the
.alpha.-Gal epitope are susceptible to lysis by both the Shiga-like
toxins and C. difficile toxin. The expression of the .alpha.-Gal
epitope is enabled by the transfection of nucleic acids encoding
-Gal transferase into tumor cells.
[0195] Listeria monocytogenes produces a hemolysin. listerolysin O
(LLO), a member of the thiol-activated family of cytolysins. LLO is
encoded by the gene hyl (also designated hylA and lisA).
Listerolysin O toxin is a pore forming toxin which degrades the
membrane of its phagocytic vacuole allowing the bacterium to escape
into the host cytoplasm. This gene cloned into Bacillus subtilis
enables the bacterium to grow rapidly intracellularly in the
cytoplasm of a macrophage-like cell line after disrupting the
phagosomal cell membrane. Tumor cells are transfected with the
above microbial nucleic acids as in Example 1-3. These
transfectants are useful in vivo against established tumor and
micrometastatic disease (Examples 5, 15, 16, 18-23).
[0196] 21. Augmentation of Tumor Cell Immunogenicity by Bacterial
Products: Transfection with Genes Encoding Bacterial Antigens or
Receptors for Bacterial Products
[0197] Tumor cell are provided with augmented antigenicity by
expressing fundamental patterns that are recognized by fundamental
recognition units of the innate immune response. Examples are LPS's
of gram negative organisms, SAgs and peptidoglycans of gram
positive organisms, fungal .quadrature.-glucans, bacterial
glycosylceramides, and mycobacterial lipoarabinans. Numerous
infectious agents with these structures cause potent immune
reactions e.g. streptococcal cellulitis induced by S. pyogenes, E.
coli induced sepsis and meningococcal meningitis induced by
Neisseria meningitidis (SEQ ID NOS:35-36)..
[0198] The T cell system is far more adept at responding to innate
pattern recognition units than to tumor associated antigens. In the
present invention, tumor cells are transfected with nucleic acids
encoding molecules or biosynthetic enzymes that result in
structures which mimic the major immunogenic structures of
bacterial antigens. This enables the tumor cells to be recognized
more effectively by the T cell system. In addition, tumor cells are
provided with receptors for bacterial antigens such as SAgs, LPS's
(CD14), and glycosylceramides (CD1). Genes encoding bacterial
antigens which produce potent immune responses are transfected into
tumor cells to include bacterial membrane and cell wall
constituents such as LPS's, peptidoglycans, glycosylceramides,
lipoproteins, lipoarabinans and capsular polysaccharides. In
addition, nucleic acids encoding the staphylococcal SAgs induce
potent T cell lymphoproliferation and TH-1 cytokine production
while LPS's are known to have a bystander effect on T cell
proliferation The two agents synergize in their capacity to induce
lethal endotoxic shock in animals. The present invention
contemplates that the optimal approach is to present the bacterial
immunogen structure (for example streptococcal capsular
polysaccharide) sequentially or concomitantly with a bacterial
mitogenic signal (SAg). Under certain conditions, these genes are
co-transfected with various bacterial invasins, toxins, autolysins
and inflammatory enzymes which together with the colonizing
properties of tumor metastasis genes produce a tumor cell capable
of migrating to metastatic sites where it induces necrotizing
cellulitis. Such genes are preferably placed under the control of
inducible promoters as described herein.
[0199] These transfectants are prepared by methods in Example 1-3.
They are useful against established tumors or metastatic tumor in
vivo as in Example 15, 16, 18-23.
[0200] 21b.Combining Expression of SAg Nucleic Acids with Nucleic
Acids Encoding Enzymes that Drive the Synthesis of Bacterial LPS,
Galactosylceramide or Capsular Polysaccharide
[0201] In general, this is accomplished by co-transfection of
nucleic acids each encoding one of the above products or by
transfection with a fusion nucleic acid that encodes the
combination.
[0202] SAg-encoding nucleic acid is fused in frame or cotransfected
into tumor cells or accessory cells with nucleic acids encoding
bacterial LPS's, peptidoglycans, and galactosylceramides. The
preferred end products are synthesized in E. coli and N.
meningitides (LPS's), Staphylococcus and Streptococcus
(peptidoglycans); Sphingomonas paucimobilis
(glycosylceramides).
[0203] The synthetic genome or cluster of genes for biosynthesis of
these products is incorporated as a whole to include multiple and
specific enzymatic transferases and trafficking proteins required
for the stepwise synthesis of each of these products. Gene clusters
are necessary to provide the requisite transferases for synthesis
of these large molecules. For example the genes required for the
biosynthesis of type 1 capsular polysaccharide of S. aureus are
localized to a 14.6-kb region. Sequencing analysis of the 14.6-kb
fragment revealed 13 open reading frames (ORFs). Ten genes are
involved in capsule biosynthesis. CapG aligned well with consensus
sequence of a family of acetyltransferases from various prokaryotic
organisms suggesting that CapG may be an acetyltransferase. The
structural requirements for endotoxic activity of LPS's are as
follows. (1) a .quadrature.(1-6)-linked D-glucosamine disaccharide
backbone; (2) biphosphorylation at positions 1 and 4' of the
disaccharide backbone; (3) a suitable number of 3-acyloxyacyl
groups per disaccharide unit; and (4) acyl groups of a-suitable
length as indicated by Kumazawa et al., and Nakatsuka et al.
Transfection with nucleic acid encoding LPS's would require the
preservation of the biphosphorylation and the acyl groups between
14 and 23 to maintain optimal activity. Derivatives may contain a
monosaccharide group in place of the disaccharide group.
[0204] LPS Structure
[0205] LPS consists of an outer region which is composed of
polymerized di- and pentasaccharide repeating units whose
compositions vary within a species or strain. The inner region is
generally conserved within a single genus, and consists of a core
oligosaccharide linked by the sugar 2-keto-3-deoxy-D-amino-octonate
(KDO to a disaccharide backbone with attached long chain fatty
acids, the lipid A. This component is responsible for much of the
biological activity of the molecule. Components conferring the
greatest biological and immunomodulatory activity are now known to
be a glucosamine disaccharide, a bis phosphorylated lipid A and
acyloxyacyl groups on the fatty acid chain. The loss of only one of
these components, for example, a phosphate group reduces the
activity of the molecule. LPS's from different genera of bacteria
vary in their immunomodulating activity and studies of the
structure have shown very subtle differences. For example,
Bacteroides spp. is apparently less active in endotoxin activity
than LPS from enteric bacteria. This was initially thought to be
related to a modification of the of KDO in the core region with an
added phosphate group. Other differences in the LPS were found when
the fatty acids from E. coli and Bacteroides were compared. E. coli
has six fatty acid chains or acyl groups per diglucosamine backbone
each with a chain length of 12-14 carbon atoms. Included in the
acyl groups is 3-hydroxytetradecanoic acid (3-OH-C14:0)which is
absent in the Bacteroides strains. In contrast, Bacteroides has 4-5
fatty acids of chain length 15-17 carbons per diglucosamine and has
branched 3-hydroxy fatty acids. Studies of synthetic lipids have
confirmed that reduced biological activity relates to fewer fatty
acids chains.
[0206] A common feature of LPS's from various species is that they
are amphiphiles, with both a hydrophobic part capable of dissolving
in lipid membranes and a hydrophilic part which remains in the
water phase. Therefore, the first step of molecular interaction is
one between the amphiphilic molecule and the mammalian cell surface
either by ionic binding, hydrogen bonding or hydrophobic
interaction. The bacterial molecule may be inserted into the
mammalian membrane by its hydrophobic moiety or attached to
membrane receptors with the hydrophilic moiety, or through charge
effects or via binding to host glycoproteins and glycolipids
resulting in signal transduction. Most of the immunomodulating
activity of these bacterial molecules is indirect and stems from
the release of host mediators. Cytokines such as IL-1, tumor
necrosis factor, and IL-6 are involved. The LPS binding protein
attaches to gram-negative bacteria or free LPS and mediates the
attachment to macrophage membrane receptor known as CD14. The
recognition of the CD14 only recognizes LPB when it is bound to
LPS. The LPS-LPB complex may directly trigger TNF release or hold
the complex at the cell surface so that other hosts cell surface
molecules trigger TNF release. LPBs also act as opsonins. Another
area where sugar residues play an important role is in cell surface
glycoprotein interactions which involve protein-carbohydrate
recognition. In the recirculation of and recruitment of leukocytes
in the body, the carbohydrate-recognizing protein domains of
glycoproteins of one cells bind specifically to the
oligosaccharides of glycoconjugates on another type of cell. These
recognition events control the movement of bloodbome lymphocytes
into lymphoid organs. Specific recognition occurs between
lymphocytes and specialized cells in the wall of blood vessels
known as high endothelial venules.
[0207] Genes Encoding Lipid A Biosynthesis
[0208] LPS is generally synthesized as two separate components, the
lipid A/core and the O polysaccharide, which are then ligated to
give the complete LPS molecule. Three genes encode enzymes that
catalyze the steps of lipid A synthesis (lpxA, lpxD and lpx B for
steps 1,3 and 5) and fabz and envA. More specifically, the enzymes
that catalyze the synthesis of lipid A are thought to act in the
following sequence (indicating the genes): lpx A, lpx C, lpx D,
lpxB. The reactions catalyzed by the products of these genes are
given in Table 1 of Schnaitman C A et al., Microbiol. Rev. 57:
655-682 (1993).
[0209] Blocks of Genes Involved in LPS Biosynthesis
[0210] Blocks of genes involving LPS synthesis have been sequenced
and analyzed. The lipid A biosynthetic pathway has been elucidated.
Four of the genes in this pathway have now been identified. Three
of them are located in a complete operon which also contains genes
involved in DNA and phospholipid synthesis. Genes involved in
synthesis of the LPS lipid A core are given in Tables 1 and 2 and
their activity at various points in the biosynthetic pathway are
given in FIG. 1 of Schnaitman C A et al., Microbiological Reviews
57: 655-682 (1993). which is incorporated by reference. Therefore,
it is likely that LPS biosynthetic enzymes are organized into
clusters on the inner surface of the cytoplasmic membrane around a
few key membrane proteins.
[0211] A cluster of assembly genes produced by various bacteria
encode LPS with homologous structures. These genes have been
transfected into E. coli and they induce identifiable LPS's. There
are also smooth and rough LPS's which have a hierarchy of potency
in terms of procoagulant activity and activation of TNF. Mutants
produced which synthesized progressively less polysaccharide
attached to the lipid A moiety. The presence of long chain
polysaccharides attached to the lipid moiety decreased the ability
to activate TNF. Rough bacteria were more effective than smooth
bacteria in inducing TNF production. Fatty acids of various chain
lengths can be produced including those that resemble
monogalactosylceramides. Transferases for biosynthesis of galactan
the LPS structure of the O antigen from Klebsiella pneumoniae have
been identified as well as genes controlling the O antigen chain
length.
[0212] The genes for LPS and glycosylceramide assembly also involve
multiple transferases. The transfection of tumor cells involves 10
genes encoding a particular stretch of the bacterial genome. In E.
coli, the 14-kilobase pair chromosomal region located between waaC
(formerly rfaC) and waaA (kdtA) contains genes encoding enzymes
required for the synthesis and of the type R2 core oligosaccharide
in the lumen of the endoplasmic reticulum. This occurs in a
stepwise fashion. The gene encoding the Haemophilus influenzae type
B outer membrane protein functions as a porin and is useful in
protective immunity has been cloned as a 10-kilobase Hib DNA insert
and expressed in E. coli. The biosynthesis of LPS's involves genes
encoding the key transferases including rfaI. The N. meningitides
highly conserved surface protein conferring protection is encoded
by a ORF of 525 nucleotides.
[0213] Genes Encoding Enzymes the Catalyze Core Biosynthesis
[0214] The rfa cluster includes the genes for all transferases for
assembly of core. It includes three operons consists of at least 17
genes. The majority of known genes whose functions are involved
exclusively in LPS core biosynthesis are located in the rfa cluster
[Pradel E et al., J. Bacteriology 174: 4736-4745 (1992)]. It
includes three operons. However, there are also genes such as kdsA
and rfaE located outside the rfa cluster which are involved in
biosynthesis of sugars unique to the core or exert direct effect on
core structure. These clusters appear to have originated by the
exchange of blocks of genes among ancestral organisms. There are
few which code for the integral membrane proteins. The promoter for
the rfa genes has been identified. Mutations have been identified
known a rough mutants traced to three loci namely rfa, rfb and
rfc.
[0215] The region of the E. coli chromosome encoding enzymes
responsible for the synthesis of the LPS core has been cloned. This
region formerly known as the rfa locus comprises 18 kb of DNA
between the markers tdh and rpmBG. The genes are arranged in three
different operons and the genetic organization of this locus seems
to be identical in E. coli K-12 and S typhimurium.
[0216] Linkage of LPS Transcription and Toxin Secretion
[0217] In E. coli and Salmonella, a link has been found between
toxin secretion and the gene regulating LPS transcription. Toxin
secretion is regulated by gene expression within the hlyCABD
operon. A recently identified activator of hlyCABD gene expression
is the 128-kDa product of the rfaH (sfrB) gene which positively
regulates transcript initiation and possibly termination in the
operons encoding synthesis of LPS of E. coli and Samonella. The
discovery of a role in hlyCABD expression for the LPS (rfa) operon
transcriptional activator rfaH is consistent with the role of LPS
in influencing both the secretion and toxic activity of the
toxin.
[0218] Genes Encoding Enzymes that Synthesize Polysaccharide
Capsule and Membrane Proteins
[0219] Genes for the biosynthesis of a polysaccharide capsule are
induced in Sphingomonas by overlapping DNA segments which span
about 50kbp restored the synthesis of sphingan. The polysaccharide
components of LPS from B. Pertussis, H. influenzae and Bacteroides
spp. will activate B-cells. The polysaccharide of Bacteroides
activates B cells indirectly by first triggering the macrophage
whereas the lipid A moiety triggers the B cells directly. Therefore
different parts of the same molecule interact with different types
of host cells. There is also evidence that immunopotentiating
activity of a glycopeptide produced by mycobacteria is dependent on
the saccharide residues of the molecule.
[0220] The capsular polysaccharide of the Streptococcus is
extremely immunogenic, consisting of glycan strands composed of
regularly alternating N-acetylglucosamine and N-acetylmuramic acid
residues joined through .quadrature.-1,4 glycosidic linkages and
attached to crosslinked peptides by amide bonds. The capsule of
strain M is composed of taurine-2-acetamido-2-deoxyfucose and
2acetamido-2-deoxy-D-galacturonic acid. The gene for this structure
called cap-1 has been cloned and is used to transfect tumor cells.
The nucleic acid sequences appear in Lin et al., J. Bacteriol. 176,
7005-7016 (1994).
[0221] A new 24-kDa group A streptococcal membrane protein known as
streptococcal protective antigen (Spa) has been identified and is
distinct from the surface M protein which evokes protective
opsonizing antibodies. The Spa-encoding gene has been cloned and
consists of a 636-bp 5' fragment. (Dale, J B et al., J. Clin.
Invest. 103: 1261-67 (1999)).
[0222] The present invention contemplates the use for cancer
treatment of these and other bacterial antigens from staphylococci,
streptococci, E. coli, N. mengitides, and other genera which
antigens evoke an immune response in mammals. In the preferred
approach, a nucleic acid encoding such an antigenic structure is
transfected and expressed in tumor cells. Methods of preparation,
use and assessment of these therapeutic constructs in tumor bearing
hosts are in Example 1, 2, 18-23.
[0223] SAg nucleic acids are fused in frame or cotransfected into
tumor cells or accessory cells with nucleic acids encoding key
transferases (gene clusters) and glycosylation sites encoding
capsular membrane from Streptococcus or Neisseria menigitidis
lipoprotein-LPS-phospholipid and cell wall peptidoglycans, i.e.,
N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM).
[0224] SAg DNA is fused in frame to DNA encoding a highly conserved
outer membrane surface protein of N. meningitides known as Nspa.
The Nspa gene has been cloned (Martin, D. et al., J. Exp. Med. 185:
1173-1183 (1997)). The LPS produced would be of weak to
intermediate strength such as that produced by Listeria or
Legionella.
[0225] Borrelia burgdorfi is the causative agent of Lyme disease.
The osp genes are located at a single genetic locus on a 49kb
double-stranded DNA linear plasmid where they are organized as an
operon ospAB. The amino acid sequences of OspA and OspB show a high
degree of similarity and resemble prokaryotic lipoproteins. Nucleic
acids encoding the ospA and ospB lipoproteins are cotransfected
into tumor cells together with SAgs.
[0226] Genes Encoding Membrane Glycosylceramide Biosynthesis
[0227] Nucleic acids encoding the synthesis of the GalCer from
Sphingomonas paucimobilis are transfected into tumor cells,
resulting in the synthesis of GalCer by the tumor cell. (Kawahara K
et al., FEBS Letters 292: 107-110, (1991) Yamazaki M et al., J.
Bacteriology 178: 2676-2687 (1996) Natori T et al., Tetrahedron
Letters 34: 5591-5592 (1993) Costantino V et al., Liebigs Ann.
Chem. 96: 1471-1475 (1995)). Nucleic acids encoding enzymes
responsible for synthesis of Neiserria meningitides LPS are
transfected into tumor cells, resulting in the synthesis of LPS by
the tumor cell (Steeghs L et al., Gene 190: 263-270 (1997)). These
nucleic acids encoding key transferases are fused to nucleic acids
encoding amplified oncogenes or transcription factors such as
Bcl-2, c-myc, K ras, bcr, c-abl or NF-.kappa.B.
[0228] Genes Involved in Mycobacterial Cell Wall Biosynthesis
[0229] SAg-encoding nucleic acid is fused in frame or cotransfected
into tumor cell with nucleic acids encoding the key enzymes
involved in the biosynthesis of mycobacterial cell wall mycolic
acid, phosphatidylinositol mannosides and lipoarabinans. A high
affinity interaction of CD1b molecules with the acyl side chains of
known T cell antigens such as lipoarabinomannan,
phosphatidylinositol mannoside and monomycolate has been
demonstrated. Hence the nucleic acid encoding the CD1 receptor are
cotransfected into tumor cells together with SAg-encoding nucleic
acid and nucleic acids encoding the multifunctional fatty acid and
mycocerosic acid synthases involved in the biosynthesis of mycolic
acid and methyl-branched fatty acids.
[0230] The multifunctional genes for mycocerosic acid synthase
involved in the biosynthesis of these molecules have been isolated.
In addition to the usual fatty acids found in membrane lipids,
mycobacteria have a wide variety of very long-chain saturated
(C18-C32) and monounsaturated (up to C26) n-fatty acids. The
occurrence of .alpha.-alkyl .quadrature.-hydroxy very long chain
fatty acids i.e., mycolic acid is a hallmark of mycobacteria and
related species. Mycobacterial mycolic acids are the largest
(C70-C90) with the largest -branch (C20-C25). The main chain
contains one or two double bonds, cyclopropane rings, epoxy groups,
methoxy groups, keto groups or methyl branches. Such acid are the
major components of the cell wall, occurring mostly esterified in
clusters of four on the terminal hexa-arabinofuranosyl units of the
major cell wall polysaccharides called arabinogalactans. They are
also found esterified to the 6 and 6' positions of trehalose to
form "cord factor". Small amounts of mycolate are also found
esterified to glycerol or sugars such as trehalose, glucose and
fructose depending on the sugars present in the culture medium.
Mycobacterium also contains several methyl-branched fatty acids.
These include 10-methyl C18 fatty acid (tuberculostearic acid found
esterified in phosphatidyl inositide mannosides), 2,4-dimethyl C14
acid and mono-, di- and trimethyl-branched C14 to C25 fatty acids
found in trehalose-containing lipo-oligosaccharides, trimethyl
unsaturated C27 acid (phthienoic acid), tetra-methyl-branched
C28-C32 fatty acids (mycocerosic acids) and shorter homologues
found in phenolic glycolipids and phthiocerol esters and
multiple-methyl-branched phthilceranic acids such as
heptamethyl-branched C37 acid and oxygenated multiple
methyl-branched acids such as
17-hydroxy-2,4,6,8,10,12,14,16,-octamethyl C40 acid found in
sulfolipids.
[0231] Genes Involved in Mycolic Acid Biosynthesis
[0232] The biosynthesis of mycolic acids involves fatty acid chain
elongation, desaturation, cyclopropanation of the olefin and a
Claissen-type condensation. The genes involved in cyclopropanation
are cma1, cma2. The methoxymycolate series found in M. tuberculosis
contains a methoxy group adjacent to the methyl branch, in addition
to the cyclopropane in the proximal position. A series of four
methyl transferase genes was cloned. The mm4 methylates the distal
olefin. The multifunctional fatty acid synthase (FAS) (type 1)
catalyses not only the synthesis of C16 and C18 fatty acids but
also elongation to produces C24 and C25 fatty acids. Cloning and
sequencing of the synthase gene revealed a 8389 bp ORF. The domain
organization is much like a head to tail fusion of the two yeast
FAS subunits; acyl transferase (AT)-enoyl reductase
(ER)-dehydratase (DH)-malonyl/palmitoyl transferase-acyl carrier
protein (ACP) fused with .quadrature.-ketoreductase
(KR)-.quadrature.-ketoacyl synthase (KS).
[0233] The MAS gene encoding mycobacterial mycocerosic acid
synthase is a dimer of the FAS gene. The cloning and sequencing of
the MAS gene revealed the domain organization in the following
order: KS-AT-DH-ER- KR-ACP. The purified MAS shows a preference for
elongation by four methylmalonyl CoA units reflecting the natural
composition of mycocerosic acids. FAS and MAS are also involved in
the biosynthesis of phthiocerol and phenolphthiocerol which involve
elongation of preformed n-C20 fatty acyl chains or an acyl chain
containing a phenol residue at the .omega.-end. The cluster of five
genes, ppsi1-5 encode the multifunctional enzymes (Fernandes N D et
al., Gene 170: 95-99 (1996) Mathur M et al., J. Biol. Chem.
267:19388-19395 (1992) Yuan Y. et al., Proc. Natl Acad. Sci. U.S.A
92: 6630-6634 (1995)).
[0234] Tumor cells are cotransfected with SAg-encoding DNA and
nucleic acids encoding the biosynthesis the above microbial
products. The transfected tumor cells acquire significant
additional immunogenicity. These cells are prepared as in Example
1-3. They are useful in vivo as a preventative or therapeutic
antitumor vaccine (Examples 5 15, 16 18-23. They are also useful ex
vivo to immunize T or NKT cells to produce a population of effector
T or NKT cells for adoptive immunotherapy of cancer (Examples 2-5.
15, 16. 18-23).
[0235] 22. SAg-Ganglioside or SAg-Galactosylceramide Complexes
Formed after Transfection of Tumor Cells with DNA Encoding SAgs:
Complete Bacterial Antigen System Recognized by CD1 Receptors
Capable of Inducing Anti-Tumor Effects
[0236] SAg-encoding nucleic acid transfected into tumor cells
express SAg on the tumor cell surface which is bound to cell
surface ganglio sides which are tumor associated antigens, oncogene
product such as EGF or IGF. In this way the tumor associated
antigen is capable of recognition and interaction with host T cells
and macrophages and of evoking a potent immune response. The SAg is
also bound or associated with the CD1 receptor alone or associated
with the glycosphingolipid tumor associated antigen.
[0237] SAgs have a natural affinity for glycosphingolipids on cell
membranes. Enterotoxin-producing-bacteria secrete enterotoxins
which in their precursor state are bound to cell membranes in
dimeric form. Enterotoxin transfected tumor cells induce an
anti-tumor response by expressing the tumor cell surface antigen in
association with the SAg. Bound to the tumor cell membrane, the SAg
may be in dimeric form associated with the ceramide lipophilic
anchor domain of a glycosphingolipid tumor associated antigen.
Likewise, the SAg may be associated with the carbohydrate moiety or
the ganglioside which protrudes from the cell surface. It may also
be secreted in monomeric or dimeric form fused to membrane
associated tumor antigen, oncogene product or receptor. If the
tumor associated glycosylceramide, glycoprotein antigens, or
glycolipid antigen with or without SAg are presented on CD1
receptors, then NKT cells may generate the predominant T cell
response. However the classical T cell system is also
responsive.
[0238] These constructs are produced and used as a vaccine against
established tumor by protocols given in Examples 2-5, 15, 16
18-23.
[0239] 23. Nucleic Acids Encoding CD1 Receptors
[0240] Nucleic acid encoding the CD1 receptor is transfected into
tumor cells, resulting in expression of the CD1 receptor on the
tumor cell surface. Promoters of CD1 synthesis are also useful in
this invention. The human genome includes five CD1 genes (A-D)which
also function in antigen presentation to T cells (Calabi, F et al.,
CD1: From Structure to Function in Immunogenetics of the Major
Histocompatibility Complex, Srivastava, R et al., eds, VCH
publishers, New York, N.Y., 1991). In mice, two homologous proteins
(mCD1.1 and 1.2) have been characterized and map to chromosome 3.
The human CD1 genes are located on chromosome 1q221-q23 in the
order D-A-C-E from the centromere on a 190 kb segment of DNA. With
the exception of CD1B, they are all in the same transcriptional
orientation. They are evenly spaced in the complex with one
exception: CD1D and CD1A are spaced two to three times farther
apart than the average. The products of CD1A, -B and -C genes have
been defined serologically. The products of CD1D and CD1E are
unknown. They share a highly conserved exon domain which is
homologous to the .quadrature.2m-binding domain (a3) of MHC class I
antigens. The CD1 molecules are not polymorphic and apart from
CD1D, are noncovalently associated with .quadrature.2m in a
TAP-independent manner. Complex alternative splicing of CD1 genes
results in tissue specific forms of the protein, which can be
intracellular, membrane bound, or secreted. In cells infected with
mycobacteria, the CD1 molecule binds and presents a mycobacterial
membrane component, mycolic acid. Surface CD1 molecules present
longer peptides than those normally found on class I molecules.
Whether CD1 molecules can also present peptide antigens is still
unclear although this has been shown for at least one member of the
CD1 family.
[0241] Tumor cells are transfected with nucleic acid encoding the
CD1 receptor. Nucleic acid encoding cell wall or cell membrane
associated glycosylceramides or .alpha. branched, .quadrature.
hydroxy long-chain fatty acids found in mycobacteria and other
bacteria are cotransfected into the CD1 transfected tumor cells.
The tumor cell therefore displays glycosylceramides bound to the
CD1 receptor. Using site directed mutagenesis, DNA encoding the CD1
receptor is provided along with DNA encoding a SAg binding site.
This SAg binding site consists of key amino acids from the SAg
receptor or from the SAg binding sites on (i) MHC class II chains
or (ii) the TCR V.quadrature. region. This may consist of a
glycosphingolipid sequence (sensitive to endoglycoceramidase)
present on some mammalian cells. The glycosylceramide used to bind
to the CD1 receptor will have an exposed SAg binding site which is
sensitive to endoglycoceramidase, an enzyme from Rhodococcus which
specifically cleaves the glycosyl moiety from glycosphingolipids.
Other ceramidases break up sphingolipid into fatty acids and
sphingosine.
[0242] These tumor cells transfectants are prepared as in Examples
1 and 2. They are used in vivo as a preventative or therapeutic
antitumor vaccine as in Example 14-16, 18-23. They are also useful
ex vivo to produce a population of tumor specific T or NKT cells
for adoptive immunotherapy of cancer (Example 2-5, 7, 15, 16,
18-23).
[0243] 24. DNA Encoding Streptococcal M Proteins and DNA Encoding
Protein A or its Fc and VH3 IgG binding Domains Transfected into
Tumor Cells Alone or SAg DNA
[0244] The streptococcal M proteins are type-specific and act as
protective or virulence factors. M protein genes are members of a
larger emm-like gene family, such that many S. pyogenes strains
express more than one M-like protein. DNA encoding the
streptococcal M protein and DNA of the larger emm-like family are
transfected into tumor cells (Kehoe M. A., "Cell-Wall Associated
Proteins in Gram-Positive Bacteria," In: Bacterial Cell Wall,
Ghuysen J M et al., eds, Elsevier, Amsterdam, 1994).
[0245] In addition, DNA encoding protein A and its domains as well
as DNA of the streptococcal fcrA 76 gene located upstream of the
emm-like gene are transfected into tumor cells individually or
together to cause the expression of IgG FcR- and VH3 IgG-binding
domains (Kehoe MA, supra). DNA encoding SAg is cotransfected into
the same tumor cells to produce a tumor cell expressing any
combination of M protein, protein A and a SAg. Such cells are used
in vivo as preventive vaccines or as therapeutic vaccines against
established tumors. See Examples 1-5, 11, 15,16, 18-23. They may
also be used ex vivo to induce populations of active tumor specific
effector T cells that are then used in adoptive immunotherapy See
Examples 2-5, 7, 15-16, 18-23. 25.
[0246] Nucleic Acids, Bacterial Cells and Phage Displays Mimicking
SAgs
[0247] Because of circulating naturally occurring antibodies in
humans, native or mutated SAgs that are administered parenterally
are not likely to reach the appropriate receptors on T cells or
tumor cells. To solve this problem, mimic oligonucleotides are
prepared--these mimic SAgs in their capacity to bind SAg receptors.
Since no natural antibodies are directed to these compositions,
they will not be prevented from reaching specific SAg receptors in
vivo.
[0248] SAg receptors are used to screen oligonucleotides for their
ability to mimic SAg binding. Useful receptors for such screening
include those described herein (as expressed on tumor cells) and T
cell TCR V chains. For example, pools of oligonucleotides are
tested for their binding to, and affinity for, immobilized SAg
receptors using nucleotide chromatography technology well known in
the art. Once these high affinity binding oligonucleotides are
identified, they are isolated (or, following sequencmg, may be
synthesized) and administered to a host. Also included here is a
bifunctional oligonucleotide-peptide chimeric molecule that binds
specifically to the SAg receptor on tumor cells as well as the
V.quadrature. region of the TCR. Such an oligonucleotide will bind
simultaneously to tumor cells and T cells (in the process of
activation) to produce an anti-tumor response. An
oligonucleotide-protein construct is prepared consisting of (a) a
peptide sequence of enterotoxin A that binds to the TCR and (b) an
oligonucleotide that binds to SAg receptor on tumor cells. The
peptide portion of this construct should be devoid of MHC class II
binding sites in order to minimize undesired binding of the
molecule to class II structures upon administration in vivo.
[0249] In another embodiment, the nucleic acid portion of the
chimeric molecule binds to the TCR while the peptide consists of a
non-enterotoxin ligand that is specific for the SAg receptor on
tumor cells. This construct has the advantage of lacking any
binding site for natural antibodies.
[0250] Yet another additional chimeric molecule consists of an
oligonucleotide portion specific for the class II (or (chain and a
second oligonucleotide or a peptide specific for the TCR
V.quadrature. chain.
[0251] Methods for preparing these constructs are given in Examples
5, 13. These constructs are especially useful for targeting tumors
in vivo while also promoting a T cell anti-tumor response. See
Examples 18-23. However, these chimeric molecules may also be used
ex vivo in the production of tumor specific effector T cells
capable of inducing, or effecting, an anti-tumor response when
administered to a tumor bearing host. See protocols in Examples
2-5, 15, 16 18-23.
[0252] SAg and GlycosylCeramide Co-Expression
[0253] This may be accomplished using intact bacteria or phage
display approaches. Since the precursors and substrates of the
glycosyltransferases are not readily available in most mammalian
cells, it is more convenient to induce dual expression of GalCer
and SAgs in bacteria, for example Sphingomonas paucimobilis, which
naturally produce GalCer. Hence, nucleic acid encoding a SAg is
transfected into this bacterium together with a suitable promoter
well known in the art. The bacterium produces both GalCer and SAg.
By ensuring that the SAg contains one or more glycosylation sites
(by using the appropriate nucleic acid sequence), a glycosylated
SAg is produced. Such a SAg binds to the glycosyl ceramide, e.g.,
GalCer to form a conjugate that is expressed on the bacterial
surface of is secreted. In either form, such a SAg-GalCer conjugate
can sensitize NKT cells to produce an anti-tumor response. In
addition, phage or plasmids encoding the appropriate transferase
are transfected into low virulence Staphylococcus species which
also produce enterotoxins. The bacterium acquires the capability of
expressing GalCer on its surface. These bacterial constructs and
compositions are used in vivo in a tumor bearing host to produce an
anti-tumor response in protocols given in Examples 5, 13, 15, 16
18-23 and Detailed Description Section 19. They are also are used
ex vivo to activate NKT cells or T cells to differentiate to tumor
specific effector cells for use in adoptive immunotherapy of cancer
by protocols in Example 1, 2, 14-16, 18-23).
[0254] Phage display technology is used to target selected SAg
sequences to targets in vivo. The selected peptide is used as a
binding sequences in lieu of the full-length polypeptide. This
permits elimination from the construct of the antigenic portion of
the SAg to which natural antibodies are directed. Cloned genes are
expressed as part of phage coat proteins, for example, as fusions
with the gene III protein (gIIIp) or the gene vIII protein
(gVIIIp). In addition to the displayed gene product, the phage
genome (of each particle) includes the gene encoding this
product.
[0255] Phage display is preferably done using the filamentous phage
f88-4 and comprises forming a fusion that results in the C terminus
of the "selected" (i.e., inserted gene's) product and the N
terminus of the phage protein gVIIp. Peptides of various
enterotoxins are expressed in the phage display--most preferably
peptides that bind to the SAg receptor on colon carcinoma cells.
These peptides retain their capacity to bind to the TCR and to
activate T cells. Also contemplated within this invention is phage
display of SAg plus nucleic acid encoding synthesis of GalCer
and/or the Gal epitope. DNA for synthesis of GalCer is preferably
isolated from Sphingomonas paucimobilis; DNA encoding the
galactosyl transferase for synthesis of Gal is preferably isolated
from Klebsiella aerobacter, Serratia, E. coli and Salmonella
organisms which naturally produce and express these epitopes. The
phage displays are adninistered in vivo and are capable of
initiating a potent immune response to the tumor using the
protocols described in Examples 5 and 13 and Section 19, above.
These preparations are also useful for activating T cells or NKT
cells ex vivo to produce a tumor specific effector cells for use in
adoptive immunotherapy (Examples 2-5, 14-16, 18-23).
[0256] Viral infection of a host cell having the galactosyl
transferase results in the shedding of virions that express the Gal
epitope. When a host mammalian cell has been transfected with
nucleic acid encoding SAg, the virus can coexpress the Gal epitope
and the SAg on its surface. Such a viral construct is administered
in vivo to achieve a therapeutic effect, or, in another embodiment,
is employed ex vivo to produce tumor specific effector T or NKT
cells for use in adoptive immunotherapy of cancer (Examples 2, 3,
7, 15, 16, 18-23).
[0257] 26. Combining SAgs with Enterotoxin Precursors (Cell-Bound
Dimers and Oligomers) and with Enterotoxin Promoters and
Transcriptional Regulatory Genes
[0258] Cell-Bound SAg Dimers and Oligomers
[0259] Staphylococcal enterotoxins are present in the membrane of
enterotoxin producing bacteria in dimeric form and retain potent
enterotoxin-like activity when isolated from the membrane. It is in
this membrane-bound form that enterotoxins are combined with tumor
associated antigens or oncogene products and presented to the T
cell system. The dimerization of the enterotoxins may promote
clustering for more effective presentation to T cells. Indeed,
dimerization or polymerization of enterotoxins or the introduction
of tandem repeats of the SAg binding sites for TCR and MHC class II
may be achieved by (1) site directed mutagenesis of the enterotoxin
plasmid and (2) introduction of sequences for gene amplification,
tandem repetition and/or recombination or by (3) introduction of
enzymes for peptide chain elongation. The duplication may be at the
level of the bacterial operon including its transcriptional
regulators, using methods well described in the art. Modified
plasmid is DNA is introduced into the target tumor cells or into
accessory cells, either or both of which are useful in vivo as a
preventative or therapeutic vaccine (Examples 1, 2, 15, 16, 18-23).
Such genetically transformed cells may also be used ex vivo to
produce effector T or NKT cells for adoptive immunotherapy
(Examples 1, 2, 7, 15, 16, 18-23).
[0260] SAg agr Locus (Accessory Gene Regulator) and Other Bacterial
Genes and Elements
[0261] At least 15 gene coding for potential virulence factors in
S. aureus are regulated by a putative multicomponent signal
transduction system encoded by the agr/hld locus. The synthesis of
at least 14 exotoxins and enzymes in S. aureus is regulated by a
set of trans-acting elements from agr. The agr gene coordinately
controls the expression of exfoliatin toxin, toxic shock syndrome
toxin, a, b, d toxins, enterotoxin B, lipases and nucleases
(Balaban, N. et al., Proc. Natl. Acad. Sci. U.S.A 92:1619-1623
(1995)). These proteins are members of the histidine protein kinase
family of regulators and control a number of virulence determinants
(Balaban supra, Novick R P, Meth Enzymol. 204: 587-637 (1991)).
Compared to wild-type, agr and hld mutants have decreased synthesis
of extracellular toxins and enzymes (such as .alpha.-,
.quadrature.-, and .gamma.-hemolysins, leucocidin lipase,
hyaluronate lyase and proteases) while having increased synthesis
of coagulase and protein A. The agr gene consists of two divergent
transcriptional units driven by promoters named P2 and P3. The P2
transcript includes four open reading frames referred to as agrA,
B, C, and D, all four of which are required to for the agr
response. The peptides predicted for agrA and agrc resemble the
response regulators and signal transducers of the two-component
bacterial signal transduction systems. The primary function of thee
four genes discussed above is to activate two promoters; the P3
transcript, RNAIII, however is the actual effector of the exotoxin
response. RNAIII activates transcription of secretory protein genes
and represses transcriptions of surface protein genes. As a global
regulatory system, agr, controls the post-exponential production of
exoproteins such as toxins, hemolysins, and exoenzymes. agr is a
complex polycistronic locus that encodes a two-component signal
transduction pathway that activates transcription of a regulatory
RNA molecule that in turn activates transcription of the exoprotein
genes.
[0262] Thus, transcriptional regulation of the enterotoxin B gene
as well as SED, SEC and staphylococcal capsular polysaccharide gene
involves the agr product. (agr does not regulate SEA
expression).
[0263] The promoter region of SEA is localized by primer extension
analysis. The 5'-end of SEA mRNA is localized 86 bp upstream of the
translational initiation codon. A DNA region with good agreement
with canonical promoter sequences was observed beginning 8 base
pairs upstream of the apparent transcriptional start site. No DNA
upstream of the 35 bp region is required for transcription. Both
the agr gene and the SEA promoter have been cloned (Peng, H. L. et
al., J Bacteriol. 170:4365-4372 (1988); Borst, D. W. et al., Infec.
Immun. 61:5421-5425 (1993)). The xpr locus and the agr locus
interact at the genotypic level; agr is autoinduced by a
proteinaceous factor produced and secreted by the bacteria and is
inhibited by a peptide from an exotoxin-deficient S. aureus mutant
strain. The inhibitor, RIP, competes with the activator, RAP. When
given as a vaccine, RIP may prove useful as a direct inhibitor of
virulence.
[0264] A chromosomal locus (sar) distinct from agr, encodes a
DNA-binding protein that is important in regulation, and is
required for expression of S. aureus exoproteins including
enterotoxin, toxic shock syndrome toxin, hemolysin and
staphylokinase. Transcription of Protein A is suppressed by sar and
agr. A list of plasmids containing bacterial virulence factors
useful in this invention is disclosed in Table 49, p. 223 of
Patrick, S. et al., Immunological and Molecular Aspects of
Bacterial Virulence, John Wiley and Son, New York, N.Y. 1995. This
invention contemplates the use of the Staphylococcal enterotoxin
promoters and transcription factors that activate the enterotoxin
biosynthetic cycle. Several Staphylococcal promoters have been
identified (Novick, supra). This invention also contemplates the
use of the peptide activator RAP which induces agr as well as the
peptide inhibitor RIP which induces or represses RNA III.
[0265] SAg-encoding nucleic acid is fused in-frame with
Staphylococcus agr nucleic acid and introduced into tumor cells or
accessory cells (or the two are cotransfected into these cells). In
another embodiment, SAg-encoding nucleic acids placed under the
control of an enterotoxin promoter, and this construct is
introduced into tumor cells or accessory cells. The agr gene is
especially useful because it can be linked to an inducible promoter
such as that for corticosteroids or the metallothionein promoter,
allowing it to be activated in a controlled manner by exogenous
administration of the inducing to the host.
[0266] Methods for introducing the above genes into tumor cells are
described in Example 1, 2, 11. The use of such cells in vivo as
preventative or therapeutic vaccines are discussed in Examples 15,
16, 18-23. Use of these genetically transformed tumor cells ex vivo
to induce effector T or NKT cells for adoptive immunotherapy is
described in Examples 2, 3, 7, 15, 16, 18-23.
[0267] 27. Combining SAg with Oncogenes, Protooncogenes, Amplified
Oncogenes, Transcription Factors or Tumor Markers
[0268] In one embodiment, the nucleic acid encoding a SAg is fused
in-frame to oncogene or protooncogene nucleic acid in tumor cells
or accessory cells to produce a chimeric nucleic acid which is
expressed in, or on the surface of, the cell. This fused gene may
be rendered inducible by judicious choice of a promoter or other
regulatory sequence. Preferably, such an inducible promoter is
induced by a hormone or a metal. A regulatory element, such as one
activated by interferon or a cytokine (e.g., Jak or a STAT), may be
included in this construct. In another embodiment, the nucleic acid
encoding SAg is fused in frame to nucleic acid encoding an oncogene
which can be amplified markedly. The fused construct is introduced
into tumor cells or accessory cells. An amplified "unit" is
initially much larger than the size of the actual gene of
importance to the oncogenic event(s) (Hellems, R E, Gene
Amplification in Mammalian Cells, Marcel Dekker, New York, N.Y. ).
Thus a silent gene is co-amplified with one or more genes expressed
on an amplicon. This is a preferred site for the inserting gene
clusters wherein one gene encodes a SAg, others encode the enzymes
of LPS lipid A biosynthesis, optionally together with their native
promoters or operons.
[0269] Transcription Factors and Amplified Oncogenes
[0270] Oncogenes are frequently amplified in human tumors and
cultured cancer cells. This is more characteristic of solid tumors
and relatively rare in lymphoid malignancies. DNA amplification was
first observed cytogenetically a double minute chromosomes (DMs) or
homogeneously staining regions (HSRs) but today, direct DNA
analysis (Southern blotting) or molecular cytogenetic
methodologies, such as fluorescence in situ hybridization (FISH)
and comparative genomic hybridization (CGH) can be applied. DMs are
episomal forms of amplified DNA that generally lack centromeres and
are unequally distributed between daughter cells at mitosis. They
appear as isodiametric extrachromosomal bodies stainable with all
chromatin dyes. HSRs are chromosomally integrated forms of
amplified DNA. They represent either the replacement of the normal
chromosome banding pattern with an extended region of homogenous
staining or the insertion of such a region into an otherwise
normally banded chromosome. DMs and HSRs tend to be mutually
exclusive and are potentially interchangeable manifestations of the
amplified DNA. Thus, DMs can potentially integrate into distant
chromosomal sites to generate heritable HSR. Of 22 human tumors
analyzed, 91% contained DMs only, 6.5% contained HSRs and 2.5%
contained both. In solid tumors of epithelial origin, DMs and HSR
were found in 40% of breast carcinomas, 17% of non small cell
carcinoma of the lung, 18% of stomach and esophageal cancers and
15% of uterine carcinomas.
[0271] The overwhelming majority of oncogene amplifications in
human tumors affect the Myc oncogene family. In small cell lung
cancers all three members of the Myc family, c-myc, N-myc and L-myc
can be involved. Myc amplification is associated with a more
invasive and more metastatic phenotype. N-myc amplification is seen
in neuroblastoma and is associated with the late stages and poor
prognosis. The amplification units on chromosome 11q13 are seen in
(a) breast cancer, (b) squamous cell carcinoma of the head and
neck, lung, and esophagus and (c) bladder tumors. The amplification
extends for over 1.5 megabase pairs of DNA and includes two bona
fide oncogenes: FGF3 and FGF4. It also includes the Bcl-1 CCND1
(cyclin D1) as well as the EMS1 gene that encodes the human
homologue of cortactin. CCND1 has a critical role in amplified DNA
since its expression is increased as a consequence of
amplification. The other major targets for amplification are the
genes encoding the EGF receptor (ErbB1/Her1) and the related
ErbB2/Her2. Both genes are amplified in breast cancer and other
malignancies. ErbB2 is associated with estrogen receptor-negative
breast cancers and poor prognosis.
[0272] Members of the myc gene family are activated in several
human tumors as a result of DNA rearrangements through chromosomal
translocations or gene amplification. When overexpressed, all myc
genes complement mutant c-ras oncogenes in the transformation of
primary rat embryonic cells and transform Rat 1-A cells without
assistance of other oncogenes. Stimulation of cellular myc
expression levels or changes in post-translational modification of
myc proteins have been following exposure of cells to many growth
promoting stimuli. These features suggest that the myc proteins
participate in the final steps of mitogenic signal transduction.
The myc proteins act as transcription factors involved in
activation and/or repression of target genes. In neuroblastoma, a
group whose tumors are generally near diploid or tetraploid with
chromosome 1p deletion(LOH) and N-myc amplification have a
generally poor response to treatment and a poor prognosis. Genomic
amplification of the N-myc cellular oncogene is present in
approximately 40% of cases of childhood neuroblastoma and
correlates with histopathological signs of advanced disease. This
genomic N-myc amplification appears to be associated with tumor
progression rather than tumor initiation since early stage tumors
rarely exhibit M-myc genomic amplification. Similarly the c-myc
family of protooncogenes including N-myc and L-myc are amplified in
small cell carcinoma of the lung.
[0273] The amplified oncogenes useful in the present invention
include genes encoding transcription factors. The preferred nucleic
acids for use in the present invention are c-myc, N-myc, c-abl,
c-myb, c-erb, c-Ki-ras, N-ras. N-myc (amplified 5-1000 fold in
neuroblastoma) is preferred. SAg-encoding nucleic acid is
cotransfected into tumor cells or accessory cells with amplified
oncogenes. The N-myc and L-myc genes have been cloned as c-myc
homologous amplified oncogenes from human tumors. In one
embodiment, SAg-encoding nucleic acid is fused in frame with
nucleic acid encoding oncogenic transcription factors such as FOS,
JUN. MYC, MYB and ETS. In another embodiment, such nucleic acid is
cotransfected with SAg-encoding nucleic acids. Either of such
constructs is introduced into tumor cells or accessory cells.
Proteins that interact with FOS and JUN are given in Table 1 p. 157
of Peters G et al., Oncogenes and Tumor Suppressors, Oxford
University Press, Oxford UK 1997, incorporated by reference.
[0274] bcr/abl Gene
[0275] SAg-encoding nucleic acid is fused in frame or cotransfected
with nucleic acids encoding the following agents and transfected
into tumor cells and fused to oncogenic nucleic acids encoding
chimeric proteins capable of immunizing the tumor bearing host. An
ideal candidates for such fusions is the bcr-abl gene which express
the bcr/abl protein in chronic myelogenous leukemia (CML). The
c-abl oncogene is amplified in chronic myelogenous leukemia.
Scherle P A et al., Proc. Natl. Acad. Sci. U.S.A 87: 1908-1917
(1990) Heisterkamp N et al., Nature 344: 251-253 (1990).
Abnormalities in the structure and expression of the human c-abl
cellular oncogene have been associated with Philadelphia
chromosome-positive CML which is present in more than 90% of cases.
This aberrant chromosome marker is generated by a reciprocal
translocation between chromosomes 9 and 22 in which the c-abl
oncogene is translocated from the distal end of the q arm of
chromosome 9 to a relatively restricted 5-6kb region on chromosome
22 termed the breakpoint cluster region (bcr). This translocation
creates a fusion gene that is transcribed as an 8 kb bcr-abl RNA
that encodes the aberrant bcr-abl fusion protein product (P210)
observed in CML cells. The bcr-abl fusion product has enhanced
tyrosine kinase activity compared with the normal p145 c-abl
product. Abnormalities in the structure and expression of the c-abl
cellular oncogene have not been described in any type of human
malignancy other than CML and Ph positive acute lymphatic leukemia.
Gene amplification correlates with progression of malignancy.
[0276] EGF Receptor Genes
[0277] SAg-encoding nucleic acid is fused in frame to the nucleic
acids encoding the EGF receptor (EGFR) (Ulrich A et al., Nature
309: 418-421 (1984)). The EGFR is the prototype of four-member
receptor family. EGFR is frequently overexpressed or mutated in
several different types of human tumor. For instance, the EGFR is
amplified in 20-40% of human glioblastomas and a variety of
epithelial tumors including head and neck squamous cell carcinomas,
breast tumors, esophageal tumors and urogenital tumors.
Amplification was accompanied by overexpression of the EGFR.
[0278] The erbB2 (her2/neu) Oncogene
[0279] SAg-encoding DNA is fused in frame to DNA encoding a tumor
marker such as PSA, c-erbB2(neu), her2/neu, bcl-2 and Brca-1. The
principal amplified and functional genes in breast cancer are the
growth factor receptor-erbB2, the nuclear transcription factor
c-myc, and the genes encoding cell cycle kinase regulatory genes
termed cyclin D1 and cyclin EG. Gene amplification is thought to
proceed via the initial formation of extrachromosomal, self
replicating units (double minute chromosomes) that become
permanently incorporated into chromosomal regions where they are
called homogeneously staining regions (HSRs) as described
above.
[0280] The human counterpart of the oncogene neu known as her2
encodes a protein of the same family as the EGFR. This family of
genes has been cloned. Its products belong to a family of receptor
tyrosine kinases each with a transmembrane domain, a cysteine-rich
extracellular domain and an intracellular catalytic domain. They
act as receptors for several peptide growth factors such as EGF,
TGF(and neuregulins. The activated receptors are then able to bind
to proteins containing src-homology-2 (SH.sub.2) domains. The
SH.sub.2 domain proteins recognize and bind to specific
phosphotyrosine-containing sequences of the activated receptor.
These SH.sub.2 containing adapter molecules then trigger downstream
signalling pathways, ultimately resulting in gene activation.
[0281] The erbB2 (neu/Her2) gene maps to chromosome 17p21 and codes
for a 185 kDa transmembrane glycoprotein related to, but not
identical to the EGF receptor (Schechter A L et al., Science 229:
976-978 (1985), Bargmann C L Nature 319: 226-230 (1986), Hung M C
et al., Proc. Natl. Acad. Sci. U.S.A 83: 261-264 (1986), Yamamoto T
et al., Nature 319: 230-234 (1986)). The EGFR bears sequence
homology with the erbBl product. The erbB2 gene is activated by a
point mutation which mutates amino acid residue 664 from valine to
glutamic acid; this change is associated with transforming its
ability. The genes are called erbB, (erbB1, EGFr), erbB2,
(neu/Her-2). erbB3(HER-3) and erb B4 (HER-4). Amplification and
overexpression of erbB2 has been found in a variety of human tumors
including carcinomas of the breast, ovaries, colon, lung, liver,
stomach, kidney, esophagus, salivary gland, and bladder. Genomic
amplification of the neu (C-erb-2) or HER2 cellular oncogene and
protein overexpression has been documented in approximately 30% of
primary human breast cancers and may correlate with advanced
disease and a relatively poor prognosis. More than 50% of all
ductal carcinomas in situ of the large cell type express HER2.
Amplification occurs in approximately 20% of invasive breast
carcinomas. Thus, it is thought that HER2 amplification increases
the growth rate but not the metastatic potential of tumor
cells.
[0282] A third member of the EGFR family is ERBB3which is present
in some human breast cancers with high expression correlating with
lymph node metastases. Overexpression of ERBB3 has been observed in
epidermoid carcinoma of the larynx and esophageal carcinoma. ERBB4,
a fourth member of the EGFR family, was overexpressed in a human
mammary tumor cell line. Fisk et al. (J. Exp. Med. 181: 2109-2117
(1995)) described an immunodominant epitope of HER/neu that is
recognized by ovarian tumor-specific cytotoxic T lymphocytes. This
epitope is useful in this invention. Failure of coexpression of a
heterodimeric partner or coinduction of a suppressor phosphatase
would explain the lack of immunogenicity of c-erbB2 in mice in nude
mice.
[0283] Additional oncogenes, protooncogenes and tumor markers which
would be candidates for the fusion in accordance with this
invention are w PSA, c-erb B2(neu), Her2/neu, bcl-2, Brca-1. Viral
and non-viral oncogenes and protooncogenes which are overexpressed
in tumor cells are shown in Table 9.2 and 9.1, p. 171-172 of Franks
et al., supra). The functions ofthe various oncogenes is shown in
Table 9.6, p. 186, of Franks et al.
[0284] IGF Receptor Genes
[0285] SAg-encoding nucleic acid is fused in frame with nucleic
acids encoding insulin-like growth factor (IGF) receptors
(IGFRs)and transfected into tumor cells. The IGFR gene is a
tyrosine kinase containing transmembrane protein that plays an
important role in cell growth control. There is a single IGF1
receptor gene with a complete coding sequence contained in 21 exons
(Abbott A M et al., J. Biol. Chem. 267: 10759-10763 (1992); Scott J
et al., Nature 317: 260-262 (1985); Liu J et al., Cell 75: 59-63
(1993)).
[0286] IGF1R is expressed at high levels in breast cancer, and
amplification of the IGF1R gene has been observed. IGFs play a
significant auxiliary role in tumor growth by suppression of
apoptosis. The apoptotic effect overexpressed myc is overcome by
IGFs. Thus, IGFs facilitate tumor growth by suppression of
apoptosis.
[0287] Fibroblast Growth Factor (FGF) Receptor Genes
[0288] SAg-encoding nucleic acid is fused in frame to nucleic acids
encoding fibroblast growth factors receptors (FGFs) and transfected
into tumor cells. FGF receptor are also be important for the
vascularization of certain types of tumors. The expression of FGF1
has been shown to be associated with a switch to an angiogenic
phenotype during the development of a fibrosarcoma. Overexpression
of FGF receptor by certain tumors may also contribute to their
growth. FGF receptors have been shown to be amplified in some
breast cancers.
[0289] Platelet Derived Growth Factor (PDGF) Receptor Genes
[0290] SAg-encoding nucleic acid is fused in frame to nucleic acids
encoding additional tumor growth factors which are produced or
overexpressed and transfected into tumor cells or accessory cells.
Growth factors include those in the tyrosine kinase receptor
families such as Platelet Derived Growth Factor A and B family
(PDGF). PDGF A and B receptors are amplified in malignant
glioblastomas in the malignant cells themselves or the stromal
cells (Fleming T P et al., Cancer Res. 52: 4550-4556 (1992);Kumabe
T et al., Oncogene 7: 627-632 (1992)). The nerve growth factor
(NGF), stem cell factor receptor (kit), colony stimulating factor-1
receptor (fms), neurotropin receptor family, transforming growth
factor .quadrature. family, the WNT family, angiogenic
receptors
[0291] Other Amplified Oncogenes
[0292] SAg-encoding nucleic acid is also fused to nucleic acid
encoding the tyrosine protein kinases which are both membrane
associated and transmembrane as described in Table 9.4, p. 179 of
Franks et al., supra. Additional chromosomal regions which are
amplified in greater than 40% of cases included the 8q24 locus of
the c-myc(O) gene, the 11q13 locus of the cyclin D (O), int2 (O),
EMS-1 (O), BCL-1 (O), FGF-4 (O) GST (M), MEN1(S) genes, the 17q21
locus of the RARa (S), RARg (S), ERBAa (S), BRCA1 (S), NM23 (S),
estradiol 17B dehydrogenase (S) ERG2 (O), HOX2, NGFR (O), WNT3 (O)
and the 20q13 locus.
[0293] Nucleic acid encoding SAg is fused or cotransfected into
tumor cells with nucleic acid encoding the above oncogenes,
amplified oncogenes and protooncogenes, transcription factors and
growth factor receptors. These transfectants are prepared as in
Examples 1. They are useful in vivo as a preventative or
therapeutic vaccine (Examples 15, 16, 18-23). They are also useful
ex vivo for inducing tumor specific effector cells for adoptive
immunotherapy (Examples 2-5, 7, 15, 16 18-23).
[0294] 28. Combining SAg with Angiogenic Receptors and Growth
Factor Receptors
[0295] SAg-encoding nucleic acid is cotransfected or fused in frame
to nucleic acid encoding an angiogenic receptor such as VEGF and
transfected into tumor cells. SAg nucleic acid is also fused to or
cotransfected with nucleic acid encoding other angiogenic receptors
such as v integrin, other integrins, cadherins or selectins and
introduced into tumor cells or accessory cells. SAg-encoding
nucleic acid is also cotransfected into tumor cells or accessory
cells with nucleic acids encoding angiogenic proteins such as VEGF.
VEGF is produced by tumor cells and stroma, and its expression
correlates with the degree of vascularization and grade of
malignancy. VEGF receptors, termed KDR and flt, are expressed
mainly by the tumor endothelium. Higher levels of VEGF are found in
metastatic than in non-metastatic colon cancers (Tischer E et al.,
J. Biol. Chem. 266: 11947-11954 (1991). VEGF is especially useful
here because it is overexpressed in tumor cells at an early stage
of tumorigenesis. The promoter of the VEGF gene lacks a TATA box,
but has six GC boxes for transcription factor SP-1 binding and also
a site for AP-1 and AP-2 binding. The expression of the gene is
modulated by several growth factors such as EGF. In some cell types
VEGF expression is regulated by IL-1, FGF, PDGF. A common element,
mediation of protein kinase C in the regulation of VEGF, has been
suggested. VEGF is expressed as a disulfide linked dimer. Long and
short forms are generated by alternative splicing and are matrix
bound or released, respectively. As a result of its specific
effects on endothelial cell migration and proliferation, VEGF is a
very potent and specific promoter of angiogenesis. Two well
characterized families of angiogenic factors act by binding to
tyrosine kinase receptors that have two or three
immunoglobulin-like domains, and VEGF binds to two related
receptors with seven immunoglobulin-like extracellular domains.
[0296] The TRKA oncogene codes for a receptor for nerve growth
factor (NGF). The TRKA gene has been found fused to genes that code
for proteins that form dimers in cells leading to the synthesis of
a constitutively dimerized and active tyrosine kinase. TRKA may
have a tumor suppressor function since its expression in
neuroblastoma correlated inversely with n-myc gene amplification.
Coexpression of mRNA for TRKA and the low affinity NGF receptor in
neuroblastoma correlated with a favorable prognosis.
[0297] Nucleic acid encoding SAg is fused to nucleic acid encoding
the above angiogenic factors or receptors and introduced into tumor
cells; alternatively, the two nucleic acids are used to
cotransfected tumor cells. These transfectants are prepared as in
Example 1. They are useful in vivo as a preventative or therapeutic
antitumor vaccine (Examples 15, 16, 18-23). They are also useful ex
vivo for inducing tumor specific effector cells for adoptive
immunotherapy of cancer (Examples 2-5, 7, 15.16 18-23).
[0298] 29. Combination of SAg with Cell Cycle Protein
[0299] SAg-encoding nucleic acid is fused in frame to nucleic acid
encoding a cell cycle protein such as a cyclin which is
overexpressed in tumor cells. Examples of these cell cycle proteins
which are preferred for such fusions are Cyclins A, B, D1, E. These
proteins are generally complexed to kinases or transcription
factors at critical checkpoints in the cell cycle. The cyclins,
CDKs and their inhibitors are shown in Table 1. p193 of Peters G et
al., supra.
[0300] In another embodiment, nucleic acid encoding SAg is
cotransfected into tumor cells with nucleic acid encoding a cell
cycle protein as above. These transfectants are prepared as in
Examples 1. They are useful in vivo as a preventative or
therapeutic antitumor vaccines (Examples 15, 16, 18-23). They are
also useful ex vivo for inducing tumor specific effector cells for
adoptive immunotherapy of cancer (Examples 2-5, 7, 15.16
18-23).
[0301] 30. Combining SAg with Tumor Suppressor Genes, p53 or
Developmental Genes
[0302] SAg-encoding nucleic acid is fused in frame with tumor
suppressor gene DNA and the fused nucleic acid is introduced into
tumor cells or accessory cells. Alternatively, the two nucleic
acids are used to cotransfected these cells. Examples of such tumor
suppressor genes are shown in Table 9.7 p.187 of Franks L M et al.,
supra. Examples of mutated tumor suppressor genes include the APC
and MCC genes and their isoforms, the DCC gene in colon cancer, the
BRCA1 tumor suppressor gene in breast cancer and the DPC gene in
pancreatic cancer.
[0303] The p53 gene and its mutations are also useful in this
embodiment. A list of p53 responsive elements and associated
proteins useful in this invention is given in Tables 1 and 2 pp.
267-269 of Peters G et al., supra.
[0304] In another embodiment, nucleic acid of developmental genes
is used in place of tumor suppressor or p53 genes. Examples of such
developmental or differentiation genes are wnt and fwt genes.
Transfectants are prepared as in Examples 1. They are useful in
vivo as a preventative or therapeutic antitumor vaccine according
to Examples 15, 16, 18-23). They are also useful ex vivo for
inducing tumor specific effector cells for adoptive immunotherapy
of cancer (Examples 2-5, 7, 15, 16, 18-23).
[0305] 31 . Combining SAg with Cell Surface Glycoproteins or their
Receptors
[0306] SAg-encoding nucleic acid is fused in frame with a nucleic
acid encoding a cell surface glycoprotein and or its receptor and
the fused nucleic acid is introduced into tumor cells or accessory
cells. Alternatively, the two nucleic acids are used to
cotransfected these cells. Examples of these glycoproteins or
receptors include integrins, vitronectin receptors, laminin
receptors, cadherins, tenascin and CD44 and isoforms, VCAM-1,
P-Selectins, E-Selectin, NCAM and MCAM. Transfectants are prepared
as in Example 1. They are useful in vivo as a preventative or
therapeutic antitumor vaccine according to Examples 15, 16, 18-23).
They are also useful ex vivo for inducing tumor specific effector
cells for adoptive immunotherapy of cancer (Examples 2-5, 7, 15, 16
18-23).
[0307] 32. Combining SAg with Cytokines and Chemokines
[0308] SAg-encoding nucleic acid is fused in frame with nucleic
acid encoding a cytokines and chemokines, and the fused nucleic
acid is introduced into tumor cells or accessory cells.
Alternatively, the two nucleic acids are used to cotransfected
these cells. Examples of chemokines and cytokines that are useful
herein include RANTES, IL-5, IL-7, IL-12, IL-13, IFN(, TNF(and
TNF(. Chemokines are small (typically 6-10 kDa) peptides that have
been divided into two classes designated C-C and CXC based on the
sequence of the first two cysteine residues. The two families
exhibit preferences for different target cell types: C-C chemokines
act primarily on macrophages.
[0309] Chemokine gene expression is induced by the action of other
growth factors and cytokines and are actively expressed in solid
tumors showing inflammatory involvement and macrophage or
neutrophil invasion. Chemokines of the C-X-C class containing the
amino acid sequence motif ELR have demonstrable angiogenic activity
which can be inhibited by C-X-C chemokines lacking the ELR motif.
Therefore chemokine expression by either tumor cells themselves or
elicited from stromal cells by the action tumor-derived growth
factors, have the potential to regulate tumor growth by modulation
of angiogenesis. G-CSF is a growth factor for granulocyte
precursors, and IL-2 is a growth factor for T cells. Nucleic acids
encoding SAgs are fused or cotransfected into tumor cells with
nucleic acids encoding the above cytokines, chemokines and
chemoattractants. The transfectants are prepared as in Example 1.
They are useful in vivo as a preventative or therapeutic antitumor
vaccine according to Examples 15, 16, 18-23). They are also useful
ex vivo for inducing tumor specific effector cells for adoptive
immunotherapy of cancer (Examples 2-5, 7, 15, 16 18-23
[0310] 33. Combining SAg with Transcription Factors AP-1 and
NF.kappa.A
[0311] Transcription factor genes may act as oncogenes. The jun
family of transcription factors bind specifically to AP-1 sites
which confer the effects of potent tumor promoting phorbol esters
on responsive genes and specifically bind to c-jun homodimers or
c-jun/c-fos heterodimers. v-rel encodes members of the NF-.kappa.B
family of transcription factors. Transforming oncogenes such as
v-ets and v-myb also encode transcription factors.
[0312] The T cell signaling system responding to SAgs activates the
JAK, TNF (TRAF), IL-2 and IL-12 pathway probably via NF.kappa.A
activation. LPS has a T cell stimulating effect and may fuse with
SAg to produce additional stimulation or epitope expansion. The NFA
nucleic acids are fused to a promoter which activates sequences
encoding the SAg receptor or the sequences encoding the key
V.quadrature. domains binding SAgs or regions in the V.quadrature.
receptor which are activated by the SAgs.
[0313] SAg-encoding nucleic acid is fused in frame with nucleic
acids encoding a transcription factor such as those above.
Transfectants are prepared as in Example 1. These transfectants are
prepared as in Example 1. They are used in vivo as a preventative
or therapeutic antitumor vaccine according to Examples 15, 16,
18-23). They are also used ex vivo for inducing tumor specific
effector cells for adoptive immunotherapy of cancer (Examples 2-5,
7, 15, 16 18-23).)
[0314] 34. SAgs Augment the Immunostimulatory Effects of Tumor
Associated Peptides, Binary and Ternary Complexes
[0315] Bacterial SAg are presented to T cells via the MHC class II
molecule by multiple low affinity attachments, resulting in
stimulation of the T cell with very low concentrations of antigen.
SAgs augment the presentation of antigenic peptides to T cells
without sterically interfering with each other's ability to bind
and activate the TCR. These augmenting peptides are incorporated
into the SAg structure. SAgs may also bind to binary or ternary
complexes of tumor peptide-MHC class I or tumor peptide-MHC class
II complexes, either in solution or affixed to a TCR or the surface
of an APC. In one embodiment, the SAg is first bound to APCs or T
cells followed by addition of complexes between MHC class I or
class II and tumor peptide. Alternatively, the SAg may first bind
to either cell-bound, soluble or immobilized MHC class I or class
II molecules, after which the tumor peptide is added. This
trimolecular complex is then presented to the T cell via the TCR.
In another embodiment, SAg is first bound to an APC or to a TCR
V.quadrature. chain on an NKT cell. Following this,
CD1-glycosylceramide complexes are added and allowed to bind to NKT
cell TCR V.quadrature. chain. SAg may be bound to first to
CD1-glycosylceramide complexes in soluble form, affixed to CD1+
cells or NKT cells via the TCR. SAgs may be bound to CD1 complexes
with glycosylceramide or a glycosphingolipid (with a conserved SAg
binding site) in solution or when fixed to CD1+ cells or NKT cells.
Alternatively, SAgs are bound to ternary complexes consisting of
CD1-glycosylceramide affixed to the NKT cell TCR or bound to
CD1-glycosylceramide on APCs, in solution or immobilized, before it
has affixed to the NKT TCR. SAg is alternatively bound to binary
complexes of (a) CD1-glycosylceramide, (b) CD1-glycosphingolipid,
(c) CD14-LPS or (d) MHC-tumor peptide complexes that have either a
SAg receptor sequence or a TCR V.quadrature. SAg-binding
sequence.
[0316] The complexes described above are used in vivo as
preventative or therapeutic antitumor vaccines according to
Examples 4, 15, 16, 18-23. They are also used ex vivo for inducing
tumor specific effector cells that are then taken for adoptive
immunotherapy of cancer. (See Examples 2-5, 7, 14, 15, 16
18-23).
[0317] 35. SAgs Combined with Products of Antigen Processing
Pathways
[0318] A chimeric gene is prepared consisting of SAg-encoding
nucleic acid fused in frame to nucleic acids encoding (a) the
endoplasmic reticulum (ER) translocation signal peptide, (b)
transmembrane domain, and (c) lysosomal targeting domain of LAMP-1.
LAMP-1 is a type 1 transmembrane protein localized predominantly to
lysosomes and late endosomes. The cytoplasmic domain of LAMP-1
contains the Tyr-Gln-Thr-Ile sequence that mediates the targeting
of LAMP-1 into the endosomal and lysosomal compartments. The
specific targeting of the SAg to the endosomal and lysosomal
compartments allows SAg peptides to complex with MHC class II
molecules and enhance presentation.
[0319] The MHC class I presentation pathway operates on a three
level system. At one level there is protein machinery dedicated to
peptide manufacture--the proteosome complex. The selective peptide
transporters deliver antigens into the ER. The class I molecules
themselves exhibit variable affinities for peptides. Genes
clustered in the region of the class II gene encode proteosome and
transporter. SAg peptides are transported into the ER--primarily
through a transmembrane "tube" consisting of two polypeptide chains
called TAP-1 (SEQ ID NOS:40-41) and TAP-2 (transporter associated
with antigen processing). In mammals, genes encoding TAP-1, TAP-2
and two proteosome polypeptides are all located within the class II
region of the MHC.
[0320] The class I pathway starts in the cytosol where proteins
produced inside the cell are degraded by the multicatalytic
proteosome complex. The peptide products are translocated into the
ER by the TAP proteins. In the lumen of the ER, the peptides bind
the class I protein groove while the latter are complexed with the
chaperone p88, .quadrature.2m and TAP. After securing a peptide in
its binding groove, the class I complex is released from TAP and
transported through the Golgi apparatus to the cell surface. TAP
genes are closely linked to the LMP2 (SEQ ID NOS:38-39) and LMP7 in
the class II MHC gene cluster and belong to a family of molecules
involved in ATP-dependent membrane translocation known as the ABC
(ATP-binding cassette) transporters. TAP1 and TAP2 function as a
heterodimer each subunit having over 500 amino acids each with two
hydrophobic domains, six membrane spanning regions and a cytosolic
ATP binding motif. Both TAP1 and TAP2 subunits are required for
peptide binding and translocation. TAP1 appears to be uniquely
involved in the interactions with class I/.quadrature..sub.2 dimers
at the luminal membrane of the ER where it interacts with the
membrane proximal region of the a3 domain of class
1-.quadrature..sub.2m complexes prior to peptide loading.
Interaction between class I and TAP is crucial for efficient
peptide loading. Antigen presentation is mediated by an additional
factor, tapasin. TAP also binds 2M independently of class I heavy
chain, perhaps facilitating rapid assembly of class I
peptide-binding complexes. TAP heterodimer may show a preference
for amphipathic molecules as T cell antigenic determinants are
often seen clustered around sequences where amphipathic helical
structures are predicted. TAP prefers peptides 8-10 residues in
length but may transport peptides ranging from 7-40 residues..
[0321] Invariant chains are transmembrane glycoproteins found in
intracellular compartments in association with class II molecules.
Multimers consisting of three class I .alpha..quadrature. dimers
and three invariant chains assemble rapidly in the ER and travel
across Golgi bodies to the trans-Golgi network that intersects with
the endocytic pathway, where class II molecules reside for about
1-3 hr before transit to the cell surface for display to T cells.
Alternative splicing of the invariant transcripts produces two
isoforms p31 and p41 both of which can operate to assist folding of
class II dimers, direct the passage of class II from the ER through
an exocytic pathway, and block loading of peptide until peptide
sampling can occur as exocytic-endocytic pathways intersect. A four
residue targeting signal at the N-terminus of the invariant chain
that is essential for intracellular transport to endosomal
compartments. The C-terminus and the transmembrane region or the
invariant chain are also necessary for sorting of class
II-invariant chain complexes to the endosome. p41 appears to
regulate the production of a stable 12-kDa SLIP-class II complex
capable of enhancing SAg presentation.
[0322] SAg-encoding nucleic acid is fused in frame with nucleic
acid encoding a protein involved in the antigen processing pathway
such as the invariant chain or TAP which facilitates the expression
of the SAg in the context of MHC class I and II, respectively.
Tumor cells, accessory cells and hybrids thereof are transfected
with fused SAg-invariant chain DNA as in Examples 1 and 5. They are
used in vivo as a preventative or therapeutic antitumor vaccine
according to Examples 15, 16, 18-23. They are also used ex vivo for
inducing tumor specific effector cells for adoptive immunotherapy
of cancer (Examples 2-5, 7, 15, 16 18-23).)
[0323] SAg polypeptide post translationally is fused or associated
with additional molecules such as mono and diglycosylceramides,
including but not limited to -anomeric mono- and
digalactosylceramides GalCer, .alpha.-Gal, glycosylated and
prenylated SAgs. These constructs translocate with the appropriate
trafficking molecule e.g., invariant chain, TAP, LMP, to selected
surface receptor such as MHC class I, MHC class II or CD1. These
transfectants are prepared as in Example 1. They are useful in vivo
as a preventative or therapeutic antitumor vaccine according to
Examples 15, 16, 18-23. They are also useful ex vivo for inducing
tumor specific effector cells for adoptive immunotherapy of cancer
(Examples 2-5, 7, 15.16 18-23).
[0324] 36. SAgs Combined with Signal Transduction Molecules or Heat
Shock Proteins (HSPs)
[0325] SAg-encoding nucleic acid is fused in frame to (or
cotransfected with) a nucleic acid encoding "signal transduction
molecules" such as Ras, JAK 1 and STAT-1A and heat shock proteins
HSP-60, HSP-70, HSP-90a, HSP-90b, Cox-2 as well as heterotrimeric G
proteins and ATPases. The genes for Staphylococcal HSP-70 (SEQ ID
NOS:42-43) useful in this invention have been cloned (Ohta, T et
al., J. Bacteriology 176: 4779-4783, (1994)). As used herein, SAg
polypeptides are ligated to any of above structures at the peptide
or nucleic acid level. Preferred proteins for this embodiment are G
proteins, ATPases and HSPs. Chemical conjugation is carried out by
conventional methods, e.g., use of preferred heterobifunctional
crosslinkers. Alternatively, conjugates are produced genetically as
fusion proteins by conventional methods. In yet another embodiment,
the conjugates are created by permitting natural binding of the
components to each other without chemical modification. Any of the
foregoing conjugates or fusion proteins may be used when
incorporated into vesicles or exosomes secreted from a cell. See
Example 36 for methods and protocols.
[0326] SAg-encoding nucleic acid is fused in frame (or
cotransfected) with nucleic acid encoding a signal transduction
protein or HSP. Transfectants are prepared as in Example 1. They
are used in vivo as a preventative or therapeutic antitumor vaccine
according to Examples 15, 16, 18-23). They are also used ex vivo
for inducing tumor specific effector cells for adoptive
immunotherapy of cancer (Examples 2-5, 7, 15, 16 18-23).) The
peptide or polypeptide conjugates are also useful for the same
purposes.
[0327] 37. SAgs with Specialized Sites for C-terminal GPI
anchoring, Glycosylation, Sulfation, N-Myristoylation,
Phosphorylation, Hydroxylation N-Methylation, Signal peptide
binding, LPS binding, HSP binding, Chemokine binding and
Prenylation
[0328] SAg-encoding nucleic acid is fused in frame to nucleic acids
encoding the above "specialized sites" and transfected into tumor
cells or accessory cells The structures of these sites is given in
Table 3, p. 48 of Rocker R B I et al., J. Nutrition 123: 977-990
(1993).
[0329] Tumor or accessory cells express SAgs in a variety of
fashions after post-translational modification (Wilkins, M R. et
al., Proteome Research: New Frontiers in Functional Genomics
Springer. Berlin, Germany (1997)). For example, myristoylated SAg
will bind to surface lipids and will be minimally secreted. In
glycosylated form, the SAg will be routed to the class II pathway
and appear bound on the cell surface. When bound to invariant
chain, the SAg will be routed to the class II receptor.
[0330] Nucleic acids encoding proteins that active in
post-translational modification of SAgs are fused in frame to
nucleic acid encoding SAgs. These posttranslational modifiable
sites include, but are not limited to, a C-terminal GPI anchor,
glycosylation site, palmitoylation site, myristoylation or
prenylation site, N-methylation site, hydroxylation site,
phosphorylation site, sulfation site, signal peptidase site,
carboxylation site and prenylation sites.
[0331] The incorporation of many membrane proteins into the lipid
environment is based on sequences of largely hydrophobic amino
acids that can form membrane spanning domains. However, a large
number of membrane associated proteins do not display hydrophobic
elements in their primary sequences. The capacity for membrane
association in these cases is often provided by covalent attachment
(either cotranslationally or post translationally) of lipid groups
to the polypeptide chain. Acylation of proteins by addition of C14
myristic acid to an N-terminal gly residue or addition of C16
palmitic acid by thioester linkage to cysteine residues is in a
variety of positions in SAgs. Palmitoylation of SAgs is not
restricted to thioester linkage and may occur through oxyester
linkages to serine and threonine residues. Furthermore, thioester
linkage of fatty acyl groups to proteins is not restricted to
palmitate. Longer chain fatty acids such as stearic acid (C18) and
arachidonic acid (C20) are also produced. The addition of palmitoyl
and/or myristoyl groups with varying lengths confers additional and
sufficient binding energy for hydrophobic binding of proteins to
receptors, membranes or lipid bilayers. The attachment of palmitate
is sufficient whereas the attachment of myristate is insufficient
in isolation. Palmitoylation thus provides a means for membrane
anchorage of SAgs and can allow effective concentration of an
enzyme or other regulatory proteins at the membrane.
[0332] Glycosylated SAg is better capable of binding to
oligosaccharide receptors on blood vessels, inflammatory cells or
immunocytes. Signal peptide sequences permit the SAg to be routed
to various cell surface receptors. Prenylation is important in the
membrane attachment and protein-protein interactions of SAgs and
oncogene activation. Prenylation, or post translational enzymatic
addition of prenyl, geranyl, famesyl or geranylgeranyl, involves
reactions of a prenyl diphosphate with a cysteinyl sulfhydryl group
near the C terminus of the protein to give a prenyl-S-Cys moiety.
Characteristically the Cys-ali-ali-Xaa sequence ("ali" is an
aliphatic amino acid; Xaa is any amino acid) is recognized by the
transferase that catalyzes the reaction. When Xaa is serine,
alanine or methionine, the protein is famesylated; when Xaa is
leucine, it is geranylgeranylated. Farnesylation of the
protooncogene p21.sup.ras is integral both for its membrane
association and transforming activity. Farnesylated proteins
mediate the induction by IL-1.quadrature. of NOS whereas a
geranylgeranylated proteins repress this induction.
[0333] Nucleic acids encoding HSPs, along with their promoters, are
fused in-frame (or cotransfected) with SAg nucleic acid. These
include but are not limited to two recently discovered HSP genes,
orf37 and orf 35 in Staphylococcus aureus that are upstream and
downstream of grpE(hsp20), dnaK(hsp70) and dnaJ(hsp40) in the
following sequence: orf37--hsp20--hsp70--hsp40--orf35. The
promoters are located upstream of orf37 and upstream of hsp40.
These fused proteins are useful as preventative or therapeutic
antitumor vaccines according to Examples 15, 16, 18-23. They are
also useful ex vivo for producing a population of anti-tumor T
cells, NKT cells or NK cells for adoptive immunotherapy of cancer
(Examples 2-5, 7, 15, 16, 18-23).
[0334] Most eukaryotic cells are decorated with chemical groups
such as phosphates, methyls, sugars, or lipids during or after
their translation from mRNA. These extra groups have various
functions, often serving as switches or localization signals. One
lipid modification is protein prenylation in which a 15-carbon
farnesyl or 20-carbon geranylgeranyl group is attached to the
protein's --COOH terminus followed by other modifications
(proteolysis, methylation, and palmitoylation).
[0335] Most prenylated proteins are members of signal transduction
cascades. For example, the -subunits of heterotrimeric guanosine
triphosphate (GTP)-binding proteins (G proteins) and virtually all
members of the Ras superfamily of proteins. Farnesylation of H, K,
N-Ras is essential for the ability of oncogenic mutants of these
proteins to transform cells. 30% of established tumor cell lines
contain mutationally activated Ras proteins. FTase inhibitors
shrink tumors in animals to an undetectable size with no
significant toxicity after weeks or months of exposure.
Farnesylation is a prerequisite for palrnitoylation. Palmitoylation
of H-Ras occurs only in the plasma membrane by a putative
membrane-bound palmitoyl transferase. Farnesylation may bring a
finite amount of H-Ras to all cell membranes, at which point and
palmitoylation is required to trap it in the plasma membrane. H-Ras
palmitoylation like G protein-subunit palmitoylation, is reversible
and may regulate signal transduction. COOH terminal proteolysis of
prenylated proteins and methylation are required for
palmitoylation, membrane binding and Ras function. Prenyl protein
specific protease and methyltransferase like Ftase may be good
targets for drugs that prevent oncogenesis.
[0336] Common N terminal additions are fatty acid acylations and
glycosylations which provide polypeptide chains with short
"lipophilic handles" or recognition sites that serve to facilitate
their vectoral transport or compartmentalization are common
N-terminal additions. For example, myristic acid in the form of
myristyl CoA serves as a substrate for specific N-terminal
acylations that are important in anchoring proteins to endoplasmic
membranes. The most common C-terminal modifications are amidations,
acylations, polyadenylations and the enzymatic additions of tyrosyl
residues. Similarly the C-terminal acylation process is complex.
Prenylation occurs at Cys residues is often associated with
proteins that end in Cys-Val-Ile-Ala. The reaction sequence
involves (1) a first prenylation (addition of a farnesyl moiety to
Cys) followed by (2) cleavage of the Ala, Ile and Val residues and
(3) the carboxymethylation of the resulting C-terminal prenylated
cysteine. In addition to providing a membrane anchor, this
modification often is essential to function of oncogenes such as
Ras.
[0337] Two separate and well characterized pathways for
carbohydrate addition: the N-linked dolichol pyrophosphate mediated
pathways and the O-linked pathways that utilize UDP sugars as
substrates and hydroxylated amino acid side chains as sites for
attachments. Side chains amino phosphorylation of specified
proteins usually at tyrosyl or serinyl residues as a way of causing
cascade-like amplifications in a metabolic system. Methylation and
methyl additions can also serve as novel on-off switches for
metabolic processes. The targeted amino acids or methyl additions
are lysine, histidine and arginine. In prokaryotes, reversible
methylations of aspartyl and glutamyl side chains can occur. The
best example is carboxymethylation of glutamate which is associated
with bacterial chemotaxis and is elaborated by the opening and
closing of membrane ion channels upon methylation and
demethylation. Post translational modifications can lead to
crosslinking and stabilization of protein matrices. Amino acids
such as L-lysine, L-glutamine, L-cysteine and L-tyrosine are
utilized extensively as sources for protein cross-linking. Examples
include the extracellular matrix cross linking of collagen and
elastin and the stabilization of keratin-derived matrices and
tubulin by -glutamyl lysine crosslinks.
[0338] In bacteria the majority of proteins that form durable wall
associations possess either distinctive N-terminal signals
(lipoproteins) or more commonly distinctive C terminal wall
associating signals although a number of wall associated proteins
possess neither of these types of signals. A number of
wall-associated proteins in gram-positive bacteria are anchored to
the external surface of the cytoplasmic membrane via a covalently
attached lipid moiety. Both gram-negative and gram-positive
lipoproteins possess similar distinctive N-terminal signal
sequences which contain a tetrapeptide consensus at the cleavage
site consisting of Leu-X-Y-Cys where X and Y are predominantly
small neutral residues and signal and signal peptidase cleavage
occurs between Y and Cys. This sequence directs either co- or post
translational modifications involving transfer of glycerol from
phosphatidylglycerol to the +1 Cys, followed by the transfer of
fatty acids from phospholipid to the glyceryl-prelipoprotein to
produce a diglyceride-prelipoprotein. The C terminal end of a large
number of Gram positive wall-associated proteins share common
structural features that are required to localize these proteins in
the cells wall. These C-terminal structures include a number of
distinct features. At the extreme C-terminus there is a stretch of
15-22 hydrophobic residues, followed by a short tail of
predominantly charged amino acids. Immediately upstream from this
hydrophobic/charged-tail domain, there is a highly conserved
Leu-Pro-X-Thr-Gly-X (LPXTGX) motif which is usually preceded by a
sequence containing a high proportion of regularly spaced prolines.
GPI anchors have not been identified on bacterial cell surface
proteins. But the strong conservation of the LPXTGX motifs and of a
hydrophobic/charged tail residue-helical domain are common
structural features that are required to localize these proteins in
the cell. Protein A is covalently coupled to the cell wall whereas
of the proteins are not. Non-covalent interactions may occur in
some proteins holding it in the cell wall while cross-linking
occurs around proline rich region to form peptidoglycans. Hydrogen
or water binding sites can be created by hydroxylation reactions,
e.g., hydroxylation of proline in collagen provides sites for
intrachain hydrogen and H.sub.2O bonding.
[0339] SAg-encoding nucleic acid is transfected into cells together
with coding regions to permit the above post translational
modifications which contribute to the production of an immunogenic
tumor cell accessory cell (preferably a DC) or a tumor
cell/accessory cell hybrid. Such nucleic acids encoding the sites
for post-translational modifications of SAgs are useful in the
structural modification, translocation, cell surface binding and
association with key energy-producing and signal transduction
molecules and receptors. The cells expressing the products of these
post-translational modifications are useful as a preventative or
therapeutic antitumor vaccine according to Examples 15, 16, 18-23).
They are also useful ex vivo for producing a population of
anti-tumor T cells, NKT cells or NK cell for adoptive immunotherapy
of cancer (Examples 2-5, 7, 15, 16, 18-23).
[0340] 38. SAgs and SAg Proteomes for Enhanced Immunogenicity,
Specificity and Intracellular Trafficking of Soluble or Cell-Bound
Binary or Ternary Complexes
[0341] SAgs with genetically engineered binding sites are provided
in order to enhance their coupling to bioreactive complexes,
peptides and LPS's and galactosylceramides. SAgs with a
glycosylation other glycosylceramide binding site bind to
glycosylceramide-CD1 or glycosylceramide-CD1 complexes alone in
soluble or immobilized form, or cell bound after binding to a
receptor on a T cell or NKT cell. SAgs are also provided with an
LPS binding site for binding to soluble, immobilized or cell bound
LPS-CD14 complexes.
[0342] SAgs are provided with a glycosphingolipid or
glycosylceramide site by which they can bind to
CD1-glycosylceramide or CD1-glycopsphingolipid complexes present in
soluble, immobilized form or affixed to CD1+ cells or NKT cells.
Glycosylated SAgs are bound to CD1-glycosylceramide complexes in
soluble form or fixed to CD1+ cells or NKT cells. SAgs are also
provided with an overexpressed site for MHC class I molecules, to
increase the effectiveness of binding to MHC class I-tumor peptide
antigen complexes or TCR-bound MHC class I-tumor peptide
complexes.
[0343] SAgs are engineered with repeating peptides which bind to
the V.quadrature. chain to increase clustering. SAgs with an
"overexpressed" (in terms of number) SAg receptor site binds to
tumor cells expressing SAg receptors. SAgs possess a site for
binding HSPs which are useful in immunizing normal or anergic T
cells in a tumor patient. SAgs bind to T cell antagonist MHC-tumor
peptide complexes converting the binary complex to a ternary
complex with T cell agonist activity. Anergic T cells are activated
by these ternary complexes.
[0344] SAgs are prepared with an overexpressed site for binding
glycosphingolipids or glycosylceramides. These complexes are loaded
onto CD1 receptors of antigen presenting cells and presented to the
tumor bearing host either in vivo or ex vivo (Examples 4, 5, 7).
SAgs with a myristoylation site will bind to bacterial glycolipids
such as lipoarabinan or a mycolic acids The binary complex is then
loaded onto APCs expressing CD1 receptors. These cells are then
used in vivo (Example 14, 15, 16, 18-23) to produce a tumoricidal
response. Alternatively, they are used ex vivo to produce tumor
specific effector T or NKT cells for adoptive immunotherapy
(Examples 2, 7, 14, 15, 16, 18-23).
[0345] A SAgs may also be prepared with signal sequences for
protein sorting and intracellular trafficking. Signal sequences
comprise short stretches of amino acids located at the N terminus
of a protein, the C terminus or in the middle of the peptide chain.
The physical properties of these sequences e.g., their polarity or
charge. Signal regions are three dimensional domains on the surface
of a protein made up of different fragments of the same peptide
chain or by different chains altogether. Structural signals are
recognized and bound by receptors located on the membranes of
organelles. Signal sequences also serve as recognition sites for
enzymes which modify the proteins altering their properties and
bring about a change in their fate. Once they have fulfilled their
function, some of the signal sequences are removed by sequence
specific hydrolases. Signal peptides fused to SAgs guide them to
the secretory or exocytosis pathway, or to proteins localized to
the endoplasmic reticulum, lysosomes, mitochondria, nucleus,
peroxisomes or secretory vesicles.
[0346] GPI-SAg-Ceramide or GPI-SAg-CD1-Ceramide Complexes Expressed
on Tumor Cells, Antigen Presenting Cells or APC/tc Hybrid and Shed
as Exosomes
[0347] Cells expressing, overexpressing or shedding GPI proteins
are prepared so that they comprise covalently- or noncovalently
bound mono- or diglycosylceramides with terminal or subterminal
.alpha.1-2, .alpha.1-4 or .alpha.1-6 configurations and SAg protein
or peptide moieties.
[0348] The synthetic pathway involves transfection of SAg DNA into
a tumor cell or accessory cell or a hybrid thereof The SAg protein
is translated in a precursor form consisting of a receptor-coding
region sandwiched between amino and carboxy-terminal sequence
signals. In the endoplasmic reticulum, the signal peptides are
cleaved and a GPI anchor comprising a glycosylceramide optionally
bonded to a phytosphingosine chain is attached at a specific site
designated .omega.. Further post-translational modifications are
made in the Golgi before trafficking to the outer leaflet of the
plasma membrane. Once GPI-SAg molecules arrives at the cell
surface, they may remain entirely mobile within the lipid bilayer
or may associate within membrane subdomains.
[0349] GPI-SAgs are released from the cell surface into the
extracellular milieu. They leave the cell surface as
SAg-glycan-lipid complexes, as SAg-glycan complexes or as free SAgs
devoid of a GPI anchor. GPI-SAgs released from intact cell are also
released free of their lipid moiety, hence their designation as
LIP(-) GPI-SAgs, whereas those presumably released with an intact
lipid moiety are termed LIP(+) GPI-SAgs. The lipid free moieties
are more hydrophilic and therefore soluble in an aqueous
environment, whereas the intact lipid-glycan-protein complexes
travel in more hydrophobic environments. In the absence of
detergents, the released or "shed" LIP(+)-GPI-SAgs in vivo are
vesicles with clearly defmed lipid bilayers or as hydrophobic
aggregates lacking a bilayer morphology. These shed vesicles, often
referred to as exosomes, contain many LIP(+) GPI-SAgs. The shedding
process itself appears to depend on GPI-proteins, because
vesiculation is reduced by 50-90% in cells lacking GPI proteins.
Shedding is enhanced by treating the tumor cells with 20 .mu.M
retinoic acid. In addition high concentrations of
glycosphingolipids on the tumor cell surface are generated by
selective transport from the site of synthesis to the cell surface.
Provision of ceramide containing the .alpha.2-hydroxy fatty acid
C.sub.6OH results in (1) conversion to galactosylceramide,
galabiosylceramide and sulfatide and (2) sorting in the trans-Golgi
network to the tumor cell surface. GPI-SAgs remain biologically
active after being released from the outer leaflet of cell
membranes. LIP(+) GPI proteins may also transit to adjacent
membranes where they associate with the exogenous membranes by
incorporating themselves into the lipid bilayer in addition to
binding to surface receptors.
[0350] Additionally, superantigen or oxyLDL receptor nucleic acids
are transfected into yeast sec mutant. The yeast sec mutant, 6-4,
contains a temperature senstive mutation in a gene product required
for the transport of secetory vesicles for the trans-Golgi network
to the plasma membrane. Gene expression is initiated by an
inducible promoter concomitant results in the arrest of vesicle
fusion and the insertion of SAg or LDL receptor protein in the
plasma membrane. Thus gene expression begins at the same time that
secretory vesicles become unable to fuse with the plasma membrane,
ensuring that the desired gene products accumulate in the membranes
of these vesicles. The purification of these vesicles is rapid and
simple, thereby facilitating the subsequent characterization of the
desired gene product. Because the Sec6 protein is known to be
involved only in the fusion of these vesicles with the plasma
membrane, translocation and processing of proteins in the
endoplasmic reticulum and processing in the Golgi are largley
unaffected by the Sec6 mutation. The transfected superantigen or
LDL nucleic acid (plasmid) is expressed as superantigen polypeptide
or oxyLDL polypeptide in vesicles in association with yeast
GPI-lipid membrane structures. The lipid portion of the
SAg-GPI-lipid complex comprises a ceramide with a C26 dihydroxy
sphingosine or phytosphingosine configuration which is essential
for activating NKT cells. The resulting SAg-GPI-phytosphingosin- e
vesicles have the capacity to activate T cells via the superantigen
and NKT cells via the phytosphingosine and thus produce a potent
anti-tumor effect. Administered preferably by direct administration
into the tumor the oxyLDL receptors induce an excessive accumuation
of endogenous or exogenously administered oxyLDL and LDL at the
tumor site. The deposited oxyLDL induces apoptosis and foam cell
formation in tumor cells and tumor microvascular enodthelial cells
resulting in potent tumoricidal response. Optionally,
SAg-GPI-phytosphingosine are expressed on these vesicles together
with vesicles expressing or oxyLDL receptor-GPI-phytosphingosine
oxy LDL receptors
[0351] Vesicles containing SAg-GPI-phytosphingosine or oxyLDL
receptor-GPI-phytosphingosine are prepared and isolated according
the method of Coury L A et al., Methods in Enzymology 306: 169-186
(1999) and as in Examples 4, 5, 7, 42, 50-51. They are useful in
vivo as a preventative or therapeutic antitumor vaccine according
to Examples 14, 15, 16, 18-23, 36 They are also useful ex vivo for
producing a population of tumor specific effector T or NKT cells
for adoptive immunotherapy of cancer (Examples 2-5, 7, 15, 16,
18-23).
[0352] 39. Effector T Cells: Methods of Lowering Activation
Threshold for Activation by SAg
[0353] Tumor peptide MHC complexes are insufficient to activate T
or NKT and may even induce antagonism or anergy. SAgs added to the
complexes are useful to overcome activating T or NKT cells and
overcoming the anergy common in tumor-bearing hosts. To enhance
responsiveness to tumor-peptide-MHC-SAg complexes and to overcome
anergy, it is desirable to reduce the threshold for signal
transduction in an effector T or NKT cell population. To accomplish
this, nucleic acids encoding SAg-specific TCR V.quadrature. regions
are transfected into T or NKT cells to duplicate or otherwise
induce overexpression. In addition, measures are taken to alter
signal transduction by dimerizing the tyrosine kinase receptors or
deleting the inhibitory region of the TCR.
[0354] Most SAgs show selective binding to well defined segments of
the V.quadrature. chain of the TCR. The TCR genes are clustered on
chromosome 7 and include 75-100 V, 2D, 13 J, and 2 C.quadrature.
genes. The entire 685-kb human locus has been sequenced, the
longest contiguous subfamilies that exhibit >75% sequence
identity at the DNA level. The human TCR locus is on chromosome 14
and consists of 42 V genes, 61 J genes and 1 C.quadrature. gene.
The TCR chain genes are on chromosome 6 and consist of
approximately 23V, 2D, 12J, and 2C gene segments. The 2
C.quadrature. genes form clusters with upstream D.quadrature. and
J.quadrature. segments: C.quadrature.1 rearranges only with
D.quadrature.1/J.quadrature- .1 genes whereas C.quadrature.B2
rearranges with both D.quadrature. and J.quadrature. segments.
Similarly, functional V.quadrature. genes appear to rearrange to
both J clusters in a random fashion. The .quadrature. chain
transcripts of antigen-specific T cell clones appear to contain
little length variation and harbor conserved N additions.
[0355] A mechanism for achieving diversity in variable
(antigen-specific) regions of the TCR involves the random addition
of nucleotides inserted at junctional positions during the joining
of V.quadrature.D.quadrature.J segments. It is at this position
that nucleic acids encoding the major V.quadrature. binding site
for a specific SAgs are inserted. This overexpression allows for
more selective recognition of SAg and a lower activation threshold
by a SAg that selectively binds at that site.
[0356] Nucleic acid encoding SAg receptor is amplified and
transfected into T cells to overexpress the SAg receptor on the
cell surface These T cells bind SAgs, and this is linked to
appropriate signal transduction pathways that deliver a mitogenic
signal to the T cell. One method of increasing T or NKT cell
reactivity to a SAg is to increase the density of their SAg
receptors. Even in the absence of ligand, the equilibrium is
shifted from monomeric inactive receptors to dimeric or oligomeric
active receptors. Concomitant expression of the corresponding
ligand reinforces the signal. Increased numbers of receptors occur
after increased transcriptional activation of, or amplification of,
the SAg receptor gene. Amplification is the preferred method.
[0357] The SAg receptor may also be mutated so that it engages in
ligand-independent dimerization. Examples of such mutations are
addition or loss of a cysteine residue in the extracellular domain
causing formation of dimeric and disulfide bonded and activated
receptors. In addition it is possible to dimerize tyrosine kinases
by fusing a tyrosine kinase catalytic domain to a protein which is
a functional dimer. These fusion partners are able to form
homodimers. Such a fusion protein results in dimerization of kinase
domains which allows their autophosphorylation and activation.
Interaction with receptors in a manner which promotes dimerization
of two different receptors is another method to enhance receptor
reactivity. The kinase domain of a receptor may be mutated to
increase catalytic activity or alter substrate specificity. Such
mutations expand quantitatively and qualitatively the repertoires
of substrates in the target cells and thereby shift the balance
towards activation and transformation. Mutations in regions
involved in negative regulation of receptor function also
contribute to the transforming properties. Loss of regions in the C
terminus that are regulatory serine phosphorylation or
autophosphorylation sites also contributes to excessive receptor
activity.
[0358] Effector cells as discussed above are prepared as in
Examples 4, 5, 7. They may also be used in vivo as tumor specific
effector (T or NKT) cells for the adoptive immunotherapy of cancer
(Examples 2-5, 7, 15, 16, 18-23).
[0359] 40. SAg Nucleic Acids Fused of Cotransfected into Tumor Cell
with Nucleic Acids Encoding Inducible Nitric Oxide Synthase
(iNOS)
[0360] SAg-encoding nucleic acid is fused in frame (or
cotransfected) with nucleic acid encoding inducible nitric oxide
synthase which produces nitric oxide (NO). NO is derived from
terminal guanido-nitrogen of L-arginine which is catalyzed by the
constitutive or inducible nitric oxide synthase (iNOS). NO is
pleiotropic and is a major cytotoxic mediator secreted by activated
endothelial cells and macrophages. Production of NO is associated
with apoptosis of tumorigenic cells and with a bystander effect on
surrounding non-NO producing tumor cells (bystander effect). Non
metastatic tumor cells show high levels of iNOS activity and NO,
whereas metastatic cells do not. There is an inverse relation
between production of endogenous NO and the tumor cells
survivability. In the present invention, tumor cells transfected
with SAg-encoding nucleic acid are cotransfected with nucleic acids
encoding iNOS. The gene for iNOS has been cloned and characterized
by Xie Q et al., Science 256: 225-228 (1992). Tumor cells
cotransfected with nucleic acids encoding SAgs and iNOS demonstrate
augmented immunogenicity via the expression of SAg as well as
enhanced auto- and bystander tumoricidal capacity via NO
production.
[0361] After administration to a patient and colonization of
metastatic sites, the transfectants induce a powerful local and
systemic tumoricidal effect. The presence of NO allows the
transfectants to die naturally via auto-apoptosis within a finite
period (usually 72 hours) after administration thus minimizing the
risk of inducing active metastatic disease. These tumor cell
transfectants may also be made to express oncogenes associated with
the metastatic phenotype to promote localization of the cells to
tumor sites in vivo. The cells may be further transformed by
nucleic acid encoding angiostatin or other angiogenesis inhibitors
for additional tumoricidal potency. The transfectant are prepared
by methods in Example 1-3 and used as a preventative or therapeutic
antitumor vaccine by methods in Example 15, 16, 18-23).
[0362] 41. DCs, Other Accessory Cells and DC/tc Hybrids Expressing
and/or Secreting SAg
[0363] Accessory' cells are necessary to generate primary antibody
responses in culture. Of the various types of accessory cells, DCs
are the most effective APC. DCs are a preferred accessory cell.
However, the invention is not confined to DCs. Any other accessory
cell type may be used in place of DCs. In particular, accessory
cells are defined in Oxford's Dictionary of Biochemistry and
Molecular Biology as including fibroblasts, synoviocytes,
macrophages, B cells, Langerhans cells and any other cell type
which assists in producing an immune response of any kind.
[0364] DCs have exceptional capability to capture antigens, process
and present antigenic peptides, migrate to lymphoid organs, and
induce primary immune responses of both CD8+ and CD4+ T cells. The
ability of DCs to act as potent APC in the induction of T cell
responses is attributed to the high expression of MHC molecules and
adhesion and/or costimulatory molecules as well as the cells'
capacity for to producing cytokines essential for the activation
and proliferation of the T cells.
[0365] The number of molecules of antigen-MHC complex on tumor (and
infected) cells is typically small (100 per cell), and are
recognized by rare T-cell clones (at a frequency 1/100,000) via a
TCR that has a low affinity (1 M). In vitro or in vivo, only a few
DCs are necessary to provoke a strong T-cell response. In the mixed
leukocyte reaction, one DC was sufficient to stimulate 100-3,000 T
cells. MHC products and MHC-peptide complexes are 10-100 times
higher on DCs than on other APCs such as B cells and monocytes.
Mature DCs resist the suppressive effect of IL-10, but synthesize
high levels of IL-12 that enhances both innate (NK cell) and
acquired (B and T cell) immunity. DCs also express many accessory
molecules that interact with various molecules or receptors on T
cells to enhance adhesion and signalling (co-stimulation): examples
of such pairs are LFA-3/CD58, ICAM-1/CD54, B7-2/CD86. Tumor cells
that express the B7 gene elicit CTLs against otherwise silent,
subdominant tumor antigens. All these properties of DCs (MHC
expression, CD1 expression, secretion of IL-12 and the expression
of co-stimulatory molecules) are upregulated within a day of
exposure to many stresses and "dangers" including microbial
products.
[0366] Infected cells and tumors frequently lack the costimulatory
molecules that drive clonal expansion of T cells, the production of
cytokines, and T cell development into killer cells. Located in
most tissues, DCs overcome challenges by capturing and processing
antigens, and displaying large amounts of MHC-peptide complexes on
their surface. They upregulate their co-stimulatory molecules and
migrate to lymphoid organs, the spleen and draining lymph nodes,
where they activate antigen-specific T cells. All of these
activities of DCs can be induced by infectious agents and
inflammatory products, so that DCs appear to function as "mobile
sentinels" that not only bring antigens to T cells but also
stimulate those T cells in the induction of immunity.
[0367] DCs are present in most tissues in a so-called "immature"
state, unable to stimulate T cells. Although these DCs lack the
requisite accessory signals for T-cell activation, such as CD40,
CD54 and CD86, they are well equipped to capture antigens, a key
event in the induction of immunity; the antigen is then able to
induce full maturation and mobilization of the DCs.
Terminally-differentiated or mature DCs can readily prime T cells
Once activated by DCs, these T cells can complete the immune
response by interacting with B cells for antibody formation,
macrophages for cytokine release, and target cells resulting in
lysis. Thus, immature DCs first handle antigens and then, as mature
DCs a day or more later, they potently stimulate T cells.
[0368] DCs stimulate CTLs, which express the accessory molecule CD8
and interact with MHC class I bearing cells, to proliferate
vigorously. In the presence of mature DCs and of IL-12,
CD4-expressing T-helper cells turn into interferon gamma
(IFN)-producing TH-1 cells. IFN activates the antimicrobial
activities of macrophages and, together with IL-12, promotes the
differentiation of T cells into killer cells (CTL). The capacity of
DCs to produce IL-12 and stimulate TH-1 cells leads to microbial
resistance. Through IL-4, DCs induce T cells to differentiate into
TH-2 cells which secrete IL-5 and IL-4, activate eosinophils and
help B cells generate an antibody response, respectively. DCs
respond to T cells as well. CD40 and the newly described
TRANCE/RANK receptor on DCs are ligated by the TNF (tumor-necrosis
factor) family of proteins expressed on activated and memory T
cells; this leads to increased DC survival and, in the case of
CD40, upregulation of CD80 and CD86, secretion of IL-2 and release
of chemokines such as IL-8 and MIP-1.alpha. and .quadrature..
[0369] Immature DCs capture antigen (and particles and microbes in
general) by phagocytosis. They then form large pinocytic vesicles
in which extracellular fluid and solutes are sampled, a process
called macropinocytosis. Finally, they express receptors that
mediate adsorptive endocytosis, including C-type lectin receptors
like the macrophage mannose receptor and DEC-205, as well as Fc,
located in most tissues, and Fc receptors. Macropinocytosis and
receptor-mediated antigen uptake make antigen presentation so
efficient that picomolar and nanomolar concentrations of antigen
suffice, much less than the nicromolar levels typically employed by
other APCs. However, once the DC has captured an antigen, which
also provides signals to mature, its ability to capture antigens
rapidly declines, and the cell begins to assemble antigen-MHC class
II complexes.
[0370] An antigen enters the endocytic pathway of the DC. DCs
produce large amounts of MHC class II-peptide complexes due to
specialized, MHC class II-rich compartments (MIICs) that abound in
immature DCs. MIICs are late-endosomal structures that contain the
HLA-DM or H-2M products, which enhance and perform editing
functions in the binding of peptide to MHC class II. During
maturation of DCs, MIICs convert to non-lysosomal vesicles that
discharge their MHC peptide complexes to the surface.
[0371] To generate cytotoxic killer cells, able to eliminate
infected cells, and attack tumor cells and transplanted foreign
cells, DCs must present peptides (complexed generally to MHC class
I proteins) to CD8+ T cells. Display of peptide-loaded MHC class I
complexes on the DC surface follows translocation by a peptide
transporter from the cytosol to the ER, where complexing occurs and
then to the surface.
[0372] Human DCs are characterized by a pattern of surface markers
and have the phenotype CD1a+, CD3.sup.neg, CD4.sup.neg,
CD8.sup.neg, CD20.sup.neg, CD40+ CD86+ in the human. The murine
phenotype is and CD3.sup.neg CD4.sup.neg, CD28.sup.neg, CD8-
B220.sup.neg, CD40+, CD80+ and CD36+.
[0373] Maturation of DCs is required for the initiation of an
immune response. Microbial products including whole bacteria and
the bacterial cell-wall component LPS and inflammatory mediators
such as IL-1, GM-CSF and TNF, stimulate DC maturation, whereas IL10
blocks it. Ceramide, which is induced by maturation signals, shuts
down antigen uptake by the DC. Mature DCs express high levels of
the NFKB family of transcriptional control proteins (RelA/p65,
RelB, RelC, p50, p52) which regulate the expression of many gene
encoding immune and inflammatory proteins. Signalling through the
TNF-receptor family, for example TNF-R
(CD-120.alpha./.quadrature.), CD40, and TRANCE/RANK, results in
activation of NF.kappa.B. Therefore, to induce an immune response
through activation of DCs, a pathogen or antigen may have to
mobilize the signal transduction pathways of the TNF-R family and
TNF-R-associated factors (TRAFs).
[0374] One explanation for the failure of the immune system to
eradicate most immunogenic tumors is the lack of tumor antigen
presentation by DCs in vivo. Several strategies using tumor
antigen-charged DCs as vaccines for cancer immunotherapy have been
developed. Immunization with DCs pulsed with purified
tumor-associated peptides or proteins has been shown to be a
powerful method of priming tumor-reactive T cells and inducing host
protective and therapeutic antitumor immunity in mice and man.
However, such a clinical approach is currently limited due to the
paucity of identified human tumor rejection antigens. The
polymorphism of the HLA system has also made it difficult to
identify tumor-associated peptides as cancer vaccines. In human
melanoma, a class of tumor-associated proteins has been identified.
However, it is unclear which antigen is the best choice for
effective tumor rejection in vivo or how effective any such antigen
may be. Thus, immunization with defmed tumor antigens is currently
limited to a small number of cancers in which candidate antigens
have been identified. Anichini et al., J. Immunol. 156:208-217
(1996), showed that the majority of CTL present in HLA-A2. 1+
melanoma patients were not directed to the known tumor antigens,
Melan-A/Mart-1, tyrosinase, gp100 or MAGE-3. Therefore,
immunization with other, yet unidentified, antigens would be more
effective in eliciting tumor immunity in these patients. Johnston
et al., J. Exp. Med. 183:791-800 (1996) demonstrated that the
enhanced immunogenicity of tumor cells engineered to express the
B7-1 gene was a result of expansion of the antigenic repertoire of
the tumor. This implies that vaccination with multiple tumor
antigens may be superior to use of a single dominant epitope.
Indeed, in situations where a tumor-associated antigen remains
unidentified, a novel approach is needed for presentation of that
antigen by a professional APC.
[0375] An alternative approach, not encumbered by these
limitations, is to use unfractionated tumor peptides or tumor
proteins as a source of tumor antigens. Two studies have shown that
administration to mice of APC (from the spleen) or epidermal
Langerhans cells pulsed with tumor fragments resulted in protective
immunity against tumor challenge. Zitvogel et al., J. Exp. Med.
183:87-97 (1996) showed that vaccination of mice with bone
marrow-derived DC pulsed with unfractionated tumor peptides reduced
the growth of subcutaneously established, weakly immunogenic
tumors. Thus, immunization with multiple tumor antigens may be
superior to use of a single dominant epitope.
[0376] One approach to overcome the possible drawbacks of
unfractionated tumor antigens is to use mRNA from tumor cells as a
"source" of antigen. mRNA can be amplified from a very small number
of cells, permitting the generation of sufficient amounts of
antigen from minute amounts of tumor tissue Moreover,
tumor-specific mRNA can be enriched by subtractive hybridization to
remove RNA that is common to normal tissue. This increases the
levels of the relevant tumor-specific antigen(s) that can be
achieved, and hence, the potency of the vaccine. More importantly,
this approach reduces the concentration of nonspecific antigens or,
possibly, self-antigens, thereby lessening the potential for
autoimmunity. Pulsing DCs with RNA is known to be effective in
empowering them to induce CTL responses and tumor immunity.
[0377] The fusion of tumor cells with DCs is another approach to
generate a hybrid vaccine that has both potent antigen
processing/presenting power along with the endogenous expression of
multiple tumor antigens. Such a hybrid cell would be more effective
in inducing antitumor immunity. Gong et al., Proc. Natl. Acad. Sci
U.S.A 26:6279-6283 (1998), demonstrated that fusion of a relatively
immunogenic mouse tumor, MC38 carcinoma, with syngeneic DCs
resulted in a vaccine that induced (1) T cell protective immunity
against tumor challenge and (2) rejection of an established tumor.
Wang et al., J. Immunol. 161:5516-5524 (1998) used the poorly
immunogenic B16 (B16.F10) melanoma which does not express MHC and
costimulatory molecules. Immunization with irradiated B16 tumor
cells failed to induce systemic immunity or elicit functional
tumor-reactive T cells. RMA-S is a Rauscher MuLV-induced T cell
lymphoma originating in a C57BL/6 ("B6") mouse that is genetically
defective in TAP, and thus, does not process endogenous antigens
for binding to MHC. Fusion of DCs with syngeneic tumor cells
generated hybrid cells that expressed both DC-associated accessory
molecules important for antigen presentation and tumor-derived
antigens. The DC/tc hybrids were processed and presented
tumor-associated antigens and elicited tumor-reactive CTLs.
Vaccination of B6 mice with B16/DC hybrid cells induced partial
protective immunity against tumor challenge. Immunization with
B16/DC or RMA-S/DC hybrid cell vaccines primed lymph node (LN) T
cells, which, after expansion ex vivo, were active in adoptive
immunotherapy. The transfer of such vaccine-primed, expanded T
cells into tumor-bearing mice reduced the number of established B16
pulmonary metastases and, in the case of RMA-S/DC, effectively
eradicated disseminated FBL-3 tumor.
[0378] The present invention includes a hybrid cell made from
fusion of a tumor cell and a DC cell further transformed or
transfected with a SAg. Nucleic acids encoding SAgs may be
introduced into either the tumor cells or the DCs prior to fusion
as in Example 1, 2, 3, 25, 26. This fused cells are prepared as in
Example 24, 25 and their phenotype established by the retention of
DC characteristics, tumor cell antigens and the expression of SAg
(Example 25). By virtue of these multiple features, this
SAg-expressing DC/tc has the unique capacity activate maximally an
anti-tumor immune response.
[0379] SAg stimulation is known to activate CD4+ and CD8+ T cells
to recognize and lyse tumors specifically both in vitro and in
vivo. The DC component of the hybrid cell provides optimal tumor
antigen presentation due to its enormous surface area together with
natural expression of costimulatory molecules B7.1, B7,2, adhesion
molecules ICAM-1 and ICAM-3, MHC class I and class II and CD1
receptors. B7.1, in particular, provides a basis for expanding the
epitope recognition spectrum from dominant to subdominant epitopes.
The expressed SAg confers upon the hybrid cell an augmented
capacity to activate various classes of cells that mediate both
innate and "acquired" or adaptive immunity, including CD4+ and CD8+
T cells, NK cells and NKT. The SAg also contributes to generation
of TH-1 cytokines by this class of T helper cells which contributes
to an optimal anti-tumor response. The DC/tc hybrid that expresses
and/or secretes SAg is abbreviated herein as an "S/D/t" cell and
combines the potent activating properties of SAg with the
specialized (tumor) antigen presenting capacity of the DC and the
tumor antigens provided endogenously by the tumor cell partner.
This S/D/t cell thus consolidates in a single cell the capacity to
unleash and amplify the full weight of the host immune response
specifically against a selected array of tumor associated
antigens.
[0380] The present invention also includes the additional
introduction, into the S/D/t cell of with additional nucleic acids.
In one embodiment, the additional nucleic acid encodes the
particular galactosyltransferase enzyme that catalyze the synthesis
of the "heterograft epitope" Gal. In another embodiment, the
additional nucleic acid encodes enzymes that synthesize
galactosylceramide which is the "natural" epitope recognized by the
invariant chain of NKT cells.
[0381] To summarize the foregoing section, the present invention
includes DCs, other accessory cells or hybrid DC/tc, each
transformed to express SAgs as described in Examples 1 and 3. The
transformed (or transfected) hybrid cell, the S/D/t cell, expresses
(1) the major accessory molecules of DCs cells (such as CD40, CD80
and CD86, MHC class I and II and CD1); (2) tumor associated
epitopes provided by the tumor cell fusion partner; and (3) SAg
either membrane bound, secreted or both which activates T cells, NK
cells and NKT cells to produce a specific or selective tumoricidal
response.
[0382] While the tumor S/D/t cells are preferred, SAg-transfected
DCs or other accessory cells are also effective in inducing
antitumor responses. These are used as a preventative or
therapeutic antitumor vaccine, or ex vivo to stimulate a population
of T cells, NK cells or NKT cells for adoptive therapy of cancer
(Examples 29).
[0383] 42. DCs Expressing SAg and Tumor Associated
Antigens--Production by Processing of Apoptotic Tumor Cells or
Tumor Cell Lysates
[0384] DCs expressing SAg and tumor associated antigens are
prepared without cell fusion (Example 28). Apoptotic, SAg
transfected tumor cells are prepared by first transfecting tumor
cells with SAg (Example 1) and then inducing apoptosis by
irradiation or other methods well known in the art (Example 28).
DCs express .alpha.v.quadrature..sub.5-binding integrins and
secrete thrombospondin which ligates vitronectin expressed on the
surface of the apoptotic tumor cell. DC surface CD36 binds to its
natural ligand, sequestrin, also expressed on apoptotic tumor
cells. The apoptotic SAg-expressing tumor cells are phagocytosed
and processed by DCs under conditions described in Example 28.
[0385] In another embodiment, lysates of tumor cells optionally
expressing SAg are also used as above. Tumor cells are first
transformed to express SAg and then lysed (Example 28. These
lysates are "fed" top DCs as in Example 28. DCs treated in this way
can now present tumor associated antigens along with SAg to the
immune system. Alternatively, DCs are first transformed to express
SAg, and these cells are allowed to phagocytose or process
apoptotic tumor cells or lysates. Optionally the tumor cells may
have been previously genetically modified with nucleic acids so
that they synthesize .quadrature.1,3-glucan, LPS, peptidoglycan or
Gal Cer. The resulting SAg-expressing DC, after phagocytosing
apoptotic tumor cells or lysates, expresses MHC class II,
costimulatory molecules CD40, CD80 and CD86, together with SAg and
tumor associated antigen. The additional expression of SAg in this
system permits more potent activation of T cells, NKT cells and NK
cells which recognize the tumor associated antigens expressed on
the DC surface in the context of MHC and costimulatory molecules.
Such DCs are used in a preventative or therapeutic antitumor
vaccine (Example 29) or ex vivo to activate a T cells, NKT cells or
NK cells for the adoptive immunotherapy (Example 29).
[0386] 43. DCs Expressing or Secreting SAg Cotransfected with a
Tumor Associated Antigen or "String of Beads" Tumor Antigens
[0387] When a dominant tumor associated antigen (protein) is known,
nucleic acid encoding such an antigen are used to transform DCs
which already express or secrete SAg (Example 35). Antigens
identified by "SELEX" technology which consists of nucleic acids
encoding tumor antigens from distinct structural and functional
categories of human tumor associated antigens, including mutants,
differentiation variants, splice variants, amplified/overexpressed
antigens or retroviral antigens may be used. Nucleic acids encoding
tumor antigens used to transfect SAg-expressing DCs or DC/tc
hybrids. This invention contemplates transfecting with individual
nucleic acids encoding a single antigen, or multiples as in a
"string of beads" carried by adenoviral or other vectors known in
the art (Example 35). Nucleic acids encoding a "string of beads" or
tumor associated antigens identified by SERAX may be fused in frame
(or cotransfected with) SAg-encoding nucleic acid into DCs or
DC/tc. These SAg- and tumor antigen-expressing DCs or DC/tc hybrids
are used as a preventative or therapeutic antitumor vaccines
(Example 29) or as stimulators ex vivo of T cells, NKT cells or NK
cells for adoptive immunotherapy (Example 29).
[0388] Furthermore, nucleic acids encoding proteins listed in
Tables I, II, IV and V, for example, angiostatin, protein A,
erb/Neu and HSPs, staphylococcal collagen adhesin, are introduced
into and expressed in tumor cells or DCs that express or secrete
SAg, or into S/D/t cells. These cells that coexpressing the
proteins and peptides of Tables I, II, IV and V together with SAg
are useful as preventative or therapeutic antitumor vaccines
(Example 29) or as stimulators ex vivo that activate T cells, NKT
cells or NK cells for adoptive immunotherapy (Example 29).
[0389] 44. Naked DNA or RNA Obtained from the Various Cells
Described Above that Express and/or Secrete SAg
[0390] DNA containing the CpG backbone is extracted from tumor
cells or DCs that express/secrete SAgs or S/D/t cells (Example
30-34). The preferred source of DNA or RNA is the S/D/t cells DCs
or tumor cells expressing SAg are also useful. Alternatively, the
DNA or RNA can be obtained from DCs, tumor cells or DC/tc into
which SAgs were introduced by the cells having phagocytosed
SAg-transformed apoptotic tumor cells or tumor cell lysates.
[0391] The extracted DNA or RNA is used as a naked DNA or RNA
preventative or therapeutic vaccine (Examples 30-34).
Alternatively, this nucleic acid material may be used ex vivo to
activate T cell, NKT cells or NK cells adoptive immunotherapy
(Example 1, 31, 33). This extracted DNA or RNA may be used in an
initial step of inducing immune reactivity in regional lymph nodes
of tumor bearing subjects. After this "priming," T cells, NKT cells
and/or NK cells are harvested from these lymph nodes, expanded in
culture in the presence of additional SAg, SAg-expressing DC or
tumor cells, or S/D/t cells to generate a T cell, NKT cell or NK
cell population for adoptive immunotherapy (Examples 29). DNA or
RNA for immunization may also be obtained from the various cells
described above that express SAg, and which additionally express or
several Staphylococcal adhesins, .quadrature.-glucans, LPS,
peptidoglycans, teichoic acids, mannose, mannan, protein A and/or
their respective binding proteins.
[0392] Also useful for naked nucleic acid immunization are
bacterial or insect nucleic acids (with CpG motifs) which encode
enzymes that catalyze the biosynthesis of .quadrature.-1,3-glucans,
LPS, peptidoglycan, -Gal, GalCer, teichoic acids, mannan or
mannose. Also useful are bacterial or insect nucleic acids that
encode the binding proteins for the above carbohydrate-based
molecules, glycoprotein lectins that bind the carbohydrate
structures, or protein A. Such nucleic acids are used to
co-immunize along with SAg expressing DCs or tumor cells or S/D/t
cells. Such combined vaccine preparations are used as a
preventative or therapeutic antitumor vaccines (Examples 29, 30).
Alternatively, they may be used to initiate adoptive T cell therapy
by priming regional lymph nodes T cells which are harvested,
expanded in vitro by stimulation with S/D/t cells, accompanied by,
or followed with IL-2. The tumor antigen-sensitized T cells are
reinfused into subjects as described in Example 29.
[0393] 45. Exosomes Derived from (1) SAg-Expressing Tumor Cells (2)
SAg Expressing-DCs (3) S/D/t cells or (4) DC/tc Hybrid Cells
[0394] MHC-peptide complexes accumulate in endosomes and lysosomes,
which compartments contain MHC class II-enriched internal vesicles
that are released outside the cell following direct fusion of the
external endosomal membrane with the plasma membrane. These
vesicles, termed "exosomes" are capable of stimulating CD4+ T cell
clones in vitro. In addition, tumor peptide-pulsed DC-derived
exosomes prime specific CTLs in vivo leading to a T cell-dependent
eradication or suppressed growth of established murine tumors. In
the present invention, the exosomes which have SAgs in addition to
tumor associated antigens and MHC class I and class II molecules
are prepared. Such preparations are significantly more potent in
their ability to induce shrinkage of established tumors and prevent
tumor outgrowth.
[0395] Exosomes are prepared from (1) tumor cells or DCs which have
been transfected with SAgs (2) S/D/t cells, (3) DCs or hybrid DC/tc
which have phagocytosed SAg-expressing apoptotic tumor cells or
tumor cell lysates (Example 36). In the above hybrids, either the
DC or tumor cell may be transfected with SAg-encoding nucleic acid
prior to fusion. The resulting exosomes express MHC class I and
class II molecules, SAgs and tumor associated antigen. In order to
ensure the routing ofthe transforming SAg to exosomes, the
SAg-encoding nucleic acid should include a sorting signal to
localize the SAg to the exosome. These cells may be pulsed with
tumor associated antigens shortly before isolation of their
exosomes. The isolated exosomes are used as preventative or
therapeutic antitumor vaccines (Example 36) or as stimulators ex
vivo that activate T cells, NKT cells or NK cells for adoptive
immunotherapy (Example 36). These various exosome preparations are
extremely effective inducers of anti-tumor responses.
[0396] 46. Cell surface Display of Recombinant SAg and Tumor
Associated Antigens in Bacteria
[0397] Heterologous proteins and various carbohydrate-containing
moieties, displayed on the surface of bacterial cells often act as
major antigenic systems that stimulate anti-tumor immunity. Such
antigens include GalCer, .alpha.Gal, .quadrature.1,3-glucans, LPS,
peptidoglycans, teichoic acids and mannan. These structures will be
referred to below collectively as "anti-tumor motifs." These
structures are created by the action of enzymes encoded by a number
of bacterial and fungal genes. For example, Sphingomonas
paucimobilis expresses GalCer, or Klebsiella aerobacter expresses
-Gal and LPS, and Cryptococcus expresses .quadrature.1,3-glucan.
Because not all the genes responsible for the biosynthesis of these
molecules have not been identified, it is difficult to isolate them
and introduce them into mammalian cells. These structures are,
however, biosynthesized in abundance by bacteria. Immunization with
live recombinant bacteria induces both local and systemic immune
responses suggesting that gram-positive bacteria might constitute
potential live bacterial vaccine delivery systems. The surface
molecules of gram-positive bacteria seem to be more permissive for
the insertion of extended sequences of foreign proteins than are
gram-negative bacteria, in which both translocation through the
cytoplasmic membrane and correct integration into the outer
membrane are required for proper surface exposure.
[0398] In the present invention, different bacterial surface
display systems are used to express natural anti-tumor motifs for
developing live bacterial vaccine vehicles. SAgs are provided to
bacteria which do not naturally bio synthesize them so that they
are expressed together with natural anti-tumor motifs made in the
bacteria. These bacteria are then used as preventive or therapeutic
antitumor vaccines (Example 28).
[0399] Sphingomonas paucimobilis bacteria express GalCer which can
activate the V14 invariant chain expressed by NKT cells. These
cells recognizes the galactosylceramide epitope. NK cells, using
their NKP1-1 receptors, recognize carbohydrate units such as
1.quadrature.,3-glucans expressed widely on fungi. NK cells are
activated directly by SAgs. Further proliferation is induced by
interferon produced by T cells in response to the SAg. Humans have
natural antibodies specific for the .alpha.Gal epitope. This
epitope is constitutively expressed on several bacteria including
Klebsiella aerobacter and E. coli.
[0400] Coexpression of SAg with the above anti-tumor motifs in
recombinant bacteria or fungi provides potent signals to activate
NKT cells, T cells and NK cells and to induce production of TH-1
cytokines. The adhesion molecule VCAM-1 expressed by some SAgs such
as enterotoxin C contributes to the process by costimulation.
Therefore, the SAg expressing bacteria (whether natural or
transformed) are capable of activating all of the major cell types
involved in the anti-tumor response.
[0401] In the present approach, the preferred SAg is SEB. SEB is
introduced for surface display into S. carnosus. E.
coli-staphylococcus shuttle vectors are constructed by taking
advantage of (1) the promoter signal sequence and propeptide region
from the lipase gene construct derived from S. hyicus and (2) the
cell surface attachment part of staphylococcal protein A. A
198-amino-acid region, designated ABP (albumin binding protein), is
expressed adjacent to the cell wall to increase accessibility to
the surface-displayed target peptides. Staphylococcal enterotoxin B
is introduced between the lipase propeptide and the ABP region and
the surface exposure of the three different regions are tested
separately with different assays.
[0402] These recombinant bacteria are useful as a preventative or
therapeutic antitumor vaccine (Example 28) or as stimulators ex
vivo that activate T cells, NKT cells or NK cells for adoptive
immunotherapy (Example 28).
[0403] 47. Introduction of Staphylococcal Collagen Binding Adhesins
into DCs, Tumor Cells or S/D/t Cells
[0404] Nucleic acids encoding SAgs are transfected into these
various cells, as described above, together with nucleic acids
encoding Staphylococcal collagen adhesin(SEQ ID NOS:44-45). Mice
immunized with a recombinant fragment of the collagen adhesin were
protected against Staphylococcus aureus-mediated septic death. Sera
from S. aureus-immunized mice promoted phagocytic uptake
(opsonized) and enhanced intracellular killing of the bacteria
compared to sera from control mice.
[0405] The collagen binding adhesin is isolated from S. aureus
strain Cowan. Sequencing of the cloned corresponding gene cna
revealed a 133-kDa polypeptide (close to that of 135 kDa reported
for the native protein). This protein is proposed to consist of a
signal sequence (S) followed by a large nonrepetitive region (A).
Immediately following the A region are three consecutive repeats of
a 167 amino acid long unit (B1, B2, B3). A cell wall (W) region
consisting of 64 amino acid proline-and lysine-rich domain is
followed by stretch of hydrophobic amino acids (M), presumably
constituting the cell membrane spanning region. Finally, the
C-terminus (C) is made up of a few positively charged amino acids.
This model structure is used as the starting point to identify the
collagen binding domain. The ligand binding site is localized
within the 135-kDa S. aureus collagen adhesin. The collagen binding
domain is localized to a 168 amino acid long segment [CBD
(151-318)] within the N-terminal portion of the adhesin. Using
biospecific interaction analysis, bovine collagen was found to
contain eight binding sites for CBD (151-318), two of which were
high affinity and six low affinity. The deduced amino acid sequence
of the ligand binding domain of the collagen adhesin is presented.
Subsequently a discrete collagen-binding domain within the collagen
adhesin was identified and localized to a region between amino
acids Asp209 and Tyr233. The FDA strain 574 of S. aureus encodes a
1185 amino acid collagen adhesin. The complete nucleotide sequence
of the cna gene as well as a schematic model of the collagen
adhesin have been published. The overall structure resembles that
of other gram positive surface structures. The lysine and proline
rich hydrophilic region which follows the repeated domains
resembles a structure in protein A, staphylococcal fibronectin
receptor and streptococcal protein G and M proteins. Also present
is the hexapeptide LPKTGM which is similar to the consensus
sequence LPXTGE which is conserved among other gram positive
surface proteins. The hydrophilic region is thought to mediate the
binding of the protein to the cell wall. The presence of
hydrophobic amino acids which may traverse the membrane followed by
a C-terminal cluster of positively charged residues, possibly
located on the cytoplasmic side of the membrane, is characteristic
of staphylococcal cell surface proteins. In the collagen adhesin, a
29 amino acid signal peptide at the N-terminus is followed by a
large nonrepetitive A domain, and the highly homologous domains B1,
B2 and B3 (probably a result of a series of stepwise gene
duplication events). Collagen binding receptors have been found on
other species of bacteria such as the 75X adhesin of uropathogenic
E. coli. Type 3 fimbrias from pathogenic enteric bacteria, some
species of oral streptococci Streptococcus pyogenes, Yersinia and
Treponema pallidium have all been reported to bind various forms of
collagen. Thus the collagen binding appears to be a common modality
used by pathogenic bacteria of a diverse group to adhere
selectively to host tissues and form a focus of infection.
[0406] Nucleic acids encoding staphylococcus collagen adhesin are
introduced into SAg-expressing tumor cells or DCs, or S/D/t cells.
The cells co-expressing the staphylococcal collagen adhesin with
SAgs are useful as a preventative or therapeutic antitumor vaccines
(Example 28) or as stimulators ex vivo that activate T cells, NKT
cells or NK cells for adoptive immunotherapy (Example 28).
[0407] 48. Co-Expression of Anti-Tumor Motifs or their Binding
Proteins with SAg
[0408] Tumor cells or DCs expressing SAgs, or S/D/t cells, are
transformed with nucleic acids encoding enzymes that catalyze the
biosynthesis of anti-tumor motifs, including the .alpha.Gal
epitope, the GalCer epitope, .quadrature.-1,3-glucans, LPS,
peptidoglycan, teichoic acids or a protein or peptide such as
Staphylococcal adhesins, protein A, and/or the binding proteins for
the above motifs or proteins. Transformation may be achieve using
bacterial plasmids or nucleic acids integrated into an appropriate
viral vector. These antigenic structures are fundamental units
recognized in the primitive host defense mechanisms ("innate
immunity") of invertebrates, but also evoke responses in mammalian
immune systems via the TOLL and NF.kappa.B systems.
[0409] DNA encoding the galactosyltransferase that synthesizes the
saccharide structure containing the .alpha.Gal epitope, and gene
clusters encoding the biosynthetic pathway for LPS are described in
Schnaitman C A, et al., Microbiol. Rev. 57: 655-682 (1993). DNA is
extracted from bacteria which biosynthesize these molecules and
used to transfect DCs, tumor cells, or S/D/t cells For creation of
the GalCer structure, the source of DNA is Sphingomonas
paucimobilis organisms. Nucleic acids encoding the pathways for
biosynthesis of .quadrature.-1,3-glucans, peptidoglycans, and
protein A have been cloned from insects and Staphylococcus aureus,
respectively. These nucleic acids are cloned into suitable
expression vectors and introduced into the target cells. Resulting
S/D/t cells thus express SAg as well as the anti-tumor motif
structure.
[0410] S/D/t cells that co-express Gal can interact with and
stimulate NKT cells through the V.alpha.14 invariant chain which
naturally recognizes the -galactosylceramide epitope. NK cells, via
their NKP1-1 receptors, will recognize carbohydrate units such as
.quadrature.-1,3-glucans on the S/D/t cells. The co-expressed SAg
induces further NKT cell expansion. The SAg is also capable of
inducing massive proliferation of conventional T cells which can be
further promoted by the co-expression of B7-1, B7-2 and ICAM-1
which are normally expressed on DCs. VCAM-1, expressed by some SAgs
such as enterotoxin C, also is capable of contributing to this
stimulation. As indicated above, NK cells are activated directly or
indirectly by T-cell derived interferon.
[0411] The S/D/t cells (as well as tumor cells or DCs expressing
SAg) that also express one or more of the anti-tumor motifs are
capable of activating all of the major cell types involved in
anti-tumor immunity: T cells specific for peptides, NKT cells
reactive with lipoproteins and glycosylceramides and NK cells that
recognize for oligosaccharides. These cells are useful as
preventative or therapeutic antitumor vaccines (Examples 29) or as
stimulators ex. vivo that activate T cells, NKT cells or NK cells
for adoptive immunotherapy (Example 29).
[0412] 49. Sags Combined with Low Density Lipoproteins (LDL),
Oxidized LDL (oxy LDL) Oxidized LDL Mimics and Apolipoproteins
[0413] In the present invention, low density lipoproteins
(collectively LDL) intermediate density LDL (IDL), chylomicrons,
very low density lipoproteins (VLDL), oxidized LDL (oxyLDL), oxyLDL
mimics as well as and apolipoproteins including but not limited to
apolipoprotein (a), B100 and E4 are conjugated to superantigens and
are useful as anti-cancer agents alone.
[0414] LDLs, oxyLDLs and apolipoproteins are physically trapped or
bind to receptors expressed in the dense network of randomly
branching blood vessels and sinusoids of the tumor neovasculature
and have the capacity to deposit or bind to LDL receptors on the
tumor endothelium and to scavenger recepors on macrophages OxyLDL
or apolipoproteins bound to tumor endotheium or macrophages they
induce apoptosis or they promote inflammation by activating
vascular cells and macrophages to generate cytokines,
chemoattractants and tissue factor.
[0415] Superantigens in nucleic acid or polypeptide form are
conjugated to the lipoproteins and amplify the inflammatory effect
of the lipoproteins by inducing apoptosis of endothelial cells,
upregulating endothelial cell integrins, adhesins and procoagulant
activity whicle activating macrophages and immunocytes. Any tumor
which is neovascularized is eligible for this therapy. These
conjugates therefore have the advantages of localizing to
disseminated and neovascularized tumor, inducing apoptosis and
initiating a powerful anti-tumor response.
[0416] Lipoproteins
[0417] Lipoproteins are globular particles of high molecular weight
that transport nonpolar lipids (primarily triglycerides and
cholesterol esters) through the plasma. Lipoproteins have been
classified on the basis of their densities into five major classes:
chylomicrons, very low density lipoproteins (VLDL),
intermediate-density lipoproteins (IDL), low-density lipoproteins
(LDL), and high-density lipoproteins (HDL). The physical-chemical
characteristics of the major lipoprotein classes are presented in
Table The core of the spherical lipoprotein particle is composed of
two nonpolar lipids hydrophobic lipids, triglyceride and
cholesteryl ester, which are present in different lipoproteins in
varying amounts. This hydrophobic core accounts for most of the
mass of the particle, and consists of triglycerides and cholesterol
esters in varying proportions. Surrounding the core is a polar
surface coat of phospholipids that stabilize the lipoprotein
particle so that it can remain in solution in the plasma. Variable
amounts of unesterified cholesterol are interdigitated with the
phospholipids of the surface coat. In addition to phospholipid, the
polar coat contains small amounts of unesterified cholesterol. Each
lipoprotein particle also contains specific proteins (termed
apoproteins) that are exposed at the surface and extend into the
core. The apoproteins bind specific enzymes or receptors on tumor
microvascular cells.
[0418] Chylomicrons
[0419] Chylomicrons are large lipoprotein particles formed within
intestinal epithelial cells from dietary triglycerides and
cholesterol which are secreted into the intestinal lymph and pass
into the general circulation where they adhere to LDL receptors on
the tumor microcapillaries. Chylomicron remnants are removed by
both LDL receptors and LDL- receptor related
protein/alpha2-macroglobulin receptor (LRP). While bound to these
endothelial surfaces, the chylomicrons are exposed to the enzyme
lipoprotein lipase. The chylomicrons contain an apoprotein,
apoprotein CII, that activates the lipase, liberating free fatty
acids and monoglycerides.
[0420] Very Low Density Lipoprotein (VLDL)
[0421] Very low density lipoprotein (VLDL)are triglyceride rich
particles which are secreted from the liver into the bloodstream
after conversion of carbohydrate to glycerol-esterified fatty acids
to form triglycerides. VLDL particles are relatively large, carry 5
to 10 times more triglycerides than cholesteryl esters, and contain
a form of apoprotein B, designated B 100, that differs from the
apoprotein B48 of chylomicrons. The VLDL particles are transported
to LDL receptors on tumor microcapillaries, where they interact
with the same lipoprotein lipase enzyme that catabolizes
chylomicrons. VLDL also binds to the VLDL receptor via
apolipoprotein E and lipoprotein lipase. Both apolipoprotein E and
lipoprotein lipase are constituents of chylomicron remnants which
are a physiological ligand for the VLDL receptor.
[0422] Plasma Apolipoproteins
[0423] Plasma apolipoproteins have a central role in plasma lipid
transport. Central to the functions of all apolipoproteins (apo) is
specialized regions termed amphiphathic helices which have the
ability to bind phospholipids. The amphiphatic helices in apoA-I,
apoA-II, and apoC-III comprise multiple repeats of 22 amino acids
or 22-mer periodicity each consisting of a tandem array of two
11-mers which tend to begin or end with a proline. The
characteristic spatial arrangement of the hydrophobic and
hydrophilic amino acids within the amphipathic helices is that the
hydrophobic face is intercalated between the fatty acyl chains of
phospholipids and the hydrophilic face is located close to the
polar head groups of phospholipids. Such an orientation allows the
interaction of protein domains with lipoprotein-modifying enzymes
and cellular receptors that control the catabolism of lipoproteins
(Lp) and their removal from the circulation. The major
apolipoproteins useful in the present superantigen-apolipoprotein
conjugates are as follows:
[0424] Apolipoprotein (a)
[0425] Apolipoprotein (a) (Lp (a)) is made by hepatocytes and is
secreted into plasma where it forms a covalent linkage by a single
interchain disulfide bond to a unique multikringle glycoprotein,
with apo B 100 of LDL to form lipoprotein(a). called
aploliprotein(a). Protein apo (a) has structural similarities to
plasminogen and consists of multiple bent repeats of amino acid
sequences. Apolipoprotein (a) exists in polymorphs distinguished by
molecular weights. The molecular basis for the size variation of
apo[a] is primarily due to multiple apo[a] alleles that differ in
the number of kringle type 2 (plasminogen kringle type 4) repeats.
Minor variability in apo(a) size might be due to differences in
glycosylation, as carbohydrates make up 25-40% of the apo (a)
weight.
[0426] A close structural similarity exists between apo(a) and
plasminogen a protease zymogen whose active form cleaves fibrin to
dissolve blood clots, is activated by tissue and urokinase
plasminogen activators via cleavage at a specific arginine residue.
Indeed, in-vitro and ex-vivo studies have shown that apo(a) binds
to immobilized fibrin (fibrinogen), to the plasminogen receptor on
endothelial cells and competes with tissue plasminogen activator in
converting plasminogen to plasmin. Lipoprotein(a) also competes
with plasminogen for its high-affmity binding sites in endothelium,
platelets, and macrophages. Because of structural homology with
plasminogen apo(a)I competively inhibits fibrin-dependent
activation of plasminogen to plasmin and plasmin-mediated
activation of cytokine transforming growth factor-.quadrature..
Hence, Lp(a) is capable of interfering with the fibrinolytic
process by acting as a procoagulant. The colocalization of apo(a)
with fibrin (fibrinogen) in the arterial wall further suggests that
Lp(a) is thrombogenic.
[0427] Lp(a) is a poor ligand for the LDL receptor and is
consequently taken up and degraded by unregulated mechanisms,
leading to tissue accumulation. Lp(a) is targeted to uptake by
macrophages, presumably through the scavenger-receptor pathway.
Owing to the lower B-carotene content, Lp(a) may be more easily
oxidized than LDL. Oxidized Lp(a) such as Lp(a) modified by
malondialdehyde, a product generated in vivo from aggregated
platelets, is avidly taken up by monocyte-macrophages. through the
scavenger-receptor pathway. Lp(a) accumulates in either the
arterial wall and in vein grafts, respectively suggesting that
Lp(a) can also traverse the endothelium of arterial vessels and
reach the intima by non-receptor-mediated mechanisms and that this
transport process is influenced by the density/size of Lp(a).
There, Lp(a) can form complexes with such tissue-matrix components
as proteoglycans, glycosaminoglycans, and collagen as well as
fibrin. The magnitude of the transfer of Lp(a) from the plasma
compartment to the arterial wall is larger when plasma Lp(a) levels
are elevated because of a gradient effect or because of a possible
direct action of Lp(a) on arterial permeability.
[0428] Apolipoprotein B
[0429] Apolipoprotein B occurs in two forms termed apoB-100 and
apoB-48. In humans apoB-48 is produced only by the intestine and
apolipoprotein B-100 originates from the liver. Apolipoprotein
B-100, which contains 4536 amino acid residues, is the major
apolipoprotein of VLDL, IDL, Lp(a) and is the sole apolipoprotein
of LDL. ApoB-48 consists of the amino-terminal half of apoB-100,
contains 2152 amino acid residues and is devoid of binding domain
for the LDL receptor.
[0430] Apolipoprotein E4
[0431] Apolipoprotein (apo) E is a 34-kCa protein coded for by a
gene on chromosome 19 and plays a prominent role in the transport
and metabolism of plasma cholesterol and triglyceride through its
ablity to interact with the low density lipoprotein (LDL) receptor
and the LDL receptor related protein (LRP). Apolipoprotein E (apoE)
is a 34-kda protein component of lipoproteins that mediates their
binding to the low density lipoprotein (LDL) receptor and to the
LDL receptor-related protein (LRP). Apolipoprotein E is a major
apolipoprotein in the nervous system, where it is thought to
redistribute lipoprotein cholesterol among the neurons and their
supporting cells and to maintain cholesterol homeostasis. Apart
from this function, apoE in the peripheral nervous system functions
in the redistribution of lipids during regeneration.
[0432] Oxidized LDL
[0433] LDL is also rapidly transported across an intact endothelium
and becomes trapped in the three-dimensional cage work of fibers
and fibrils secreted by the artery wall cells. This
concentration-dependent process does not require receptor-mediated
endocytosis. LDL entrapped in arteries or bound to receptors on
endothelium or the tumor microcirculation undergoes diverse enzymic
and chemical modifications. It can also be introduced into the cell
a variety of lipophilic invaders such as lipid peroxidation
products and cholesterol oxides that may irreversibly modify
cellular functions. The early oxidative modification of the trapped
LDL in vivo occurs before monocytes are recruited and results in
the oxidization of lipids in LDL with little change in apoB.
[0434] Monocytes recruited to the lesion, are converted into
macrophages and the LDL lipids are further oxidized. Once the LDL
contains fatty acid lipid peroxides, there follows (especially in
the presence of metal ions) a rapid propagation that amplifies
dramatically the number of free radicals and leads to extensive
fragmentation of the fatty acid chains with the generation of a
broad spectrum of oxysterols, shorter-chain aldehydes (e.g.,
malondialdehyde and 4-hydroxynonenal) some of which involve the
covalent binding of short-chain substituents to the amino groups of
lysine residues in apoprotein B (and possibly to other portions of
the apoprotein B molecule) masking lysine 6-amino groups. Acetyl
LDL and scavenger receptors recognize modifications effected by
chemical acetylation and highly oxidized LDL.
[0435] Incubation of LDL with endothelial cells, smooth muscle
cells, and macrophages in vitro induces oxidation of
polyunsaturated fatty acids. Lipid peroxides formed fragment fatty
acyl chains and attach covalently to apoB or fragments thereof,
thereby rendering the modified particles competent for endocytosis
by the scavenger receptor. LDL particles also undergo peroxidation
of polyunsaturated fatty acids which produces oxidative
modification and conversion of LDL lecithin to lysolecithin.
[0436] Modification of LDL with malondialdehyde, a product of
arachidonic acid metabolism or oxidation of LDL leads to foam cell
formation. Unlike native LDL, oxidized LDL is mitogenic or induces
apoptosis in arterial endothelial and smooth muscle cells. It also
induces endothelial cells and monocytes to express high levels of
tissue factor and plasminogen activator inhibitor. Levels of
P-selectin are increased intracellularly and are released by
oxy-LDL which can also directly stimulate PDGF production in
endothelial cells. Oxidized LDL also induce the expression of
endothelin, to inhibit the expression of nitric oxide synthase, and
to inhibit the resulting vasodilation. Platelet accumulation and
local increases in thromboxane A, serotonin, ADP, platelet
activating factor, and activated thrombin, together with a local
reduction in prostacyclin further contribute to a procoagulant
state.
[0437] Another stable end product of cellular oxidative
modification of LDL is lysophosphatidylcholine, which is generated
by phospholipase A2 hydrolysis. This lipid selectively induces the
expression of adhesion molecules for monocytes, vascular cell
adhesion molecule-1 (VCAM-1), and ICAM-1 in cultured human arterial
endothelial cells. TNF-a activation is a prerequisite for the
observed lysophosphatidylcholine induction of VCAM-1.
Lysophosphatidylcholine also induces monocyte chemotaxis, arrests
macrophage migration and induces macrophage proliferation through
SR-A-mediated internalization of modified lipoprotein. Finally,
lysophosphatidylcholine induces gene expression for smooth
muscle/fibroblast growth factors, the A and B chains of PDGF, and
heparin-binding epidermal growth factor-like protein in cultured
endothelial cells.
[0438] oxy LDL Mimics
[0439] The cytotoxic effects of highly oxidized LDL are mimicked by
higher concentrations of oxysteroid. particularly
7b-hydroperoxycholesterol. 7b-hydroxycholesterol, 7-ketocholesterol
and 5a-6a-epoxycholesterol. These oxysterols can induce apoptosis
in a variety of cells. Of these end products,
73-hydroperoxy-choles-5-en-3B-ol has been identified as the primary
cytotoxin in highly oxidized LDL. This molecule accounts for
approximately 90% of the cytotoxicicy of lipids extracted from
highly oxidized LDL in vitro. Fatty acid hydroperoxides and
aldehydes found in oxidized LDL also alter intracellular functions.
For example, 4-hydroxynonenal (4-HNE). a component of oxidized LDL,
induces binding of the coagulation protein, Factor Xa to
endothelial cells. In addition, oxidized LDL and mm-LDL can
significantly induce the release of IL-1 from macrophages.
Saponified Cu.sup.2+-oxidized LDL and mm-LDL have been shown to
contain 9-HODE, 13-HODE, and cholesterol-9-HODE, which increase
IL-1 release from macrophages. 4-HNE also causes a variety of
effects on monocytes, including stimulation of monocyte migration
through induction of chemoattractant proteins and initiation of
apoptosis
[0440] Mildly Oxidized LDL (mm-LDL)
[0441] Mildly oxidized LDL (mm-LDL) induces elevated levels of cAMP
by a G protein-mediated mechanism and induces inflammatory
molecules both by increasing the rates of gene transcription and by
stabilizing the MRNA for these genes. Exposure of the arterial wall
to (mm-LDL) or biologically active products of lipid peroxidation
results in binding to the LDL-R. mm-LDL also induces monocytes to
bind to endothelial cells. and induces changes which affect
monocyte binding, tethering, activation, and attachment. mm-LDL
also induces an inflammatory phenotype in endothelial cells and
proinflammatory cytokines accompanied by increase the levels of the
transcription factor, NF kB, which has been linked to the
expression of a variety of adhesion molecules. In particular,
lysophosphosphatidylcholine, a product of LDL oxidation, has been
shown to be a chemoattractant for monocytes and T-lymphocytes, to
induce the adhesion molecules VCAM-1 and ICAM-1, and to increase
levels of PDGF and heparin-binding epidermal growth factor mRNA in
endothelial cells and smooth muscle cells. Increases in ICAM-1
expression lead to enhanced monocyte adhesion to the vessel
wall.
[0442] Moreover, mm-LDL induces endothelial cells to produce the
potent monocyte activators monocyte chemoattractant protein 1
(MCP-1) and monocyte colony stimulating factor (M-CSF). Macrophage
Class A scavenger receptors and CD36, a Class B scavenger receptor
are up-regulated by M-CSF. Once bound to specific scavenger
receptors, mm-LDL can initiate cell signaling events in vascular
cells stimulating phosphoinositide metabolism and calcium flux as
well as stimulate phospholipase E1 activity through a tyrosine
kinase-dependent mechanism independent of protein kinase C. This
induces the release of phosphatidic acid or arachidonic acid for
eicosanoid production in the vessel wall. A portion of this
activity may be mediated by the Class A scavenger receptor ligands
which stimulate macrophage urokinase expression and IL-1 production
a growth factor for smooth muscle cells.
[0443] The biological properties of the lipids in mildly oxidized
LDL differ from those induced by the lipids in highly oxidized LDL.
For example, the expression of tissue factor by endothelial cells
is induced by mildly oxidized LDL but not by highly oxidized LDL.
The lipids in highly oxidized LDL are cytotoxic, whereas the lipids
in mildly oxidized LDL are not. Mildly oxidized LDL induced the
activation of the NFKB-like transcription factor and the increase
in the appearance of specific oxidized phospholipids. With
continued oxidation, highly oxidized LDL such as
lysophosphatidylcholine and oxidized sterols are produced with
different biological activity as given above.
[0444] The ability of mm-LDL to induce monocyte adherence to
endothelial cells is mimicked by three polar bioactive lipids
isolated from mm-LDL as well as oxidized
1-palmitoyl-2-arachidonyl-sn-glycerophosphocholine. The molecular
structure of two bioactive lipids were identified
1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine (m/t
594.3) and 1-pahnitoyl-2-glutaryl-sn-glycero-3-phosphocholine (m/t
610.2). The third lipid (m/t 831) has tentatively been described as
an arachidonic acid-containing phospholipid containing three or
four oxygen molecules, potentially forming a conjugated triene
structure characteristic of leukotrienes. The latter serves as a
substrate for paraoxonase, and those with fragmentation products
such as 5-oxyvalerate at the sn-2 position may represent substrates
for PAF acetylhydroxylase.
[0445] Glycated LDL
[0446] Glycated LDL is recognized less well by the LDL receptor,
but is taken up more rapidly by macrophages. Very prolonged
exposure of LDL to high concentrations of glucose leads to
glucose-mediated cross-linking and the generation of advanced
glycosylation end products, which macrophages recognize in a
specific saturable fashion.
[0447] Artificial Complexes of LDL
[0448] Artificial complexes of LDL formed by incubation with
fibronectin, heparin, and fibrillar collagen are also candidates,
and the uptake there appears to be through recognition of the
fibronectin. Complexes of LDL with itself are taken up more rapidly
than native LDL via the LDL receptor. After incubation with
neutrophils LDL is taken up more rapidly by macrophages. This is
attributable to the dimerization of LDL by the action of secreted
neutrophil elastase on native LDL
[0449] Apoprotein Genes
[0450] The genes for the major apoproteins associated with the
lipoproteins have been cloned. These include apolipoprotein (a)
(McLean J W Nature 330: 132-137 (1987)), apolipoprotein B-100 (Chen
S H J. Biol Chem. 261: 12918-12921 (1986)), apolipoprotein E4
provided by Drs. S Lauer and J. Taylor. Lp(a) has been cloned from
cDNA libraries constructed from human liver mRNA (McLean J W Nature
330: 132-137 (1987)). Complete sequence analysis of a 14
000-base-pair (bp) DNA copy of apo(a) mRNA showed many exact or
nearly exact repeats of a 342-bp sequence occurred. Indeed, most of
the mRNA consist of 22 tandem exact repeats and 15 modified
repeats. Apolipoprotein (a) belongs to a gene family that includes
genes encoding clotting factors, structural proteins, and growth
factors. Domains shared by these proteins are protease-like
domains, kringle units, calcium binding domains, and epidermal
growth factor precursor domains.
[0451] In the present invention, superantigens are ligated to the
major classes of lipoproteins in human plasma including LDL, IDL,
HDL, VLDL, chylomicons and remnants containing apoproteins and
mm-LDL, oxy LDL isosterols, inositols, lysophosphatidlycholine,
synthetic mimics of LDL activity and oxyLDL byproducts by methods
given in Example 47 Because of their unique capacity to adhere to
tumor niicrovasculature and evoke an
apoptotic/inflammatory/prothrombotic response, the lipoprotein
structures preferred for ligation to SAg include but are not
limited to Lp(a), LpB-1000 or B-47, oxyLDL, oxyLDL byproducts,
oxyLDL mimics and IDL.
[0452] The lipoproteins used for conjugation are prepared as in
Examples 48-49. The superantigens used for conjugation are
preferentially in nucleic acid or phage form but may also be in
peptide, polypeptide nucleic acid or phage display form. They are
coupled to the various LDL, oxyLDL or apolipoproteins via methods
given in Examples 3, 5, 47. Alternatively, SAg are incorporated or
bound or conjugated to a vesicular, exosomal structures shed from
normal, tumor or sickled cells expressing LDL, oxy LDL, oxyLDL
mimics or apolioproteins. Superantigens are also integrated into
liposomal structures prepared to express natural or synthetic LDL,
oxyLDL, apolipoprotens or oxyLDL mimics as described in Section 45
and Examples 3, 5, 6, 36, 42. Optionally, integrin ligand sequences
such as RGD are added to facilitate the localization of the
conjugates to the tumor microvasculature binding to the
a.sub.vb.sub.3 integrin and a.sub.vb.sub.5 integrin which are
expressed therein (see Example 6). These superantigen-lipoprotein
conjugates are physically trapped in the dense network of randomly
branching blood vessels of the tumor microcirculation and also bind
to LDL or scavenger receptors expressed in the tumor
neovasculature.
[0453] Constructs consisting of naked Sag nucleic acids containing
CpG backbone fused to apoprotein nucleic acids alone or
incorporated into liposomes are prepared as in Example 3, 6, 14,
30-31 and delivered to the tumor sites in vivo as in Examples 14,
30-31.
[0454] These constructs are useful in vivo as a therapeutic
antitumor vaccines according to Examples 14, 15, 16, 18-23. They
are also useful ex vivo for producing a population of tumor
specific effector T or NKT cells for adoptive immunotherapy of
cancer (Examples 2-5, 7, 15, 16, 18-23).
[0455] Tumor Cells or Sickled Erythrocytes and Vesicles Expressing
SAg and Apolipoproteins
[0456] Superantigen nucleic acids are fused in frame to nucleic
acids encoding apoproteins including but not limited to apoproteins
Lp(a), B-48 and 100 and E3 and transfected into tumor cells in vivo
to produce tumor cells expressing superantigens and apoproteins.
These tumor cells are recognized by apoprotein receptors in tumor
microvasculature. Tumor cells are also transfected ex vivo with the
identical nucleic acid constructs. A RGD sequence is added to
promote deposition in the tumor microvasculature which are useful.
These tumor cell transfectants expressing Sag, apoprotein and RGD
bind to apoprotein receptors and integrins respectively expressed
in tumor microvasculature wherein they initiate a potent and
localized anti-tumor response.
[0457] Superantigen nucleic acids together with nucleic acids
encoding either apo(a), apoB and apoE4 are also transfected into
nucleated sickled erythrocytes (e.g., proerythroblast or normoblast
phase) by methods given in Examples 1 and 6. The integrin ligand
RGD nucleic acids are transfected into tumor cells or sickled cells
to facilitate the localization of the transfected tumor cells and
sickled cells to integrins expressed in the tumor neovasculature in
vivo (see Example 6). Alternatively, the sickled erythrocytes or
tumor cells acquire the apolipoprotein or oxyLDL by coculture with
liposomes which express the apolipoprotein or oxyLDL (see Section 7
& Example 5).
[0458] These tumor cells or sickle cell transfectants are
adminstered parenterally and are capable of trafficking to tumor
microvascuature wherein they bind to apolipoprotein and scavenger
receptors on endothelial cells and macrophages. The transfectants
are phagocytosed by macrophages cells and induce endothelial cell
apoptosis. SAgs expressed on the tumor cells and sickle cells also
induce a local T cell inflammatory anti-tumor response which
envelops the neighboring tumor cells.
[0459] These tumor cell and sickle cell constructs are prepared by
methods given in Examples 1 & 6 and are useful in vivo against
primary and/or metastatic tumors according to Examples 14, 15, 16,
18-23.
[0460] Tumor Cells & Endothelial Transfected in vivo with SAg
and Lipoprotein Receptors or Oxidized Lipoprotein Receptors
[0461] The genes encoding the LDL oxyLDL, VLDL, LRP, CD36, SREC and
LOX-1 receptors as well as macrophage scavenger receptors,
expressed on endothelial cells and macrophages and have been
cloned. Nucleic acids encoding receptors for various
apolipoproteins including but not limited to the LDL or apo a, apoB
or apo E receptor, CD36 receptor, LRP receptor, macrophage
scavenger receptor, endothelial cell oxyLDL receptor (LOX-1) and
endothelial cell scavenger cell receptor (SREC) alone or together
with nucleic acids encoding superantigens are injected directly
into tumor sites. The same nucleic acids are transfected into tumor
cells in vivo. Transfection of these receptors into tumor cells and
tumor microvascular endothelial cells results in the expression of
the LDL receptor protein with high affinity binding specificity for
LDL oxyLDL and Lp(a).
[0462] Exposure of the transfected tumor cells or endothelial cells
to exogenously introduced oxidized LDL (especially sterol and
lysocholinephosphatidic acid) induces tumor endothelial cell
apoptosis analogous to that seen in endothelial cell after exposure
to oxyLDL. The transfected tumor cells internalize and degrade the
oxyLDL and because they, like macrophages, have no means of down
regulating the scavenger receptor are transformed to "foam cells"
and undergo apoptosis.
[0463] LDL Receptor (LDL-R)
[0464] The high affinity receptor for LDL known as the apoB
receptor or the LDL receptor (LDL-R) found on tumor microvascular
cells as well as hepatic cells and macrophages binds LDL, VLDL and
chylomicron remnants via their associated apoproteins.
Apolipoprotein B-100 gene has been cloned (Chen S H J. Biol Chem.
261: 12918-12921 (1986)). The LDL gene is more than 45 kilobases in
length and contains 18 exons. Thirteen of the 18 exons encode
protein sequences that are homologous to sequences in other
proteins: five of these exons encode a sequence similar to one in
the C9 component of complement; three exons encode a sequence
similar to a repeat sequence in the precursor for epidermal growth
factor (EGF) and in three proteins of the blood clotting system
(factor IX, factor X, and protein C); and five other exons encode
nonrepeated sequences that are shared only with the EGF precursor.
The LDL receptor appears to be a mosaic protein built up of exons
shared with different proteins, and it therefore belongs to several
supergene families (Sudhof T C et al., Science 228: 815-22
(1985)).
[0465] Regulation of LDL-R expression occurs primarily at the
transcriptional level and is controlled by levels of free
cholesterol in the cell. Inflammatory mediators such as growth
factors and cytokines can promote the binding and uptake of LDL.
These mediators include PDGF, TGF-b, basic fibroblast growth
factor, TNFa, and IL-1. Some of these mediators, such as TNF-a and
IL-1, affect transcriptional regulation of the LDL-R gene at the
level of the promoter.
[0466] VLDL Receptor
[0467] The VLDL receptor has been described as a new member of the
LDL receptor supergene family that specifically binds VLDL and
chylomicron remnants via apolipoprotein E and lipoprotein lipase.
Both apolipoprotein E and lipoprotein lipase are constituents of
chylomicron remnants, and a physiological ligand for the VLDL
receptor (Niemeier A et al., J. Lipid Res. 37: 1733-42 (1996)).
[0468] LRP Receptor
[0469] The alpha 2-macroglobulin receptor or lipoprotein
receptor-related protein (LRP) (LRP) is a cell-surface glycoprotein
of 4525 amino acids that functions as a multifunctional receptor
which binds and rapidly internalizes several plasma proteins. These
include alpha 2-macroglobulin-protease complexes, free plasminogen
activators as well as plasminogen activators complexed with their
inhibitors, and beta-migrating very low density lipoproteins
complexed with either apolipoprotein E or lipoprotein lipase tissue
and urokinase-type plasminogen activators, plasminogen activator
inhibitor-1, lipoprotein lipase, and lactoferrin. The active
receptor protein is derived from a 600-kDa precursor, encoded by a
15-kb mRNA, cloned and sequenced in human, mouse, and chicken. The
entire human gene (LRP1) coding for A2MR/LRP has been cloned. The
gene covers about 92 kb and a total of 89 exons, varying in size
from 65 bases (exon 86) to 925 bases (exon 89) have been
identified. The introns vary from 82 bases (intron 53) to about 8
kb (intron 6). In the introns, 3 complete and 4 partial Alu
sequences have been identified. Interexon PCR from exon 43 to 45
yielded a fragment of 2.5 kb. Attempts to subclone this fragment
yielded inserts ranging between 0.8 and 1.6 kb. Sequencing of 3
subclones with different-size inserts revealed a complex repetitive
element with a different size in each subclone. In the mouse LRP
gene this intron is much smaller, and no repetitive sequence was
observed. In 18 unrelated individuals no difference in size was
observed when analyzed by interexon PCR (Van leuven, F et al.,
Genomics 24: 78-89 (1994))
[0470] The LRP receptor is mainly responsible for the binding and
internalization of chylomicron remnants as well as apoE-containing
HDL. ApoE-containing lipoproteins are taken up and degraded by
receptor-mediated endocytosis. Apolipoprotein E3- and
apoE4-containing lipoproteins have a similar binding affinity and
cause a similar degree of lipoprotein internalization via the LDL-R
and the LRP. LRP can mediate the degradation of tissue factor
pathway inhibitor (TFPI), a Kunitz-type plasma serine protease
inhibitor that regulates tissue factor-induced blood
coagulation
[0471] The 3 9-kDa receptor-associated protein (RAP) associates
with the multifunctional low density lipoprotein (LDL)
receptor-related protein (LRP) and thereby prevents the binding of
all known ligands, including alpha 2-macroglobulin and chylomicron
remnants. RAP is predominantly localized in the endoplasmic
reticulum and functions as a chaperone or escort protein in the
biosynthesis or intracellular transport of LRP. RAP promotes the
expression of functional LRP in vivo and stabilizes LRP within the
secretory pathway.
[0472] Macrophage Scavenger Receptors
[0473] Scavenger receptors mediate the endocytosis of chemically
modified lipoproteins, such as acetylated low density lipoprotein
(Ac-LDL) and oxyLDL. Functional MSR are trimers of two C-terminally
different subunits that contain six functional domains. The MSR
gene has been cloned in an 80-kilobase human and localized to band
p22 on chromosome 8 by fluorescent in situ hybridization and by
genetic linkage using three common restriction fragment length
polymorphisms. The human MSR gene consists of 11 exons, and two
types of mRNAs are generated by alternative splicing from exon 8 to
either exon 9 (type II) or to exons 10 and 11 (type I). The
promoter has a 23-base pair inverted repeat with homology to the T
cell element. Exon 1 encodes the S-untranslated region followed by
a 12-kilobase intron which separates the transcription initiation
and the translation initiation sites. Exon 2 encodes a cytoplasmic
domain, exon 3, a transmembrane domain, exons 4 and 5, an
alpha-helical coiled-coil, and exons 6-8, a collagen-like domain.
The position of the gap in the coiled coil structure corresponds to
the junction of exons 4 and 5. The human MSR gene consists of a
Macrophage scavenger receptors (MSR) mediate the binding,
internalization, and processing of a wide range of negatively
charged macromolecules. Functional MSR are trimers of two
C-terminally different subunits that contain six functional
domains. The MSR gene has been cloned in an 80-kilobase human and
localized to band p22 on chromosome 8 by fluorescent in situ
hybridization and by genetic linkage using three common restriction
fragment length polymorphisms. The human MSR gene consists of 11
exons, and two types of mRNAs are generated by alternative splicing
from exon 8 to either exon 9 (type II) or to exons 10 and 11 (type
I). The promoter has a 23-base pair inverted repeat with homology
to the T cell element. Exon 1 encodes the S-untranslated region
followed by a 1 2-kilobase intron which separates the transcription
initiation and the translation initiation sites. Exon 2 encodes a
cytoplasmic domain, exon 3, a transmembrane domain, exons 4 and 5,
an alpha-helical coiled-coil, and exons 6-8, a collagen-like
domain. The position of the gap in the coiled coil structure
corresponds to the junction of exons 4 and 5. The human MSR gene
consists of a mosaic of exons that encodes the functional domains.
Furthermore, the specific arrangement of exons played a role in
determining the structural characteristics of functional domains
(Emi M et al., J. Biol. Chem. 268: 2120-5 (1993)).
[0474] Scavenger receptors on tumor endothelium and stroma bind
oxidized LDL, apoptotic cells, and anionic phospholipids. Class A
receptors, includes the type I and II macrophage scavenger
receptors (SR-M and SR-MI). They are found predominantly on
macrophages and activated smooth muscle cells. SR-M and SR-MI are
homotrimeric membrane proteins, which are derived from
alternatively spliced MRNA products of a single gene. Ligands for
class A receptors include acetylated LDL, oxidized LDL, fucoidan,
and carrageenan. The second class, Class B scavenger receptors,
includes CD36 and SR-E1, which are found in adipose tissue, lung,
liver, and macrophages.
[0475] Acetyl LDL Receptor
[0476] Acetyl LDL receptor or the scavenger receptor, is distinct
from the LDL receptor and does not recognize native LDL. It has
been found on tumor microvascular cells as well as
monocyte/macrophages, Kupfer's cells, and endothelial cells,
particularly the sinusoidal endothelial cells in the liver. The
same receptor also recognizes other chemically modified forms of
LDL, including acetoacetyl LDL and malondialdehyde-conjugated LDL.
The acetyl LDL receptor binds OxLDL LDL modified by incubation with
cultured endothelial cells. LDL incubated with cultured endothelial
cells for 12 to 18 hours, undergoes a physical and chemical changes
and the resulting endothelial cell-modified form of LDL is taken up
by cultured macrophages 10 times more rapidly than native LDL.
Thus, all three the major cell types in the artery wall can convert
LDL to a form recognized by the acetyl LDL receptor.
[0477] CD36 Receptor
[0478] CD36, a multigland glycoprotein structurally related to
SR-BI and CLA-1 found on monocytes, endothelial cells is a high
affinity receptor for the native lipoproteins HDL, LDL, VLDL and
for OxLDL and AcLDL. The CD36 gene has been cloned (Endemann G et
al., J. Biol. Chem. 268:11811-6 (1993)).
[0479] Endothelial Receptors for OxyLDL: The LOX-1 Receptor (C-Type
Lectin Receptor)& Scavenger Receptor Expressed by Endothelial
Cells (SREC)
[0480] Endothelial dysfunction or activation elicited by
oxidatively modified low-density lipoprotein (Ox-LDL) is
characterized by intimal thickening and lipid deposition in the
arteries. Ox-LDL and its lipid constituents impair endothelial
production of nitric oxide, and induce the endothelial expression
of leukocyte adhesion molecules and smooth-muscle growth factors.
Vascular endothelial cells in culture and in vivo internalize and
degrade Ox-LDL through a putative receptor-mediated pathway that
does not involve macrophage scavenger receptors.
[0481] LOX-1 Receptor
[0482] LOX-1, a novel receptor for oxy-LDL, is a membrane protein
that belongs structurally to the C-type lectin family, and is
expressed in vivo in vascular endothelium and vascular-rich organs.
The LOX-1 receptor from vascular endothelial cells has been cloned
(Hoshikawa H et al., Biochem. Biophys. Res. Commun. 245: 841-6
(1998)). Mouse LOX-1 is composed of 363 amino acids with a C-type
lectin domain type II membrane protein structure and triple repeats
of the sequence in the extracellular "Neck domain," which is unlike
human and bovine LOX-1. LOX-1 binds oxidized LDL with two classes
of binding affinity in the presence of serum. The binding component
with the higher affinity showed the lowest value of Kd among the
known receptors for oxidized LDL. With respect to ligand
specificity, LOX-1 is a receptor for oxy-LDL but not for Ac-LDL and
recognizes a protein moiety of oxy-LDL with a ligand specificity
that is distinct from other receptors for oxy-LDL, including class
A and B scavenger receptors.
[0483] Scavenger Receptor Expressed by Endothelial Cells
(SREC),
[0484] The primary structure of the SREC molecule has no
significant homology to other types of scavenger receptors,
including the LOX-1 receptor. The cDNA encodes a protein of 830
amino acids with a calculated molecular mass of 85, 735 Da (mature
peptide). The cloned has an N-terminal extracellular domain with
five epidermal growth factor-like cysteine pattern signatures and
long C-terminal cytoplasmic domain (391 amino acids) composed of a
Ser/Pro-rich region followed by a Gly-rich region (Adachi H et al.,
J. Biol. Chem. 272:31217-20 (1997)
[0485] The SREC mediates the binding and degradation of
acetoacetylated (AcAc) and acetylated (Ac) low density lipoproteins
(LDL). Isolated sinusoidal endothelial cells from the rat liver
show saturable, high affinity binding of AcAc LDL and degrade AcAc
LDL 10 times more effectively than aortic endothelial cells.
Specific sinusoidal endothelial cells bearing the SREC not the
macrophages of the reticuloendothelial system, are primarily
responsible for the removal of these modified lipoproteins from the
circulation in vivo. For this reason, the SREC receptor and the
LOX-1 receptors are preferred for use in transfecting tumor cells
tumor endothelium in vivo.
[0486] Polypeptide or naked DNA encoding receptors for LDL oxyLDL,
VLDL, LRP, CD36, SREC, LOX-1 and macrophage scavenger receptor
(collectively o-LDL receptors) are used individually or together
with SAg polypeptidee or naked DNA containing the CpG backbone are
prepared as in Examples 1, 2, 3, 30-31. Alternatively, SAg are
incorporated or bound or conjugated to vesicular or exosomal
structures shed from cells expressing the LDL, oxy LDL receptors.
Superantigens are also incorporated into liposomal structures which
express natural or synthetic LDL, oxyLDL receptors as described in
Section 45 and Examples 3, 5, 6, 36, 42. All of these constructs
are administered in vivo by any route but preferably by
intratumoral injection as in Examples 2, 6, 14, 30-31. Once
localized, and expressing o-LDL receptor(s) in tumor sites in vivo,
lipoprotein preparation(s) containing their respective ligands are
administered to the host. These LDL, oxyLDL or lipoproteins are non
toxic to the host generally but upon binding to a dense populaton
of receptors in the tumor induce apoptosis of tumor cells and
endothelial cells expressing the receptors and initiate a well
localized anti-tumor response. The presence of the SAg at the same
site amplifies the immune and inflammatory anti-tumor effect. The
advantage of this system is the minimal toxicity to the host since
the o-LDL receptors are of host origin and the lipid infusions
consist of substances which are indigenous to the host. These
constructs are useful in vivo against primary or metastatic tumors
according to Examples 14, 15, 16, 18-23.
[0487] 50. SAg Combined with Tumor Viruses (Nucleic Acid or Peptide
Forms)
[0488] SAgs are chemically conjugated to HPV-E6 or 7 human
papilloma virus tumor antigens by methods given in Examples 3.
Alternatively, the naked nucleotides containing immunostimulatory
sequence of the superantigen and the HPV-E6 or E7 are prepared
individually or as a fusion nucleotide or protein as in Examples 5,
30, 31. Alternatively, the the SAg-HPV fusion gene is transfected
into tumor cells as given in Example 1. In this case, the virus
serves as the vector for tranfecting the cells with the
superantigen nucleic acids. The superantigen-HPV-E6 or E7
conjugates, fusion proteins, naked DNA fusions or tumor cells
expressing the superantigens and HPV are used as preventative or
therapeutic vaccines under protocols given in Examples 14, 15, 16,
18-23, 30, 31. Further, SAg and HPV-E6 or E7 transfected tumor
cells are subjected to irradiation or other apoptosis inducing
agents or stimuli arter which the apoptotic tumor cell
transfectants are presented to dendritic cells ex vivo which ingest
the apoptotic tumor cells. of In the dendritic cells, the viral
antigens and superantigen undergo cross priming to the class I
pathway and these dendritic cells are then harvested and
administered to the tumor bearing host as given in Examples 26-28.
The DNA and RNA from these SAg and HPV-E6 or E7 transfected tumor
cells or dendritic cells is extracted and utilized for in vivo
therapy as in Examples 30-34. While the HPV-E7 is exemplified
herein, the method is applicable to other viruses which are known
to be associated or etiopathogenic in the malignant state including
but not limited to adenovirus, EB virus, herpesvirus, hepatitis B,
cytomegalovirus and Kaposi's sarcoma herpesvirus.
[0489] Having now generally described the invention, the same will
be more readily understood through reference to the following
examples which are provided by way of illustration, and are not
intended to be limiting of the present invention, unless
specified.
EXAMPLE 1
Preparation of Plasmids for Making DNA Templates for any Gene of
Interest and the Process Transfection
[0490] Mammalian oncogenes, and genes for oncogenic transcription
factors, angiogenic factors, growth factor receptors and amplicons
as well as bacterial and SAg plasmids and DNA are prepared as
described in the text references. When necessary, they are modified
to forms suitable for transfection into mammalian tumor cells or
accessory cells using methods well described in the art. (Old R W
et al., Principles of Gene Manipulation, 5th Ed., Blackwell
1994).
[0491] As a representative SAg, enterotoxin B plasmid DNA is
prepared by the method of Jones C L et al., J. Bacteriology 166
29-33 (1986) and Ranelli et al., Proc. Natl. Acad. Sci. USA
82:5850-5854 (1985) using the CsCl-ethidium bromide density
gradient centrifugation of cleared lysates as described (Clewell, D
B et al., Proc. Natl. Acad. Sci. USA 62-1159-1166 (1969)). S.
aureus chromosomal DNA was isolated as described by Betley M et
al., Proc. Natl. Acad. Sci. USA 81: 5179-5183 (1984). E. coli HB101
was transformed with plasmid DNA by the CaCl.sub.2 procedure of
Morrison D A et al., Meth. Enzymol. 68:326-331 (1979). Restriction
digests were analyzed by 1% agarose and 5% acrylamide gel
electrophoresis using Tris/Borate/EDTA buffer as described in
Greene P J et al., Methods Mol. Biol. 7: 87-111 (1974). Additional
methods for isolation and cloning of specific bacterial and
mammalian plasmid DNA useful in tumor or accessory cell
transfection are cited in references given previously in the text
or in Snyder L et al., Molecular Genetics of Bacteria, ASM Press,
Washington, D.C.(1997); Peters et al., supra; Franks et al.,
supra.
[0492] Suitable template DNA for production of mRNA encoding a
desired polypeptide may be prepared using standard recombinant DNA
methodology as described in Ausubel F et al. Short Protocols in
Molecular Biology 3rd Ed. John Wiley, New York, N.Y. (1995). There
are numerous available cloning vectors and any cDNA containing an
initiation codon can be introduced into the selected plasmid and
mRNA can be prepared from the resulting template DNA. The plasmid
can be cut with an appropriate restriction enzyme to insert any
desired cDNA coding for a polypeptide of interest. For example the
readily available cloning vector pSP64T can be used after
linearization and transcription with SP6 RNA polymerase. Smaller
sequence may be inserted into the Hind III/EcoTI fragment with T4
ligase. Resulting plasmids are screened for orientation and
transformed into E. coli. These plasmids are adapted to receive any
gene of interest at a unique BglII restriction site which is placed
between the two Xenopus .quadrature.-globin sequences.
[0493] Subcloning of SEB into pHb-Apr-1-neo Expression Vector
[0494] The Staphylococcal enterotoxin B (SEB) gene has been
subcloned into pH.quadrature.-Apr-1-neo expression vector. The
final construct contained only the coding sequence of SEB and
conferred resistance to ampicillin and G-418.
[0495] Materials and Methods
[0496] PCR:
[0497] 1. The following two primers are designed and made at Life
Technologies, Inc.:
[0498] PrimerSEB1: total 24 bp 5' to 3'
GGC.GTC.GAC.ATG.TAT.AAG.AGA.TTA
[0499] SalI site
[0500] Primer SEB2: total 24 bp 5' to 3'
GCC.GGA.TCC.TCA.CTT.TTT.CTT.TGT
[0501] BamHI site
[0502] Both primers were dissolved in filter-sterilized ddH.sub.2O
to a final concentration of 20 mM (stock solution).
[0503] 2. The volume (in ml) of reagents for each PCR reaction is
listed below:
3 Reagent Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 ddH.sub.2O 76 72 67 49
59 10 .times. PCR buffer 10 10 10 10 10 10 .times. dNTP (2 mM
stock) 10 10 10 10 10 Primer SEB1 1 5 1 10 10 (20 mM stock) Primer
SEB2 1 1 1 10 10 (20 mM stock) SEB Template 1 1 10 10 0 (50 mg
stock) PfuTurbo Enz 1 1 1 1 1 Final Volume 100 100 100 100 100
[0504] 3. The following cycling parameters were applied:
4 95.degree. C. 1 minute 1 cycle initial denature 95.degree. C. 45
seconds denature 52.degree. C. 1 minute 20 cycles anneal 72.degree.
C. 1 minute extension 72.degree. C. 1 minute 1 cycle final
extension 4.degree. C. hold
[0505] 4. To verify that the PCR reactions yielded the correct size
fragment, 10 ml of the reaction mixture was electrophoresed on a 1%
agarose gel in 1.times.TAE buffer.
[0506] Vector
[0507] 1. The pHb-Apr-1-neo expression vector was spotted the
vector on a filter paper. See FIG. 1
[0508] 2. To recover the DNA, the circle was cut out and added to
100 ml of H.sub.2O to allow rehydration for 5 minutes. After a
brief centrifugation, the supernatant was used to transform E. coli
XL1Blue (Stratagene), and selected by ampicillin (final
concentration 100 mg/ml).
[0509] 3. To verify that the vector is correct, 4 ampR clones were
randomly selected and the clones were cultured in LB amp media. DNA
was isolated and digested with SalI, BAmHI (single digest) and
EcoRI/HindIII (double digest). The digested products were
electrophoresed on a 1% agarose gel in 1.times.TAE buffer. The
profile of the restriction digest confirmed that the vector is
correct.
[0510] Cloning and Verification
[0511] 1. The correct PCR fragments in experiments 2, 3, and 4 were
pooled and gel-purified. A portion of the fragments was digested
with restriction enzymes SalI and BamHi, and was ligated into the
digested pHb-Apr-1-neo expression vector.
[0512] The ligation products were transformed into E. coli XL1Blue
(Stratagene). Insert containing clones were selected by
ampicillin.
[0513] 2. Ten ampicillin resistant clones were randomly selected,
cultured in 5 ml of LB amp media, and their plasmid DNA was
isolated. Insert containing clones (SEB construct) were verified by
digesting the DNA with SalI and BamHI restriction endonucleases and
electrophoresis at 0.8% agarose gel. (FIG. 2)
[0514] 3. One of the SEB constructs (clone #2) was verified by
sequencing and aligned with the published SEB sequence (FIG.
3).
[0515] Purified DNA templates from bacteria and human cells are
prepared for introduction of plasmid into human and bacterial cells
by additional methods given in Ausubel F et al., supra. The plasmid
DNA is grown up in E. coli in ampicillin containing LB medium. The
cells were then pelleted by spinning a 5000 rpm for 10 min. at 5000
rpm., resuspended in cold TE pH 8.0, centrifuged again for 10
minutes. at 5000 rpm., resuspended in a solution of 50 mM glucose,
25 mM Tris-Cl pH 8.0, 10 mM EDTA and 40 mg/ml lysozyme. After
incubation for 5-10 min. with occasional inversion, 0.2 N NaOH
containing 1% SDS was added, followed after 10 minutes at 0.degree.
C. with 3 M potassium acetate and 2 M acetic acid. After 10 more
minutes, the material was again centrifuged a 6000 rpm, and the
supernatant was removed with a pipet. The pellet was then mixed
into 0.6 vol. isopropanol (-20.degree. C.), mixed, and stored at
-20.degree. C. for 15 minutes. The material was then centrifuged
again at 10,000 rpm for 20 min., this time in an HB4 singing bucket
rotor apparatus after which the supernatant was removed and the
pellet was washed in 70% EtOH and dried at room temperature. Next,
the pellet was resuspended in 3.5 ml TE, followed by addition of
3.4 g CsCl and 350 l of 5 mg/ml EtBr. The resulting material was
placed in a quick seal tube, filled to the top with mineral oil.
The tube was spun for 3.5 hours at 80,000 rpm in a VTi80
centrifuge. The band was removed and the material was centrifuged
again making up the volume with 0.95 g CsCl/ml and 0.1 ml or 5
mg/ml EtBr/ml in TE. The EtBr was then extracted with an equal
volume of TE saturated N-Butanol after adding 3 volumes of TE to
the band. Next, 2.5 vol. EtOH was added, and the material was
precipitated at -20.degree. C. for 2 hours. The resultant DNA
precipitate is used as a DNA template.
[0516] Transfection of B16F10 Melanoma Cells
[0517] G418 sensitivity: B16F10 melanoma cells (B16s) were first
tested for sensitivity to G418 which will be used as the selectable
marker. At 400 ug/mL G418, B 16s did not survive, while 200 and 300
ug/mL allowed some survival.
[0518] Transfection:
[0519] Lipofectamine was used to produce stably transfected B16s.
The conditions for transfection were those described protocol
provided by Life Technologies. B16s were plated at 4.times.105
cells/well in 6 well plates, using Murine Complete Medium (MCM)
described in Report 2. Cells were cultured overnight. Optimal
density is 50-80% confluent and is usually achieved by 18-24 after
seeding at 1-3.times.105 cells/well. DNA sources consisted of
SEB-G418 resistance containing vector, vector DNA with G418
resistance gene only, and control DNA from PSK401 (no G418
resistance marker). DNA concentrations were determined for the SEB
containing and control vectors.
5 DNA source A260 DNA (ug/ml) SEB 0.09 0.45 Vector only 0.13 0.65
PSK 401 0.15 0.75
[0520] Lipofectamine solutions and DNA solutions were prepared in
12.times.75 mm tubes, using OPTI-MEM (Life Technologiies 31985).
DNA solutions contained approximately 2 ug in 100 uL OPTI-MEM; the
LIPOFECTAMINE Reagent was diluted by adding 6 or 12 uL to OPTI-MEM
at a final volume of 100 uL. The solutions were mixed and held at
room temperature for 30 minutes. Specific DNA and Lipofectamine
conditions were as follows:
[0521] Plated cells were rinsed once with 2 ml/well OPTI-MEM. To
the above tubes, 0.8 mL OPTI-MEM. This mixture was then overlayed
onto the washed cell monolayers according to the above well
designations. Cells were incubated for 5 hours at 37.degree. C. in
5% CO2. Murine Complete Medium with 20% FBS but no antibiotics was
then added at 1 ml/well. Cultures were refed with standard MCM, at
3 mL/well, after 24 hours. Three days after transfection, cells
from each transfection condition were subcultured by splitting the
total cell suspension 90:10 into 150 mm plates (one plate received
90% of the cell suspension, the other received the remaining
10%).
[0522] G418 Selection
[0523] All plates were refed at 6 days after transfection with
medium containing 400 ug/mL G418. Plates were refed every 2 to 3
days with G418 containing medium until day 17 after transfection.
No growth was observed in wells 1-4 as expected. Plates initiated
with 90% of the cell suspension and showing growth were harvested,
frozen, and stored at -80.degree. C.
[0524] Primary Subcloning
[0525] Ten colonies were selected from each well for wells 5, 7, 9,
and 11. Subcloning was accomplished by the use of cloning cylinders
as follows: After seating the cylinder, medium was aspirated and
the isolated colony was washed once with 100 uL of warmed
trypsin-EDTA. This was aspirated and replaced with fresh
tyrpsin-EDTA. After incubation at 37.degree. C. for 2 minutes, the
cells were recovered by trituration and transferred to a tube
containing 1 ml MCM, then replated by addition of 20 uL of cell
suspension to 15 mL MCM with G418 in 150 mm plates. The remaining
cell suspension was plated into 24 well plates, 4 wells/clone and
all plates were maintained at 37.degree. C., 5% CO2. The 6 well
plates were used to assess SEB expression on the cell surface as
desribed under Detection of positive clones.
[0526] Secondary and Tertiary Subcloning and Preparation of Frozen
Stocks
[0527] These and all subsequent procedures were performed by me.
Secondary suncloning was performed as above at 7 days after
initiation of primary subclones. One colony/plate was selected for
further subcloning (a total of 40 colonies) The cell suspension was
prepared in a total volume of 1 mL; 100 uL was replated into 100 mm
plates containing 10 mL MCM with G418. The remaining cell
suspension was plated in 96 well plates at 100/well, 2 replicates
for assay. The 96 well plate was used for detection of
intracellular expression of SEB desribed under Detection of
positive clones.
[0528] Primary subcloning plates were cultured one additional day,
then harvested, frozen, and stored at -80.degree. C. These frozen
stocks are designated primary subclones. Secondary subclones were
refed after 4 days. Of 40 secondary clones, 36 regrew. Tertiary
subcloning was performed after 8 days and frozen stocks of
secondary clones were prepared after 9 days. Tertiary clones were
refed after 3 days in culture and subcultured after 7 days in
culture. Plates were harvested, cells were resuspended in a total
of 1 mL, and replated by addition of 100 uL of the cell suspension
to 100 mm plates with 15 mL MCM or 100 uL/well in a 96 well plate.
Frozen stocks of tertiary clones were prepared.
[0529] Generation of Conditioned Medium for Assay of
Supernatents
[0530] After 7 days, 100 mm plates of tertiary clones were again
replated. This time, cell counts were performed and
4.5.times.10.sup.5 cells were plated in 12 well plates, one
well/clone. The remaining cell suspension was frozen and stored at
-80.degree. C. After 4 days in culture, supernatents were
harvested, stored at 4.degree. C., and the cells were replated into
100 mm plates. Supernatents were obtained from the 100 mm plates
after 7 days in culture. See Detection of positive clones. Frozen
stocks were also generated from these plates.
[0531] Development of ELISA with HRP Rabbit anti-SEB.
[0532] Final ELISA conditions were as follows:
6 Assay Plate ProBind (Falcon #3915) Capture Antibody Rabbit
anti-SEB (Toxin Technologies #LBI202), 10 ug/mL in PBS, 50 uL/well,
1 hr, RT Wash 3 .times. with 0.1% casein, 0.1% Tween 20 in PBS
Blocking 1% casein in PBS, 250 uL/well, overnight, 4.degree. C.
Antigen Supernatant used neat or SEB diluted in PBS, 50 uL/well, 2
hr, RT Wash As above Primary Ab HRP Rabbit anti-SEB (Toxin
Technologies # LBC202), 1/300 in block buffer, 50 uL/well, 2 hr, RT
Substrate OPD, 2.5 mg/mL in citrate buffer, pH 5.0, 0.03%
H.sub.20.sub.2, 100 ul/well, 15 min, RT Stop 4 M H2SO4, 100 uL/well
Read-out OD 490 nm
[0533] Results: SEB produced a dose response curve (linear range 60
fg-60 pg/mL) and the background was very low. Vector only clones
produced only background, signals. One SEB transfected clone
produced a strong signal, three produced moderate signals, and one
other produced a weak but definite signal.
7 OD 490 nm SEB+ Vector only 1 2 mean 1 2 mean 9.1 0.097 0.112
0.104 0.079 0.102 0.091 9.2 0.127 0.123 0.125 0.081 0.076 0.078 9.3
0.109 0.104 0.106 0.087 0.070 0.079 9.4 0.444 0.393 0.418 0.077
0.077 0.077 9.5 0.163 0.087 0.125 0.075 0.074 0.074 9.6 0.516 0.522
0.519 0.066 0.064 0.065 9.7 0.087 0.091 0.089 0.096 0.084 0.090 9.8
0.386 0.450 0.418 0.080 0.071 0.075 9.9 0.137 0.122 0.130 0.071
0.070 0.071 11.1 0.083 0.075 0.079 0.068 0.078 0.073 11.2 1.847
1.802 1.824 0.063 0.076 0.070 11.3 0.071 0.077 0.074 0.076 0.074
0.075 11.4 0.087 0.084 0.086 0.083 0.085 0.084 11.5 0.161 0.220
0.191 0.092 0.086 0.089 11.8 0.221 0.100 0.160 0.080 0.081 0.080
11.9 0.080 0.091 0.085 0.077 0.072 0.074 11.10 0.290 0.254 0.272
0.081 0.112 0.097 11.10 0.268 0.263 0.265 0.093 0.114 0.103
[0534] Based on the the SEB standard curve, the following
concentrations were derived.
8 Clone number(pg/ml) SEB 11.2 4.146 9.6 0.152 9.4 0.118 9.8 0.118
11.10 0.081
[0535] Cells are transfected ex vivo or in vivo and implanted in a
cancer-bearing host. These transfected cells are also used to
stimulate host lymphocytes ex vivo. Once activated, the lymphocytes
are administered to the host. The ex vivo or in vitro introduction
of DNA into cells is accomplished by methods that (1) form DNA
precipitates which are internalized by the target cell; (2) create
DNA-containing complexes with charge characteristics that are
compatible with DNA uptake by a target cell; or (3) result in the
transient formation of pores in the plasma membrane of a target
cell exposed to an electric pulse (these pores are of sufficient
size to allow DNA to enter the target cell).
[0536] Generally, two factors determine the method used: the
duration of expression required (i.e., transient versus stable
expression) and the type of cell to be transfected. The specific
details of exemplary procedures are described herein.
[0537] Transfections are carried out by well established methods
including calcium phosphate precipitations, DEAE Dextran
transfection, and electroporation.
[0538] Calcium Phosphate Precipitation
[0539] A commonly used ex vivo and in vitro method to transfer DNA
into recipient cells involves the co-precipitation of the DNA of
interest with calcium phosphate. With this technique, DNA enters
the cell in sufficient quantities such that the treated cells are
transformed with relatively high frequency. Using a variety of cell
types, transfection efficiencies of up to 10-3 have been obtained.
This is the method of choice for the generation of stable
transfectants.
[0540] Variations of the basic technique have been developed. If
the transfection involves the transfer of plasmid DNA, then high
molecular weight genomic DNA isolated from a defined cell or tissue
source can be included. The addition of such DNA, called carrier
DNA, often increases the efficiency of transfection by the plasmid
DNA. Upon arrival of the plasmid DNA/carrier DNA/calcium phosphate
co-precipitate to the nucleus of the treated cell, the plasmid DNA
integrates into the carrier DNA, often in the tandem array, and
this assembly of plasmid and carrier DNA, called a transgenome,
subsequently integrates into the chromosome of the host cell.
[0541] Another procedural option is the addition of a chemical
shock step to the transfection protocol. Either dimethylsulfoxide
or glycerol are appropriate. The optimal concentrations and lengths
of treatment vary according to cell type. The use of these agents
dramatically affect cell viability and can be optimized as
described elsewhere [Chen and Okayama, Mol. Cell. Biol. 7:2745
(1987)]. Specifically, incubation of cells with the co-precipitate
is optimal at 35.degree. C. in 2-4% CO.sub.2 for 15-24 hours. In
addition, circular DNA is more active than linear DNA and a finer
precipitate is obtained when the DNA concentration is between 20-30
mg/ml in the precipitation mix.
[0542] It is noted that incubator temperature, CO.sub.2
concentration, and DNA concentration can be varied to obtain the
desired result. In addition, the temperature and CO.sub.2
concentrations described below are not optimal for cell growth and
should be maintained only temporarily.
[0543] Method
[0544] Day 1: 1.3.times.10.sup.6 cells are seeded per 100-mm dish.
Cells are about 75% confluent when used to seed the dishes.
[0545] Day 2: A large calcium phosphate cocktail mixture to
transfect many plates simultaneously is prepared. This protocol is
given for 1 ml (or 1.times.100-mm dish equivalent) of solution.
These amounts are scaled up as necessary, allowing for an
appropriate amount of sample-transfer errors. Adherence to sterile
technique is critical. Sterile reagents, tips, and tubes are
used.
[0546] 1. Add 1-20 g DNA (1 mg/ml in sterile TE, 10 mM Tris-HCl 1
mM EDTA pH 7.05) to 0.45 ml sterile H.sub.2O. Note: First
"sterilize" DNA by ethanol precipitation with NaCl (0.15293 M final
aqueous concentration) and 2.times. volume 200% ethanol.
[0547] 2. Add 0.5 ml 2.times.HEPES buffered saline. Mix well.
[0548] 3. Add 50 ml of 2.5 M CaCl.sub.2, vortex immediately.
[0549] 4. Allow the DNA mixture to sit undisturbed for 15-30
minutes at room temperature.
[0550] 5. Add 1 ml of the DNA transfection cocktail directly to the
medium in the 100-mm dish (plated with cells on day 1).
[0551] 6. Incubate the dishes containing the DNA precipitate for 16
hours at 37.degree. C. Remove the media containing the precipitate
and add fresh complete growth media.
[0552] 7. Allow the cells to incubate for 24 hours.
Post-incubation, the cultures can be split for subsequent
selection. Split cultures 1:5; however, to isolate individual
colonies for further analysis, split cultures 1:10 and 1:100.
[0553] DEAE Dextran Transfection
[0554] Typically, DEAE dextran transfection is used to transiently
transfect cells in culture. This method is highly efficient and the
DNA/DEAE dextran mixture used for transfection is relatively easy
to prepare. For example, this method yields transfection
efficiencies of as high as 80 percent. DNA introduced into cells
with this method, however, appears to undergo mutations at a higher
rate than that observed with calcium phosphate-mediated
transfection.
[0555] Method
[0556] Briefly, a DEAE dextran mixture is prepared and the DNA
sample of interest is added, mixed, and then transferred to the
cells in culture.
[0557] Day 1: Cells are seeded at a concentration of
2.times.10.sup.4 cells/cm2 in a total volume of 2 ml/well
(1.92.times.10.sup.5 cells/well of a six-well cluster dish). Cells
should be about 75% confluent when used to seed the dishes.
[0558] Day 2: Resuspend 0.5 ml DEAE Dextran in Tris-buffered saline
(TBS). Final DEAE Dextran concentration should be about 0.04%.
Observe cell monolayers microscopically. Cells should appear about
60-70% confluent and well distributed. Bring all reagents to room
temperature. Aspirate off growth media and wash monolayer once with
3 ml of phosphate buffered saline (PBS), followed by one wash with
3 ml of TBS. Aspirate off TBS solution and add 100-125 ml of the
appropriate DNA/DEAE-Dextran/TBS mixture to the wells. Incubate
dishes at room temperature inside a laminar flow hood. Rock the
dishes every 5 minutes for 1 hour, making sure the DNA solution
covers the cells. After the 1-hour incubation period, aspirate off
the DNA solution and wash once with 3 ml of TBS followed by 3 ml of
PBS. Remove the PBS solution by aspiration and replace with 2 ml of
complete growth media containing 100 M chloroquine.
[0559] Incubate the dishes in an incubator set at 37.degree. C. and
5% CO.sub.2 for 4 hours. Remove the media containing chloroquine
and replace with 2-3 ml of complete growth media (no chloroquine).
Incubate the transfected cells for 1-3 days, after which the cells
will be ready for analysis. The exact incubation period depends on
the intent of the transfection. Optimal expression typically occurs
at 3days post-transfection.
[0560] Electroporation
[0561] Electroporation is a process whereby cells in suspension are
mixed with the DNA to be transferred. This cell/DNA mixture is
subsequently exposed to a high-voltage electric field. This creates
pores in the membranes of treated cells that are large enough to
allow the passage of macromolecules such as DNA into the cells.
Such DNA molecules are ultimately transported to the nucleus and a
subset of these molecules are integrated into the host genome. The
reclosing of the membrane pores is both time and temperature
dependent and thus is delayed by incubation at 0.degree. C.,
thereby increasing the probability that the molecule of interest
will enter the cell.
[0562] Electroporation appears to work on virtually every cell
type. With this technique, the efficiency of nucleic acid transfer
is high for both transient transfection and stable transfection.
One important technical difference between electroporation and
other competing technologies is that the number of input cells
required for electroporation is considerably higher.
[0563] Method
[0564] 1. Harvest exponentially growing cells such as tumor cells
or accessory cells by trypsinization, pellet, and wash twice with
electroporation buffer (Kriegler, M. Gene Transfer and Expression,
W.H. Freeman and Co., New York, N.Y. (1991)).
[0565] 2. Resuspend cells in electroporation buffer at a
concentration of 2-20.times.10.sup.6 cells/ml in an electroporation
cuvette.
[0566] 3. Add 5-25 mg of DNA that has been linearized to the cell
suspension
[0567] 4. Insert or connect the electroporation electrode according
to the manufacturer's instructions and subject cell/DNA mixture to
an electric field (pulse).
[0568] 5. Return cell/DNA mixture to ice and incubate for 5
minutes.
[0569] 6. Plate cells in non-selective medium. Biochemical
selection may be carried out 24-48 hours later.
[0570] Lipofectamine
[0571] In vitro cell transfections can be done in 12-well plates,
using 3.0 g plasmid DNA and Lipofectamine (GIBCO BRL), at
37.degree. C. for 4 hours. After transfection, the cells are
cultured in 2.0 ml complete medium for 48 hours and the cells are
harvested. The cells are then washed in PBS. Stably transfected
Chinese hamster ovary (CHO) and B 16 lines are isolated by
selection in 1.0 mg/ml G418 (GIBCO BRL). Cells are grown and
passaged in medium containing G418 for 3-4 weeks Mock transfected
cell lines (cells transfected with vector only) are used as
controls.
[0572] Viral Vectors
[0573] Recombinant viral vectors containing the nucleic acid of
interest can also be used to introduce nucleic acid into a cell ex
vivo or in vitro. It is noted that viral vectors are also used to
transfect cells in vivo. These viral vectors can be DNA viruses
such as herpesviruses, adenoviruses, and vaccinia viruses or RNA
viruses such as retroviruses. The method and materials required to
produce and use these viral vectors ex vivo, in vitro, and in vivo
are commonly known in the art and are used in the invention
described herein (Sambrook, J. et al., supra).
[0574] Selection
[0575] Regardless of the method used to transfect a particular cell
type, stably transfected cells are identified as follows. The DNA
of interest contains a selectable marker. Typically, a selectable
marker encodes a polypeptide that confers drug resistance and the
DNA containing this resistance conferring nucleic acid is
transfected into the recipient cell. Post transfection, the treated
cells are allowed to grow for a period of time (24-48) hours to
allow for efficient expression of the selectable marker. After an
appropriate incubation time, transfected cells are treated with
media containing the concentration of drug appropriate for the
selective survival and expansion of the transfected and now drug
resistant cells.
[0576] Many drug as well as non-drug selection methods are known in
the art and can be used in the invention described herein. For
example, a detailed description of currently available drug
selection strategies is provided in Kriegler M., Gene Transfer and
Expression, A Laboratory Manual, W.H. Freeman and Co. New York,
N.Y. pp. 103-107 (1991).
[0577] General Method
[0578] Sixteen hours after transfection, the transfected/infected
cells are fed with fresh, non-selective media. Twenty-four to
forty-eight hours later, the cultures are split to a 1:5 or greater
dilution and plated in drug-containing media. It is noted that
cells are not placed in drug-containing media immediately after
transfection in order to allow a sufficient amount of time for the
drug resistance nucleic acid to be expressed and thus confer the
drug resistant phenotype. Cell cultures are re-fed with
drug-containg media every three days, at which time cultures are
examined under a microscope to determine the efficiency of drug
selection.
[0579] Site-Directed Mutagenesis by Polymerase Chain Reaction:
Introduction of Restriction Endonuclease Sites by PCR
[0580] PCR is the preferred method for introducing any desired
sequence change into the DNA. The basic protocol is as follows:
[0581] Materials
[0582] DNA sample to be mutagenized, pUC19 plasmid b vector or
similar high-copy number plasmid having M13 flanking primer
[0583] 500 ng/ml (100 pM/.mu.l) flanking sequence primers
incorporating the restriction enzyme site
[0584] TE buffer
[0585] 10.times. amplification buffer
[0586] 2 mM 4dNTP mix
[0587] 500 ng/ml (100 pM/ml) M13 flanking sequence primers: forward
(NEB) and reverse (NEB)
[0588] 5 U/ml Taq DNA polymerase
[0589] Mineral oil
[0590] Chloroform
[0591] Buffered phenol
[0592] 100% ethanol
[0593] Appropriate restriction endonucleases
[0594] 500 ml microcentrifuge tube
[0595] Automated thermal cycler
[0596] 1. Subclone DNA to be mutagenized into high-copy number
vector using restriction sites flanking the area to be mutated.
[0597] 2. Prepare template DNA by plasmid miniprep. Resuspend 100
ng in TE buffer to 1 ng/ml final.
[0598] 3. Synthesize oligonucleotide primers and purify by
denaturing polyacrylamide gel electrophoresis. Resuspend
oligonucleotides in 500 1 TE buffer. Determine absorbance at A260
and adjust to 500 ng/ml.
[0599] 4. Combine the following in each of two 500 l
microcentrifuge tubes, adding oligonucleotides 1 and 2 to separate
tubes:
[0600] 10 ml (10 ng) template DNA
[0601] 10 ml 10.times. amplification buffer
[0602] 10 ml 2 mM 4dNTP mix
[0603] 1 ml (500 ng) oligonucleotide 1 or 2 (100 pM final)
[0604] 1 ml (500 ng) appropriate M 13 flanking sequence primer,
forward or reverse (100 pM final).
[0605] H.sub.2O to 99.5 .mu.l
[0606] 0.5 ml Taq DNA polymerase (5U/ml)
[0607] Overlay reaction with 100 ml mineral oil.
[0608] 5. Carry out PCR in an automated thermal cycler for 20 to 25
cycles under the following conditions:
[0609] 45 sec 93.degree. C.
[0610] 2 min 50.degree. C.
[0611] 2 min 72.degree. C.
[0612] After last cycle, extend for an additional 10 min at
72.degree. C.
[0613] 6. Analyze 4 l by nondenaturing agarose or occurrence gel
electrophoresis to verify that the amplification has yielded the
predicted product.
[0614] 7. Remove mineral oil and extract once with chloroform to
remove remaining oil. Extract with buffered phenol and concentrate
by precipitation with 100% ethanol.
[0615] 8. Digest half the amplified DNA with the restriction
endonucleases for the flanking and introduced sites. Purify
digested fragments on a low gelling/melting agarose gel.
[0616] 9. Ligate and subclone both fragments into an appropriately
digested vector to obtain a recombinant plasmid containing a single
DNA fragment incorporating the new restriction site.
[0617] 10. Transform plasmid into E. coli. Prepare DNA by plasmid
miniprep.
[0618] 11. Analyze amplified fragment portion of plasmid by DNA
sequencing to confirm the addition of the mutation.
[0619] Introduction of Point Mutation by PCR:
[0620] Materials
[0621] DNA sample to be mutagenized
[0622] Oligonucleotide primers incorporating the point mutation
[0623] Klenow fragment of E. coli DNA polymerase I
[0624] Appropriate restriction endonuclease
[0625] Procedure
[0626] 1. Prepare template DNA (steps 1 and 2 of Basic
Protocol).
[0627] 2. Synthesize and purify oligonucleotide primers (3 and
4).
[0628] 3. Amplify template DNA (steps 4 and 5 of Basic Protocol 1).
After final extension step, add 5 U Klenow fragment and incubate 15
min at 30.degree. C.).
[0629] 4. Analyze and process reaction (steps 6 and 7 of Basic
Protocol).
[0630] 5. Digest half the amplified fragments with the restriction
endonucleases for the flanking sequences. Purify digested fragments
on a low gelling/melting agarose gel.
[0631] 6. Subclone the two amplified fragments into an
appropriately digested vector by blunt-end ligation.
[0632] 7. Carry out steps 10 and 11 of Basic Protocol.
[0633] Introduction of a Point Mutation by Sequential PCR Steps
[0634] 1. Prepare the template DNA (steps 1 and 2 of Basic Protocol
1).
[0635] 2. Synthesize and purify the oligosaccharide primers (5 and
6).
[0636] 3. Amplify the template and generate blunt-end fragments
(step 3 of Basic Protocol).
[0637] 4. Purify fragments by nondenaturing agarose gel
electrophoresis. Resuspend in TE buffer at 1 ng/ml.
[0638] 5. Combine the following in 500 ml microcentrifuge tube:
[0639] 10 ml (10 ng) each amplified fragment
[0640] 1 ml (500 ng) each flanking sequence primer (each 100 pM
final)
[0641] 10 ml 10.times. amplification buffer
[0642] 10 ml 2 mM 4dNTP mix
[0643] 0.5 ml Taq DNA polymerase (5 U/ml)
[0644] Overlay with 100 ml mineral oil.
[0645] 6. Carry out PCR for 20 to 25 cycles (step 5 of Basic
Protocol 1). Analyze and process the reaction mix (steps 6 and 7 of
Basic Protocol 1).
[0646] 7. Digest cDNA fragment with appropriate restriction
endonuclease for the flanking sites. Purify fragment on a low
gelling/melting agarose gel. Subclone into an appropriately
digested vector.
[0647] 8. Carry out steps 10 and 11, Basic Protocol 1.
[0648] Genomic Targeting and Genetic Conversion in Cancer
Therapy
[0649] A number of cellular transformations are due, in large part,
to a single base mutation that alters the function of the expressed
protein. Alterations in the DNA sequence of a gene involved in cell
proliferation can have a significant effect on the viability of
particular cells. Thus, the capacity to modulate the base sequence
of such a gene would be a useful tool for cancer therapeutics. An
experimental strategy that centers around site-specific DNA base
mutation or correction using a unique chimeric oligonucleotide has
been developed. This chimeric molecule has demonstrated higher
recombinogenic activities than identical oligonucleotides
containing only DNA residues, both in vitro and in vivo. The
chimeric molecule is designed to hybridize to a target site within
the genome and induce a single base mismatch at the residue
targeted for mutation. The DNA structure created at this site is
recognized by the host cell's repair system which mediates the
correction reaction. For example, the bcr-abl fusion gene, the
product of a translocation between human chromosomes 9 and 22, and
the cause of chronic myelogenous leukemia (CML) can be targeted for
gene correction. Fusion genes or mutations which abound in cancer
cells are excellent targets for correction especially if (1) they
are unique and are recognized by the immune system as dominant or
subdominant epitopes, (2) they are a single copy target; (3) the
DNA sequence of the fusion gene or mutation is unique. The goal of
such experiments is to knock-out the fusion gene by changing an
amino acid codon into a stop codon through a chimeric directed DNA
repair system.
[0650] Targeted Gene Correction of Episomal DNA in Mammalian Cells
Mediated by a Chimeric RNA/DNA Oligonucleotide
[0651] An experimental strategy to facilitate correction of
single-base mutations of episomal targets in mammalian cells has
been developed. The method utilizes a chimeric oligonucleotide
composed of a contiguous stretch of RNA and DNA residues in a
duplex conformation with double hairpin caps on the ends. The
RNA/DNA sequence is designed to align with the sequence of the
mutant locus and to contain the desired nucleotide change. Activity
of the chimeric molecule in targeted correction is used in a with
the aim of correcting a point mutation in the gene encoding the
human liver/bone/kidney alkaline phosphatase. When the chimeric
molecule is introduced into cells containing the mutant gene on an
extrachromosomal plasmid, correction of the point mutation is
accomplished with a frequency approaching 30%. These results extend
the usefulness of the oligonucleotide-based gene targeting
approaches by increasing specific targeting frequency.
[0652] The site directed mutagenesis is used to carry out using the
chimeric DNA/RNA structure which enables the construct to target
tumor cells in vivo and in vitro. Such targeting structures include
target seeking moieties and can in principle be any structure that
is able to bind to a cell surface structure or that binds via
biospecific affinity. The target seeking moiety is primarily a
disease specific structure selected among hormones, antibodies,
growth factors. The biospecific affinity counterpart may include
interleukins (especially interleukin-2) antibodies (full length
antibody, Fab, F(ab'.sub.2, Fv, single chain antibody and any other
antigen binding antibody fragments (such as Fab) directed to a
cells surface epitope or more preferably towards the binding
epitope for the a specific antibody. They may also include
polypeptides binding to the constant domains of immunoglobulins
(e.g., protein A and G and L), lectins, streptavidin, biotin etc.
The term antibodies comprises monoclonal as well as polyclonal
preparations. The targeting moiety may also be directed toward
unique structures on more or less healthy cells that regulate or
control the development of a disease. or ligands for specific
receptors on tumor cells). The targeting structure may be a nucleic
acid, lipid or carbohydrate and variations thereof which target
receptors on the diseased cell. The targeting is not confined to
diseased cells but may include additional normal cells as well.
[0653] Synthesis and Purification of Oligonucleotides.
[0654] The chimeric oligonucleotides are synthesized on a 0.2-mol
scale by using the 1000 .ANG.-wide-pore CPG on the ABI 394 DNA/RNA
synthesizer. The exocyclic amine groups of DNA phosphoramidites
(Applied Biosystems) are protected with benzoyl for adenosine and
cytidine and isobutyryl for guanosine. The 2'-O-methyl RNA
phosphoramidites (Glen Research, Sterling, Va.) are protected with
a phenoxyacetyl group for adenosine, dimethylformamide for
guanosine and an isobutyryl group for cytidine. After the synthesis
is complete, the base-protecting groups are removed by heating in
ethanol/concentrated ammonium hydroxide, 1:3 (vol/vol), for 20 h at
55.degree. C. The crude oligonucleotides are purified by
polyacrylamide gel electrophoresis. The entire oligonucleotide
sample is mixed with 7 M urea/10% (vol/vol) glycerol. heated to
70.degree. C., and loaded on a 10% polyacrylamide gel containing 7
M urea. After gel electrophoresis, DNA is visualized by UV
shadowing, dissected from the gel, crushed, and eluted overnight in
TE buffer (10 mM Tris-HCl/1 mM EDTA, pH 7.5) with shaking. The
eluent containing gel pieces are centrifuged through 0.45-um (pore
size) spin filter (Millipore) and precipitated with ethanol.
Samples are further desalted with a G-25 spin column (Boerhinger
Mannheim) and greater than 95% of the purified oligonucleotides are
found to be full length.
[0655] Transient Transfection and Measurements of Activity
[0656] CHO cells were maintained in Dulbecco's modified Eagle's
medium (DMEM) (BRL) containing 10% (vol/vol) fetal bovine serum
(FBS; BRL). Transient transfection is carried out by addition of 10
g of the plasmid with 10 g of Lipofectin in 1 ml of Optimem (BRL)
to 2.times.10.sup.5CHO cells in a 6-well plate. After 6 h. various
amounts of oligonucleotide is mixed with 10 g of Lipofectin in 1 ml
of Optimem and added to each well. After 18 h, the medium is
aspirated and 2 ml of DMEM containing 10% FBS was added to each
well. Histochemical staining was carried out (19), 24 h after
transfection of the oligonucleotide. Spectrophotometric
measurements are carried out by the ELISA amplification system
(BRL). Transfection is carried out in triplicate in a 96-well
plate. The amounts of reagents and cells are 10% of that used for
the 6-well plate. Cells were washed three times with 0.1 SM NaCl
and lysed in 100 .mu.l of buffer containing 10 mM NaCl, 0.5 Nonidet
P-40, 3 mM MgCl2, and 10 mM Tris-HCl (pH 7.5), 24 h after
transfection with chimeric oligonucleotides. A fraction of cell
lysates (20 .mu.l) incubated with 50 l of ELISA substrate and 50
.mu.l of ELISA amplifier (BRL), the reaction is stopped by addition
of 50 .mu.l of 0.3 M H.sub.2S04 after 5 min of incubation with
amplifier. The extent of reaction is carried out within the linear
range of the detection method. The absorbance is read by an ELISA
plate reader (BRL) at a wavelength of 490 nm.
[0657] Hirt DNA Isolation, Colony Hybridization and Direct DNA
Sequencing of PCR Fragments
[0658] The cells are harvested for vector DNA isolation by a
modified alkaline lysis procedure, 24 h after transfection with the
chimeric oligonucleotide. Hirt DNA is transformed into Escherichia
coli DH5a cells (BRL). Colonies from Hirt DNA are screened for
specific hybridization for each probe designed to distinguish the
point mutation. Colonies were grown on ampicillin plates, lifted
onto nitrocellulose filter paper in duplicates, and processed for
colony hybridization.
[0659] The blots were hybridized to .sup.32P-end-labeled
oligonucleotide probes at 37.degree. C. in a solution containing
5.times. Denhardt's solution, 1% SDS, 2.times.SSC, and denatured
salmon sperm DNA (100 .mu.g/ml). Blots were washed at 52.degree. C.
in TMAC solution (3.0 M teramethylammonium chloride/50 mM Tris-HCl,
pH 8.0/2 mM EDTA/0.1% SDS). Plasmid DNA was made from 20 colonies
shown to hybridize to either of the probes by using the Qiagen
miniprep kit (Chatsworth. Calif.). Several hundred bases flanking
key positions of each plasmid are sequenced in both directions by
automatic sequencing (ABI 373A, Applied Biosystems). A 192-bp
PCR-amplified fragment are generated by Vent polymerase (New
England Biolabs. MA), utilizing primers corresponding to positions
of the known cDNA flanking position. The fragment is gel-purified
and subjected to automatic DNA sequencing (ABI 373A, Applied
Biosystems).
[0660] Oligonucleotide Synthesis
[0661] Chimeric RNA/DNA oligonucleotides for both transcribed and
nontranscribed factor IX were synthesized by Applied Biosystems,
Inc. (Foster City, Calif.) as previously described. The
oligonucleotides are prepared with DNA and 2-O-methyl RNA
phosphoramidite nucleoside monomers on an ABI 394 DNA/RNA
synthesizer, purified by HPLC and quantified by UV absorbance. More
than 95% of the purified oligonucleotides are determined to be full
length.
[0662] Cell Isolation and Transfections
[0663] Cells are isolated, by a two-step collagenase perfusion as
previously described. The purified cells are plated on Primaria
plates (Becton Dickinson, Franklin Lakes, N.J.) at a density of
4.times.10.sup.6 cells per 35-mm dish and maintained in
supplemented William's E medium. Eighteen hours after plating, the
cells are washed and transfected with the chimeric molecules
complexed to polyethylenimine (PEI). A pH 7.0, 10 mM stock solution
of PEI (800 kDa) (Fluka Chemical Corp., Ronkonkoma, N.Y.) is
prepared. Briefly, the chimeric oligonucleotides are complexed with
10 mM PEI at 9 equivalents of PEI nitrogen per chimeric phosphate
in 100 1 of 0.15 M NaCl and transfected in 1 ml of medium at final
concentrations of 150, 300 or 450 nM. PEI is lactosylated by
coupling lactose to 30% of the nitrogen amines using sodium
cyanoborohydride (Sigma Chemical Company, St. Louis, Mo.). Cells
are also transfected 1with 100 l of 0.15 M NaCl containing the
lactosylated 800-kDa and 25-kDa PEI chimeric complexes (Sigma) at
final concentrations of 90, 180 or 270 nM. After 18 h, an
additional 2 ml of medium is added to the transfected cultures for
the remaining 6 or 30 h of incubation. Vehicle control
transfections utilize the same amount of PEI, but substituted an
equal volume of 10 mM Tris-HCl, pH 7.6, for the
oligonucleotides.
[0664] DNA/RNA Isolation and Cloning
[0665] The cells were harvested by scraping 48 h after
transfection. Genomic DNA larger than 100-150 base pairs was
isolated using the highly pure PCR template preparation kit
(Boehringer Mannheim, Indianapolis, Ind.). RNA was isolated using
RNAzoI 8 (Tel-Test, Inc., Friendswood, Tex.), according to the
manufacturer's protocol. PCR amplification of a fragment of the
gene in question gene is performed with 300 ng of the isolated DNA
from either the primary cell culture.
[0666] The primers were designed (Oligos Etc., Wilsonville, Oreg.)
corresponding to nucleotides to cDNA to be corrected (ref 25).
Primer annealing is carried out at 59.degree. C., and the samples
are amplified for 30 cycles using Expand Hi-fidelity polymerase
(Boehringer Mannheim). To rule out PCR artifacts, 300 ng of control
DNA is incubated with 0.5, 1.0 and 1.5 g of the oligonucleotide
before the PCR-amplification reaction. Additionally, 1.0 g of the
chimeric alone is used as the "template" for the PCR
amplification.
[0667] RT-PCR amplification is done utilizing the Titian one tube
RT-PCR system (Boehringer Mannheim) according to the manufacturer's
protocol and by using the same primers as those used for the DNA
PCR amplification. To rule out DNA contamination, the RNA samples
are treated with RQ 1 DNase-free RNase (Promega Corp., Madison,
Wis.) and RT-PCR negative controls of RNased RNA samples were
performed in parallel with the RT-PCR reaction. Each of the PCR
reactions is ligated into the TA cloning vector pCR 2.1
(Invitrogen, San Diego, Calif.) and transformed into frozen
competent E. coli.
[0668] Nuclear Uptake of the Chimeric Molecules
[0669] Nuclear localization of fluorescently labeled chimeric
oligonucleotides was determined in the isolated cells. For in vivo
studies, 250 l saline containing 75 g of fluorescently labeled
chimeric oligonucleotides complexed to PEI is injected directly
into the exposed caudate lobe. The animals are killed 24 h post
injection, the tumor targeted is removed, bisected longitudinally,
embedded using OCT and frozen cryosections were cut .about.10 pm
thick, fixed, processed and examined using a MRC1000 confocal
microscope (Bio-Rad, Inc., Hercules, Calif.).
[0670] In vivo Delivery of the Chimeric Oligonucleotides
[0671] Vehicle controls and lactosylated 25-kDa PEI at a ratio of 6
equivalents of PEI nitrogen per chimeric phosphate are prepared in
300 l of 5% dextrose. The aliquots are administered either as a
single dose of 100 g or divided doses of 150 g and 200 g on
consecutive days. Five days post injection, tumor tissue is removed
for DNA and RNA isolation. DNA is isolated. RNA is isolated for
RT-PCR amplification of the same region as the genomic DNA using
RNAexol and RNAmate (Intermountain Scientific Corp., Kaysville,
Utah) according to the manufacturer's protocol.
[0672] Colony Hybridization and Sequencing
[0673] Eighteen to 20 h after plating, the colonies were lifted
onto MSI MagnaGraph nylon filters (Micron Separations, Inc.,
Westboro, Mass.), replicated and processed for hybridization
according to the manufacturer's recommendation. The filters were
hybridized for 24 h with 32P-end-labeled oligonucleotide probes
(Life Technologies, Inc., Gaithersburg, Md.), where the underlined
nucleotide is the target of mutagenesis. Hybridizations are
performed at 37.degree. C., and the filters are processed following
hybridization for autoradiography. Plasmid DNA isolated from
colonies identified as hybridizing with the 32P-labeled probes is
subjected to automatic sequencing using the forward and reverse
primers, as well as gene specific primer corresponding to
nucleotides of the normal gene.
EXAMPLE 2
Cells Transfected with Nucleic Acids Encoding SAgs
[0674] Cultured VX-2 carcinoma cells were shown to retain their
tumorigenic activity after implantation into New Zealand white
rabbits. Progressive tumor outgrowth was observed over a 3 week
period. Nucleic acid encoding SEB isolated and characterized by
Gaskill et al, J. Biol. Chem. 263:6276 (1988) and Ranelli et al.,
Proc. Natl Acad. Sci. U.S.A 82:5850 (1985) were used to transfect
tissue cultured VX-2 carcinoma cells using transfection methodology
described in Example 1. Transfectants were selected using G418 and
the survival of SEB-transfected VX-2 carcinoma cells was observed.
In additional experiments, attempts were made to transfect murine
205 and 207 tumor cells with nucleic acid encoding SEB(the kind
gift from Dr. Saleem Khan) and Streptococcal pyrogenic exotoxin A
(the kind gift of Dr. Joseph Ferretti). Successfiil transfection of
murine MCA 205 and B16 cells by nucleic acids encoding SEA and SEC2
was achieved shortly thereafter by integrating the SAg DNA into
several retroviral vectors (MFG NEO) containing a growth hormone
leader sequence under the control of a chick B-actin promoter
(Krause J C et al., J. Hematotherapy 6: 41-51 (1997)). In addition,
murine tumors MCA 205 fibrosarcoma cells and a spontaneous mammary
carcinoma cells were successfully transfected with nucleic acids
encoding SEB (provided by Dr. Saleem Khan) using the
.quadrature.-actin promoter. Transfected mammary carcinoma cells
induced T cell proliferation in vitro. To demonstrate the
anti-tumor capacity of tumor cells transfected with nucleic acid
encoding a SAg, these transfectants were injected i.p. into
syngeneic hosts with established mammary carcinomas. These
transfectants demonstrated a capacity to reduce micrometastases of
wild type mammary tumor in vivo assessed in a clonogenic lung
metastases assay. The anti-tumor effect produced by the SEB
transfectants was enhanced significantly by the co-administration
of tumor cells transfected with nucleic acids encoding the
costimulating molecule B7-1.
EXAMPLE 3
Naked SAg DNA and Cells Co-Transfected with SAg DNA and with
Additional Nucleic Acid Encoding Anti-Tumor Motifs or Products
[0675] Nucleic acids encoding a SAg are injected in naked or
plasmid form into a host with cancer as a means of activating T
cells and initiating an anti-tumor response. They may also be used
as a vaccine to prevent the occurrence or recurrence of tumor in a
host. Under circumstances where it is desirable to activate CD4
cells to produce a TH-1 cytokine response the nucleic acid
construct used to transfect cells contains immunostimulatory
sequences such as unmethylated CpG sequences. Nucleic acids
encoding SAgs may be co transfected into tumor cells together with
nucleic acid encoding other constituents capable of promoting an
anti-tumor response. A list of possible components of nucleic acid
constructs for direct administration and/or transfection of tumor
cells which are administered to the host is presented in Table
II.
[0676] The nucleic acid construct or constructs are administered to
a host intramuscularly, intradermally, systemically, parenterally,
intratumorally, orally or locally (in the vicinity of the tumor).
Alternatively, the construct is administered via a catheter or
other devices known in the art into the tumor vasculature supplying
all or part of a tumor. When the construct is injected
systemically, the nucleic acid construct is directed to the tumor
using an anti-tumor antibody or ligand specific for a tumor
receptor or receptor on the tumor neovasculature or stroma. The
antibody or ligand or other targeting structures are conjugated to
the SAg nucleic acid construct in order to facilitate the
introduction of the construct into tumor cells. Nucleic
acid/polypeptide complexes or nucleic acid/viral complexes are used
to target a specific receptor on the tumor vasculature or
stroma.
9TABLE II Nucleic Acid Constructs and Cells SAg-encoding DNA is
used alone or together with DNA encoding other cell surface
moieties useful in generating antitumor immunity. Genes or their
products are shown in column 1, source information is shown in
column 3, preferred cells to be transformed, transfected or
transduced with the DNA are shown in column 2. All of references
are incorporated by reference in their entirety. Gene or Gene
Product Cells transformed Reference or Source 1. SAg (SEQ ID NOS:
46-47) Tumor [See text] 2. Enterotoxin (SEQ ID NOS: 7-16) Tumor
[See text] 3. SAg receptor (SEQ ID NOS: 46-47) Tumor [See text] 4.
Enterotoxin receptor (SEQ ID NOS: 7-16) Tumor [See text] 5. CD1
receptor(s) (SEQ ID NOS: 48-49) Tumor Martin LH et al., ProcNatl.
Acad. Sci. 83: 9154-9158 (1986) 6. CD14 receptor (SEQ ID NOS:
50-51) Tumor Ferrero, E et al., J. Immunol. 145: 331-336 (1990) 7.
CD44 encoding nucleic acids (SEQ ID NO: 52) T or NKT Nottenburg, C
et al. Proc. Natl. Acad. Sci. 86: 8521-8525 (1989) 8. Carbohydrate
modifying enzymes(SEQ ID NO: 53) Tumor, T or NKT Sheng, Y et al.
Int. J. Cancer 73: 850-858 (1997) 9. TCR V.beta.&chain (SEQ ID
NOS: 54-55 Tumor Tillinghast, JP et al., Science 233: 879-883
(1986) 10. Staph/Strep hyaluronidase (SEQ ID NOS: 57-58) Tumor
Hynes WL et al., Infect. Immun., 63: 3015-3020 (1995) 11.
Staph/Strep erythrogenic toxin (SEQ ID NOS: 58-59) Tumor McShan WM,
et al., Adv. Exp. Med. Biol. 418: 971-973 (1997) 12. Staphylococcal
.quadrature.-hemolysin (SEQ ID NOS: 60-261) Tumor Projan SJ et al.,
Nucleic Acid Res. 3305-3309 (1989) 13. Strep capsular
polysaccharide (SEQ ID NOS: 62-63) Tumor Lin, WS et al., J.
Bacteriol. 176: 7005-7016 (1994) 14. Staph staphylocoagulase (SEQ
ID NOS: 64-65) Tumor Kaida S. et al., J. Biochemistry 102:
1177-1186 (1987) 15. Staph Protein A (SEQ ID NOS: 66-67) Tumor
Shuttleworth, HL et al., Gene 58: 283-295 (1987) 16. Staph Protein
A domain D (SEQ ID NOS: 68-69) Tumor Roben, PW et al., J. Immunol.
154: 6347-6445 (1995) 17. Staph Protein A Domain B (SEQ ID NO: 70)
Tumor Gouda, H et al., Biochemistry, 31: 9665-9672 (1992) 18.
Immunostimulatory protein Tumor, T or NKT Tokunaga, T et al.,
Microbiol. Immunol. 36: 55-66, (1992) 19. Costimulatory protein
Tumor Entage, PC et al., J. Immunol. 160: 2531-2538 (1998) 20.
SAg-mimicking nucleic acid T or NKT 21. Glycophorin (SEQ ID NOS:
71-72) Tumor Siebert, PD. et al., Proc. Natl. Acad. Sci. USA 83
1665-1669 (1986) 22. Mannose receptor (SEQ ID NOS: 73-74) Tumor Kim
SJ. et al., Genomics 14: 721-727 (1992) 23. Angiostatin (SEQ ID NO:
75) Tumor Cao, Y. et al., J. Clin. Invest 101: 1055-1063 (1998) 24.
Chemoattractant (SEQ ID NOS: 76-77) Tumor Ames, RS. et al., J.
Biol. Chem. 271: 20231-20234 (1996) 25. Chemokine (SEQ ID NOS:
78-79) Tumor Nagira, M et al., J. Biol. Chem. 272: 19518-19524
(1997) 26. Transcription factor (SEQ ID NO: 80) Tumor, T or NKT
Schwab M et al., Mol. Cell Biol. 6: 2752-2758 (1986) 27.
Transcription factor-binding Tumor, T or NKT nucleic acid 28.
SAg/peptide conjugate Tumor 29. Glyco-SAg Tumor 30. Staph. global
regulator gene agr (SEQ ID NOS: 81-83) Tumor Balaban, N. et al.,
Proc. Natl. Acad. Sci. USA 92: 1619-1623 (1995) 31. Lipid A
biosynthetic (SEQ ID NOS: 84-91) Tumor Schnaitman CA et al., genes
lpxA-D Microbiological Reviews 57: 655-682 (1993) 32. Mycobacterial
mycolic acid (SEQ ID NOS: 92-93) Tumor Fernandes ND et al., Gene
170: 95-99 (1996); Mathur M et al., J. Biol. Chem. 267: 19388-19395
(1992) 33. c-abl oncogene amplified in (SEQ ID NOS: 94-95) Tumor
Scherle PA et al., chronic myel. Leukemia Proc. Natl. Acad. Sci.
USA 87: 1908 (1990); Heisterkamp N et. al., Nature 344: 251-253
(1990) 34. erbB2 (HER2/neu) oncogene (SEQ ID NOS: 96-97) Tumor
Schechter AL et al., Science 229: 976 (1985); Bargmann CL Nature
319: 22 (1986); Hung MC et al., Proc. Natl. Acad Sci. 83: 261
(1986); Yamamoto T et al., Nature 319: 230 (1986) 35. IGF-1
receptor gene (SEQ ID NOS: 98-99) Tumor Abbott AM et al., J. Biol.
Chem. 267: 10759-10763 (1992); Scott J et al., Nature 317: 260-262
(1985); Liu J et al., Cell 75: 59-63 (1993) 36. VEGF (SEQ ID NOS:
100-101) Tumor Tischer E et al., J. Biol. Chem. 266: 11947-11954
(1991) 37. Strep emm-like gene family Tumor Kehoe MA, In: Cell-
Wall Associated Proteins in Gram-Positive Bacteria in Bacterial
Cell Wall, Ghuysen JM et al., eds, Elsevier, Amsterdam, 1994 38.
iNOS(SEQ ID NOS: 102-103) Tumor Xie QW et al., Science 256: 225-228
(1992) 39. Apolipoproteins (e.g., Lp(a), Tumor [See Text] apoB-100,
apoB-48, apoE) (SEQ ID NOS: 104-109) 40. LDL & oxyLDL receptors
Tumor [See Text] (e.g., LDL oxyLDL, acetyl-LDL, VLDL, LRP, CD36,
SREC, LOX-1, macrophage scavenger receptors) (SEQ ID NOS:
110-121)
[0677] Chemical Conjugation of SAg Nucleic Acids to VTs,
Apolipoproteins, HPV Epitopes or Other Polypeptides/Proteins Listed
in Tables I and II.
[0678] The following section describes actual physical conjugates
between poly- or oligonucleotides and peptides or proteins. SAg
nucleic acid _conjugates are prepared by chemical modification of
nucleic acids at specific sites within individual nucleotides or
within oligonucleotides such that a protein can be bound to a DNA
or RNA polymer.
[0679] Derivatization may be accomplished through discrete sites on
the available bases, sugars, or phosphate groups to create primary
amines, sulfhydryls, carboxylates or phenolates. The chemical
modification of nucleic acids can encompass several strategies. The
initial derivatization may be the addition of a spacer arm to a
particular reactive group on the nucleotide structure. Such a
spacer typically contains a terminal functional group, such as an
amine, that can be used to couple another molecule. The spacer may
be used to react with a cross-linking agent, such as a
heterobifunctional compound that can facilitate the conjugation of
a protein or another molecule to the modified nucleotide.
[0680] If enzymatic methods are used to incorporate a small spacer
into an oligonucleotide, subsequent chemical conjugation steps
still are needed to add the protein moiety. In some cases, if an
oligonucleotide contains the appropriate functional group, a
protein may be directly coupled using chemical methods. Many of the
chemical derivatization methods employed in these strategies
involve the use of an activation step that produces a reactive
intermediary. The activated species then can be used to couple a
molecule containing a nucleophile, typically a primary amine.
[0681] A preferred method is to amidate the 5' PO.sub.4 of the
oligonucleotide with EDC and then couple cystanmine to the 5'
amidated oligonucleotide. EDC will add an amide to the
oligonucleotide to form a phosphoramidate linkage. After the
addition of cystamine the disulfide is reduced with an agent such
as dithiothreitol (DTT) to produce a free 5' sulfhydryl. The
derivatized oligonucleotide is then coupled to a protein chain
(e.g., a verotoxin A or B chain) that has been activated with a
heterobifunctional cross-linker such as succinimidyl
4(N-maleimidomethyl)cyclohexane 1-carboxylate (SMCC ) which reacts
with the amines on the protein which then react with the
sulfhydryls on the derivatized oligonucleotide. N-succinimidyl
S-actylthioacetate (SATA) is useful for adding a free thiol or
sulfhydryl group to a molecule lacking this moiety. With this
modification, "protected" sulfhydryl is formed which may be stored
indefinitely in this protected state.
[0682] When needed, the acetyl group on the protected sulfhydryl is
removed to reveal the sulfhydryl for conjugation to another
molecule. A heterobifunctional agent such as SMCC or N-Succinimidyl
3-(2-pyridylthio)propionate (SPDP) may be directly added to the
amidated oligonucleotide phosphate group to produce a free
sulfhydryl unit for reactivity with the protein or peptide.
[0683] Chemical Conjugation of Polypeptides/Proteins to SAg DNA via
Carbodiimide Reaction with the 5'-Phosphates (Phosphoramidate
Formation)
[0684] The water-soluble carbodiimide EDC, rapidly reacts with a
carboxylate or phosphate to form an active complex able to couple
with a primary amine-containing compound. The carbodiimide
activates an alkyl phosphate group to a highly reactive
phosphodiester intermediate. Diamine spacer molecules or
anine-containing peptides then may react with this active species
to form a stable phosphoramidate bond. Alternatively, bis-hydrazide
compounds may be coupled to DNA using this protocol to yield a
terminal hydrazide functional group able to react with
aldehyde-containing molecules (Ghosh et. al., 1989). These methods
permit specific labeling of SAg DNA only at the 5' end.
[0685] The following protocol describes the modification of SAg DNA
or RNA oligonucleotides at their 5'-phosphate ends with a
bis-hydrazide compound, such as adipic acid dihydrazide or
carbohydrazide. A similar procedure for coupling the diamine
compound cystamine is described below.
[0686] Protocol
[0687] 1. Weigh out 1.25 mg of the carbodiimide
1-ethyl-3-(3-dimethylamino- -propyl)carbodiimide hydrochloride
(EDC) into a microfuge tube.
[0688] 2. Add 7.5 .mu.l of SAg RNA or DNA that has 5' phosphate
groups. The concentration of the oligonucleotide should be 7.5-15
nmol or a total of about 57-115.5 .mu.g. Also immediately add 5
.mu.l of 0.25 M bis-hydrazide compound dissolved in 0.1 M
imidazole, pH 6.
[0689] 3. Mix (e.g., by vortexing) and centrifuge in a microfuge
for 5 min at maximal rpm.
[0690] 4. Add an additional 20 .mu.l of 0.1 M imidazole, pH 6. Mix
and allow to react for 30 mm at room temperature.
[0691] 5. Purify the hydrazide-labeled oligonucleotide by gel
filtration on Sephadex G-25 using 10 mM sodium phosphate, 0.15 M
NaCl, 10 mM EDTA, pH 7.2. The oligonucleotide now may be conjugated
with an aldehyde-containing molecule.
[0692] Sulfhydryl Modification of SAg DNA
[0693] Creating a sulfhydryl group on SAg DNA allows conjugation
reactions to be done with sulfhydryl-reactive heterobifunctional
cross-linkers providing increased control over the derivatization
process. Proteins are activated with a cross-linking agent
containing an amine-reactive and a sulfhydryl-reactive end, such as
SPDP, leaving the sulfhydryl-reactive portion free to couple with
the modified DNA molecule. Having a sulfhydryl group on the SAg DNA
directs the coupling reaction to discrete sites on the nucleotide
strand, thus better preserving hybridization ability in the final
conjugate. In addition, heterobifunctional cross-linkers of this
type allow two- or three-step conjugation procedures which result
in better yield of the desired conjugate than do homobifunctional
reagents.
[0694] Cystamine Modification of 5' Phosphate Groups on
Superantigen Nucleotides Using EDC
[0695] SAg DNA or RNA is modified with cystamine at the 5'
phosphate groups using the carbodiimide reaction described above.
In some procedures, the reaction is carried out in a two-step
process by first forming a reactive phosphorylimidazolide by EDC
conjugation in an imidazole buffer. Next, cystamine is reacted with
the activated oligonucleotide, causing the inidazole to be replaced
by the amine and creating a phosphoramidate linkage. Reduction of
the cystamine-labeled oligonucleotide using a disulfide reducing
agent releases 2-mercaptoethylamine and creates a thiol group.
[0696] Protocol
[0697] 1. Weigh out 1.25 mg of the carbodiimide
1-ethyl-3-(3-dimethylamino- -propyl)carbodiimide hydrochloride
(EDC) into a microfuge tube.
[0698] 2. Add 7.5 .mu.l of SAg RNA or DNA that has 5' phosphate
groups. The concentration of the oligonucleotide should be 7.5-15
nmol or a total of about 57-115.5 .mu.g. Also immediately add 5
.mu.l of 0.25 M cystamine in 0.1 M imidazole, pH 6.
[0699] 3. Mix (e.g., by vortexing) and centrifuge in a microfuge
for 5 min at maximal rpm.
[0700] 4. Add an additional 20 .mu.l of 0.1 M imidazole, pH 6. Mix
and allow to react for 30 mm at room temperature.
[0701] 5. For reduction of the cystamine disulfides, add 20 .mu.l
of 1 M DTT and incubate at room temperature for 15 mm. This will
release 2-mercaptoethylamine from the cystamine modification site
and create the free sulfhydryl on the 5' terminus of the
oligonucleotide.
[0702] 6. Purify the SH-labeled oligo by gel filtration on Sephadex
G-25 using 10 mM sodium phosphate, 0.15 M NaCl, 10 mM EDTA, pH 7.2.
The oligonucleotide now may be used to conjugate with an activated
protein containing a sulfhydryl-reactive group.
[0703] SPDP Modification of Amines on Superantigen Nucleotides
[0704] SAg DNA that has been modified with an amine-terminal spacer
arm may be thiolated to contain a sulfhydryl residue.
Theoretically, any amine-reactive thiolation reagent may be used to
convert an amino group on a SAg DNA molecule into a thiol. A
preferred reagent both for cross-linking and for thiolation
reactions is the heterobifunctional reagent SPDP. The NHS ester end
of SPDP reacts with primary amine groups to produce stable amide
bonds. The other end of the cross-linker contains a thiol-reactive
pyridyldisulfide group that also can be reduced with DTT to create
a free sulfhydryl. The reaction of a 5'-diamine-modified SAg DNA
oligonucleotide with SPDP proceeds under mildly alkaline conditions
(optimal pH 7-9) yields the pyridyldisulfide-activated
intermediate. This derivative can be used to couple directly with
sulfhydryl-containing compounds, or it may be converted into a free
sulfhydryl for coupling to thiol-reactive compounds. In an
alternative approach, 2,2'-dipyridyldisulfide is used to create
reactive pyridyldisulfide groups on a reduced 5'-cystamine-labeled
SAg oligonucleotide. This derivative then can be used to couple
with sulfhydryl-containing molecules, forming a disulfide bond.
Reduction of the pyridyldisulfide end after SPDP modification
releases the pyridine-2-thione leaving group and generates a
terminal-SH group.
[0705] Protocol
[0706] 1. Dissolve the amine-modified SAg oligonucleotide to be
thiolated in 250 .mu.l of 50 mM sodium phosphate, pH 7.5.
[0707] 2. Dissolve SPDP at a concentration of 6.2 mg/ml in DMSO to
make a 20 mM stock solution. Alternatively, LC-SPDP may be used and
dissolved at a concentration of 8.5 mg/ml in DMSO (also makes a 20
mM solution). If the water-soluble Sulfo-LC-SPDP is used, a stock
solution in water may be prepared just prior to addition of an
aliquot to the thiolation reaction. In this case, prepare a 10 mM
solution of Sulfo-LC-SPDP by dissolving 5.2 mg/ml in water. Since
an aqueous solution of the cross-linker will degrade by hydrolysis
of the sulfo-NHS ester, it should be used quickly.
[0708] 3. Add 50 .mu.l of the SPDP (or LC-SPDP) solution to the SAg
oligonucleotide solution. Add 100 .mu.l of the Sulfo-LC-SPDP
solution, if the water-soluble cross-linker is used. Mix.
[0709] 4. Allow to react for 1 h at room temperature.
[0710] 5. Remove excess reagents from the modified SAg
oligonucleotide by gel filtration. The modified oligonucleotide now
may be used to conjugate with a sulfhydryl-containing molecule, or
it may be reduced to create a thiol for conjugation with
sulfhydryl-reactive molecules.
[0711] 6. To release the pyridine-2-thione leaving group and form
the free sulfhydryl, add 20 .mu.l of 1M DTT and incubate at room
temperature for 15 mm. If present in sufficient quantity, the
release of pyridine-2-thione is followed by its characteristic
absorbance at 343 nm (.epsilon.=8.08.times.10.sup.3 M.sup.-1
cm.sup.-1). For many oligonucleotide modification applications,
however, the leaving group will be present in too low a
concentration to be detectable.
[0712] 7. Purify the thiolated oligonucleotide from excess DTT by
dialysis or gel filtration using 50 mM sodium phosphate, 1 mM EDTA,
pH 7.2. The modified oligonucleotide should be used immediately in
a conjugation reaction to prevent sulfhydryl oxidation and
formation of disulfide cross-links.
[0713] N-succinimidyl S-actylthioacetate (SATA ) Modification of
Amines on Superantigen DNA Nucleotides
[0714] SAg oligonucleotides containing amine groups introduced by
enzymatic or chemical means may be modified with SATA to produce
protected sulfhydryl derivatives. The NHS (N-hydroxylsuccinimide)
ester end of SATA reacts with a primary amine to form a stable
amide bond. After modification, the acetyl protecting group can be
removed as needed by treatment with hydroxylamine under mildly
alkaline conditions. The result is terminal sulfhydryl groups that
can be used for subsequent labeling with thiol-reactive probes or
activated-protein derivatives.
[0715] Protocol
[0716] 1. Dissolve the amine-modified SAg oligonucleotide to be
thiolated in 250 .mu.l of 50 mM sodium phosphate, pH 8.
[0717] 2. Dissolve SATA in DMF at a concentration of 8 mg/ml.
[0718] 3. Add 250 .mu.l of the SATA solution to the oligo solution.
Mix.
[0719] 4. React for 3 h at 37.degree. C.
[0720] 5. Remove excess reagents by gel filtration.
[0721] 6. To deprotect the thioacetyl group, add 100 .mu.l of 50 mM
hydroxylamine hydrochloride, 2.5 mM EDTA, pH 7.5, and react for 2
h.
[0722] 7. The sulfhydryl-containing oligonucleotide may be used
immediately to conjugate with a sulfhydryl-reactive label, or it
can be purified from excess hydroxylamine by gel filtration.
[0723] Conjugation of a Polypeptide to SAg DNA
[0724] As indicated, the DNA molecule must be modified to contain
one or more suitable reactive groups, such as nucleophiles like
amines or sulfhydryls. The modifications that employ enzymatic or
chemical methods can result in random incorporation of modification
sites or can be directed exclusively to one end of the DNA
molecule, e.g., 5' phosphate coupling.
[0725] Some of the more common procedures for preparing
DNA-polypeptide conjugates are given below.
[0726] Polypeptide (e.g., VT) Conjugation to Cystamine-Modified SAg
DNA Using Amine- and Sulfhydryl-Reactive Heterobifunctional
Cross-linkers
[0727] Cystamine groups are added to the 5' phosphate of SAg DNA as
described above. Once a sulffiydryl-modified DNA has been prepared,
the following protocol may be used. The protein is activated with
SPDP. Reacting the SAgic DNA probe in excess allows easy separation
of uncoupled SAg oligonucleotide from conjugated molecules.
[0728] Protocol
[0729] 1. Dissolve a 5'-sulfhydryl-modified SAg oligonucleotide in
water or 10 mM EDTA at a concentration of 0.05-25 .mu.g/.mu.l.
Calculate the total nanomoles of oligonucleotide present based on
its molecular weight.
[0730] 2. Add 0.15M NaCl, 10 mM EDTA, pH 7.2. Add the
oligonucleotide solution to the activated protein in a 10-fold
molar excess.
[0731] 3. React at room temperature for 30 mm with gentle
mixing.
[0732] 4. The protein-DNA conjugate is purified away from excess
SAg oligonucleotide by dialysis or gel filtration, or through the
use of centrifugal concentrators. Centricon-30 concentrators
(Amicon) that have a molecular weight cutoff of 30,000 are also
used to remove unreacted oligonucleotides. Since the polypeptide
molecular weight is approximately 140,000 and the conjugate is even
higher, a relatively small DNA oligomer will pass through the
membranes of these units while the conjugate will not. To purify
the prepared conjugate using Centricon-30s, add 2 ml of the
phosphate buffer from step 2 to one concentrator unit, then add the
reaction mixture to the buffer and mix. Centrifuge at 1000 g for 15
mm or until the retentate volume is about 50 .mu.l. Add another 2
ml of buffer and centrifuge again until the retentate is 50 .mu.l.
Invert the Centricon-30 unit and centrifuge to collect the
retentate in the collection tube provided by the manufacturer.
[0733] Administration of Peptide-DNA (pDNA), Naked DNA, or Protein
or Peptide Conjugates
[0734] Naked DNA, pDNA, nucleic acid-peptide or -polypeptide
conjugates or genetic fusion products are administered parenterally
(for example, iv, ip, im, subcutaneously, intrathecally,
intratumoral, rectally, transcutaneously) or orally. Administration
may also be by a gene gun using a 1 ml syringe and a 28 gauge
needle. The nucleic acid is administered intradermally or
intramuscularly in a total volume of 100 .mu.l. A Tyne applicator
is used to deliver doses of 1-1000 .mu.g of DNA at 3.times. weekly
intervals. SAg-encoding nucleic acid is injected directly into the
tumor. The nucleic acid either contains or does not contain
immunostimulatory sequences that induce activation of T cells and
skew the response toward production of TH1 cytokines. For example,
if nucleic acids encoding a tumor associated antigen are used then
the nucleic acids are engineered to incorporate ISS sequences in
order to fully activate a TH1 response. Likewise, if nucleic acid
encoding a tumor associated antigen is cotransfected with nucleic
acid encoding a SAg, then one of the nucleic acid constructs is
engineered to contain an ISS.
[0735] Viral DNA, nucleic acid expression cassettes or plasmids or
bacteriophages encoding the constructs given in Table II may be
used for in vivo immunization in place of naked DNA. Viruses may
also acquire the .alpha.Gal epitope after transfection into tumor
cells which contain the .alpha.-galactosyltransferase enzyme either
naturally or via transfection. The virus must possess the intact
N-acetyllactosamine substrate for the galactosyl-transferase in
order to express the .alpha.Gal. The viruses shedding from these
cells will express the .alpha.Cal epitope. The virus also contains
peptide sequences for SAg and tumor associated antigen acquired
from the tumor cells which were previously transfected with nucleic
acids encoding SAg and tumor antigen. The shed virus may also
express staphylococcal or streptococcal hyaluronidase and capsular
polysaccharide sequences obtained from host tumor cell or accessory
cells previously transfected with nucleic acids encoding these
genes. The shed virus expressing Gal, SAg, hyaluronidase and
capsular polysaccharide is capable of initiating a potent
tumoricidal response when administered to hosts with established
tumors or when used as a tumor vaccine against potential
tumors.
[0736] These constructs are also used as vaccines. Further, the
nucleic acid construct is pre-processed ex vivo in muscle cells
before selective delivery into host tumor tissue. Cationic
liposomes or other liposomes or drug carriers well known in the art
are used as vehicles to deliver the nucleic acids in vivo.
[0737] The transfection process is also carried out ex vivo.
Nucleic acids encoding SAgs together with the nucleic acid
constructs given in Table II are transfected into tumor cells of
all types and antigen presenting cells such as MHC class I and
class II as well as APCs expressing CD1 and mannose receptors.
These include but are not limited to DCs, immunocytes, monocytes,
macrophages, and fibroblasts. SAg is transfected alone or together
with one or more of the above constructs given in Table II. The
transfected cell expresses/secretes preferentially a SAg plus an
immunogenic oncogene product, anti-angiogenesis factor,
glycosylceramide, LPS or Gal. The transfectants present their gene
products on cell surface receptors such as conventional MHC
molecules for SAgs or in the case of the glycosylceramides or LPS
on a CD-1 or mannose receptor. (APC). Glycosylated SAgs show
preference for presentation on mannose receptors.
EXAMPLE 4
SAgs, Tumor Antigens, Glycosylceramides, LPS's, Binary and Ternary
Complexes Applied to MHC Class I, Class II, CD1 or Mannose
Receptors
[0738] CD1 represents a family of non-polymorphic antigen
presenting molecules unlinked to the MHC molecules expressed by
most professional APCs. The NKT cells that recognize CD1 presented
antigens express NKR-P1, Ly49 receptors, an invariant chain and a
V8.2 variable region. With respect to these receptors, they share
identity and their natural ligands with NK cells. Specifically, CD1
binds peptides with extended NH.sub.2 and COOH termini flanking the
core binding motif. Long peptides (greater than 8 to 10 amino
acids) with amino acid residues at their hydrophobic binding sites
and greatly restricted anchors are preferred. This recognition of
CD1-presented antigens depends on the type and distribution of
sugar residues. Mycobacterial cell wall antigens namely mycolic
acids and lipoarabinomannan also bind to CD1. Recently several
glycosylceramides, in particular, monogalactosyl ceramides GalCer)
were shown to bind to CD1 and to activate NKT cells Specifically,
CD1 molecules are capable of presenting mannosides with 1,2
linkages and a phosphatidylinositol unit. CD1 bound antigens are
recognized by NKT cells (/TCR positive; CD4 and CD8 negative). For
instance, NKT cells are activated by a lipoarabimannan (LAM)
presented on CD1 receptors and become cytolytic while producing
abundant INF.
[0739] In the present invention, a SAg bound to a
monogalactosylceramide such as GalCer is loaded onto CD1 or MHC
class I or II receptors expressed by APCs. The CD1 or MHC receptors
are in soluble or immobilized form produced by methods well
described in the art. According to this invention, CD1 receptors
present SAg polypeptides complexed with GalCer lipids or
oligosaccharides to T cell and/or NKT cell population which
recognize the conjugates and commence differentiation to tumor
specific effector cells. These ligands are be loaded on the CD1
receptor sequentially, simultaneously or as a preformed conjugates.
Alternatively, they are positioned on the CD1 receptor after
internal processing of their nucleic acid counterparts in the
antigen presenting cells. These cells are then harvested and used
for adoptive immunotherapy (Examples 7, 15, 16. 18-23). These
complexes are also useful in vivo as a preventative or therapeutic
antitumor vaccine (Example 14, 15, 16, 18-23).
[0740] SAgs and tumor associated antigen (TAA) are loaded
sequentially on to class II receptors of antigen presenting cells.
Alternatively, preformed complexes of tumor associated antigen and
SAg are loaded onto MHC class II receptors. The SAg may be in the
native or glycosylated form. The tumor associated antigen is also
fused genetically to the .quadrature. chain of the MHC class II
receptor. A SAg is added once the TAA is expressed bound to the MHC
class II. The sequence may also be reversed so that a SAg is
genetically processed and bound to the .quadrature. chain after
which the TAA is added. Consensus or repeating nucleic acid
sequences shared by a tumor associated antigen and a SAg are cloned
into a single sequence and transfected into APCs which display the
consensus peptide in the context of the class II receptor.
Methodology for production of the fusion genes is well described in
the art. (See Ausubel. F M et al., supra; Sambrook, J et al.,
supra) T cells or NKT cells are activated after exposure to SAg and
TAA producing an expanded tumor specific T cell effector population
which is useful in adoptive immunotherapy of cancer (Examples 7,
15. 16, 18-23).
[0741] Antigen presenting cells in this system are chosen from a
group consisting of DCs, fibroblasts, macrophages, and lymphocytes,
but other professional APCs or any other cell transfectants, phage
displays or liposomes expressing the class I or class II receptors
are also used. Alternatively, a tumor associated antigen is bound
to an APC that is pharmacologically or genetically inhibited from
antigen processing. SAg is added and the complex of SAg and protein
bound to class II is then presented to a T cell population to
produce a tumor specific effector cell population for use in
adoptive immunotherapy of cancer as in Example 15, 16, 18-23).
These complexes are also useful in vivo as a preventative or
therapeutic antitumor vaccine (Example 14, 15, 16, 18-23).
[0742] Soluble SAg MHC class II proteins with covalently bound
single peptides are produced using a baculovirus system to express
in insect cells two murine class II molecules with peptides
attached by a linker to the N terminus of their .quadrature.-chains
(Kozono H. et al., Nature 369: 151-154 (1994)). The resulting
peptide is engaged by the peptide binding groove of the secreted
MHC molecule and this complex is recognized by T cells bearing
receptors specific for the combination. In this method, the
approximately 100 bp fragment encoding the SAg and a flexible
linker with an embedded thrombin cleavage site is introduced in
frame by the PCR just after the third codon of the b1 domain. This
assures a recognizable leader peptide cleavage site and flexible
link between the C-terminus of the foreign peptide bound in the
cleft of the MHC molecule and the N terminus of the b1 domain of
SAg amino acids. Soluble complexes consisting of receptors and
various SAg are prepared in this way and are used to activate T
cells for use in adoptive immunotherapy. Similarly, preparations
consisting of MHC class I receptors, CD1 or mannose receptors
complexed with SAgs, glycosylceramides or LPS's are produced which
are useful in activating T cells or NKT cells for adoptive
immunotherapy of cancer in protocols given in Examples 7, 15, 16,
18-23). These complexes are also useful in vivo as a preventative
or therapeutic antitumor vaccine (Example 14, 15, 16, 18-23).
[0743] To produce complexes composed of SAgs with class I or II MHC
or soluble DR .alpha. or .quadrature. (lacking the transmembrane
domain) and TCR heterodimer, a soluble human TCR heterodimer which
has specificity for various tumor associated antigens bound to the
human class I or II MHC molecules or human soluble CD1 molecules is
used. A typical system for preparing ternary SAg-tumor peptide-MHC
or ternaryCD1-glycosylceramid- e (preferably GalCer)-SAg complexes
capable of triggering T cells or NKT cells is as follows. CD1, DR-1
or HLA-A2 restricted tumor antigen specific T cell or NKT cell
clones are used although primary unsensitized T or NKT cells may be
used as well. The DR-1 and HLA-A2 homozygous Epstein-Barr
virus-transformed B cell line LG-2 or DCs expressing CD1 receptors
are used as APCs either live or fixed in 0.5% paraformaldehyde for
20 minutes. LG-2 and DCs (2.67.times.10.sup.5 per ml) in RPMI 1640
with 1% fetal bovine serum are pulsed with tumor antigen and
glycosylceramide respectively for 2 hours at 37.degree. C. and then
washed in RPMI 1640/1% fetal bovine serum to remove unbound
antigen. SAg is added for 2 hours at 37.degree. C. Pulsed APCs
(4.times.10.sup.4 per well) are co cultured with resting T cells or
NKT cells (2.times.10.sup.4 per well) in round-bottom microtiter
plates in RPMI 1640/5% human serum, Twenty four hours later, the
cells are harvested. The APCs are separated and the T cells or NKT
cells may be optionally expanded further with IL.-2 Optionally,
complexes comprising soluble recombinant DR.alpha. or .quadrature.
chain with bound superantigen are presented to the T cell or NKT
cells which are then expanded with IL-2. These cells are then
harvested and used for adoptive immunotherapy (Examples 7, 15, 16.
18-23). The APC containing the complexes are also useful in vivo as
a preventative or therapeutic antitumor vaccine (Example 14, 15,
16, 18-23).
[0744] Also useful for tumor therapy are the complexes LIP.sup.+
GPI-SAg (from Section 38), either free or in the form of vesicles
or exosomes comprising SAg-GalCer complexes or SAg-tumor peptide
(including but not limited to normal mutated structures). The
ternary complexes of SAg-GalCer-heat shock protein and tumor
peptide-heat shock protein are also useful, These complexes may be
in or soluble or immobilized form, attached to a CD1 or MHC or as
part of a vesicle or exosome. the complexes are also useful in vivo
as a preventative or therapeutic antitumor vaccine (Example 14, 15,
16, 18-23).
[0745] The tumor associated antigen or SAg-tumor associated antigen
complex is conjugated to oxidized mannan (polymannose) by methods
described by Apostolopoulos, V et al., Proc. Natl. Acad. Sci. USA
92: 10128-10132 (1995) which is then loaded onto mannose receptors
of antigen presenting cells for stimulation of a T cell anti-tumor
response. Alternatively, the SAg (optionally conjugated to tumor
peptides)-mannan conjugate is administered to tumor bearing hosts
by methods in Example 15, 16, 18-23).
[0746] The SAg alone or conjugated to a tumor associated antigen is
recognized by the mannose receptor on macrophages. This requires a
glycosylated SAg which is recognized by the mannose receptor on
macrophages. A native or glycosylated tumor associated antigen-SAg
conjugate or a consensus peptide of both polypeptides is presented
to mannose receptors expressed on antigen presenting cells which
are exposed to a T cell or NKT cell population to produce a tumor
specific effector cells by methods in Example 15, 16, 18-23). These
complexes are also useful in vivo as a preventative or therapeutic
antitumor vaccine (Example 14, 15, 16, 18-23). They are also used
ex vivo to produce a population of tumor specific effector T or NKT
cells for the adoptive immunotherapy cancer by methods and
protocols given in Examples 7, 15, 16, 18-23 and 36.
[0747] The mannose receptor delivers the complex to the late
endosomal and lysosomal vesicles and the MHC class II loading
compartment where the antigen is loaded onto CD1b molecules. The
C1b molecule is endocytosed at the plasma membrane in coated pits
and vesicle structures, transits to early endosomes and is then
delivered to the MHC class II antigen loading compartment. The
endosomal localization motif on the tail of the CD1b molecule is
essential for antigen trafficking of CD1b through the lysosomal
compartment required for loading of antigen into CD1b and its
ultimate transport to the membrane. The antigen binding groove of
CD1 is deeper and narrower than the MHC class I molecule groove
containing a hydrophobic binding site which accommodates the lipid
portion of the molecules such as lipoarabinomannan or GalCer and
the SAg-LPS constructs given herein. APCs expressing the above
constructs are exposed to NKT cell populations which recognize the
antigens in the context of the CD1 receptor. If carried out ex vivo
this results in the formation of tumor specific effector NKT cells
which are used for adoptive immunotherapy by protocols given in
Examples 7, 15, 16, 18-23).
EXAMPLE 5
SAg Conjugation to Glycosylceramides Gangliosides LPS's, Glycans,
Peptidoglycans Lipoproteins, oxyLDL and Lipoarabinomannans
[0748] Selection of the SAg peptide to be used for coupling is
governed by several criteria. In practice, a 10-15 residue peptide
is selected. For SAgs, the sites chosen for coupling are those
presumed not to be vitally involved in T cell binding and
activation. In most SAgs, these sites are broadly distributed
throughout the molecule. They are available at flexible regions of
the protein and on reverse turns or loop structures. C termini are
more mobile than the rest of the molecule and frequently exposed on
the protein surface. This region is accessible to be coupled to
another ligand especially using
m-maleimidobenzoyl-N-hydroxysuccinimid- e ester (MBS) via a Cys
residue that has been added to the N terminus of the peptide. By
coupling the peptide via its N-terminal end, the peptide is exposed
in a fashion similar to that found in the native antigen.
Additional criteria for selection of the coupling site such as
exposed hydrophilic regions, secondary structure, hydropathicity
profiles, and probability of helix formation may not be useful.
However, care is take not to disrupt predicted polysaccharide
attachment sites, most notably the sequence Asn-X-Ser or Asn-X-Thr,
which predicts the presence of Asn-linked polysaccharide moieties.
In addition to location of transmembrane regions, Asn-linked
glycosylation sites and sites of signal sequence cleavage are all
important. After due consideration, the C using 7-15 residues
terminus is preferred and is modified to accommodate MBS. This
procedure requires a free sulfhydryl group on the synthetic peptide
and free amino groups on the ligand. Therefore, to use this method,
it is necessary to add a Cys residue to the C or N terminus of the
peptide.
[0749] Biochemical Conjugation Methods:
[0750] SAgs are conjugated to polysaccharide containing structures
using several methods well described in the art (Hermanson, GT
Bioconjugate Techniques Academic Press, San Diego, Calif. 1996).
Two methods are given here one utilizing the isolated complex
carbohydrate obtained from the purified ganglioside which is then
chemically conjugated to SAg and in another method wherein the
ganglioside and SAg are both incorporated into a liposomal
membrane. Either method is used to produce complexes which are
included within the scope of this invention. However they are by no
means exhaustive of all the techniques which could be employed to
conjugate human tumor antigens to SAg molecules. Other conjugation
strategies may be utilized to produce an immunologically active
complex as described by this invention. (See Offord, R E. in
Protein Engineering ed. A R Rees, Oxford, 1992)
[0751] Direct Conjugation of Ganglioside, LPS or Peptidoglycan to
SAg Molecules
[0752] 1. Ganglioside or LPS antigens are purified and are then
dissolved in aqueous solution at pH 6.0 at a concentration of 1.0
mM/ml
[0753] 2. Endoglycoceramidase from Rhodococcus (Genzyme) is added
to the ganglioside solution to a level of 5 milliunits. The
solution is incubated overnight at 37.degree. C. with gentle
agitation. The endoglycoceramidase specifically cleaves at the
ceramide-polysaccharide bond liberating ceramide and clipping off
the complex carbohydrate making up the ganglioside
[0754] 3. The polysaccharide is isolated by HPLC size exclusion
chromatography or by ultrafiltration
[0755] 4. SAg is dissolved in 1M sodium phosphate, 0.15 M NaCl, pH
7.5, at a concentration of 1 mg/ml. The purified polysaccharide
antigen is added to this solution to a concentration of at least 1
mM/ml.
[0756] 5. In a fume hood, 20 microliters of 5 M sodium
cyanoborohydride solution in 1 M NaOH (Aldrich) is added to each ml
of the SAg solution.
[0757] 6. The reaction is mixed gently and incubated at room
temperature for 72 hours or 4.degree. C. for 1 week. This reaction
reductively aminates the reducing end of the polysaccharide (at the
point it was cleaved by the endoglycoceramidase) to the amine
groups on the SAg protein creating stable conjugate coupled through
a secondary amine linkage. The degree of polysaccharide coupling
can be controlled by limiting the time of reaction.
[0758] 7. Remove unreacted carbohydrate and cyanoborohydride by gel
filtration on Sephadex G-25 or by dialysis.
[0759] In a second method, SAg-GalCer, SAg-GalCer-CD1,
SAg-glycosphingolipid, or SAg-glycosphingolipid-CD1 complexes are
produced which have the added benefit of presenting the
glycosylceramide in a polyvalent array which is important for high
affinity binding to complementary receptors. They retain nearly all
of their original structure including most of the ceramide moiety
and the entire oligosaccharide chain. The principle of preparation
derived from Mahoney, J A et al., Meth. Enzymol 242: 17-27 (1994)
is as follows. The fatty acid amide is hydrolyzed from the intact
ganglioside converting it to its lyso form which has a unique
primary amine at the 2-position of sphingosine. The lysoganglioside
is treated with a bifunctional cross-linking reagent, succinimidyl
4(N-maleimidomethyl)cyclohexane 1-carboxylate (SMCC), which forms
an amide bond to the 2-position of sphingosine and results in a
sulfhydryl-reactive maleimidyl moiety attached through a linker
arm, to the original position of the fatty acid amide on the
ceramide portion of the ganglioside. The SAg protein is treated
with a reagent, N-succinimidyl S-acetylthioacetate (SATA), which
converts the lysine e-amino groups to acetylated sulfhydryls.
Subsequent treatment with hydroxylamine reveals the desired free
sulfhydryls. Treatment of sulfhydryl-derivatized SAg with
maleimidyl derivatized ganglioside results in a stable thioester
linkage between the ganglioside and the protein. The final product
is chromatographically purified and characterized by protein and
carbohydrate analysis. The SAg-GalCer or SAg-glycosphingolipid
complex is then loaded onto a soluble CD1 receptor.
[0760] LPS's and peptidoglycans are conjugated to SAg by methods
well described in the art. The most convenient and preferred method
to target specifically the polysaccharides on the protein is
through mild sodium periodate oxidation. Periodate cleaves adjacent
hydroxyl groups in sugar residues to create highly reactive
aldehyde functional groups. The generated aldehydes are used to in
coupling reactions with amine or hydrazide containing molecules to
form covalent linkages. Amines react with formyl groups under
reductive amination conditions using a suitable reducing agent such
as sodium cyanoborohydride. The result of the reaction is a stable
secondary amine linkage. Hydrazides spontaneously react with
aldehydes to form hydrazone linkages, although the addition of a
reducing agent greatly increases the efficiency of the reaction and
the stability of the bond. (See Hermanson, G T. Bioconjugate
Techniques, Academic Press, San Diego Calif. 1996).
[0761] Production of Liposomes Displaying Glycolipid or
Apolipoprotein or oxyLDL-SAg Complexes
[0762] Liposomes composed of the highly immunogenic constructs
described herein are prepared. They may include lipoproteins such
as SAgs coupled to Gal, GalCer or SAg-glycosphingolipid or and
other glycosylceramides. Liposomes comprising SAgs conjugated to
apolipoproteins or oxyLDL receptors are useful for targeting
endothelial or macrophage oxyLDL receptors in tumor
microvasculature. Cationic liposomes are also useful as a means of
transferring the nucleic acid constructs of this invention to tumor
tissue. GalCer (a monogalactosylceramide) comprises the major
portion of the liposome. The most effective lengths of fatty acyl
chain and sphingosine (or ceramide) base are C.sub.26 and C.sub.18
respectively and a phytosphingosine backbone. Sphingolipids lend
structural advantages to the integrity of liposomal membranes and
have prolonged duration in vivo. The Gal carbohydrate epitope is
linked to liposomes via the amphipathic properties of the surface
sphingolipids. The Gal is converted to a glycolipid with a
sphingosine backbone possessing a hydrophobic fatty acid tail that
embeds them into membrane bilayers. The hydrophilic carbohydrate
ends of these amphipathic molecules can interact with molecules
dissolved in the surrounding environment. Sphingosine glycolipids
consisting of lactosylceramide, GalGal(1-3)Gal(1-4)GlcNAc-R) or
glycosphingolipids with terminal Gal(.alpha.1-4)Gal are prepared in
a manner similar to that of sphingolipids. All methods of
preparation of liposomes have several steps in common: (1)
dissolution of the lipid mixture in an organic solvent, (2)
dispersion in an aqueous phase, and (3) fractionation to isolate
the correct liposomal population.
[0763] In the first stage, the desired mix of lipid components is
dissolved in organic solvent (usually chloroform:methanol (2:1 by
volume) to create a homogenous mixture. This mixture includes any
phospholipid derivatized to contain reactive groups as well as
other lipids used to form and stabilize the bulk of the liposomal
structure. The correct ratio of lipid constituents to form stable
liposomes is important A reliable liposomal composition for
encapsulating aqueous substances contains molar ratios of
lecithin:cholesterol:negatively charged phospholipid (e.g.,
phosphatidyl glycerol) of 0.9:1:0.1. Apolipoproteins (e.g., LP(a))
or oxyLDL (e.g., 7.quadrature.-hydroperoxycholesterol or
7.quadrature.-hydroperoxy-choles-5-en-3B-ol) can substitute for
cholesterol in the preparation of the liposomes. In general, to
maintain membrane stability, the PE derivative should not exceed a
concentration ratio of about 1-10 mol PE per 100 mol of total
lipid. Once the desired mixture of lipid components is dissolved
and homogenized in organic solvent, several techniques are used to
disperse the liposomes in aqueous solution. These methods are
broadly classified as (1) mechanical dispersion, (2)
detergent-assisted solubilization, and (3) solvent-mediated
dispersion. With mechanical dispersion to form vesicles, the lipid
solution is dried to remove all traces of organic solvent prior to
dispersion in aqueous media. The dispersion process is key to
producing liposomal membranes of the correct morphology. Methods
utilized include simple shaking, high pressure emulsification,
sonication, extrusion through small-pores membranes and various
freeze-thaw techniques. Detergent-assisted solubilization is also
used to bring the lipid more effectively into the aqueous phase for
dispersion. Triton X, alkyl glycosides or bile salts such as sodium
deoxycholate are employed. Other modalities or dispersion include
the steps of dissolving phospholipids and other lipid to be part of
the liposomal membrane in ethanol. This ethanolic solution is then
rapidly injected into an aqueous solution of 0.16 M KCl using a
Hamilton syringe resulting in a maximum concentration of no more
than 7.5% ethanol. Using this method, single bilayer liposomes of
about 25-nm diameter are produced. To remove the excess aqueous
components that are not encapsulated during the vesicle formation,
gel filtration using Sephadex G-50 or dialysis is employed. To
fractionate the liposome population according to size, gel
filtration is carried out using a column of Sepharose 2B or 4B
[0764] SAgs are conjugated to the GalCer or glycosphingolipids with
terminal Gal(.alpha.1-4)Gal, apolipoproteins, LDL or oxyLDL or LDL
receptors before incorporation into the liposomal membrane or they
may be incorporated into the membrane during the preparation of the
liposomal membrane. Likewise, the SAg is conjugated to GalCer or
glycosphingolipids with terminal Gal(.alpha.1-4)Gal at the
glycolipid's polar head region by methods well known in the art
including using heterobifunctional crosslinkers or periodate
oxidation techniques. Alternatively, after the GalCer or
glycosphingolipids with terminal Gal(.alpha.1-4)Gal is incorporated
into the membrane, the liposomes are derivatized for further
binding to the SAg proteins using the sodium periodate which
oxidizes the ceramide's free hydroxyl to an aldehyde which is
further modified by reductive amination. Using the
phosphatidylethanolamine of the lipid in the liposome, SAgs are
coupled to the liposome using various bifunctional agents including
carbodiimide, glutaraldehyde, dimethyl suberimidate, periodate
oxidation followed by reductive, amination, N-succinimidyl
3-(2-pyridyldithio)propionate (SPDP),
succinmidyl-4-(p-maleimidophenyl)bu- tyrate (SMPB), iodoacetate,
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate
(SMCC).
[0765] Two general methods are used to prepare immunogenic (i)
SAg-GalCer, (ii) GalCerGal, (iii) GalCerGal-SAg and (iv)
SAg-glycosphingolipid complexes: The molecules (1) are dissolved in
solution and encapsulated within the vesicle construction, or (2)
covalently coupled to phospholipid constituents in the lipids using
standard cross-linking chemical reactions. Covalent coupling of SAg
to liposomes is done through the head groups using various
phospholipid derivatives and cross-linking chemical reactions.
These are done via the PE molecules. Simple encapsulation is also a
viable technique as described in Hermanson (supra).
[0766] A sample method using periodate oxidation and reductive
amination is given below.
[0767] 1. A 5 mg/ml liposome suspension is prepared in 20 mM sodium
phosphate 0.15 M NaCl, pH 7.4. containing, on a molar ratio basis
as mixture of phosphatidyl choline:cholesterol:phosphatidyl
glycerol of 8:10:1. Other liposome compositions may be used, for
example methods without cholesterol, as long as a
periodate-oxidizable component containing vicinal hydroxyls (e.g.,
phosphatidyl glycerol) is present. Any method of liposome formation
may be used that is common to those skilled in the art including
mechanical dispersion.
[0768] 2. Sodium periodate is dissolved to a concentration of 0.6 M
by adding 128 mg/ml of water. 200 ml of this stock periodate
solution is added to each mol of the liposome suspension with
stirring.
[0769] 3. React for 30 min. at room temperature in the dark.
[0770] 4. The oxidized liposomes are dialyzed against 20 mM sodium
borate, 0.15 M NaCl, pH 8.4, to remove unreacted periodate. This
buffer is ideal for the subsequent coupling reaction.
Chromatographic purification using a column of Sephadex G50 is also
done. The periodate-oxidized liposomes are used immediately to
couple with SAg molecules or they may be stored in a lyophilized
state in the presence of sorbitol for later use.
[0771] 5. SAg is added to the periodate oxidized liposome solution
to obtain a 1 mg/ml concentration.
[0772] 6. In a fume hood, add 20 ml of 5 M sodium cyanoborohydride
solution in 1 M NaOH (Aldrich) to each ml of the SAg solution.
[0773] 7. The reaction is mixed gently and incubated at room
temperature for 6 hours.
[0774] 8. Excess SAg and cyanoborohydride are removed by size
exclusion chromatography on a column of Sephadex G-50 or by
dialysis using a membrane with a molecular weight cutoff of 100,000
daltons.
[0775] 9. Ganglioside antigens isolated by the method described
previously are incorporated into SAg-containing liposomes by
detergent dialysis. An amount of ganglioside is added representing
twice the amount of phosphatidyl glycerol (on a molar basis)
originally added to form the liposome (prior to periodate
oxidation). To this solution, concentrated sodium deoxycholate is
added to obtain a final concentration of 0.7% (w/w) and mixed
thoroughly using a Vortex mixer. Finally, the liposome suspension
is dialyzed against PBS, pH 7.5. A sample of the encapsulation
technique is given in Hermanson, supra.
[0776] An additional method for preparation of liposomes containing
GalCer or glycosphingolipids with terminal Gal(.alpha.1-4)Gal is as
follows: The donor liposomes consist of liver phosphatidylcholine,
dicetyl phosphate, cholesterol, 3-(Man1-3Man-sn-1,2diacylglycerol)
and galactosylceramide. These are mixed in various percentages to
permit optimal expression of the galactosylceramide. Constituent
lipids in chloroform-methanol are mixed and dried under a stream of
nitrogen. Buffer consisting of 0.15M NaCl, 10 MM sodium Phosphate,
pH 7.4, 1 mM dithiothreitol, 0.02% NaN.sub.3 is added to the dried
lipids at a volume of 1 ml per 0.9 .mu.mol of lipid phosphorus in
the donor liposomes. After a 30-min incubation at 25.degree. C.,
the lipids are dispersed into the buffer by sonication with a
Bransom sonifier for 30 min under nitrogen at 0.degree. C. The
liposome suspension is used the same day after centrifugation at
1500 g for 30 min to remove any undispersed lipid and titanium
fragments released from the sonication probe.
[0777] Liposomes used for transfer of nucleic acid constructs given
herein have unique structures as described below. A cationic
liposome composed of dimyristyloxypropyl-3-dimethyl-hydroxyl
ammonium (DMRIE) with DOPE has allowed up to 100 fold higher
concentrations of lipid and DNA to be administered in vivo with
minimal toxicity. Improved transfection techniques have been
observed with the DMRIE/DOPE of two to seven fold. The prototype
cationic lipid for gene transfer is DOTMA
(N[1-(2,3-dioleyloxy)propyl]-N,N,N-tri-methylammonium chloride)
which is mixed with a equimolar amount of DOPE (dioleoyl
phosphatidylethanolamine)- . The lipid DOTMA/DOPE comprise the
cationic liposome known a Lipofectin. For human studies, two
different cationic liposomes formulations are used. The first
includes DC-cholesterol(3b[N-(N'N'-dimethylaminoethane)-c-
arbamoyl] cholesterol) mixed with DOPE. DC-cholesterol/DOPE is low
concentrations has proven to reduce toxicity to cells in vitro, is
metabolized in vivo, and has provided successful gene transfer into
malignant tumors in humans (See Example 17 for use in humans).
[0778] Genetic Fusion of SAgs to LPS's
[0779] N-linked glycosylation occurs exclusively in the ER, where
Glc.sub.3Man.sub.9GlcNAc.sub.2 is added to Asn residues present in
the sequence Asn X Ser/Thr (X, any residue except Pro). To produce
a glycosylation site on a SAg capable of binding a LPS, recombinant
vaccinia virus expressing SAg is produced with Gln149 or Asn149
directed to the ER by appendage of NH.sub.2-terminal ER insertion,
The SAg is directed to the secretory pathway using signal sequence
from IFN. Recombinant vaccinia viruses(rVVs) expressing TAP and SAg
nucleoprotein are used. The full length SAg gene modified by
standard molecular genetic methods to encode glycosylation sites is
inserted into the thymidine kinase locus of vaccinia viruses (VVs)
by homologous recombination as described using the pSX11 plasmid to
express foreign proteins under the control of the VV p7.5
early/late promoter. SAg nucleoprotein is directed to the secretory
pathway using the signal sequence from IFN.quadrature.. The SAg
coding sequences of all of the rVVs are verified by sequencing
PCR-amplified copies of full-length NP genes isolated from the rVV.
The resulting SAg-LPS or SAg-lipoprotein complexes are used to
immunize a population of T or NKT effector cells for use in the
adoptive immunotherapy of cancer (Examples 2, 5, 7 15, 16, 18-23).
They may be preloaded onto CD1 or MHC Class I or II receptors on
APCs as described below in the course of ex vivo immunization.
These complexes may also be used in vivo as a preventative or
therapeutic antitumor vaccine as in Example 14, 15, 16, 18-23).
[0780] Preparation of Fusion Proteins
[0781] Preferred fusion proteins comprise SAgs linked to other
proteins or peptides such as VTs or their A and B subunits,
IFN.alpha. receptors, CD19 peptides or carbohydrate recognition
units which are designed to target the SAg to glycosphingolipid
receptors on tumor cells or .alpha..sub.v.quadrature..sub.3 ligand
Arg-Gly-Asp or .alpha..sub.v.quadrature..sub.5 ligand Asn-Gly-Arg
in vivo or in vitro. These fusion proteins induce apoptosis of the
tumor cells. The fusion proteins are produced by conventional
methods in a variety of cells using a variety of vectors such as
phage .lambda. regulatory sequences. Techniques are well
established for producing fusion proteins that include the lacZ
protein(.quadrature.-galactosidase), trpE protein,
glutathione-S-transferase, and thioredoxin. Expression in E. coli
is most conventional but baculoviral expression systems are also
useful. Fusion proteins are produced in bacteria by placing a
strong, regulated promoter and an efficient ribosome-binding site
upstream of the cloned gene. Exemplified below is a procedure using
a representative lacZ vector. However, it should be recognized that
other vectors well known in the art would be useful. Plasmids
encoding the above proteins are prepared as previously
described.
[0782] Construction of Expression Plasmids and Detection of Fusion
Proteins
[0783] 1. The appropriate pUR (or pEX or pMR100) vector is ligated
in-frame to cDNA fragments to be expressed as fusion partners using
the above plasmids to create an in-frame fusion. cDNA encoding the
verotoxins may be obtained from Dr. G. Lingwood, University of
Toronto; murine p31 Ii are from Dr. R. Germain, National Institutes
of Health and J. Miller, University of Chicago.
[0784] 2. Bacteria of the following strains are transformed: E.
coli K12 71/18 or JM103 with pUR vectors, M5219 with pEX vectors or
LG90 for pMR100 vectors. The cells are plated on LB medium
containing ampicillin (100 .mu.g/ml) and incubated overnight at
37.degree. C. (or 30.degree. C. in the case of the pEX vector).
MacConkey lactose indicator plates should be used for pMR100.
[0785] 3. Individual colonies are tested for the presence of the
desired insert by plasmid minipreps.
[0786] If most of the colonies can be assumed to contain a cDNA
(because directional cloning or a dephosphorylated vector was used
in step 1), they can be screened for protein production in parallel
(see step 4b). If not, clones that contain a cDNA, as determined by
plasmid minipreps, can be screened for protein expression later.
cDNA inserts into a pMR100 plasmid can be detected readily as red
colonies on the MacConkey lactose indicator plates.
[0787] 4. Colonies are screened as follows for expression of the
fusion protein.
[0788] a. Grow small cultures from 5-10 colonies in LB medium
containing ampicillin (100 .mu.g/ml). Incubate overnight at
37.degree. C. (or at 30.degree. C. for pEX).
[0789] b. Inoculate 5 ml of LB medium containing ampicillin (100
.mu.g/ml) with 50 .mu.l of each overnight culture. Incubate for 2
hours at 37.degree. C. (or at 30.degree. C. for pEX) with aeration.
Remove 1 ml of uninduced culture, place it in a microfuge tube, and
process as described in steps d and e. If screening for protein
production is being done in parallel, prepare plasmid minipreps
from 1-ml aliquots of the overnight cultures.
[0790] c. Induce each culture as follows: For pUR or pMR100
vectors, add isopropylthio-.quadrature.-D-galactoside (IPTG) to a
final concentration of 1 nM and continue incubation at 37.degree.
C. with aeration. For pEX vectors, transfer the culture to
40.degree. C. and continue incubating with aeration.
[0791] d. At various time points during the incubation (i.e., 1, 2,
3, and 4 hours), transfer 1 ml of each culture to a microfuge tube,
and centrifuge at 12,000 g for 1 minute at room temperature in a
microfuge. Remove the supernatant by aspiration. The kinetics of
induction varies with different proteins, so it is necessary to
determine the time at which the maximum amount of product is
produced.
[0792] e. Resuspend each pellet in 100 .mu.l of 1.times.SDS
gel-loading buffer, heat to 100.degree. C. for 3 minutes, and then
centrifuge at 12,000 g for 1 minute at room temperature. Load 15
.mu.l of each suspension on a 6% SDS polyacrylamide gel. Use
suspensions of cells containing the vector alone as a control. (For
pEX and ORF vectors, also use .quadrature.-galactosidase as a
control.) The fusion protein should appear as a novel band
migrating more slowly than the intense .quadrature.-galactosidase
band in the control. It is not uncommon for a protein the size of
.quadrature.-galactosidase to be present along with the fusion
protein.
[0793] Composition of 1.times.SDS gel-loading Buffer
[0794] 50 mM Tris Cl (pH 6.8)
[0795] 100 mM dithiothreitol (DTT)
[0796] 2% SDS (electrophoresis grade)
[0797] 0.1% bromophenol blue
[0798] 10% glycerol
[0799] 1.times.SDS gel-loading buffer lacking dithiothreitol can be
stored at room temperature. Dithiothreitol should then be added,
just before the buffer is used, from a 1 M stock.
[0800] Loading of SAg-LPS or SAg-Lipoprotein Conjugates onto CD1 or
MHC Receptors
[0801] For loading of SAg LPS or SAg-lipoprotein complexes onto CD1
receptors, recombinant soluble CD1-2M complexes in Drosophila
melanogaster cells are used to screen a random peptide phage
display library(RPPDL). The absence of peptide-loading machinery in
D. melanogaster cells results in the expression of class 1
molecules that are properly folded and functionally competent but
essentially devoid of bound peptide. This approach has been shown
to be useful in defining peptide binding motifs for classical and
nonclassical MHC Class I and Class II molecules. (Jackson et al.,
Proc. Natl. Acad. Sci. 89:1217-1224, 1992; Hammer et al., J. Exp.
Med 175,1007-1012, 1992; Hammer et al., Cell 74, 197-201, 1993).
Each clone of SAg-lipoprotein contains a random 22-amino acid
sequence at the mature NH.sub.2 terminus of the gene VIII
(filamentous coat protein of the M13 bacteriophage). Recombinant
soluble mCD1 is engineered with a C-terminal hemagglutinin (HA)
tag, an epitope derived from the influenza HA protein. In this way,
the mCD1-phage complexes are identified with a HA tag specific
antibody. For immunizing usage, isolated receptor or antigen
presenting cells of various types which express CD1 or MHC class II
molecule pretreated with formaldehyde may be used for loading the
SAg-LPS or SAg-lipoprotein complexes. These APCs with bound
complexes are then used to immunize T cells or NKT cells for use in
adoptive immunotherapy of cancer (Examples 2, 7, 15, 16 18-23).
[0802] Incorporation of Exogenous Lipid e.g. Glycolipid,
Apolipoprotein or oxyLDL into Cells by Fusion with Liposomes
[0803] To prepare glycolipid, apolipoprotein, oxyLDL or Receptor
containing liposomes, 400 .mu.g of galabiosylceramide (Gb2)
globotriosylceramide (Gb3), globotetraosylceramide (Gb4),
galactosylceramide (GalCer),glucosylceramide (GlcCer) oxyLDL or
apolipoprotein are dried with 200 .mu.g of phosphatidylethanolamine
(PE) and 200 .mu.g of phosphatidylserine (PS) under a stream of
nitrogen gas. 400 .mu.l of sterile isotonic PBS, pH 7.4, is added
to the lipid, and the mixture is sonicated using a water bath
sonicator for 30 minutes. Liposome preparations are used
immediately.
[0804] To incorporate exogenous glycolipid into cells, tumor cells
in late logarithmic growth phase, sickled erythrocytes or vesicles
(1.6.times.10.sup.7 cells) are washed twice with PBS to remove
serum proteins and then suspended in serum-free RPMI 1640 medium at
4.times.10.sup.6 cells/ml. The cells are incubated in the presence
of the liposomes (or PBS for controls) prepared as above with
rotary shaking (100 rpm) at 37.degree. C. for 1 hr., washed twice
(5 min. 800.times.g) with PBS. and incubated for 18-24 hr at
37.degree. C. in the presence of medium supplemented with 10% fetal
calf serum prior to use.
EXAMPLE 6
Targeting SAg Nucleic Acids, Phage Display Systems and Polypeptides
to Tumor Sites
[0805] Parenterally administered nucleic acid is targeted to a
particular cell population as follows. Nucleic acid is attached to
a desialylated galactose moiety that targets asialo-orosomucoid
receptors in liver cells. Nucleic acid is attached to other ligands
such as transferrin and TAP-1 as well as antibodies to surface
structures such as the Le.sup.y receptor. These ligands and
antibodies bind to surface structures and are internalized. Thus,
the attached nucleic acid is delivered to a cell of choice.
[0806] Sickled Erythrocytes as Gene Carriers
[0807] Erythrocytes from patients with sickle cell anemia contain a
high percentage of SS hemoglobin which under conditions of
deoxygenation aggregate followed by the growth and alignment of
fibers transforming the cell into a classic sickle shape.
Retardation of the transit time of sickled erythrocytes results in
vaso-occlusion. SS red blood cells have an adherent surface and
attach more readily than normal cells to monolayers of cultured
tumor endothelial cells. Reticulocytes from patients with SS
disease have on their surface the integrin complex
.alpha..sub.4.quadrature..sub.1 which binds to both fibronectin and
VCAM-1, a molecule expressed on the surface of tumor endothelial
cells particularly after activation by inflammatory cytokines such
as TNF, interleukins and lipid-mediated agonists (prostacyclins).
Activated tumor endothelial cells are typically procoagulant.
Similar molecules are upregulated on the neovasculature of tumors.
In addition, upregulation of the adhesive and hemostatic properties
of tumor endothelial cells are induced by viruses, such as herpes
virus and Sendai virus. Sickled erythrocytes lack structural
malleability and aggregate in the small tortuous microvasculature
and sinusoids of tumors. In addition, the relative hypoxemia of the
interior of tumors induces aggregation of sickled erythrocytes in
tumor microvasculature. Hence, sickled erythrocytes with their
proclivity to aggregate and bind to the tumor endothelium are ideal
carriers of therapeutic genes to tumor cells.
[0808] Red blood cell mediated transfection is used to introduce
various nucleic acids into the sickled erythrocytes. The extremely
plastic structure of the erythrocyte and the ability to remove its
cytoplasmic contents and reseal the plasma membranes enable the
entrapment of different macromolecules within the so-called
hemoglobin free "ghost." Combining these ghosts and a fusogen such
as polyethylene glycol has permitted the introduction of a variety
of macromolecules into mammalian cells (Wiberg, F C et al., Nucleic
Acid Res. 11: 7287-7289 (1983); Wiberg, F C et al., Mol. Cell.
Biol. 6: 653-658 (1986); Wiberg, F C et al., Exp. Cell. Res. 173:
218-227 (1987). Both transient and stable expression of introduced
DNA are achieved by this method. Sickled cells can also be
transfected with a nucleic acid of choice e.g., apolipoproteins,
RGD in the nucleated prereticulocyte phase (e.g.proerythroblast or
normoblast stage) by methods given in Example 1. Sickled
erythrocytes transfected with nucleic acids encoding a SAg and/or
carbohydrate modifying enzyme to induce expression of the a Gal
epitope, apolipoproteins, RGD and/or any construct described
herein. Nucleic acids encoding additional polypeptides alone or
together with SAg as described in Tables I and II to including but
not limited to angiostatin, apolipoproteins, RGD, streptococcal or
staphylococcal hyaluronidase, chemokines, chemoattractants and
Staphylococcal protein A are transfected into and expressed by
sickled erythrocytes. These sicled cell transfectants are
administered parenterally and localize to tumor neovascular
endothelial sites where they induce a anti-tumor response. The
methods of in vivo transfection of tumor cells are given in the
Examples 17. Protocols for use of these transfectants in the
induction of anti-tumor immune response are described in Examples
14, 15, 16, 18-23, 31
[0809] Vesicles from Sickled Erythrocytes
[0810] Vesicles from sickled erythrocytes are shed from the parent
cells. The contain membrane phospholipids which are similar to the
parent cells but are depleted of spectrin. They also demonstrate
that a shortened Russell's viper venom clotting time by 55% to 70%
of control values and become more rigid under acid pH conditions.
Rigid sickle cell vesicles induce hypercoagulability, are unable to
pass through the splenic circulation from which they are rapidly
removed. Sickled erythrocytes are transfected in the nucleated
prereticulocyte phase with superantigen and apolipoprotein nucleic
acids as well as RGD nucleic acids. Nucleic acids encoding
additional polypeptides alone or together with SAg as described in
Tables I and II are transfected into and expressed by sickled
erythrocytes. Any of the the immature or mature sickled
erythrocytes and their shed vesicles expressing the molecules given
in Tables I and II are capable of localizing to tumor microvascular
sites where they bind to apolipoprotein receptors and induce an
anti-tumor effect. Because of their adhesive and hypercoagulable
properties as well as their rigid structure, these sickled cell
vesicles expressing superantigen and apolipoproteins are especially
useful for targeting the tumor microvascular endothelium and
producing a prothrombotic, inflammatory anti tumor effect. Sickled
erythrocytes and their vesicles are capable of acquiring oxyLDL via
fusion with oxyLDL containing liposomes as in Example 5. The
resulting sickle cell or liposome expresses oxyLDL alone or
together with SAg. Binding of oxyLDL to the SREC receptor on tumor
microvascular endothelial cells induces apoptosis and simultaneous
superantigen deposition produces a potent T cell anti-tumor
effect.
[0811] Vesicles are prepared and isolated as follows: Blood is
obtained from patients with homozygous sickle cell anaemia. The PCV
range is 20-30%, reticulocyte range is 8-27%, fetal hemoglobin
range is 25-13% and endogenous level of ISCs is 2-8%. Blood is
collected in heparin and the red cells are separated by
centrifugation and washed three times with 09% saline. Cells are
incubated at 37.degree. C. and 10% PCV in Krebs-Ringer solutions in
which the normal bicarbonate buffer is replaced by 20 mM Hepes-NaOH
buffer and which contains either 1 mM CaCl2 or 1 mM EGTA. All
solutions contain penicillin (200 u/mI) and streptomycin sulphate
(100 ug/mI). Control samples of normal erythrocytes are incubated
in parallel with the sickle cells. Incubations of 10 ml aliquots
are conducted in either 100% N2 or in room air for various periods
in a shaking water bath (100 oscillations per mm). N2 overlaying is
obtained by allowing specimens to equilibrate for 45 mm in a sealed
glove box (Gallenkamp) which was flushed with 100% N2. Residual
oxygen tension in the sealed box was less than 1 mmHg. The
percentage of irreversibly sickled cells is determined by counting.
1000 cells after oxygenation in room air for 30 mm and fixation in
buffered saline (130 mM Cl, 20 mM sodium phosphate, pH 74)
containing 2% glutaraldehyde. Cells whose length is greater than
twice the width and which possessed one or more pointed extremities
under oxygenated conditions are considered to be irreversibly
sickled. After various periods of incubation, cells are sedimented
at 500 g for 5 mm and microvesicles ) are isolated from the
supernatant solution by centrifugation at 15,000 g for 15 mm. The
microvesicles form a firm bright red pellet sometimes overlain by a
pink, flocculent pellet of ghosts (in those cases where lysis was
evident) which is removed by aspiration. Quantitation of
microvesicles is achieved by resuspension of the red pellet in 1 ml
of 05% Triton X100 followed by measurement of the optical density
of the clear solution at 550 nm. Optical density measurements at
550 nm give results that are relatively the same as measurements of
phospholipid and cholesterol content in the microvesicles. Cell
lysis is determined by measurement of the optical density at 550 nm
of the clear supernatant solution remaining after sedimentation of
the microvesicles. Larger samples of microvesicles for biochemical
and morphological analysis are prepared from both sickle and normal
cells following incubation of up to 100 ml of cell suspension at
37.degree. C. for 24 h in the absence or presence of Ca.sup.2+.
Ghosts are prepared from sickle cells after various periods of
incubation. The cells are lysed and the ghosts washed in 10 mM Tris
HCl buffer, pH 73, containing 02 mM EGTA.
[0812] These vesicles are useful as a preventative or therapeutic
vaccine as in Examples 15, 16, 18-23, 36.
[0813] Phage Displayed SAgs
[0814] Phages displaying or free tumor homing peptides ligands such
as the tripeptides Arg-Gly-Asp and Asn-Gly-Arg which tripeptides
bind to the integrins .alpha..sub.v.quadrature..sub.3 and
.alpha..sub.v.quadrature..s- ub.5, respectively, that are located
on tumor microvasculature, are conjugated to (1) a SAg peptide, (2)
naked DNA encoding a SAg peptide or (3) phage displaying a SAg
peptide. These constructs are prepared as in Examples 3 and 5 and
are further described in Jackson R H. et al., In: Protein
Engineering: A Practical Approach, A. R. Rees et al. (eds), pp.
277-301, Oxford Press, London, 1992. Similarly tumor cells or
sickled cells transfected with and expressing SAgs and other
molecules given in Tables I and II are also transfected with
nucleic acids encoding RGD which facilitates their localization to
tumor microvasculature. These conjugates or transfectants are
administered i.v. and localize to the tripeptides' integrin
receptors situated on the tumor microvasculature. Neovascular
endothelial cells to which these constructs have been targeted are
transfected by SAg-encoding DNA so that they express or secrete
SAgs locally. This induces potent local T cell activation and
engender a tumoricidal immune response. Protocols for use of such
conjugates, i.e., (1) naked SAg DNA conjugated to the
integrin-binding peptides or (2) naked SAg DNA conjugated to phage
that display the integrin-binding peptides, and transfectants in
the induction of anti-tumor immune response are described in
Examples 7, 15, 16, 18-23, 31
[0815] Nucleic Acid and Nucleoprotein SAg Mimics
[0816] SAgs are often incapable of homing to tumor cells expressing
SAg receptors in vivo because of the existence of naturally
occurring SAg-specific antibodies and the affinity of SAgs for
class II receptors on a wide variety of cells. To solve this
problem, DNA chromatography is used to identify oligonucleotides
instead of SAg peptides that bind to SAg receptors which are
naturally expressed on tumor cells. The SAg receptor-specific
oligonucleotides are conjugated to a SAg peptide with a functional
TCR or NKT cell binding site. Oligonucleotides are also substituted
for peptides in the SAg molecule which bind to MHC class receptors
and naturally occurring SAg-specific antibodies. These conjugates
are used to target SAgs to tumor cells in vivo that either
endogenously express a SAg receptor or are pre-transfected with
nucleic acid encoding a SAg receptor. These peptide-oligonucleotide
complexes are prepared by chemical conjugation methods well known
in the art. Such receptor specific oligonucleotides may have
several fold greater affinity for the SAg receptor compared to the
native SAg. While these peptide-oligonucleotide complexes are used
predominantly in vivo to target tumor cells bearing SAg receptors,
they are also used ex vivo to stimulate T cells to become tumor
specific effector cell which are useful for adoptive immunotherapy
of cancer (Example 7, 15, 16, 18-23).
[0817] In appropriate recombinant bacteria, nucleic acids encoding
the SAg receptor binding site expressed on tumor cells are fused to
nucleic acids encoding SAgs. The resultant SAg polypeptide
construct consists of the amino acid sequence of a SAg and its SAg
receptor binding site (which is overexpressed if desired). The SAg
with its expressed or overexpressed SAg binding site is useful in
targeting tumor cells expressing SAg receptors after administration
to a tumor-bearing host. In a related construct, the nucleic acid
encoding a SAg with an overexpressed SAg receptor specific binding
site is fused to the nucleic acid encoding a native or chimeric SAg
with its binding site for naturally occurring antibodies and its
MHC class II binding site removed, mutated or replaced by peptides
from another SAg against which there are no known naturally
occurring antibodies. The TCR binding and activating region of this
molecule is conserved. This resulting SAg polypeptide molecule
binds to SAg receptors on tumor cells but also retains its capacity
to activate the TCR. It is administered parenterally or orally to a
tumor bearing host (orally to a colon carcinoma patient) and will
effectively target tumor cells with SAg receptors (such as colon
carcinoma cells) without being diverted by naturally occurring
antibodies or class II receptor bearing cells present in whole
blood. As such, this construct is useful in producing an anti-tumor
effect when administered to a tumor bearing host as in Example
18-23).
[0818] Using DNA chromatography techniques, nucleic acid specific
for SAg receptors on tumor cells are identified. These nucleotides
are conjugated to SAg polypeptides which are optionally devoid of
class II binding sites and naturally occurring antibody binding
sites but with conserved TCR binding and activating sites. These
constructs are useful in targeting tumor cells bearing SAg
receptors in vivo while retaining SAg amino acid sequences specific
for the TCR which are capable of producing a tumor specific T cell
population effective in adoptive immunotherapy of cancer. The
selected amino acid sequences are deleted, replaced or added to the
SAg molecules using molecular cloning and site directed mutagenesis
techniques well established in the art.
EXAMPLE 7
General Ex Vivo Immunization Methods to Produce Tumor Specific
Effector Cells for Adoptive Immunotherapy of Cancer
[0819] Several days (3 to 60 days) after intratumoral immunization
with a nucleic acid construct described herein, tumor draining
lymph nodes are removed and placed in tissue culture. These cells
are further expanded in vitro with SAg polypeptide for 2-4 days
and/or IL-2 in vitro for a total of 3-15 days. These T cells are
then harvested and reinfused into the host. T effector cells
produced after in vivo immunization with nucleic acid encoding a
SAg are expected to display potent anti-tumor activity.
[0820] Cells transfected ex vivo, are administered to the host
wherein they activate lymphocytes in a number of ways. In one
embodiment, the initial step involves in vivo immunization of hosts
using various transfectants and constructs as described in Table
II. The transfected cells are introduced into the host tumor, a
nearby region, subcutaneously in close proximity to regional lymph
nodes, or the lymph nodes draining the tumor. Transfected cells
types, constructs and agents used in this step are given in Table
II. Tumor cells are irradiated or treated with mitomycin C after
transfection with nucleic acid encoding a SAg and/or another
polypeptide so that polypeptides are expressed and fixed on the
cell surface and the tumor cells do not proliferate when
administered to the host. In another embodiment, the initial step
involves in vivo immunization of the tumor bearing host with
transfectants, constructs and cells as described in Table III.
These agents are administered in close proximity to the regional
lymph nodes with or without a bacterial adjuvant such as bacillus
Calmette-Guerin (BCG) or Corynebacterium parvum. The lymph node
cells are harvested 10 days later and tissue cultured for further
in vitro immunization/stimulation with SAg or SAg expressing cells
that, optionally, coexpress a tumor associated antigen,
costimulatory molecule or antigen presenting molecule.
[0821] Cryopreserved autologous tumor cells for subsequent tumor
vaccination and culture are obtained from patients. Fresh resected
tumors are dissociated under sterile conditions into single cell
suspensions by mechanically mincing tumor into 5-mm3 pieces
followed by enzymatic digestion. Generally, 1 gm of tumor is
digested in a minimum volume of 40 ml of an enzyme mixture
consisting of Hank's balanced salt solution (HBSS) containing 2.5
units/ml of hyaluronidase type V, 0.5 mg/ml of collagenase type IV,
and 0.05 mg/ml of deoxyribonuclease type I (all commercially
available from Sigma Chemical Co.; St. Louis, Mo.). The digestion
is performed at room temperature with constant stirring in a
trypsinizing flask for 2 to 6 hours.
[0822] The resulting cell suspension is filtered through a layer of
No. 100 nylon mesh (Nytek: TETKO, Inc.; Briarcliff Manor, N.Y.) and
cryopreserved in 90% human AB serum (GIBCO; Grand Island, N.Y.)
plus 10% dimethyl sulfoxide (Sigma) at -178.degree. C. in liquid
nitrogen for subsequent immunization and culture.
[0823] Tumor cells are used in native form, with dinitrophenyl
(DNP) or other haptens conjugated to them and then irradiated or
treated with cytostatic drugs prior to use. Optionally, the tumor
cells are transfected with nucleic acid encoding a SAg, and/or
tumor associated antigen, and/or antigen presenting molecule,
and/or costimulatory molecule, and/or adhesion molecule, and/or
xenogeneic antigen, and/or carbohydrate modifying enzyme. The
nucleic acid is introduced by methods given previously. The cells
are then irradiated to a dose of 25 Gy or treated or with
cytostatic drugs, viable cells counted by trypan blue exclusion and
the cells resuspended so that a volume of 0.2 to 0.4 ml contains
1-2.times.10.sup.7 with or without .sup.7 colony forming units of
fresh frozen TICE BCG.
[0824] Patients are vaccinated intradermally (i.d.) at two sites
approximately 10 cm from superficial inguinal lymph nodes. If
necessary, axillary lymph nodes are used. Lymph node regions with
previous dissections or clinical evidence of tumor are avoided.
[0825] Accessory cells including DCs, fibroblasts, endothelial
cells, monocytes, and macrophages are used after transfection with
nucleic acid encoding a tumor associated antigen, and/or SAg,
and/or xenogeneic antigen, and/or carbohydrate modifying enzyme. If
desired, these accessory cells or APCs are transfected with
recombinant viral vectors containing nucleic acid the encode a SAg,
and/or tumor associated antigen, and/or costimulatory molecule,
and/or antigen presenting molecule, and/or costimulatory molecule,
and/or adhesion molecule, and/or xenogeneic antigen. These cells
need not be irradiated prior to administration. These cells are
administered using the same cell numbers given above with or
without BCG.
[0826] Alternatively, patients are vaccinated with various tumor
associated antigens and other agents as described in Table II. The
agents are bound to MHC class I, class II or CD1 receptors or to
cells expressing these receptors. They are also given alone in
doses ranging from 0.1 to 10 mg emulsified in various adjuvants
well described in the art. A vaccination course includes up to 6
inoculations of the above agents at 1-3 week intervals.
10TABLE III Single Step in vivo Immunization of Tumor Bearing Hosts
with SAg Nucleic Acids Alone, Combined with Nucleic Acid Encoding
Other Peptides and SAg Nucleic acids Conjugated to Polypeptides or
Liposomes I. Intratumoral injection of nucleic acid 1. Direct
injection of SAg nucleic acids into tumor. 2. Direct i.v. or
intra-arterial injection of SAg nucleic acids into tumor
microvasculature. a. SAg nucleic acids conjugated to a polypeptide
ligand specific for a tumor cell, tumor stromal cell, tumor
microvascular or neovascular cell receptors b. Nucleic acid within
liposomes containing a monoclonal antibody. 3. Recombinant viruses
containing nucleic acid. a. Inactivate the virus in the host with
gancyclovir II. After in vivo immunization (3-14 days), harvest
regional lymph nodes and place in tissue culture. III. Activate and
expand lymphocytes. 1. Treat with SAg for 2 days. 2. Treat with
IL-2 for 3 days. IV. Inject tumor specific effector T cells into
host.
[0827] Regional lymph node cells draining tumor sites, lymphoid
cells obtained after the above priming, peripheral blood T cells,
and tumor infiltrating lymphocytes (TILs) are suitable sources of T
cells that are activated to function as effector cells (T cells
activated against the cancer cells). T cells are obtained from
tumor infiltrating lymphocytes either before or after tumor vaccine
immunization in vivo by the methods described herein.
[0828] Approximately 10 days after in vivo immunization, an
enlarged draining lymph node is removed and cultured. An immunized
lymph node used herein is exemplary. A single cell suspension of
lymph node cells is obtained by mechanical dissociation. Briefly,
lymph nodes are minced into 2 mm.sup.3 pieces in cold HBSS with a
scalpel. The fragments are then pressed through a stainless steel
mesh with a glass syringe plunger. The resultant cell suspension is
filtered through nylon mesh and washed in HBSS. Cultures are
established in 300-ml culture bags (Livecell Flasks; Fenwal,
Deerfield, Ill.) with 200 to 250 ml of culture medium (CM: RPMI
1640 with 10% human AB serum, 2 mM fresh L-glutamine, 1 mM sodium
pyruvate, 100 mg/ml of streptomycin, and 50 mg/ml of gentamicin all
from GIBCO; Grand Island, N.Y.), containing 1-2.times.10.sup.5
lymph node cells/ml and 1-4.times.10.sup.5 irradiated (60 Gy) tumor
cells/ml. Optionally, the lymph node cells are further separated
into populations CD4+ CD8+ T cells, NKT cells and/+ T cells. Some
SAg complexes are presented bound to MHC class II receptors and
some such as SAg-LPS complexes or SAg-glycosylceramide complexes
are presented bound to CD1 receptors either free or on APC cell
surfaces.
[0829] After 24 hours, various SAgs or SAg transfected cell types
(STCT) given in Table III are added in doses of 10.sup.5 to 10
.sup.7 cells for 8-72 hours. The cells are harvested and used for
in vivo administration at this point. Specific cell populations are
selected such as those having a particular TCR V profile or
expressing CD44 using magnetic beads or other separation techniques
well known in the art. Optionally, the SAg activated T cells are
expanded. Recombinant IL-2 (Cetus, Emeryville, Calif.: provided by
Cancer Treatment Evaluation Program, National Cancer Institute) is
added at the initiation of the cultures at a concentration of 600
IU/ml (1 Cetus unit=6 IU of IL-2). Culture bags are incubated at
37.degree. C. in humidified 5% CO.sub.2. Cell counts from aliquots
obtained from random bags are followed to observe lymphoid cell
proliferation. Lymph node cells are harvested when cells reached
maximal density, usually after a total of 5-7 days in culture
followed by IL-2 at 24 IU/ml for 3 days. These intervals are
shortened depending on the cell viability, CD44 expression, or V
expression or other conditions that adversely affect survival,
viability, or therapeutic success.
11TABLE IV Two Step in vivo/in vitro Methods and Agents for
Producing Tumor Specific Effector T cells A. In vivo immunization
with SAg transfected tumor cells, accessory cells, or virus. 1.
Tumor cells transfected with: a. Nucleic acid encoding a SAg b.
Nucleic acid encoding a tumor associated antigen c. Nucleic acid
encoding a carbohydrate modifying enzyme 2. Accessory cells
transfected with: a. Nucleic acid encoding a SAg b. Nucleic acid
encoding a tumor associated antigen c. Nucleic acid encoding a
carbohydrate modifying enzyme d. Nucleic acid encoding an MHC
molecule 3. Recombinant viruses containing: a. Nucleic acid
encoding a SAg b. Nucleic acid encoding a tumor associated antigen
c. Nucleic acid encoding a carbohydrate modifying enzyme d. Nucleic
acid encoding an MHC molecule B. *In vivo immunization with: 1.
Irradiated tumor cells. 2. Tumor associated antigens. 3. Irradiated
tumor cells conjugated with DNP. 4. Tumor associated antigen/SAg
conjugate or fusion polypeptides. 5. Naked nucleic or plasmid or
phage displayed nucleic acid encoding a SAg or attached to
liposomes or albumin microspheres. 6. Naked or plasmid or phage
displayed nucleic acid encoding a SAg/tumor associated antigen
polypeptide conjugate. 7. Tumor cells or accessory cells
transfected with nucleic acids encoding structures given in Table I
Group IA, (pages 5 and 6) GM-CSF, IL-2 and other cytokines. (Berns,
AJM. et al., Human Gene Therapy 6: 347-368 (1995). 8. Tumor cells
transfected with nucleic acids encoding chemokines (T and NKT cell
chemoattractants) and granulocyte chemoattractants (C3a, C5a, MAP).
9. SAg naked DNA fused or in mixture with DNA or structures
non-transfected given in Table 1 IA B and C (pages 5 and 6) C.
Lymphoid cells from draining lymph nodes are harvested 3-21 days
later and placed in tissue culture for further stimulation. They
are divided into T cell, NKT cell and/T cell populations.
Alternatively, T cells, NKT cells and/T cells are obtained from the
peripheral blood and also placed in tissue culture for further
stimulation. D. In vitro stimulation of T or NKT cell populations
to produce tumor specific effector cells as described in "C" is
carried out with STCT (SAg transfected cell types) or with
constructs alone or applied to appropriate receptors on APCs. MHC
class II APCs are used for presentation of SAg constructs. APCs
expressing mannose, or CD1 or CD14 receptors are used for
presentation of glycosylated SAg, SAg-LPS complexes,
SAg-peptidoglycan complexes or SAg-glycosylceramide complexes.
Isolated MHC class I, class II, mannose, CD1 or CD14 receptors
immobilized on solid supports such as polystyrene plates may be
used in place of APCs methods well known in the art. In this form
they bind corresponding ligands in the constructs given above for
presentation to T cells or NKT cells. STCT include tumor cells,
accessory cells, antigen presenting cells, prokaryotic cells,
autologous, allogeneic or xenogeneic cells lines and viruses.
Accessory cells include the following: DCs, monocytes, macrophages,
endothelial cells, fibroblasts and NK cells. These cells are
transfected with nucleic acids encoding SAgs in combination with
the nucleic acids given below. These nucleic acids may include the
ISS sequence; SAg genes may be used with or without the ISS
sequence. *In vivo immunization may be by various routes, e.g.,,
i.d., i.m., or as organoids or in adjuvants proximate to regional
lymph nodes e.g., inguinal lymph nodes. For tumor peptide genes an
ISS is useful as is cotransfection of MHC class I genes. For SAg
and tumor associated antigen genes, the ISS is useful.
[0830] Antibodies or Fab fragments having specificity for CTLA-4
are added with or without IL-2 at any point to expand the T cell
population and avert apoptosis. The cells are washed once at the
end of STCT incubation and before the addition of IL-2 and/or
anti-CTLA-4 antibodies.
12TABLE V Ex vivo Modes of Antigen Presentation to T Cells or NKT
Cells to Produce Tumor Specific Effector Cells A. Tumor Cells,
Accessory Cells, Accessory Cell/Tumor Cell Hybrids, e.g., DC/Tumor
Cell) Transfected with: 1. SAg-encoding nucleic acid 2.
SAg-encoding nucleic acid and tumor associated antigen nucleic
acids (to include arrays of tumor associated epitopes) 3. SAg
nucleic acid and MHC class I or II nucleic acids. 4. SAg-encoding
nucleic acid and co-stimulatory nucleic acids. 5. SAg-encoding
nucleic acid and adhesion molecule nucleic acids. 6. SAg-encoding
nucleic acid and .alpha.-galactosyltransferase synthetic nucleic
acids or xenogeneic species specific nucleic acids. 7. SAg-encoding
nucleic acid and chemoattractant nucleic acids 8. SAg-encoding
nucleic acid and glycosylceramide synthesis nucleic acids 9. SAg
nucleic acid and lipopolysaccharide synthesis nucleic acids 10.
SAg-encoding nucleic acid and microbial lipoprotein or
polysaccharide or peptidoglycan membrane or capsular synthesis
nucleic acids 11. SAg-encoding nucleic acid and SAg receptor
nucleic acids 12. SAg-encoding nucleic acid and CD1 receptor
synthesis nucleic acids 13. SAg-encoding nucleic acid and CD14
receptor synthesis nucleic acids 14. SAg-encoding nucleic acid and
SAg promoter and/or global regulator nucleic acids 15. SAg-encoding
nucleic acid and oncogene and/or transcription factor nucleic acids
16. SAg-encoding nucleic acid and angiogenesis factor or receptor
nucleic acids 17. SAg-encoding nucleic acid and growth factor
receptor nucleic acids18. SAg- encoding nucleic acid and cell cycle
protein nucleic acids 19. SAg-encoding nucleic acid and heat shock
protein nucleic acids 20. SAg-encoding nucleic acid and chemokine
nucleic acids 21. SAg-encoding nucleic acid and cytokine nucleic
acids 22. SAg-encoding nucleic acid and tumor suppressor nucleic
acids 23. SAg-encoding nucleic acid and antigen processing and
trafficking nucleic acids B. Additional in vitro Stimulatory Agents
(preferred receptor) 1. Tumor peptides (Class I or Class II) 2.
Tumor peptide-SAg conjugates or fusion proteins (Class I or Class
II). 3. Lipopolysaccharide-SAg conjugate (Class II or CD14) a.
arabinose b. mycolic acid c. teichoic acid d. muramic acid
(Staphylococcal cell wall glycoprotein) e. mannan proteoglycans f.
chondroitin-sulfate 4. Glycosylated SAgs. (Class II or mannose) 5.
SAg-glycosylceramide conjugates (class II or CD1) a. GalCer
conjugate b. Gal conjugate 6. SAg-proteosome conjugates 7. SAg or
glycosylated SAg or SAg-glycosylceramide conjugates or SAg-
lipopolysaccharide or SAg-peptidoglycan conjugates coupled to
proteosomes 8. SAg or glycosylated SAg or SAg-glycosylceramide
conjugates or SAg- lipopolysaccharide conjugates or
SAg-peptidoglycan conjugates expressed on or coupled to liposomes
C. STCT or SAg-tumor peptide conjugates are incubated with in vivo
immunized T cells or NKT cells for 2-4 days and then with IL-2 for
2-5 days. D. The tumor specific effector cells are then harvested
and injected in doses of 10.sup.10-10.sup.12 every 3-7 days for 1-6
treatments. E. Viruses are transfected into tumor cells, accessory
cells, antigen presenting cells, allogeneic or xenogeneic cells.
They are pre-programmed with DNA for SAgs alone or in combination
with genes given in D. They may also utilize the host genome to
produce a new gene product as for example the
host-galactosyltransferase. Viruses may include the following: 1.
Adenoviruses. 2. Vaccinia virus. 3. Equine encephalitis virus. 4.
Influenza virus. F. In an additional method, tumor associated
antigens are bound to MHC class I positive cells and used to
activate T cells. SAg-lipopolysaccharide complexes and
SAg-glycosylceramide complexes are bound to CD1 or class II
receptors on APCs. In addition, SAg-lipopolysaccharide complexes or
SAg-glycosylceramide complexes are presented bound to class II
positive APCs. Alternatively, unbound tumor associated antigen/SAg
conjugates or fusion products are added at a 0.1 to 200 .mu.g/ml
dose for 2 days. This is followed by STCT incubation or by native
or mutant SAg treatment for 2 days.
[0831] For comparative analysis, peripheral blood lymphocytes (PBL)
are obtained from patients the same day as the lymph node harvest.
PBL are isolated by Ficoll-Hypaque gradients from 60 ml of
heparinized blood samples. The PBL are placed in culture utilizing
24-well tissue culture plates at the same cell density as lymph
node cells. PBL are harvested at maximal cell density and
characterized by phenotype analysis and cytotoxicity.
[0832] T cells, NKT cells, and NK cells are isolated by well known
methods described in the art (Colligan, J E et al., eds, Current
Protocols in Immunology, John Wiley, New York, 1996).
[0833] PBL are separated by Ficoll/hypaque sedimentation. Cells are
recovered from the interface, washed in PBS, and pelleted.
Peripheral blood mononuclear cells enriched for MHC class I
molecules or MHC class II molecules are used to bind tumor
associated antigens or tumor associated antigen/SAg conjugates for
in vitro or in vivo immunization.
[0834] Cryopreserved groups of autologous PBMCs are thawed, washed
twice in PBS, resuspended at 5 to 8.times.10.sup.6 cells/ml in CM
and pulsed with 1 mg/ml peptide in 15 ml conical tubes (5 ml/tube)
for 3 hours at 37.degree. C. These PBMC stimulators are then
irradiated at 3000 rads, washed once in PBS, and added to the
responder cells at responder stimulator ratios ranging between 1:3
and 1:19.
[0835] Tumor infiltrating lymphocytes are isolated from fresh
surgical biopsies. Briefly, tumor tissues are minced into 1-mm3
pieces that are then dissociated into single cell suspensions in
Dulbecco's modified minimum essential medium (Gibco; Grand Island,
N.Y.) supplemented with 10% heat-inactivated human AB serum (NABI,
Miami, Fla.), 0.05% collagenase (type 4; Sigma Chemical Co., St.
Louis, Mo.), and 0.002% DNase (type 1; Sigma) on a magnetic stirrer
for 1 hour. Subsequently, the tissue digests are washed and passed
through a nylon mesh and tumor infiltrating lymphocytes and tumor
cells are separated on discontinuous (75%/100%) Ficoll/Hypaque
gradients.
[0836] Lymph node lymphocytes are obtained by mechanical
dissociation of tissues, followed by washing in medium and
centrifugation on Ficoll/Hypaque gradient [Newell K A, et al.,
Proc. Natl. Acad. Sci. USA, 88:1074 (1991)]. Cryopreserved
suspensions of tumor cells/tumor infiltrating lymphocytes are
defrosted, washed, and separated by allowing tumor cells to adhere
to the surface of plastic wells. The recovered non-adherent tumor
infiltrating lymphocytes are transferred to 6-well plates and
cultured in serum-free AJM-V medium (Gibco) supplemented with 6,000
U/ml of IL-2 (Cetus-Chiron, Emeryville, Calif.) for 8 days. Tumor
cells are cultured as adherent monolayers in Dulbecco's modified
Eagle's medium (DMEM, Gibco) supplemented with 10% (v/v) of fetal
calf serum. Any activated lymphocytes can be used in the method
given above. In a preferred embodiment, lymphocytes expressing a
predominant TCR V phenotype in tumor tissue or peripheral blood
before or after treatment are isolated and expanded by standard
procedures.
[0837] Antibodies to various TCR V.quadrature. subsets are
immobilized on inert solid supports and incubated with blood cells
and/or tissue cells to include bone marrow and peripheral blood or
lymphoid tissue cells and tumor infiltrating lymphocytes. The bound
T cells are eluted with various buffers. Suitable biocompatible
inert supports include polystyrene, polyacrylamide, nylon, silica,
and charcoal as well as others known in the art. The supports are
derivatized for covalent binding of antibodies with agents well
known in the art including heterobifunctional compounds,
carbodiimide, and glutaraldehyde. The enriched population of
V-bearing T cells is then used for in vitro immunization with a SAg
in native or mutant form capable of activating the dominant TCR V
bearing lymphocytes. IL-2 is used to further expand the cell
population as described above.
[0838] Effector lymphocytes obtained after in vivo sensitization
are stimulated in vitro with tumor associated antigens bound to
irradiated PBMC (which act as stimulator cells) for 8-72 hours.
DCs, macrophages, or other class I-bearing cells are used to
present the tumor associated antigens. The T cells are then
analyzed for TCR V and/or CD44 expression. An STCT expressing a SAg
is then added to the culture (1 picogram to 10 microgram). If a
given V predominance is noted after antigen stimulation, then an
STCT or SAg known for its ability to specifically stimulate that V
subset is selected for use in activation. Culture proceeds for
18-72 hours. The TCR V and CD44 profile of stimulated T cells are
then rechecked. IL-2 (12-25 IU) and/or anti-CTLA-4 antibodies are
added for an additional 8-72 hours after which the cells are
harvested for use. The optimal timing of STCT introduction after
tumor antigen stimulation is between 3 and 14 days.
[0839] Antigen-presenting cells (APCs) of all kinds such as DCs, B
cells or macrophages with appropriate MHC class II molecule binding
sites for soluble SAgs are used or the SAgs are presented alone or
in immobilized form without APCs. Optionally, STCTs are used
without APCs. Before IL-2 administration, effector cells are
re-stimulated weekly by washing and replating in 24 well plates at
a concentration of 2.5.times.10.sup.5 cells/ml in CM. This is
continued for 3-10 cycles until enough cells are available for IL-2
expansion. T cells are cloned 7 days after the several cycles of
stimulation in 96-well round bottom plates at 0.3 cells/well with
5.times.10.sup.4 stimulator tumor antigen-PBMC, SAg, or STCT and
25-50 U recombinant IL-2 in a volume of 200 ml.
[0840] For long term growth, clones are transferred to 24 well
plates and 1.times.10.sup.6 cells/well and stimulated weekly with
SAg or STCT plus optimally 5.times.10.sup.5 tumor associated
antigen-PBMC and 25-50 U/ml of IL-2. After clones grow to greater
than 2.times.10.sup.6 cells, the clones are maintained by culturing
with STCT only for 48 hours, washing to remove STCT, and replating
in fresh media for 5-7 days with 25-50 U/ml IL-2.
[0841] The initial incubation is with the selected tumor associated
antigen such as MART-1 for 1-3 days with the latter reagents
followed by V profiling and re-stimulation with SAg by methods
given above. The MART-1 is presented attached to HLA-A1.sup.+ cells
of PBMC. Cytotoxic activity is tested after the first and/or second
rounds of sequential stimulation with tumor associated antigen and
SAg given below.
[0842] The tumor-specific effector T cell population is
immortalized as tumor specific T cell hybridomas. These hybridomas
are generated by immunization in vitro of human T cells as
described herein. The expanded T cells are then fused to a thymoma
and cloned by limiting dilution or other methods well known in the
art.
[0843] Cells are cultured in complete tumor medium composed of
Eagle's minimal essential medium supplemented with 10 mM
2-mercaptoethanol, 10% fetal calf serum, 10% Mishell-Dutton
Nutrient cocktail, 100 U/ml penicillin G, and 200 mg/ml
streptomycin sulfate. Other well known culture media can also be
used.
[0844] For SAg immunization in vitro, various antigen presenting
cells are used including MHC class II-positive T cells as well as
those expressing CD1. Purified MHC class II or CD1 molecules alone
or immobilized are substituted for APCs in some cases. Moreover, T
cells are activated by some SAgs without APCs when presented to T
cells in immobilized form or in the presence of various cytokines
such as IL-1, IL-2, IL-4, or IL-6 or xenogeneic antigens. Various
costimulants such as B7-1 and B7-2, adhesion molecules such as
ICAM-1 and VCAM-1, or GalCer are used together with SAgs and MHC
class II positive APCs or immobilized MHC class II peptides to
augment the T cell or NKT cell response.
[0845] Tumor associated antigen immunization is also involved in
the binding of peptides to MHC class I bearing APCs of multiple
origins. Various cytokines including, but not limited to, IL-1,
IL-2, IL-4, IL-12, or LPS are used in vitro or in vivo to expand
the antigen specific clone of T cells and avert the development of
T cell anergy.
[0846] Specialized Forms of Tumor Specific Effector Cells and
Hybridomas
[0847] Tumor specific T or NKT cells with TCR V and/or CD44
selectivity are produced by transfecting uncommitted stem cells
with nucleic acids encoding particular TCR V chains. Likewise, a T
cell clone overexpressing CD44 is produced by transfecting T cells
with nucleic acids encoding CD44. A hybridoma expressing a tumor
associated antigen with a dominant TCR V phenotype or CD44
expression is produced in this way. Such a T cell hybridoma or cell
line is stimulated exogenously by a SAg or a SAg mutant with a TCR
V or CD44 selectivity corresponding to that expressed predominantly
by the T cell hybridoma. The result is a clone of tumor specific T
cells capable of being expanded by exposure to SAg in vitro or in
vivo.
[0848] CD44 expression is induced in a T cell, NKT cell or TCR/T
cell population after activation in vitro or in vivo with SAgs
alone or together with any of the T or NKT cell stimulating
constructs and methods described herein. The in vivo and in vitro
activation steps and immunization protocols are given in Examples
7, 15, 16. 18-23. The CD44 positive T cell population exhibits
upregulated primary adhesion properties and is capable of
effectively trafficking and homing to tumor cells in vivo and
particularly to sites of SAg (in native or nucleic acid form)
injection i.e. tumor Nucleic acids encoding CD44 or a carbohydrate
modifying agent will induce CD44 expression on the T cell surface.
A preferred in vivo method of use involves intratumoral injection
of SAg DNA into tumor sites which induces expression of CD44 on T
cells resulting in enhanced T cell trafficking to the site of SAg
administration.
[0849] T cells are genetically engineered to overexpress CD44 after
SAg stimulation. This is accomplished by transfection of T cells or
NKT cells with nucleic acid encoding CD44 as well as nucleic acids
encoding glycosyltransferases. This results in the overexpression
of CD44 upregulation of the adhesive properties of CD44. Such CD44
enriched clones are harvested after SAg stimulation, enriched, and
administered for adoptive immunotherapy of cancer (Examples 6, 7,
15, 16, 18-23).
[0850] Additionally, T or NKT cell clones or hybridomas are
produced which express a chimeric TCR consisting of an invariant
chain with specificity for GalCer or and a chain that binds a SAg.
The V region which is specific for the SAg is overexpressed on the
TCR permitting greater responsiveness to exogenous SAg. This
chimeric TCR recognizes and is stimulated by an exogenous SAg with
a TCR V selectivity corresponding to the predominant TCR V
phenotype of the T or NKT cell. Such T or NKT cell lines are cloned
and hybridomas produced by methods well known in the art.(Current
Protocols in Immunology, pp. 7.21.-7.21.9 John Wiley, New York,
1991) The expanded clone of tumor specific T cells produced in this
way is useful for adoptive immunotherapy of cancer by methods given
in Examples 7. 15, 16, 18-23.
[0851] T cell clones are produced due to asynchronous TCR V locus
rearrangements at low but significant frequency in which both TCR V
segments are part of two functional TCRs. Such clones are produced
from uncommitted stem cells in which nucleic acid encoding two
chains are transfected, one having specificity for a tumor
associated antigen and another having SAg specificity. Hence, a
clone of T cells with dual V TCR expression is produced which is
capable of reacting with a tumor specific and a SAg. This clone is
expanded by binding either or both ligands. These expanded clones
consisting of tumor specific effector T cells are used for adoptive
immunotherapy of cancer by protocols given in Examples 7, 15, 16,
18-23).
[0852] T cells or NKT cells clones or hybridomas expressing TCR
V.alpha. and V.quadrature. chains with specificity for GalCer and
SAg, respectively, are produced by fusion of NKT cell DNA encoding
the GalCer and SAg receptors with DNA from an appropriate thymoma.
This GalCer receptor and SAg receptors are expressed on the and
chain of the TCR, respectively. Upon exposure to GalCer or SAg,
these cells are further activated to express CD44 which enhances
their homing and adhesive properties. NKT or T cells expressing
high levels of IFN, GM-CSF, and IL-10 are selected and cloned. The
clone of T cells producing IFN and expressing GalCer, SAg and CD44
is then expanded and immortalized. With its properties of tumor
recognition, SAg and glycosylceramide activation, IFN production
and effective in vivo trafficking, this T or NKT effector cell
population is preferred for adoptive immunotherapy of cancer by
methods given in Examples 7, 15, 16, 18-23).
[0853] Additional measures to avert apoptosis and augment
proliferation capacity in SAg activated T cells include the use of
anti-CD28 antibodies and inhibition of CTLA-4 on T cells. CTLA-4 on
T cells is blocked by specific antibodies or fragments.
Alternatively, a T cell clone is used in which CTLA-4 is
genetically deleted. When stimulated by SAg, these cells
proliferate to a greater extent compared to SAg alone. Cell
populations in which CTLA-4 is deleted or blocked are selected to
have a predominant V bearing lymphocyte population that is
activated after in vivo or ex vivo tumor associated antigen
stimulation. After CTLA-4 deletion or blockade, the appropriate SAg
with V selectivity is chosen to expand this population. To avert
uncontrolled proliferation in vivo, the thymidine kinase gene of
the HSV is co-transfected to enable elimination of these cells in
vivo if desired.
[0854] Measures to produce an effector T cell population with an
overexpressed TCR V and/or V chains specific for a given SAg
involve the transfection of nucleic acids encoding the desired V or
V regions into T cells as in Example 1. To lower the activation
threshold of the T cell or NKT cells to SAg or SAg-tumor
peptide-MHC or CD1, the T cell or NKT cells are transfected with
nucleic acid encoding a tyrosine kinase or other signal
transduction initiating molecules which can dimerize in the
membrane with the TCR tyrosine kinases thereby lowering the
threshold for activating the signal transduction pathway. The
deletion of the signal transduction inhibitory region of the TCR to
produce sustained signal transduction is done by site directed
mutagenesis as in Example 24.
EXAMPLE 8
Prevention of Anergy in T or NKT Tumor Specific Effector Cells
[0855] The SAg stimulated tumor specific effector T cells used for
adoptive immunotherapy of cancer may not function when infused
unless measures are taken to prevent T cell anergy or
activation-induced cell death (AICD) by interdicting the Fas
mediated pathway. The Fas ligand (FasL) has been identified as a
type II transmembrane polypeptide of the TNF family. These two
related receptor-ligand systems signal apoptosis through closely
related but distinct pathways. T cell phenotypes that have
diminished expression of Fas or FasL show delayed anergy induction
and shortened periods of non-reactivity compared to Fas-expressing
cells. Activation-induced cell death (AICD) induced by SAgs in
vitro or in vivo is averted using Fas-deficient T cells, including
those with down-regulated Fas or FasL receptors as well as those
with masked or blocked Fas receptors. A Fas-IgG fusion protein is
added during the SAg activation phase to prevent AICD or anergy
induction. Measures such as those above (or by treating with
anti-CTLA-4 antibodies or activation of CD28 before, during, or
after STCT stimulation) protect T cells from anergy or AICD. In
this way, these manipulations prolong T cell survival in vitro and
enhance tumoricidal activity in vivo after the T cells are
activated by tumor associated antigen plus SAg or tumor associated
antigen-SAg conjugates in vitro.
[0856] SAg nucleotide alone or fused to tumor peptide nucleotide
may be further fused with an antisense nucleotide capable of
inhibiting the apoptosis pathway. When expressed in T cells, this
combination of genes would promote the generation of tumor specific
effector T cells which would be resistant to AICD. Oligonucleotide
antisense molecules that inhibit key steps leading to apoptosis may
be fused to SAg DNA in order to prevent the T cells from undergoing
AICD. SAg DNA may also be fused with the multi-drug resistance
(MDR) gene to make the T cells refractory to chemotherapeutic
agents and sensitive to anti-apoptosis drugs. Certain drugs or
radiation may be used together with SAg DNA for additive or
synergistic inhibition of the apoptosis pathway in the doubly or
multiply transfected T cells.
[0857] SAg DNA may also be linked operatively to promoter genes
such as those inducible by corticosteroids or heavy metals (e.g.,
the metallothionein promoter) and regulatory DNA sequences that act
as T cell on/off sensors responsive to exogenous cytokines,
inflammatory stimuli and changing external conditions such as
oxygen tension and pH. A particular advantage of SAg DNA is that
its expression will promote V receptor downregulation and
internalization so that these receptors are unavailable to
exogenous SAg. SAg DNA is modified in several ways to introduce
protein binding sites for key transcriptional elements which may
inhibit apoptosis. Insertion of such sites at the bending domains
of SAg oligonucleotides renders them capable of inducing key TH-1
cytokines and cell proliferation while averting AICD. SAg DNA is
also capable of reversing the T cell anergy and signaling defect
which may be localized to the chain in cancer patients. This is
accomplished by providing transcriptional binding sites on the SAg
DNA which bypass the conventional chain activating signals and the
pathway to IFN and IL-2 production. In the same way, SAg DNA also
bypasses the defective signal by activating a complex that contains
STAT-1 which binds a GAS-like palindromic sequence located in the
IFN response region of the FcRI gene. Such anergy in T cells may
also be reversed by alternate cytoplasmic tails that are activated
by SAg binding to the TCR V and V chains. Moreover, nucleic acid
encoding Protein A and especially domain D (that binds to the Ig
VH.sub.3 region) may be fused to SAg DNA in order to bring about
activation of the IL-2 and IFN genes that resulting in T cell
proliferation and IFN production coupled with up-regulated surface
receptors for the Ig VH.sub.3 domain.
[0858] Anergy in SAg-activated tumor-specific T or NKT effector
cells (or hybridomas) is known to be averted by in vitro or in vivo
co-administration of IL-2, IL-1, LPS and tumor specific peptides
specifically interfere with SAg driven anergy. Methods and doses
for use of these agents with SAg activated T or NKT cells are given
in Examples 7, 15, 16, 18-23.
[0859] Tumor specific T or NKT effector cells or hybridomas
prepared by various methods described above are administered
according to the adoptive therapy protocol of Examples 7, 15, 16,
18-23 (the preferred method). The experimental tumor models and
human cancers for which the anti-cancer efficacy of these cells can
be demonstrated are provided in Example 16.
EXAMPLE 9
Reactivation of Anergized Tumor-specific T or NKT Cells by SAg and
SAg Receptors
[0860] Preferred tumor-specific effector cells for adoptive
immunotherapy of cancer are autologous T cells. However, in the
course of tumor growth, T cells become anergized to the host's own
tumor and are incapable of an adequate immune response to the
tumor. Dampened TCR-triggered responses are caused by suppression
of effector molecules that couple cell surface receptors to early
and late intracellular signaling events. For example, basal and
induced tyrosine phosphorylation of many signaling proteins is
reduced due to deficits at multiple points, including the inositol
phosphatase pathway. This down-regulates cytokine production and
decreases nuclear transcription factors of TH1 helper cells. Two
functionally distinct signal transduction pathways are coupled to
the TCR. Native or mutant SAgs activate anergic T cells via an
alternate pathway without the conventional increases in Ca++
mobilization or detectable phosphatidylinositol hydrolysis that
follow ligation of the TCR by peptide/MHC complexes. Native, mutant
or derivatized SAgs are administered to stimulate anergized T
and/or NKT cells to become tumor-specific effector cells now fully
reactive against tumors. Such cells are used also in adoptive
immunotherapy of cancer as described in Examples 7, 15, 16, 18-23.
Nucleic acid constructs comprising DNA encoding SAg and SAg
receptor are provided to reverse T cell anergy in cancer
patients.
[0861] Anergic T (or NKT) cells transfected with DNA encoding a SAg
receptor express the receptor on the cell surface. Binding of
exogenous SAg to this receptor generates T cell activating signals,
so that the activated T cells can be used for adoptive
immunotherapy.
[0862] DNA encoding a SAg peptide is transfected into cancer
patients' anergized T and/or NKT cells. These DNA constructs also
contain the ISS (described above). The T and/or NKT cell
transfectants have revitalized proliferative activity when
stimulated by tumor-specific antigen and exogenous SAg. The cells
are used for adoptive immunotherapy of cancer (Examples 7, 15, 16,
18-23).
[0863] Anergic T cells from cancer patients are transfected in vivo
or in vitro, resulting in a population of tumor reactive effector T
cells in vivo or ex vivo. The ex vivo transfected T cells are used
for adoptive immune therapy as described in Example 15, 16, 18-23.
In the case where SAg receptor is expressed by transfected T cells,
these cells are activated by locally or systemically by SAgs to
result in tumor-specific effector cells.
[0864] Additional manipulations that assist in restoring
responsiveness to anergic T cells include removal of the (T or NKT)
cells from the immunosuppressive microenvironment and transfer into
tissue culture for a short period before stimulation with SAg.
Furthermore, defective signaling in patient T or NKT cells may be
reconstituted by transfection with DNA encoding CD3-2 or fyn that
is either in a single construct with, or cotransfected with, DNA
encoding SAg and/or SAg receptor. Now, surface activation of the
SAg receptor triggers CD3-signaling and T cell proliferation.
[0865] SAg activation of a T cell surface ganglioside (such as GD3)
is also used to reverse T cell anergy in cancer patients. SAg
coupled to GalCer, lipopolysaccharides or proteosomes are even more
effective in activating such anergized T cells. Coordinate
activation of CD69 with phorbol esters in combination with SAg
stimulation also reverses T cell anergy.
EXAMPLE 10
Tumor Specific Effector T or NKT Cells as Lymphoid Organoids
[0866] Tumor specific T and/or NKT effector cells (or hybridomas
with such cells) are prepared ex vivo in the form of a lymphoid
organoid and implanted into tumor-bearing hosts. The organoid
consists of the tumor specific lymphocytes either activated by
SAgs, transfected to express SAg alone or in combination with the
other proteins or anti-tumor moieties described herein. The cells
are encased in semi-permeable membranes that allow for their
progressive entry into the blood and lymphatics after implantation
into the host. Such organoids are implanted preferentially at sites
adjacent to lymphatics or blood vessels that drain organs or
regions of known tumor involvement. However, they may also be
implanted subcutaneously, intraperitoneally in addition to
intra-tumorally or adjacent to a tumor site. The advantage of the
organoid is that it continuously provides proliferating
tumor-specific effector cells that recognize traffic to tumor sites
in a physiological manner. This approach avoids negative selection,
functional deficiencies and storage problems associated with long
term cultured cells.
[0867] Organoids are encased in macrocapsules, sheaths, rods,
discs, or spherical dispersions or microcapsules. Microcapsules are
made of hydrogels such as polysaccharide alginate that are
optionally coated with polyanions and again with alginate.
Macrocapsule and vascular devices consists of acrylonitrile-vinyl
chloride copolymers or cellulose nitrate membranes. In one
approach, scaffolds composed of synthetic polymers serve as cell
transplant devices. The polymers are degradable or non-degradable
materials that disappear from the body after they perform their
function to obviate concerns about long-term biocompatibility.
[0868] These devices serve as structural and functional tissue
units by the transplanted cells. The open system implants are
designed so that the polymer scaffold guides cell organization and
growth and allows diffusion of nutrients and cells. The cell
polymer matrix is pre-vascularized or becomes vascularized as the
cell mass expands after implantation. Vascularization is induced
naturally by the host or artificially by secretion of angiogenic
factors from host cells. Optionally, the angiogenic proteins are
genetically engineered into the host T cells in vitro before
implantation or in vivo before or after implantation.
[0869] To maintain or facilitate targeting of the cells to tumors
or involved organs, the lymphocytes are transfected with DNA
encoding polypeptides that enhance homing and trafficking ability
to the sites of tumor burden (e.g., brain, liver, lung). The
organoid lymphocytes express no CTLA so that they may proliferate
(in vitro and in vivo) without the need for exogenous IL2.
Alternatively, cells are transformed to express herpes simplex
virus thymidine kinase, making them susceptible to killing by
gancyclovir. This curtails uncontrolled proliferation caused by the
CTLA-4 deletion (or inhibition). Exogenous control of antitumor
activity is achieved through the use of inducible promoters, such
as those responsive corticosteroids or metals.
EXAMPLE 11
Tumor Specific Effector Cells or Tumor Cells Expressing Protein A,
Protein A Domains and/or Angiostatin
[0870] It is desirable to express Fc receptors (FcR) or Ig VH3
domains on tumor cells to promote binding by immunoglobulins and
enhance damage by antibody dependent cellular cytotoxicity. By
introducing Staphylococcal Protein A, or its domains A-D into tumor
cells which overexpress FcR and VH3 the tumor cells bind
immunoglobulins (including those with.alpha.Gal specificity).
Signaling of T cells occurs via high affinity binding to FcR (FcRI
) of protein A-IgG complexes; such binding bypasses the CD3-
blockade in tumor bearing patients. These transfected tumor cells
are useful as a vaccine. Likewise, nucleic acids encoding protein A
and its domains A-D are transfected into partially or fully
anergized T or NKT cells of cancer patients. Exogenous
immunoglobulins stimulate the generation of tumor-specific effector
T or NKT cells which are used in adoptive immunotherapy (Examples
7, 15, 16, 18-23).
[0871] DNA encoding Staphylococcal protein A and its domain D are
co-transfected into these tumor cells resulting in the joint
surface expression of: (1) protein A and FcR to which it binds
and/or (2) domain D and Ig VH3 to which it binds. When DNA encoding
protein A or domain D, fused to a signal sequences that route and
anchor the protein A peptide to the tumor cell surface, is
introduced into tumor cells, such tumor cells are excellent targets
for parenterally administered SAg polypeptides (particularly those
for which no natural antibodies exist). Tumor cells expressing
protein A and domain D and also expressing FcRs on the cell
surface, have heightened sensitivity to complement mediated lysis.
Tumor cells cotransfected to express protein A and Gal (by
introduction of the appropriate glycosyltransferase) are capable of
reacting with natural anti-Gal antibodies, Ig Fc fragments and Ig
VH3 domains, which stimulate an enhanced tumoricidal response.
[0872] Angiostatin is a circulating angiogenesis inhibitor which is
38-kDa internal fragment of (mouse) plasminogen that contains the
first four disulfide-linked kringle domains. In vivo, angiostatin
suppresses neovascularization in several traditional assays (chick
chorioallantoic membrane assay and mouse corneal assay). Proteases
released by tumor cells cleave circulating plasminogen to generate
angiostatin. Metalloelastase produced by tumor infiltrating
macrophages generated angiostatin production by murine Lewis lung
carcinoma. In the present invention, nucleic acid encoding
angiostatin (Cao Y et al., J. Clin. Invest. 101: 1055-1063, (1998))
are cotransfected into tumor cells with nucleic acid encoding SAg
(as in Example 1). The tumor cell cotransfectants express and
secrete SAg and angiostatin. Such cells are used directly as a
preventative vaccine (Example 8) or as a therapeutic vaccine to
treat established tumor including micrometastases. Methods for
using these cells in vivo are in Examples 7, 12, 16, 18-23.
[0873] In addition, tumor cells are cotransfected to express
angiostatin and protein A (and/or its domains). Any nucleic acid
construct shown in Table I may also be used in combination to
transfect tumor cells together with protein A, its domains and
angiostatin.
EXAMPLE 12
SAg Receptor
[0874] Colon carcinoma is used as the tissue source for the SEB
receptor. Mixtures of different detergents at low concentrations
are used. The protocol for screening detergents for solubilization
of MAChRs is readily adaptable to other receptor types. The
membranes are suspended at 5-10 pH 7.5, 20 mM Tris-HCl, pH 7.5, or
20 mM sodium phosphate, pH 7.0-7.5. For screening purposes it is
unnecessary to add complex proteolysis inhibitor cocktails. The
presence of EDTA (1 mM) to inhibit calcium-activated proteases and.
of PMSF or benzamidine (0.1 mM) to inhibit serine proteases is
sufficient. Mg2.sup.++ (2 mM) is added. The membranes are
prelabelled with a radioligand in the presence and absence of a
suitable unlabelled ligand to determine the total and non-specific
binding. Non-specific binding is subtracted from total binding to
obtain the specific binding. A high enough concentration of labeled
ligand to saturate the binding site(10.times.K.sub.d) is used, so
that the binding capacity is measured. The unlabelled ligand is
used at a concentration of 1000.times.K.sub.d. The normal criteria
for specific binding must be fulfilled. The incubation is
sufficient to reach equilibrium. Prelabelled membrane suspension
(0.5 ml) is added to a series of centrifuge tubes a 4.degree. C. An
equal volume of detergent solution in the same buffer is added to
obtain a series of different final detergent concentrations, e.g.,
0, 0.1, 0.2, 0.5, 1.0, 2.0% w/v. The tubes are mixed and incubated
for 60 min. at 4.degree. C. Solubilization is assisted by stirring
or mixing, e.g., with a rotating-wheel end-over-end mixer. The
tubes are centrifuged for 30-60 min at 100,000.times.g for 60 min.
For screening, a lower speed spin, e.g., 10,000.times.g for 5 min
(such as in a microfuge) is acceptable. Supernatant, 0.2 ml, is
applied to a 2 ml column of Sephadex G50 equilibrated with the
selected detergent at 0.1%. When the sample has run in, 2.times.0.2
ml of detergent-buffer is applied and then the void volume fraction
is eluted with 0.5 ml of detergent buffer. This procedure is
carried out, the remaining material is removed, and 10 ml of
aqueous scintillation cocktail is added and the radioactivity
counted. Sephadex G50 is substituted for G50F for hydrophilic
ligands, which do not partition into detergent micelles. This gives
a more rapid separation. The recovery of specifically bound ligand
is calculated in absolute terms:
bound ligand=(dpm(total)-dpm(non-spec.).times.5/(2220.times.spec.
.act) pmol/ml
[0875] An aliquot of the pellets is resuspended and counted to
calculate recovery of unsolubilized receptors. The concentration of
protein in the solubilized supernatant is measured, for example, by
measuring UV absorbance at 280 nm against a detergent-buffer blank.
(If necessary, the supernatant is diluted to get the absorbance on
scale.) Protein concentration in the solution is approximately
equal to the absorbance at 280 nm. Alternatively, the Lowry method
is used. The above steps are repeated without first prelabeling the
receptors in the membrane. Instead, the solubilized supernatant is
incubated in the absence and presence of labeled ligand. Again,
concentration of the labeled ligand is used that saturates the
binding sites. Incubation is carried out for 2 h at 4.degree. C.,
and the binding is assayed by gel filtration as above. The pellet
is resuspended and assayed for residual binding to check overall
recovery. The molecular size of the receptors in solubilized
preparations is estimated by a combination of gel filtration
chromatography and sucrose density gradient centrifugation in
H.sub.2O and D.sub.2O. Affinity chromatography is the principal
method use for purification of all of the receptors, combined with
gel permeation HPLC, and ion exchange. SDS PAGE is carried out on
the final product. Affinity chromatography is carried out using
immobilized SEB, and the column is eluted with acid buffer or
different concentrations and ionic strengths of eluting buffer.
[0876] Determination of Amino-Acid and Oligonucleotide Sequences of
SAg Receptors
[0877] Receptor material is eluted from the SDS-PAGE, and the
N-terminal amino acid sequence is determined. When free amino
termini are not available, the purified receptor material must be
subjected to partial hydrolysis. The specific cleavage of peptide
bonds is performed with endoproteases, such as V8 protease or
trypsin, or with chemicals such as cyanogen bromide(CNBR). The
resulting peptides are separated by SDS-PAGE when they are over
residues or by reverse phase HPLC. The peptides thus analyzed are
subjected to amino-acid sequence analysis with a gas phase or solid
phase sequencer.
[0878] Antibodies are raised against the peptides and the resultant
antibodies used to confirm that the peptide is a part of the
receptor by immunoprecipitation or Western blot.
[0879] To determine the full sequence of the receptor gene,
oligodeoxynucleotide probes synthesized on the basis of peptide
sequences are used to screen an appropriate cDNA library. Either a
mixture of relatively short oligonucleotides with all possible
sequences or a relatively short oligonucleotides with a sequence
based on codon usage frequency is used. Genomic libraries as well
as cDNA libraries are screened to obtain genes for receptors and to
deduce their amino acid sequence. The amino acid sequence deduced
from the nucleotide sequence is compared to the known sequences of
other receptors. Among the useful structural information derived
from the sequence analysis is the hydropathy profile. The presence
of hydrophobic domains with a length of approximately 20 amino
acids residues suggests that the regions are transmembrane
segments. Genomic or cDNA clones ligated into expression vectors
are used to transform suitable cell lines.
[0880] Alternatively, mRNA transcribed from these clones is
injected into recipient cells such as Xenopus oocytes. The
expression of receptors in these cells is confirmed by measuring
ligand binding, reactivity of cell homogenates or membrane
preparations with antibodies or the responses induced by receptor
agonists in recipient cells. The direct function of the receptors
is elucidated by reconstituting purified receptors in phospholipid
vesicles with or without other components. An additional method is
based on the isolation of cDNA or genomic clones for receptors
without using purified receptors. The structure of receptors and
cellular responses to them is examined using these clones.
Substantial amounts of receptor material is produced from these
clones. Monoclonal antibodies to the SAg receptors are used to
screen clones for receptors derived from cDNA libraries constructed
with expression vectors.
[0881] Transfection of SAg receptor involves the ligation of the
receptor gene into an appropriate expression vector, transformation
of a suitable bacterial host, and isolation of an individual
bacterial colony containing the plasmid vector. The plasmid DNA is
harvested from the lysed bacteria. The preferred method of
purification of plasmid DNA for use in transfections involves
Triton-lysozyme equilibrium gradient. The cells to be used in
transfection are maintained in the log phase of growth at all
times. The calcium phosphate method is useful and efficient means
for introduction of cloned genes in plasmid vectors into mammalian
cells as described earlier in this document is preferred. However,
the other methods given are useful as well. A partial list of
plasmid vectors and promoters suitable for transfection of cultured
mammalian cell is given in Fraser, C. M., Expression of Receptor
Genes in Cultured Cells in Receptor Biochemistry, A Practical
Approach, Hulme, E. C., ed., Oxford University Press, pp. 263-275,
1993.
EXAMPLE 13
Avoiding Interference with SAg-Specific Antibodies
[0882] Naturally antibodies are found in mammals that are specific
for the SAg molecule (e.g., a Staph enterotoxin). Such antibodies
bind and interfere with the SAg expressed and secreted by
transfected cells. Such antibodies also hinder therapeutic action
of SAg infused directly (as native protein, peptide or fusion
protein).
[0883] It is desirable to neutralize or otherwise remove such
before the cells of this invention are administered to a subject.
One way to achieve this is to pre-treat the subject with
antiidiotypic antibodies specific for the variable region of
SAg-specific antibodies. Another way is to infuse SAg peptides that
represent the major immunogenic portions of the overall protein.
Alternatively, SAg is immobilized to a solid support by covalent
bonding and the blood or plasma is perfused extracorporeally
through a device containing the immobilized protein, thereby
removing the antibodies by immunoadsorption. In another approach,
SAg-expressing cells (prokaryotic or eukaryotic) preferably of host
origin, or phage displays, are encapsulated and used as
immunoadsorbents to binds circulating SAg-specific antibodies. An
organoid containing these adsorbing cells is positioned
subcutaneously or placed into the circulation via catheter and then
removed once the adsorption process is complete. Alginate
encapsulated cells expressing SAg are preferred but other known
modes of cell encapsulation may be used. Liposomes with
surface-bound SAg are another form of immunoabsorbent that are
employed either as an organoid or by direct injection.
[0884] Induction of Immunological Tolerance
[0885] The induction of tolerance to epitopes of the SAg molecule
which induce a humoral antibody response would be desirable. The
portion of the SEA molecule which binds to natural antibodies is
the linear sequence of residues 232-262. Immune tolerance is
induced using this sequence by the method of Dintzis et al., Proc.
Natl. Acad. Sci. 89: 1113-1117 (1992). in which low molecular
weight peptide arrays are administered to patients with circulating
antibodies to enterotoxins. The peptides are delivered parenterally
or orally once weekly in doses of 1-500 mg/kg for three to six
weeks after which there is a reduction and disappearance of
circulating antibody specific for the tolerogen.
[0886] After one or more of the foregoing treatments, native SAg or
SAg conjugated to a monoclonal tumor-specific antibody and
administered to the host can now localize to tumor sites without
diversion by circulating SAg-specific antibodies.
[0887] Phage Displayed SAgs
[0888] Phage display technology may also be used neutralize
circulating anti-enterotoxin antibodies. The SAg and/or SAg
receptor is expressed at the surface of bacteriophage as a fusion
protein with the gene VIII protein (gVIIIp). This phage-displayed
SAg fusion protein retains the properties of the natural protein.
For this invention, the filamentous phage vector f88-4 which forms
a fusion protein between the C terminus of the inserted gene
product and the N terminus of gVIIIp is used. The phage expressing
SEA is injected intravenously into patients that have natural
antibodies to SEA. The amount of phage (transducing units) required
to neutralize the circulating pool of antibodies is predetermined
by antigen binding inhibition assay. The number of transducing
units required to neutralize the pool of circulating SEA specific
antibodies is administered intravenously. Shortly after this
injection, the host is ready for treatment with active SEA which is
no longer hindered from finding its "target," ie., enterotoxin
receptors expressed by tumor cells or T cells.
[0889] SEA clone pKH-X35 is employed. PCR with Vent Polymerase 9NEB
is used to mutate the 5'- and 3'-ends of the SEA gene for cloning
into f88-4. The construct is as follows. The 5' oligonucleotide
used is 5'-CTCCAAGCTTTGVCCAGCGAGAAAAGCGAAG-3'. Two 3'
oligonucleotide primers are used. For the construct with the five
amino acid linker between SEA and gVIIIp (SEA L), the primer
5'-GCCTCCTGCAGATCCACCGCCTCCGGATGT-ATATAAATATAT- ATC-3' and for the
non-linker version (SEA-P); 5'-GCCTCCTGCAGATGTATATAAATA- TATATC-3'
are used. The two SEA PCR products are cut with HindIII and PstI
and cloned into f88-4. They are transformed by electroporation into
E. coli strain DH5a and sequenced. Phage are produced by growing
the transformed bacteria overnight in 0.5 L of broth with 20 mg/ml
tetracycline. The culture is pelleted twice (800.times.g for 15
min) and the phage precipitated out of the cleared supernatant by
the addition of 0.15 vols. of PEG/NaCl solution (17% PEG 8000, 19%
NaCl in water). After incubation at 4.degree. C. for 2 hours, the
phage are resuspended in TBS and sterile-filtered through a 0.22-m
membrane. Phage are selected by the micropanning technique and by
cell binding. Binding to antibody is assessed by attaching mAb to
the surface of 96-well ELISA plates, blocking with 1% BSA,
incubating with 100 mg/ml of SEA or PBS as a control and then
incubating with the various phage preparations for >2 hours at
4.degree. C. The phage is then eluted with 0.1 M HCl pH 2 (adjusted
with glycine) for 10 minutes, neutralized and used to infect
starved E. coli MC 10161 F' Kan. The infected bacteria are then
spread on tetracycline (20 mg/ml) LB agar plates. After overnight
culture tetracycline resistant colonies are counted representing
the number of transducing units (TU) recovered. To determine the
number of SEA-bearing phage among the tetracycline-resistant
colonies, colony blotting is performed by standard techniques
probing with a .sup.32P-labeled SEA probe. An antibody based
variant of this technique is involves probing with a rabbit
anti-SEA serum as for Western blots.
[0890] Chimeric Enterotoxins
[0891] Likewise, hybrid or chimeric SAgs that are non-immunogenic
are used to stimulate cells. When these molecules are injected into
hosts that have natural antibodies, they are not rapidly eliminated
from the circulation. Such chimeric molecules lacking the binding
site for natural antibodies preserve the T cell mitogenic and
cytokine-inducing properties of the native SAg. A peptide sequence
from another SAg to which antibodies do not exist is substituted
using genetic or biochemical methods well known in the art. This is
particularly useful in the case of enterotoxins such as SEB or SEA
to which a large percentage of humans have naturally occurring
circulating antibodies. The antibody binding region of these
molecules near the C terminal regions is delineated. The
substitution of the antibody binding sequences in SEA or SEB for
sequences from SEE or SED to which a very small number of humans
have circulating antibodies markedly enhances the tumor killing
efficacy of the injected chimeric enterotoxins.
[0892] A hybrid molecule consisting of a 26 amino acid peptide
corresponding to the N-terminal portion of SEA, the loop structure
of SEA, a conserved mid-molecular sequence of SEA and SEB, and a C
terminal sequence of SEB was synthesized in collaboration with
Multi-Peptide Systems, La Jolla, Calif. Peptides were prepared
using a variation of Merrifield's original solid phase procedure in
conjunction with simultaneous multiple peptide synthesis using
t-Boc chemistries. Peptides were cleaved from the resins using
simultaneous liquid HF cleavage. The cleared peptides were then
extracted with acetic acid and ethyl ether and lyophilized. Reverse
phase HPLC analysis and mass spectral analysis revealed a single
major peak with the molecular weight corresponding closely to
theoretical.
[0893] Synthetic SAgs
[0894] Amino acid sequences of SEA and SEB known to be involved in
the interaction with the TCR and MHC class II molecules are
retained. The loop structure of SEA is retained because it is
devoid of histidine moieties that are associated with the emetic
response. Residues 1-10 of the N-terminal region of SEA are
retained because they have MHC class II binding activity. The loop
structure of SEA is retained because it and associated disulfide
linkages are considered to be important for T lymphocyte
mitogenicity, stabilization of the molecule, and resistance to in
vivo degradation. A conserved sequence in the central portion of
SEA and SEB adjacent to the disulfide loop (amino acids 107-114)
was retained. Histidine moieties are deleted from the molecule
because of their association with the emetic response.
[0895] Synthesis Procedure
[0896] The preparation of all peptides was carried out using a
variation of Merrifield's original solid phase procedures in
conjunction with the method of Simultaneous Multiple Peptide
Synthesis using t-Boc chemistries (Merrifield R B I, J. Amer. Chem.
Soc. 85:2149-2154 (1963)); Houghten R A, Proc. Natl. Acad. Sci. USA
82:5131-5135 (1985); and Houghten R A et al., Intact. J. Peptide
Protein Res. 27:673-678 (1985)).
[0897] 4-methylbenzhydrylamine (mBHA) and phenylacetamidomethyl
(PAM) resins were purchased from Advanced Chemtech (Louisville,
Ky.) and Bachem (Torrance, Calif.), respectively. All of the amino
acids contained the t-butyloxycarbonyl (t-Boc)-amino protecting
group and were purchased from Bachem. The side chain protecting
groups included benzyl (threonine, serine and glutamic acid),
chlorobenzyloxycarbonyl (lysine), bromobenzyloxycarbonyl
(tyrosine), cyclohexyl (aspartic acid), p-toluene sulfonyl
(arginine), formyl (tryptophan), methyl benzyl (cysteine), and
dinitrophenyl or benzyloxycarbonyl (histidine). Cysteine with the
HF stable acetamidomethyl (ACM) protecting group was used, upon
request, for internal cysteines. Each lot of amino acid derivative
was tested by melting point analysis. Reagent grade methylene
chloride (CH.sub.2Cl.sub.2), isopropanol (IPA), and
dimethylformamide (DMF) were obtained from Fisher Scientific
(Tustin, Calif.). diisopropylcarbodiimide (DIPCDI) and
diisopropylethylamine (DIEA) were purchased from Chem Impex (Wood
Dale, Ill.). Trifluoroacetic acid was purchased from Halocarbon
(Hackensack, N.J.).
[0898] The appropriate resin, mBHA for C-terminal amides and PAM
for C-terminal acids, was weighed with a Mettler AE 240 balance
(Highstown, N.J.) into separate polypropylene mesh (74 mm) packets
which had been pre-sealed on 3 of 4 sides using a TSW TISH-300
Impulse Sealer (San Diego Bag and Supply; San Diego, Calif.). Each
packet was also pre-labeled with a reference code using a KOH I
NOOR Rapidograph pen with graphite based ink to allow them to be
easily identified during resin addition and during the synthesis
process. Each packet was then careftully sealed completely to make
sure there would be no resin leakage. All the resin containing
packets (up to 150) were then placed in a common Nalgene bottle.
Enough CH.sub.2Cl.sub.2 to cover all the packets was then added to
the bottle, which was then capped and vigorously shaken for 30
seconds on an Eberbach Shaker (Fisher Scientific; Tustin, Calif.)
to wash and swell the resin. The CH.sub.2Cl.sub.2 solution was then
removed. All subsequent steps involved the addition of enough
solvent to cover all the packets and vigorous shaking to ensure
adequate solvent transfer. The N--t-Boc was removed by acidolysis
using a solution of 55% TFA in CH.sub.2Cl.sub.2 for 30 minutes,
leaving the TFA salt of the .alpha.-amino group. The TFA wash
solution was then removed. The packets were then washed for 1 min
with CH.sub.2Cl.sub.2 (2.times.), IPA (2.times.) and
CH.sub.2Cl.sub.2 (2.times.) to squeeze out excess TFA and to
prepare for neutralization. The TFA salt was neutralized by washing
the packets three times with 5% DIEA in CH.sub.2Cl.sub.2 for two
minutes each. This was followed by two washes with CH.sub.2Cl.sub.2
to remove excess base.
[0899] The resin packets were then removed from the common Nalgene
bottle and sorted according to computer generated checklists in
preparation for coupling. This was double checked to ensure the
packets were added to the correct amino acid solution. The packets
were then added to bottles containing the appropriate 0.2 M amino
acid in CH.sub.2Cl.sub.2 and/or DMF depending on solubility. These
solutions were also prepared using computer generated information.
An equal volume of 0.2 M DIPCDI was then added to activate the
coupling reaction. The bottles were then shaken for one hour to
ensure complete coupling. At completion, the reaction solution was
discarded and the packets were washed with DMF for 1 min to remove
excess amino acid and the by-product, diisopropylurea. A final
CH.sub.2Cl.sub.2 wash as then used to remove DMF. The packets were
then removed from their individual coupling bottles and placed back
into the common Nalgene bottle. The peptides were then completed by
repeating the same procedure while substituting for the appropriate
amino acid at the coupling juncture. The packets were then taken
through a final acidolysis along with subsequent CH.sub.2Cl.sub.2,
IPA and CH.sub.2Cl.sub.2 washes to leave the peptides in the TFA
salt form. The packets were then dried in preparation for the next
process.
[0900] Final side chain deprotection and cleavage of the anchored
peptide from the resin was achieved through simultaneous liquid HF
cleavage (Houghten R A et al., supra.
[0901] Gaseous N2, HF, and argon were acquired from Air Products
(San Diego, Calif.). Anisole was purchased from Aldrich Chemical
Co. (Milwaukee, Wis.). Acetic acid (HOAc) and ethyl ether were
purchased from Fisher Scientific (Tustin, Calif.). Each packet
along with a Teflon coated stir bar was placed into an individual
reaction vessel of a multi-vessel hydrogen fluoride apparatus
(Multiple Peptide Systems; San Diego, Calif.). An amount of anisole
equaling 7.5% of the expected volume of HF was then added to act as
a carbonium ion scavenger. The reaction tubes were lubricated with
vacuum grease at the point where each contacts the apparatus and
sealed onto the HF system. The system was then purged with N.sub.2
while cooling the reaction vessels to -70.degree. C. using an
acetone/dry ice bath. HF (g) was condensed to the desired level and
temperature elevated to -10.degree. C. using ice and water. The
reaction was allowed to proceed for 90 minutes with the temperature
slowly rising from -10.degree. C. to 0.degree. C. HF was removed
using a strong flow of N.sub.2 for 90 minutes followed by the use
of aspirator vacuum for 60 minutes while maintaining the
temperature at 0.degree. C. The reaction vessels were then removed
from the apparatus and capped. The residual anisole was removed
with two ethyl ether washes. The peptide was then extracted with
two 10% HOAc washes. A 50 ml sample of the crude peptide was taken
and run on an analytical Beckman 338 Gradient HPLC System (Palo
Alto, Calif.) using a Vydac C18 column to profile the initial
purity of the compound. The crude peptide was then lyophilized
twice on a Virtis Freezemobile 24 Lyophilizer, weighed and stored
under argon.
[0902] Analytical RP-HPLC was used to determine the homogeneity and
approximate elution conditions of the peptides produced. HPLC grade
acetonitrile (ACN) was purchased from Fisher Scientific (Tustin,
Calif.). HPLC grade TFA was obtained from Pierce Chemicals
(Rockford, Ill.). RP-HPLC analysis was carried out on a Beckman 338
Gradient HPLC system (Palo Alto, Calif.) equipped with a BioRad
AS-100 autosampler and a Shimadzu CR4A integrator. The column used
for all analyses this quarter was a Vydac C-18 column
(4.6.times.250 mm). The solvent system used was 0.05% aqueous TFA
(A) and 0.05% TFA in ACN (B) with a flow rate of 1 ml/min.
Absorbance was measured at 215 nm. Most peptides were analyzed
using the following special gradient; 5.60% (B) in 28 minutes.
Hydrophobic peptides were analyzed using the following special
gradient: 5-40% (B) in 9 minutes, 40-90% (B) for 10 additional
minutes, 95% (B) for the last 9 minutes.
[0903] Analytical data was reviewed. The product peak was
identified and marked based upon knowledge of common impurities and
the use of predicted HPLC retention times.
[0904] Peptides that did not meet normal purity requirements for
crude material were purified using preparative RP-HPLC techniques.
HPLC grade acetonitrile (CAN) was purchased from Fisher Scientific
(Tustin, Calif.). HPLC grade TFA was obtained from Pierce Chemicals
(Rockford, Ill.). Purification was carried out on a Waters Delta
Prep 3000 with a Preparative Waters Prep Pak Module Radial
Compression C18 column (5 cm.times.25 cm, 10-20 m). The solvent
system used was 0.05% aqueous TFA (A) and 0.05% TFA in ACN (B). The
crude peptides were solubilized in an HOAc/H.sub.2O mixture and
injected onto the column with 0.25% to 0.50% ACN per minute linear
gradient. The absorbance was measured at 230 nm and 40 ml fractions
were collected upon elution with an ISO Fraction Collector
(Lincoln, Nebr.). The preparative profile was reviewed and selected
fractions were analyzed by analytical RP-HPLC. The analytical data
was reviewed and fractions were combined and lyophilized. The
lyophilized material was weighed, sampled for a final analytical
RP-HPLC analysis and stored under argon in powder form. This
process was repeated if the purity level attained was not
sufficient. Mass spectral analysis was used to determine the
molecular weight of the peptides produced. 95% ethanol was
purchased from Fisher Scientific (Tustin, Calif.). HPLC grade TFA
was obtained from Pierce Chemicals (Rockford, Ill.). Nitrocellulose
matrices (targets) were purchased from Applied Biosystems (Foster
City, Calif.).
[0905] The samples were solubilized in a 1:1 solution of 95%
ethanol and 0.1% TFA (aqueous). The samples were applied to a
nitrocellulose matrix (Target). The mass spectra were obtained
using an ABI Bio-Ion 20 Mass Spectrometer (Foster City, Calif.).
The apparatus makes use of plasma desorption ionization via a Cf252
source. The ionized molecules are then analyzed via time-of flight.
An accelerating voltage of 15,000 V is used to accelerate the
particles.
[0906] The Protocol for Intramolecular Disulfide Bridge:
[0907] Dissolve crude peptide (300-500 mg) in 200 ml of
deoxygenated water and adjust the pH to 8.5 using NH.sub.4OH
28%=Solution A. Note: If the peptide is not very soluble in water,
some MeOH can be added.
[0908] Dissolve 0.5 g K.sub.3Fe(CN)6 in 200 ml of deoxygenated
water and adjust the pH to 8.5 using NH4OH 28%=Solution B. Note:
0.5 g K.sub.3Fe(CN).sub.6 is an average value for 500 mg of a 10
mer peptide. The excess of K.sub.3Fe(CN).sub.6 should be
approximately 3.times.. It can be adjusted.
[0909] Solution A is then dropped slowly into solution B over a 2
hour period. The mixture is then allowed to react, for an
additional 1 hour with stirring. The pH is then adjusted to 4.0-4.5
with 10% ACTH. This solution is injected directly into a
preparative RP-HPLC. The major peak is then collected. This "pseudo
dilution" technique favors the intramolecular disulfide. Therefore,
the major peak is the cyclic product.
[0910] The chimeric enterotoxin molecule was tested in normal
rabbits and rabbits with established VX2 carcinoma. It was
administered intravenously and peripherally with adjuvant. The
chimeric molecule (1 mg/ml) was diluted initially in 1 ml of
sterile H.sub.2O. When the solution was clear, 9 ml of normal
saline was added. The solution was filtered through a 0.45 m filter
and stored in 0.5-1 ml aliquots. Dosage ranged from 2.6-5.0 mg/kg
and was described over 3 minutes via the lateral ear vein in a
volume of 0.05 ml diluted further in 1.0 ml of 0.15 M NaCl:
[0911] The i.v. line was then washed with 3 ml of 0.15M NaCl. In
two animals, the temperature rose only 0.3 F over the ensuing 24
hours and there was no discernible toxicity over the ensuing 14
days of observation. One animal was described a second dose of the
chimeric molecule in pluronic acid triblock adjuvant. This was
described in a dose of 8.5 mg subcutaneously in each thigh with a
total dose 5 mg/kg. The pluronic acid triblock preparation was
prepared as follows: 4.23 cc PBS; 0.017 cc Tween; 0.05 cc Squalene;
and 0.25 cc Pluronic. The PBS and Tween were mixed first then
squalene was added followed by pluronic acid. The total mixture was
vortexed for 3-4 minutes. Two ml of above plus 0.34 ml of the
chimeric protein (34 mg) plus 1.66 cc PBS were added to the
mixture. The mixture was vortexed vigorously for 1-2 minutes. One
ml was injected into each thigh (total vol. injected was 0.17 ml or
17 mg protein or 5 mg/kg).
[0912] For nearly 5 weeks after injection, no adverse effects were
noted. The tumor showed slow, but progressive growth over this
period of time. To date, the chimeric enterotoxin molecule appears
to be safe in animals and no untoward side effects were
demonstrated. The adjuvant used for these studies was the pluronic
acid triblock copolymer which has been used to boost the immune
response to various antigens in animal models and which is under
testing at this point in humans with hepatitis and herpes simplex
infections. Other adjuvants including those prepared in water and
oil emulsion and aluminum hydroxide to administer various SAgs in
vivo to tumor bearing rabbits were also used.
[0913] Additionally, enterotoxins such as SEE, SED, SEC, and TSST-1
are used to prepare hybrid molecules containing amino acid
sequences and homologous to the enterotoxin family of molecules. To
this extent, mammary tumor virus sequences, heat shock proteins,
stress peptides, Mycoplasma and mycobacterial antigens, and minor
lymphocyte stimulating loci bearing tumoricidal structural homology
to the enterotoxin family are useful as anti-tumor agents. Hybrid
enterotoxins and other sequences homologous to the native
enterotoxins are immobilized or polymerized genetically or
biochemically to produce the repeating units and stoichiometry
required for (a) binding of accessory cells to T lymphocytes and
(b) activation of T lymphocytes.
EXAMPLE 14
Pharmaceutical Compositions and their Manufacture
[0914] The pharmaceutical compositions may be in the form of a
lyophilized particulate material, a sterile or aseptically produced
solution, a tablet, an ampoule, etc. Vehicles such as water
(preferably buffered to a physiological pH such as PBS or other
inert solid or liquid material may be present. In general, the
compositions are prepared by being mixed with or dissolved in,
bound to or otherwise combined with one of more water-insoluble or
water-soluble aqueous or non aqueous vehicles, if necessary
together with suitable additives and adjuvants. It is imperative
that the vehicles and conditions shall not adversely affect the
activity of the conjugate. Water as such is comprised within the
expression vehicles. A suitable therapeutic composition is used in
the treatment of cancer of any kind including but not limited to
carcinomas, sarcomas, lymphomas, leukemias and comprises a
combination of:
[0915] (1) a recombinant DNA molecule encoding SAg in combination
with, preferably fused with, another recombinant DNA sequence
encoding another protein;
[0916] (2) a recombinant DNA molecule encoding SAg-in combination
with another peptide or polypeptide; or
[0917] (3) a recombinant DNA molecule encoding a protein other than
a SAg in combination with a SAg peptide or polypeptide.
[0918] These compositions that may comprise more than one
components are administered together or sequentially and they may
be combined (separately or together) with a delivery vehicle,
preferably liposomes as disclosed herein. Upon entering its
intended or targeted cells, the therapeutic composition leads to
the production of SAg and a second protein that may result in (a)
apoptosis of the cancer cell and (b) with or without such
apoptosis, the activation of effector cells of the immune system,
including any or all of the following: cytotoxic T cells, NKT
cells, NK cells, T helper cells and macrophages. The present
therapeutic compositions are useful for the treatment of cancers,
both primary tumors and tumor metastases.
[0919] Use of the present therapeutic composition overcomes the
disadvantages of traditional treatments for metastatic cancer. For
example. compositions of the present invention can target dispersed
metastatic cancer cells that cannot be treated using surgery. In
addition, administration of such compositions is not accompanied by
the harmful side effects of conventional chemotherapy and
radiotherapy.
[0920] A therapeutic composition also comprises a pharmaceutically
acceptable carrier defined as any substance suitable as a vehicle
for delivering a nucleic acid molecule (alone or in some
combination with a protein) to a suitable in vivo or in vitro site.
Preferred carriers are capable of maintaining DNA in a form that is
capable of entering the target cell and being expressed by the
cell. Preferred carriers include: (1) those that transport, but do
not specifically target a nucleic acid molecule to a cell (referred
to herein as "non-targeting carriers"); and (2) those that deliver
a nucleic acid molecule to a specific site in an animal or a
specific cell ("targeting carriers"). Examples of non-targeting
carriers are water, phosphate buffered saline (PBS), Ringer's
solution, dextrose solution, serum-containing solutions, Hank's
balanced salt solution, other aqueous, physiologically balanced
solutions, oils, esters and glycols. Aqueous carriers can contain
suitable additional substances which enhance chemical stability and
isotonicity, such as sodium acetate, sodium chloride, sodium
lactate, potassium chloride, calcium chloride, and other substances
used to produce phosphate buffer, Tris buffer, and bicarbonate
buffer and preservatives, such as thimerosal, m- and o-cresol,
formalin and benzyl alcohol.
[0921] Preferred substances for aerosol delivery include surfactant
substances such as esters or partial esters of fatty acids
containing from about 6-22 carbon atoms. Examples are esters of
caproic, octanoic. lauric, palmitic, stearic, linoleic, linolenic,
olesteric, and oleic acids.
[0922] Other carriers can include metal particles (e.g., colloidal
gold particles) for use with, for example, a biolistic gun through
the skin.
[0923] Therapeutic compositions of the present invention can be
sterilized by conventional methods and may be lyophilized.
[0924] The compositions of the present invention are delivered
using a delivery vehicle that can be modified to target a
particular site in a subject. Suitable targeting agents include
ligands capable of selectively (i.e., specifically) binding to
another molecule at a particular site. Examples are antibodies,
antigens, receptors and receptor ligands. For example, an antibody
specific for an antigen on the surface of a cancer cell can be
placed on the outer surface of a liposome delivery vehicle to
target the liposome to the cancer cell. By manipulating the
chemical formulation of the lipid portion of a liposome
preparation, it is possible to modulate its extracellular or
intracellular targeting. For example, the charge of the lipid
bilayer of a liposome surface can be varied chemically to promote
fusion with cells having particular charge characteristics.
Preferred liposomes comprise a compound that targets the liposome
to a tumor cell, such as a ligand on the outer surface of the
liposome that binds a molecule on the tumor cell surface.
[0925] Although the DNA constructs of the present invention can be
administered in naked form, a liposome is a preferred vehicle for
delivery in vivo. A liposome can remain stable in an animal for a
sufficient amount of time, at least about 30 minutes, more
preferably for at least about 1 hour and even more preferably for
at least about 24 hours, to deliver a nucleic acid molecule to a
desired site. A liposome of the present invention comprises a lipid
composition that can fuse with the plasma membrane of the targeted
cell to deliver the encapsulated nucleic acid molecule into a cell.
Preferably, the liposomes' transfection efficiency is about 0.5
.mu.g DNA per 16 nmol of liposome delivered to about 10.sup.6
cells, more preferably about 1.0 .mu.g DNA per 16 nmol of liposome
delivered to about 10.sup.6 cells, and even more preferably about
2.0 .mu.g DNA per 16 nmol of liposome delivered to about 10.sup.6
cells.
[0926] For use in the present invention, any liposome that is used
in art-recognized gene delivery methods is appropriate. Preferred
liposomes have a polycationic lipid composition and/or a
cholesterol backbone conjugated to polyethylene glycol. Complexing
a liposome with nucleic acids for uses described herein is achieved
using conventional methods. A suitable concentration of DNA to be
added to a liposome preparation a concentration that is effective
for delivering a sufficient amount of DNA molecules to a cell so
that the cell can produce sufficient SAg and/or a other transduced
protein to induce tumoricidal activity or to stimulate or regulate
effector cells in a desired manner. Preferably, between about 0.1
.mu.g and 10 .mu.g of DNA is combined with about 8 nmol liposomes;
more preferably, between about 0.5 .mu.g and 5 .mu.g of DNA is used
even more preferably, about 1.0 .mu.g of DNA is combined with about
8 nmol liposomes.
[0927] Another preferred delivery system is the sickled erythrocyte
containing the nucleic acids of choice a given in Example 6. The
sickled erythorcytes undergo ABO and RH phenotyping to select
compatible cells for delivery. The cells are delivered
intravenously or intrarterially in a blood vessel perfusing a
specific tumor site or organ e.g. carotid artery, portal vein,
femoral artery etc. over the same amount of time required for the
infusion of a conventional blood transfusion. The quantity of cells
to be administered in any one treatment would range from one tenth
to one half of a full unit of blood. The treatments are generally
given every three days for a total of twelve treaments. However,
the treatment schedule is flexible and may be given for a longer of
shorter duration depending upon the patients response.
[0928] Another preferred delivery vehicle is a recombinant virus
particle, for example, in the form of a vaccine. A recombinant
virus vaccine of the present invention includes the DNA encoding
the therapeutic composition packaged in a viral coat that allows
entrance of the transducing DNA into a cell and its expression. A
number of recombinant virus particles can be used, for example,
alphaviruses, poxviruses, adenoviruses, herpesviruses, arena virus
and retroviruses. Also useful as a delivery vehicle is a
"recombinant cell vaccine," preferably tumor vaccines, in which
allogeneic (though histocompatible) or autologous tumor cells are
transfected with a DNA preparation encoding the therapeutic
proteins or peptides to be expressed. The cells are preferably
irradiated and then administered to a patient by any of a number of
known injection routes.
[0929] The therapeutic compositions that are administered by "tumor
cell vaccine," includes the recombinant molecules without carrier.
Treatment with tumor cell vaccines is useful for primary or
localized tumors as well as metastases. When used to treat
metastatic cancer, which includes prevention of further metastatic
disease, as well as, the cure existing metastatic disease.
[0930] As used herein, the term "treating" a disease includes
alleviating the disease or any of its symptoms and/or preventing
the development of a secondary disease resulting from the
occurrence of the initial disease.
[0931] An "effective treatment protocol" includes a suitable and
effective dose of an agent being administered to a subject, given
by a suitable route and mode of administration to achieve its
intended effect in treating a disease.
[0932] Effective doses and modes of administration for a given
disease can be determined by conventional methods and include, for
example, determining survival rates, side effects (i.e., toxicity)
and qualitative or quantitative, objective or subjective,
evaluation of disease progression or regression. In particular, the
effectiveness of a dose regimen and mode of administration of a
therapeutic composition of the present invention to treat cancer
can be determined by assessing response rates. A "response rate" is
defmed as the percentage of treated subjects that responds with
either partial or complete remission. Remission can be determined
by, for example, measuring tumor size or by microscopic examination
of a tissue sample for the presence of cancer cells.
[0933] In the treatment of cancer, a suitable single dose can vary
depending upon the specific type of cancer and whether the cancer
is a primary tumor or a metastatic form. One of skill in the art
can test doses of a therapeutic composition suitable for direct
injection to determine appropriate single doses for systemic
administration, taking into account the usual subject parameters
such as size and weight. An effective anti-tumor single dose of a
therapeutic recombinant DNA molecule or combination thereof is an
amount sufficient amount to result in reduction, and preferably
elimination, of the tumor after the DNA molecule or combination has
transfected cells at or near the tumor site.
[0934] A preferred single dose of SAg-encoding DNA molecule or
fusion product thereof is an amount that, when transfected into a
target cell population, leads to the production of SAg in an
amount, per transfected cell, ranging from about 250 femtograms
(fg) to about 1 .mu.g, preferably from about 500 fg to about 500 pg
and more preferably from about 1 pg to about 100 pg.
[0935] When the SAg-encoding DNA is combined with a second DNA
molecule encoding a second protein product, an effective single
dose of a the second DNA molecule is an amount that when
transfected into a target cell population leads to the production
of the second protein product in an amount, per transfected cell,
ranging from about 10 fg to about 1 ng, more preferably from about
100 fg to about 750 pg.
[0936] An effective cancer-treating single dose of SAg-encoding DNA
and a second DNA molecule encoding a second protein when
administered to a subject using a non-targeting carrier, is an
amount capable of reducing, and preferably eliminating, the primary
or metastatic tumor following transfection by the recombinant
molecules of cells at or near the tumor site. A preferred single
dose of such a therapeutic composition is from about 100 .mu.g to
about 4 mg of total recombinant DNA, more preferably from about 200
.mu.g to about 2 mg, most preferably from about 200 .mu.g to about
800 .mu.g of total recombinant molecules. A preferred single dose
of liposome-complexed, SAg-encoding DNA, is from about 100 .mu.g of
total DNA per 800 nmol of liposome to about 4 mg of total DNA
molecules per 32 .mu.mol of liposome, more preferably from about
200 .mu.g per 1.6 .mu.mol of liposome to about 3 mg of total
recombinant DNA per 24 .mu.mol of liposome, and even more
preferably from about 400 .mu.g per 3.2 .mu.mol of liposome to
about 2 mg per 16 .mu.mol of liposome.
[0937] One of skill in the art recognizes that the number of doses
required depends upon the extent of disease and the response of an
individual to treatment. Thus, according to this invention, an
effective number of doses includes any number required to cause
regression of primary or metastatic disease.
[0938] A preferred treatment protocol comprises monthly
administrations of single doses (as described above) for up to
about 1 year. An effective number of doses (per individual) of a
SAg-encoding DNA molecule and a second DNA molecule encoding a
second protein, when administered in a non-targeting carrier or
when complexed with liposomes, is from about 1 to about 10 dosings,
preferably from about 2 to about 8 dosings, and even more
preferably from about 3 to about 5 dosings. Preferably, such
dosings are administered about once every 2 weeks until signs of
remission appear, followed by about once a month until the disease
is gone.
[0939] The therapeutic compositions can be administered by any of a
variety of modes and routes, including but not limited to, local
administration into a site in the subject animal, which site
contains abnormal cells to be destroyed. An example is the local
injection within the area of a tumor or a lesion. Another example
is systemic administration.
[0940] Therapeutic compositions that are best delivered by local
administration include recombinant DNA molecules
[0941] (a) in a non-targeting carrier (e.g., "naked" DNA molecules
as taught in Wolff K et al., 1990, Science 247, 1465-1468); and
[0942] (b) complexed to a delivery vehicle.
[0943] Suitable delivery vehicles for local administration include
liposomes, and may further comprise ligands that target the vehicle
to a particular site.
[0944] A preferred mode of local administration is by direct
injection. Direct injection techniques are particularly useful for
injecting the composition into a cellular or tissue mass such as a
tumor mass or a granuloma mass that has been induced by a pathogen.
Thus, the present recombinant DNA molecule complexed with a
delivery vehicle is preferably injected directly into, or locally
in the area of, a tumor mass or a single cancer cell.
[0945] The present composition may also be administered in or
around a surgical wound. For example, a patient undergoes surgery
to remove a tumor. Upon removal of the tumor, the therapeutic
composition is coated on the surface of tissue inside the wound or
injected into areas of tissue inside the wound. Such local
administration will treat cancer cells that were not successfully
removed by the surgical procedure, as well as prevent recurrence of
the primary tumor or development of a secondary tumor in the
surgical area.
[0946] Therapeutic compositions that are best delivered by systemic
administration include recombinant DNA molecules complexed to a
tumor binding ligand or a ligand that binds to the tumor
vasculature or stroma. Examples are antibodies, antigens, receptor,
receptor ligand or a targeted delivery vehicle as disclosed herein.
These delivery vehicles may be liposomes into which are
incorporated targeting ligands, preferably ligands that targeting
the vehicle to the site of tumor cells or another type of lesion.
For cancer treatment, ligands that selectively bind to cancer
cells, or to cells within the area of a cancer cell, are preferred.
Systemic administration is used to treat primary or localized
tumors and, in particular, tumor metastases wherein the cancer
cells are dispersed. Systemic administration is advantageous when
targeting cancer in organs, especially those difficult to reach for
direct injection, (e.g., heart, spleen, lung or liver).
[0947] Preferred modes and routes of systemic administration
include intravenous injection and aerosol, oral and percutaneous
(topical) delivery. Intravenous injection methods and aerosol
delivery are performed conventionally. Oral delivery is achieved
preferably by complexing the therapeutic composition to a carrier
capable of withstanding degradation by digestive enzymes in the
subject's digestive system. Examples of such carriers, includes
plastic capsules or tablets as are known in the art. For topical
delivery, the therapeutic composition is mixed with a lipophilic
reagent (e.g., DMSO) that can pass into the skin.
[0948] The therapeutic compositions and methods of the present
invention are intended for animals, preferably mammals and birds,
in particular house pets, farm animals and zoo animals as these
terms are generally understood. By "farm animals" are intended
animals that are eaten or those that produce useful products (e.g.,
wool-producing sheep). Examples of preferred animal subjects to be
treated are dogs, cats, sheep, cattle, horses and pigs. The present
compositions and methods are effective in inbred and outbred animal
species. Most preferably, the animal is a human.
[0949] Another component useful in combination with the therapeutic
nucleic acids of this invention is an adjuvant suited for use with
a nucleic acid-based vaccine. Examples of adjuvant-containing
compositions include
[0950] 1) SAg-encoding DNA and a second DNA encoding a recombinant
protein; or
[0951] 2) SAg-encoding DNA combined with another peptide or
polypeptide; or
[0952] 3) DNA encoding a second recombinant protein and a SAg
peptide or polypeptide.
[0953] As indicated above, effective doses of a SAg-encoding DNA
combined with a second DNA molecule, or a vaccine nucleic acid
molecule are determined conventionally by those skilled in the art.
One measure of an effective dose is that produces a sufficient
amount of SAg and second protein to stimulate effector cell
immunity in a manner that enhances the effectiveness of the
vaccine. Adjuvants of the present invention are particularly suited
for use in humans because many traditional adjuvants (e.g.,
Freund's adjuvant and other bacterial cell wall components) are
toxic whereas others are relatively ineffective (e.g.,
aluminum-based salts and calcium-based salts).
EXAMPLE 15
General Procedures for In Vivo and Ex Vivo Sensitization to Produce
Tumor Specific Effector Cells for Adoptive Immunotherapy
[0954] Tumor growth is initiated by subcutaneous inoculation of
mice on both flanks with 1.5.times.10.sup.6 tumor cells suspended
in 0.05 ml of HBSS. After 9-12 days of tumor growth (approximately
8 mm in diameter), tumor-draining inguinal LN are removed
sterilely. Lymphocyte suspensions are prepared by teasing LN with
needles followed by pressing with the blunt end of a 10-ml plastic
syringe in HBSS. Tumor draining LN cells are stimulated in vitro in
a two-step procedure. Briefly, 4.times.10.sup.6 LN cells in 2 ml of
complete medium (CM) containing the SAg constructs are incubated in
a well of 24-well plates at 37.degree. C. in a 5% CO.sub.2
atmosphere for 2 days. CM consisted of RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, 2 mM freshly prepared
L-glutamine. 100 .mu.g/ml streptomycin, 100U/ml penicillin, a 50
mg/ml gentamycin, 0.55 mg/ml fungizone (all from GIBCO, Grand
Island, N.Y.) and 5.times.10.sup.-5M 2-mercaptoethanol (Sigma). The
cells were harvested, then washed and further cultured a
3.times.10.sup.5/well in 2 ml of CM with IL-2. After 3-day
incubation in IL-2, the cells are collected and counted to
determine the degree of proliferation. Finally, the cells are
suspended in appropriate media for flow cytometric analysis,
evaluation of cytotoxicity and lymphokine secretion, or for
adoptive immunotherapy.
EXAMPLE 16
General Adoptive Immunotherapy Protocol
[0955] Mice are injected with 2 to 3.times.10.sup.5 syngeneic tumor
cells suspended in 1 ml of HBSS to initiate pulmonary metastases.
On day 3, activated cells are given i.v. at numbers indicated
generally 10.sup.6-10.sup.7. In some instances, mice are also
treated with 15,000 U IL2 in 0.5 ml HBSS twice daily for 4
consecutive days to promote the in vivo function and survival of
the activated cells. On day 20 or 21, all mice are randomized,
killed and metastatic tumor nodules on the surface of the lungs
enumerated as previously described. If pulmonary metastases
exceeded 250, this number is arbitrarily assigned for statistical
analysis. The significance of differences in metastases numbers
between experimental group is determined by the Wilcoxon rank sum
test. Two sided p values of <0.1 are considered significant.
Each experimental group consists of at least five mice and no
animal was excluded from the statistical evaluation.
[0956] For testing SAg-glycosylceramide complexes and SAg
lipopolysaccharide complexes, additional models are used to assess
the dependence of the antitumor effect on NKT cells. Natural killer
T cells (NKT) lymphocytes express an invariant TCR encoded by the
V14 and J.sub.a281 gene segments. Mice with a deletion of
J.sub.a281 exclusively lack V14. The V14 NKT cell-deficient mice no
longer mediate IL-12 induced rejection of tumors.
[0957] Also generated are transgenic mice lacking recombination
activating gene(RAG) which preferentially generate V14 NKT cells
but block the development of other lymphocyte lineages, including
NK, B, and T cells. These mice are termed V14 NKT mice.
J281+/+(wild type), J281-/-(deleted of V14) and RAG-/-V14tgV8.2tg
(deleted of NK, T and B cells but preferentially generate V14 NKT
cells) mice are injected
[0958] (a) with 2.times.10.sup.6 B16 or FBL-3 (erythroleukemia)
cells in the spleen to induce liver metastasis,
[0959] (b) intravenously with 3.times.10.sup.5 B16 or
2.times.10.sup.6 LLC (Lewis lung carcinoma) cells for pulmonary
metastases or
[0960] (c) subcutaneously with 2.times.10.sup.6 B16 cells
(melanoma) for subcutaneous tumor growth on day 0.
[0961] SAg conjugates or fusion proteins are injected in doses of
0.1 to 50 mg on days 3, 5, 7, and 9 after the day of tumor
implantation. Control animals are injected with PBS on the same
schedule. On day 14, the mice are killed and either metastatic
nodules counted or GM3 melanoma antigens measured by
radioimmunoassay as previously described. For subcutaneous tumor
growth, injection of IL-12 or PBS is initiated on day 5, and the
mice are treated five times per week. The diameters of tumors are
measured daily with calipers. The sizes of the tumor are expressed
as the products of the longest diameter times the shortest diameter
(in mm.sup.2).
EXAMPLE 17
Preparation and Administration of DNA Liposome Complexes
[0962] A representative protocol for administration of DNA-liposome
complexes is as follows: DNA liposome complexes are mixed
immediately prior to injection by adding 0.1 ml of lactated
Ringer's solution into a sterile vial of plasmid DNA (20 mg/ml; 0.1
ml). An aliquot of this solution (0.1 ml) is added at room
temperature to 0.1 ml of 150 mM (dioleoyl
phosphatidylethanolamine/3.quadrature.[N-(N',N'-dimethylaminoet-
hane)-carbamoyl] cholesterol) liposome in lactated Ringer's
solution in a separate sterile vial. The DNA and liposome vials are
prepared in accordance with FDA guidelines and quality control
procedures. After incubation for 15 minutes at room temperature, an
additional 0.5 ml of sterile lactated Ringer's solution is added to
the vial and mixed. The DNA liposome solution (0.2 ml) is injected
into the patient's tumor nodule under sterile conditions at the
bedside after administration of local anesthesia (1% lidocaine)
using a 22-gauge needle. For catheter delivery, the DNA liposome
solution (0.6 ml) is delivered into the artery using percutaneous
delivery. Additional protocols for administration of DNA liposomal
constructs are given in Nabel, G J, Methods for Liposome-Mediated
Gene Transfer to Tumor Cells in vivo, in: Methods in Molecular
Medicine, Gene Therapy Protocols, Robbins P ed. Humana Press,
Totowa N.J. (1996). Cationic liposomes for delivery of DNA
construct to the tumor endothelium are prepared by the method of
Thurston et al., J. Clin Invest., 101: 1401-1413, (1998).
EXAMPLE 18
General Procedures for Administering Constructs in Human Tumor
Models and Human
Patients
[0963] The constructs described herein are tested for therapeutic
efficacy in several well established rodent models which are
considered to be highly representative as described in "Protocols
for Screening Chemical Agents and Natural Products Against Animal
Tumors and Other Biological Systems (Third Edition)", Cancer
Chemother. Reports, Part 3, 3: 1-112, which is hereby incorporated
by reference in its entirety. Additional tumor models of carcinoma
and sarcoma originating from primary sites and prepared as
established tumors at primary and/or metastatic sites are utilized
to test further the efficacy of the constructs.
EXAMPLE 19
General Procedures for Administering Tumor Cells or Sickled
Erythrocytes Transduced with SAgs and SAg-Activated T or NKT Cells
in Human Tumor Models and Human
Patients
[0964] A. Tumor Cells Transduced with SAg Nucleic Acids Alone or
Cotransfected with Oncogenes or Nucleic Acids Encoding Potent
Immunogens and Bacterial Products
[0965] In a representative protocol, using the B16 melanoma or A20
lymphoma or other models given above, 10.sup.5-10.sup.7 transfected
tumor cells are implanted subcutaneously and 1-6 months later
10.sup.5-10.sup.7 untransfected tumor cells, are implanted. In the
case of tumor cells cotransfected with several therapeutic nucleic
acids, controls are established consisting of groups transfected
with only one of the nucleic acids. These single transfectants are
administered on the same schedule as the cotransfectants and
assessed for capacity to prevent or reverse tumor growth compared
to positive controls receiving tumor alone. The animals receiving
the SAg transfected tumor cells show no evidence of growth of the
wild type tumor and prolonged survival compared to the controls in
which there is 100% appearance of the tumors. The differences are
statistically significant. SAg transfected tumor cells are also
used to treat established tumors as follows. Transfected tumor
cells, 10.sup.5-10.sup.7 are given 3-10 days after the appearance
of established tumors. Results show statistically significant
arrest of tumor growth, prolongation of survival in treated animals
compared to untreated controls.
[0966] B. SAg Activated Effector T or NKT Cells
[0967] Effector T or NKT cells are generated as described elsewhere
and are infused intravenously in doses of 10.sup.6-10.sup.8 into
syngeneic hosts that have pulmonary metastatic lesions established
by injecting tumor cells intravenously 3 to 12 days earlier. Twenty
days later, the animals are sacrificed and pulmonary metastases
measured in treated animals compared to untreated controls. Results
show statistically significant reduction in total number of
pulmonary nodules and prolonged survival in the treated group
compared to untreated controls.
EXAMPLE 20
General Test Evaluation Procedures for Constructs and SAg Activated
Effector T or NKT Cells
[0968] I. General Test Evaluation Procedures
[0969] A. Calculation of Mean Survival Time
[0970] Mean survival time is calculated according to the following
formula: 1 Mean survival time ( days ) = S + AS ( A - 1 ) - ( B + 1
) NT S ( A - 1 ) - NT
[0971] Definitions:
[0972] Day: Day on which deaths are no longer considered due to
drug toxicity. Example:
[0973] with treatment starting on Day 1 for survival systems (such
as L1210, P388, B16, 3LL, and W256):
[0974] Day A: Day 6.
[0975] Day B: Day beyond which control group survivors are
considered "no-takes."
[0976] Example: with treatment starting on Day 1 for survival
systems (such as L1210, P388, and W256), Day B-Day 18. For B16,
transplanted AKR, and 3LL survival systems, Day B is to be
established.
[0977] S: If there are "no-takes" in the treated group, S is the
sum from Day A through Day B. If there are no "no-takes" in the
treated group, S is the sum of daily survivors from Day A
onward.
[0978] S.sub.(A-1): Number of survivors at the end of Day (A-1).
Example: for 3LE21, S.sub.(A-1)=number of survivors on Day 5.
[0979] NT: Number of "no-takes" according to the criteria given in
Protocols 7.300 and 11.103.
[0980] B. T/C Computed for all Treated Groups
[0981] T/C is the ratio (expressed as a percent) of the mean
survival time of the treated group divided by the mean survival
time of the control group. Treated group animals surviving beyond
Day B, according to the chart below, are eliminated from
calculations:
13 No. of survivors in Percent of "no-takes" treated group beyond
Day B in control group Conclusion 1 Any percent "no-take" 2 <10
drug inhibition .gtoreq.10 "no-takes" .gtoreq.3 <15 drug
inhibitions .gtoreq.15 "no-takes" Positive control compounds are
not considered to have "no-takes" regardless of the number of
"no-takes" in the control group. Thus, all survivors on Day B are
used in the calculation of T/C for the positive control. Surviving
animals are evaluated and recorded on the day of evaluation as #
"cures" or "no-takes."
[0982] Calculation of Median Survival Time
[0983] Median Survival Time is defmed as the median day of death
for a test or control group. If deaths are arranged in
chronological order of occurrence (assigning to survivors, on the
final day of observation, a "day of death" equal to that day), the
median day of death is a day selected so that one half of the
animals died earlier and the other half died later or survived. If
the total number of animals is odd, the median day of death is the
day that the middle animal in the chronological arrangement died.
If the total number of animals is even, the median is the
arithmetical mean of the two middle values. Median survival time is
computed on the basis of the entire population and there are no
deletion of early deaths or survivors, with the following
exception:
[0984] C. Computation of Median Survival Time From Survivors
[0985] If the total number of animals including survivors (N) is
even, the median survival time (days) (X+Y)/2, where X is the
earlier day when the number of survivors is N/2, and Y is the
earliest day when the number of survivors (N/2)-1. If N is odd, the
median survival time (days) is X.
[0986] D. Computation of Median Survival Time From Mortality
Distribution
[0987] If the total number of animals including survivors (N) is
even, the median survival time (days) (X+Y)/2, where X is the
earliest day when the cumulative number of deaths is N/2, and Y is
the earliest day when the cumulative number of deaths is (N/2)+1.
If N is odd, the median survival time (days) is X.
[0988] Cures and "No-Takes": "Cures" and "no-takes" in systems
evaluated by median survival time are based upon the day of
evaluation. On the day of evaluation any survivor not considered a
"no-take" is recorded as a "cure." Survivors on day of evaluation
are recorded as "cures" or "no-takes," but not eliminated from the
calculation of the median survival time.
[0989] E. Calculation of Approximate Tumor Weight From Measurement
of Tumor Diameters with Vernier Calipers
[0990] The use of diameter measurements (with Vernier calipers) for
estimating treatment effectiveness on local tumor size permits
retention of the animals for lifespan observations. When the tumor
is implanted sc, tumor weight is estimated from tumor diameter
measurements as follows. The resultant local tumor is considered a
prolate ellipsoid with one long axis and two short axes. The two
short axes are assumed to be equal. The longest diameter (length)
and the shortest diameter (width) are measured with Vernier
calipers. Assuming specific gravity is approximately 1.0, and Pi is
about 3, the mass (in mg) is calculated by multiplying the length
of the tumor by the width squared and dividing the product by two.
Thus, 2 Tumor weight ( mg ) = length ( mm ) .times. ( width [ mm ]
) 2 2 Or L .times. ( W ) 2 2
[0991] The reporting of tumor weights calculated in this way is
acceptable inasmuch as the assumptions result in as much accuracy
as the experimental method warrants.
[0992] F. Calculation of Tumor Diameters
[0993] The effects of a drug on the local tumor diameter may be
reported directly as tumor diameters without conversion to tumor
weight. To assess tumor inhibition by comparing the tumor diameters
of treated animals with the tumor diameters of control animals, the
three diameters of a tumor are averaged (the long axis and the two
short axes). A tumor diameter T/C of 75% or less indicates activity
and a T/C of 75% is approximately equivalent to a tumor weight T/C
of 42%.
[0994] G. Calculation of Mean Tumor Weight from Individual Excised
Tumors
[0995] The mean tumor weight is defmed as the sum of the weights of
individual excised tumors divided by the number of tumors. This
calculation is modified according to the rules listed below
regarding "no-takes." Small tumors weighing 39 mg or less in
control mice or 99 mg or less in control rats, are regarded as
"no-takes" and eliminated from the computations. In treated groups,
such tumors are defined as "no-takes" or as true drug inhibitions
according to the following rules:
14 Percent of small tumors Percent of "no-takes" in treated group
in control group Action .ltoreq.17 Any percent no-take; not used in
calculations 18-39 <10 drug inhibition; use in calculations
.gtoreq.10 no-takes; not used in calculations .gtoreq.40 <15
drug inhibition; use in calculations .gtoreq.15 Code all nontoxic
tests "33"
[0996] Positive control compounds are not considered to have
"no-takes" regardless of the number of "no-takes" in the control
group. Thus, the tumor weights of all surviving animals are used in
the calculation of T/C for the positive control. T/C are computed
for all treated groups having more than 65% survivors. The T/C is
the ratio (expressed as a percent) of the mean tumor weight for
treated animals divided by the mean tumor weight for control
animals. SDs of the mean control tumor weight are computed the
factors in a table designed to estimate SD using the estimating
factor for SD given the range (difference between highest and
lowest observation). Biometrik Tables for Statisticians (Pearson E
S, and Hartley H G, eds.) Cambridge Press, vol. 1, table 22, p.
165.
[0997] II. Specific Tumor Models
[0998] A. Lymphoid Leukemia L1210
[0999] Summary: Ascitic fluid from donor mouse is transferred into
recipient BDF.sub.1 or CDF.sub.1 mice. Treatment begins 24 hours
after implant. Results are expressed as a percentage of control
survival time. Under normal conditions, the inoculum site for
primary screening is i.p., the composition being tested is
administered i.p., and the parameter is mean survival time. Origin
of tumor line: induced in 1948 in spleen and lymph nodes of mice by
painting skin with MCA. J Natl Cancer Inst. 13:1328, 1953.
[1000] Animals
[1001] Propagation: DBA/2 mice (or BDF.sub.1 or CDF.sub.1 for one
generation).
[1002] Testing: BDF.sub.1 (C57BL/6.times.DBA/2) or CDF.sub.1
(BALB/c.times.DBA/2) mice.
[1003] Weight: Within a 3-g weight range, with a minimum weight of
18 g for males and 17 g for females.
[1004] Sex: One sex used for all test and control animals in one
experiment.
[1005] Experiment Size: Six animals per test group.
[1006] Control Groups: Number of animals varies according to number
of test groups.
[1007] Tumor Transfer
[1008] Inject i.p., 0.1 ml of diluted ascitic fluid containing
10.sup.5 cells.
[1009] Time of Transfer for Propagation: Day 6 or 7.
[1010] Time of Transfer for Testing: Day 6 or 7.
[1011] Testing Schedule
[1012] Day 0: Implant tumor. Prepare materials. Run positive
control in every odd-numbered experiment. Record survivors
daily.
[1013] Day 1: Weigh and randomize animals. Begin treatment with
therapeutic composition. Typically, mice receive 1 ug of the test
composition in 0.5 ml saline. Controls receive saline alone. The
treatment is given as one dose per week. Any surviving mice are
sacrificed after 4 weeks of therapy.
[1014] Day 5: Weigh animals and record.
[1015] Day 20: If there are no survivors except those treated with
positive control compound, evaluate study.
[1016] Day 30: Kill all survivors and evaluate experiment.
[1017] Quality Control
[1018] Acceptable control survival time is 8-10 days. Positive
control compound is 5-fluorouracil; single dose is 200
mg/kg/injection, intermittent dose is 60 mg/kg/injection, and
chronic dose is 20 mg/kg/injection. Ratio of tumor to control (T/C)
lower limit for positive control compound is 135%
[1019] Evaluation
[1020] Compute mean animal weight on Days 1 and 5, and at the
completion of testing compute T/C for all test groups with >65%
survivors on Day 5. A T/C value 85% indicates a toxic test. An
initial T/C 125% is considered necessary to demonstrate activity. A
reproduced T/C 125% is considered worthy of further study. For
confirmed activity a composition should have two multi-dose assays
that produce a T/C 125%.
[1021] B. Lymphocytic Leukemia P388
[1022] Summary: Ascitic fluid from donor mouse is implanted in
recipient BDF.sub.1 or CDF.sub.1 mice. Treatment begins 24 hours
after implant. Results are expressed as a percentage of control
survival time. Under normal conditions, the inoculum site for
primary screening is ip, the composition being tested is
administered ip daily for 9 days, and the parameter is median
survival time. Origin of tumor line: induced in 1955 in a DBA/2
mouse by painting with MCA. Scientific Proceedings, Pathologists
and Bacteriologists 33:603, 1957.
[1023] Animals
[1024] Propagation: DBA/2 mice (or BDF.sub.1 or CDF.sub.1 for one
generation)
[1025] Testing: BDF.sub.1 (C57BL/6.times.DBA/2) or CDF.sub.1
(BALB/c.times.DBA/2) mice.
[1026] Weight: Within a 3-g weight range, with a minimum weight of
18 g for males and 17 g for females.
[1027] Sex: One sex used for all test and control animals in one
experiment.
[1028] Experiment Size: Six animals per test group.
[1029] Control Groups: Number of animals varies according to number
of test groups.
[1030] Tumor Transfer
[1031] Implant: Inject ip
[1032] Size of Implant: 0.1 ml diluted ascitic fluid containing
10.sup.6 cells.
[1033] Time of Transfer for Propagation: Day 7.
[1034] Time of Transfer for Testing: Day 6 or 7.
[1035] Testing Schedule
[1036] Day 0: Implant tumor. Prepare materials. Run positive
control in every odd-numbered experiment. Record survivors
daily.
[1037] Day 1: Weigh and randomize animals. Begin treatment with
therapeutic composition. Typically, mice receive lug of the
composition being tested in 0.5 ml saline. Controls receive saline
alone. The treatment is given as one dose per week. Any surviving
mice are sacrificed after 4 weeks of therapy.
[1038] Day 5: Weigh animals and record.
[1039] Day 20: If there are no survivors except those treated with
positive control compound, evaluate experiment.
[1040] Day 30: Kill all survivors and evaluate experiment.
[1041] Quality Control
[1042] Acceptable median survival time is 9-14 days. Positive
control compound is 5-fluorouracil: single dose is 200
mg/kg/injection, intermittent dose is 60 mg/kg/injection, and
chronic dose is 20 mg/kg/injection. T/C lower limit for positive
control compound is 135% Check control deaths, no takes, etc.
[1043] Evaluation
[1044] Compute mean animal weight on Days 1 and 5, and at the
completion of testing compute T/C for all test groups with >65%
survivors on Day 5. A T/C value 85% indicates a toxic test. An
initial T/C 125% is considered necessary to demonstrate activity. A
reproduced T/C 125% is considered worthy of further study. For
confirmed activity a synthetic must have two multi-dose assays
(each performed at a different laboratory) that produce a T/C 125%;
a natural product must have two different samples that produce a
T/C 125% in multi-dose assays.
[1045] C. Melanotic Melanoma B16
[1046] Summary: Tumor homogenate is implanted ip or sc in BDF.sub.1
mice. Treatment begins 24 hours after either ip or sc implant or is
delayed until an sc tumor of specified size (usually approximately
400 mg) can be palpated. Results expressed as a percentage of
control survival time. The composition being tested is administered
ip, and the parameter is mean survival time. Origin of tumor line:
arose spontaneously in 1954 on the skin at the base of the ear in a
C57BL/6 mouse. Handbook on Genetically Standardized Jax Mice.
Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine, 1962. See
also Ann NY Acad Sci 100, Parts 1 and 2, 1963.
[1047] Animals
[1048] Propagation: C57BL/6 mice.
[1049] Testing: BDF.sub.1 (C57BL/6.times.DBA/2) mice.
[1050] Weight: Within a 3-g weight range, with a minimum weight of
18 g for males and 17 g for females.
[1051] Sex: One sex used for all test and control animals in one
experiment.
[1052] Experiment Size: Ten animals per test group. For control
groups, the number of animals varies according to number of test
groups.
[1053] Tumor Transfer
[1054] Propagation: Implant fragment sc by trochar or 12-gauge
needle or tumor homogenate (see below) every 10-14 days into
axillary region with puncture in inguinal region. Testing: Excise
sc tumor on Day 10-14.
[1055] Homogenate: Mix 1 g or tumor with 10 ml of cold balanced
salt solution and homogenize, and implant 0.5 ml of this tumor
homogenate ip or sc.
[1056] Fragment: A 25-mg fragment may be implanted sc.
[1057] Testing Schedule
[1058] Day 0: Implant tumor. Prepare materials. Run positive
control in every odd-numbered experiment. Record survivors
daily.
[1059] Day 1: Weigh and randomize animals. Begin treatment with
therapeutic composition. Typically, mice receive 1 .mu.g of the
composition being tested in 0.5 ml saline. Controls receive saline
alone. The treatment is given as one dose per week. Any surviving
mice are sacrificed 8 weeks of therapy.
[1060] Day 5: Weigh animals and record.
[1061] Day 60: Kill all survivors and evaluate experiment.
[1062] Quality Control
[1063] Acceptable control survival time is 14-22 days. Positive
control compound is 5-fluorouracil: single dose is 200
mg/kg/injection, intermittent dose is 60 mg/kg/injection, and
chronic dose is 20 mg/kg/injection. T/C lower limit for positive
control compound is 135% Check control deaths, no takes, etc.
[1064] Evaluation
[1065] Compute mean animal weight on Days 1 and 5, and at the
completion of testing compute T/C for all test groups with >65%
survivors on Day 5. A T/C value 85% indicates a toxic test. An
initial T/C 125% is considered necessary to demonstrate activity. A
reproduced T/C 125% is considered worthy of further study. For
confirmed activity a therapeutic composition should have two
multi-dose assays that produce a T/C 125%.
[1066] Metastasis after IV Injection of Tumor Cells
[1067] 10.sup.5 B16 melanoma cells in 0.3 ml saline are injected
intravenously in C57BL/6 mice. The mice are treated intravenously
with Ig of the composition being tested in 0.5 ml saline. Controls
receive saline alone. The treatment is given as one dose per week.
Mice sacrificed after 4 weeks of therapy, the lungs are removed and
metastases are enumerated.
[1068] C. 3LL Lewis Lung Carcinoma
[1069] Summary: Tumor may be implanted sc as a 2-4 mm fragment, or
im as a 2.times.10.sup.6-cell inoculum. Treatment begins 24 hours
after implant or is delayed until a tumor of specified size
(usually approximately 400 mg) can be palpated. The composition
being tested is administered ip daily for 11 days and the results
are expressed as a percentage of the control.
[1070] Origin of tumor line: arose spontaneously in 1951 as
carcinoma of the lung in a C57BL/6 mouse. Cancer Res 15:39, 1955.
See, also Malave, I. et al., J. Nat'l. Canc. Inst. 62:83-88
(1979).
[1071] Animals
[1072] Propagation: C57BL/6 mice.
[1073] Testing: BDF.sub.1 mice or C3H.
[1074] Weight: Within a 3-g weight range, with a minimum weight of
18 g for males and 17 g for females.
[1075] Sex: One sex used for all test and control animals in one
experiment.
[1076] Experiment Size: Six animals per test group for sc implant,
or ten for im implant. For control groups, the number of animals
varies according to number of test groups.
[1077] Tumor Transfer
[1078] Implant: Inject cells im in hind leg or implant fragment sc
in axillary region with puncture in inguinal region.
[1079] Time of Transfer for Propagation: Days 12-14.
[1080] Time of Transfer for Testing: Days 12-14.
[1081] Testing Schedule
[1082] Day 0: Implant tumor. Prepare materials. Run positive
control in every odd-numbered experiment. Record survivors
daily.
[1083] Day 1: Weigh and randomize animals. Begin treatment with
therapeutic composition. Typically, mice receive lug of the
composition being tested in 0.5 ml saline. Controls receive saline
alone. The treatment is given as one dose per week. Any surviving
mice are sacrificed after 4 weeks of therapy.
[1084] Day 5: Weigh animals and record.
[1085] Final Day: Kill all survivors and evaluate experiment.
[1086] Quality Control
[1087] Acceptable im tumor weight on Day 12 is 500-2500 mg.
Acceptable im tumor median survival time is 18-28 days. Positive
control compound is cyclophosphamide: 20 mg/kg/injection, qd, Days
1-11. Check control deaths, no takes, etc.
[1088] Evaluation
[1089] Compute mean animal weight when appropriate, and at the
completion of testing compute T/C for all test groups. When the
parameter is tumor weight, a reproducible T/C 42% is considered
necessary to demonstrate activity. When the parameter is survival
time, a reproducible T/C 125% is considered necessary to
demonstrate activity. For confirmed activity a synthetic must have
two multi-dose assays (each performed at a different laboratory); a
natural product must have two different samples.
[1090] D. 3LL Lewis Lung Carcinoma Metastasis Model
[1091] This model has been utilized by a number of investigators.
See, for example, Gorelik, E. et al., J. Nat'l. Canc. Inst.
65:1257-1264 (1980); Gorelik, E. et al., Rec. Results Canc. Res.
75:20-28 (1980); Isakov, N. et al., Invasion Metas. 2:12-32 (1982)
Talmadge J. E. et al., J. Nat'l. Canc. Inst. 69:975-980 (1982);
Hilgard, P. et al., Br. J. Cancer 35:78-86(1977)).
[1092] Mice: male C57BL/6 mice, 2-3 months old.
[1093] Tumor: The 3LL Lewis Lung Carcinoma was maintained by sc
transfers in C57BL/6 mice. Following sc, im or intra-footpad
transplantation, this tumor produces metastases, preferentially in
the lungs. Single-cell suspensions are prepared from solid tumors
by treating minced tumor tissue with a solution of 0.3% trypsin.
Cells are washed 3 times with PBS (pH 7.4) and suspended in PBS.
Viability of the 3LL cells prepared in this way is generally about
95-99% (by trypan blue dye exclusion). Viable tumor cells
(3.times.10.sup.4-5.times.10.sup.6 ) suspended in 0.05 ml PBS are
injected into the right hind foot pads of C57BL/6 mice. The day of
tumor appearance and the diameters of established tumors are
measured by caliper every two days.
[1094] Typically, mice receive lug of the composition being tested
in 0.5 ml saline.
[1095] Controls receive saline alone. The treatment is given as one
or two doses per week.
[1096] In experiments involving tumor excision, mice with tumors
8-10 mm in diameter are divided into two groups. In one group, legs
with tumors are amputated after ligation above the knee joints.
Mice in the second group are left intact as nonamputated
tumor-bearing controls. Amputation of a tumor-free leg in a
tumor-bearing mouse has no known effect on subsequent metastasis,
ruling out possible effects of anesthesia, stress or surgery.
Surgery is performed under Nembutal anesthesia (60 mg veterinary
Nembutal per kg body weight).
[1097] Determination of Metastasis Spread and Growth
[1098] Mice are killed 10-14 days after amputation. Lungs are
removed and weighed. Lungs are fixed in Bouin's solution and the
number of visible metastases is recorded. The diameters of the
metastases are also measured using a binocular stereoscope equipped
with a micrometer-containing ocular. under 8.times. magnification.
On the basis of the recorded diameters, it is possible to calculate
the volume of each metastasis. To determine the total volume of
metastases per lung, the mean number of visible metastases is
multiplied by the mean volume of metastases. To further determine
metastatic growth, it is possible to measure incorporation of
.sup.125IdUrd into lung cells (Thakur, M. L. et al., J. Lab. Clin.
Med. 89:217-228 (1977). Ten days following tumor amputation, 25
.mu.g of FdUrd is inoculated into the peritoneums of tumor-bearing
(and, if used, tumor-resected mice. After 30 min, mice are given 1
.mu.Ci of .sup.125IdUrd. One day later, lungs and spleens are
removed and weighed, and a degree of .sup.125IdUrd incorporation is
measured using a gamma counter.
[1099] Statistics: Values representing the incidence of metastases
and their growth in the lungs of tumor-bearing mice are not
normally distributed. Therefore, non-parametric statistics such as
the Mann-Whitney U-Test may be used for analysis. Study of this
model by Gorelik et al. (1980, supra) showed that the size of the
tumor cell inoculum determined the extent of metastatic growth. The
rate of metastasis in the lungs of operated mice was different from
primary tumor-bearing mice. Thus in the lungs of mice in which the
primary tumor had been induced by inoculation of large doses of 3LL
cells (1-5.times.10.sup.6) followed by surgical removal, the number
of metastases was lower than that in nonoperated tumor-bearing
mice, though the volume of metastases was higher than in the
nonoperated controls. Using .sup.125IdUrd incorporation as a
measure of lung metastasis, no significant differences were found
between the lungs of tumor-excised mice and tumor-bearing mice
originally inoculated with 1.times.10.sup.6 3LL cells. Amputation
of tumors produced following inoculation of 1.times.10.sup.5 tumor
cells dramatically accelerated metastatic growth. These results
were in accord with the survival of mice after excision of local
tumors. The phenomenon of acceleration of metastatic growth
following excision of local tumors had been observed by other
investigators. The growth rate and incidence of pulmonary
metastasis were highest in mice inoculated with the lowest doses
(3.times.10.sup.4-1.time- s.10.sup.5 of tumor cells) and
characterized also by the longest latency periods before local
tumor appearance. Immunosuppression accelerated metastatic growth,
though nonimmunologic mechanisms participate in the control exerted
by the local tumor on lung metastasis development. These
observations have implications for the prognosis of patients who
undergo cancer surgery.
[1100] E. Walker Carcinosarcoma 256
[1101] Summary: Tumor may be implanted sc in the axillary region as
a 2-6 mm fragment, im in the thigh as a 0.2-ml inoculum of tumor
homogenate containing 10.sup.6 viable cells, or ip as a 0.1-ml
suspension containing 10.sup.6 viable cells. Treatment of the
composition being tested is usually ip. Origin of tumor line: arose
spontaneously in 1928 in the region of the mammary gland of a
pregnant albino rat. J Natl Cancer Inst 13:1356, 1953.
[1102] Animals
[1103] Propagation: Random-bred albino Sprague-Dawley rats.
[1104] Testing: Fischer 344 rats or random-bred albino rats.
[1105] Weight Range: 50-70 g (maximum of 10-g weight range within
each experiment).
[1106] Sex: One sex used for all test and control animals in one
experiment.
[1107] Experiment Size: Six animals per test group. For control
groups, the number of animals varies according to number of test
groups.
[1108] Time of Tumor Transfer
[1109] Time of Transfer for Propagation: Day 7 for im or ip
implant; Days 11-13 for sc implant.
[1110] Time of Transfer for Testing: Day 7 for im or ip implant;
Days 11-13 for sc implant.
[1111] Tumor Transfer
[1112] Sc fragment implant is by trochar or 12-gauge needle into
axillary region with puncture in inguinal area. Im implant is with
0.2 ml of tumor homogenate (containing 10.sup.6 viable cells) into
the thigh. Ip implant is with 0.1 ml of suspension (containing
10.sup.6 viable cells) into the ip cavity.
[1113] Testing Schedule
[1114] Prepare and administer compositions under test on days,
weigh animals, and evaluate test on the days listed in the
following tables.
15 Test system Prepare drug Administer drug Weight animals Evaluate
5WA16 2 3-6 3 and 7 7 5WA12 0 1-5 1 and 5 10-14 5WA31 0 1-9 1 and 5
30
[1115] Day 0: Implant tumor. Prepare materials. Run positive
control in every odd-numbered experiment. Record survivors
daily.
[1116] Day 1: Weigh and randomize animals.
[1117] Final Day: Kill all survivors and evaluate experiment.
[1118] Quality Control
[1119] Acceptable im tumor weight or survival time for the above
three test systems: 5WA16: 3-12 g. 5WA12: 3-12 g. 5WA31 or 5WA21:
5-9 days.
[1120] Evaluation
[1121] Compute mean animal weight when appropriate, and at the
completion of testing compute T/C for all test groups. When the
parameter is tumor weight, a reproducible T/C 42% is considered
necessary to demonstrate activity. When the parameter is survival
time, a reproducible T/C 125% is considered necessary to
demonstrate activity. For confirmed activity a therapeutic agent
must have activity in two multi-dose assays.
[1122] F. A20 lymphoma
[1123] 10.sup.6 murine A20 lymphoma cells in 0.3 ml saline are
injected subcutaneously in Balb/c mice. The mice are treated
intravenously with 1 g of the composition being tested in 0.5 ml
saline. Controls receive saline alone. The treatment is given as
one dose per week. Tumor growth is monitored daily by physical
measurement of tumor size and calculation of total tumor volume.
After 4 weeks of therapy the mice are sacrificed.
[1124] Treatment Regimens and Results (Constructs)
[1125] For determining efficacy in the tumor models described above
the general categories of therapeutic constructs used are given
below. For all of the classes of conjugates listed below, the SAg
component can be prepared as either a DNA encoding SAg or as the
SAg polypeptide itself. In either form the SAg DNA or protein may
be conjugated to additional molecules, either nucleic acid or
polypeptides. Operationally, for therapeutic use in vivo or ex
vivo, these conjugates may be prepared by chemical coupling or by
recombinant means (whichever is appropriate) and conjugated to a
tumor-targeting structure or incorporated into a vehicle (e.g.,
liposomes) that themselves comprise a tumor targeting structure(s).
Again, examples of such targeting structures include, but are not
limited to, an antibody, antigen, receptor or receptor ligand.
Methods are disclosed in Examples 1, 3, 4, 5, 6, 7, 14, 17, 18,
30-32.
[1126] 1. SAg Nucleic Acid Constructs including Phage Displays and
SAg Transfected Bacterial Cells
[1127] 2. Glycosylated SAgs
[1128] 3. Chimeric SAgs
[1129] Conjugates having a Superantigen component (polypeptide or
nucleic acid) and a partner that is either a single component or a
conjugate of 2 or more components (protein, carbohydrate, lipid or
DNA) as indicated below.
16 Superantigen (Protein or DNA) Partner (Single Component or
Conjugate) 4. DNA coding sequence 5. Polypeptide 6. Nucleic acid 7.
Tumor associated Peptide 8. Tumor Antigen-MHC protein 9. LPS 10.
Lipoarabinomannan 11. Ganglioside 12. Glycosphingolipid 13.
Ganglioside-CD1 receptor 14. Glycosphingolipid-CD1 receptor 15.
Glycosylceramide (e.g., Gal-Cer) 16. GalCer-CD1 receptor 17. Gal
18. Arg-Gly-Asp or Asn-Gly-Arg 19 iNOS 20. Gb2 or Gb3 or Gb4 18.
(Gb2 or Gb3 or Gb4)-CD1 receptor 19. -GPI-(Gb2 or Gb3 or Gb4) 21.
-GPI-(Gb2 or Gb3 or Gb4)-CD1 receptor 22. Verotoxin 23. Verotoxin A
or B Subunit 24. IFN.alpha. receptor peptide homologous to VT 25.
CD19 peptide homologous to VT 26. LDL, VLDL, HDL, IDL 27.
Apolipoproteins (e.g., Lp(a), apoB-100, apoB-48, apoE) 28. OxyLDL,
oxyLDL mimics, (e.g., 7.quadrature.- hydroperoxycholesterol,
7.quadrature.-hydroxychole- sterol, 7-ketocholesterol,
5.alpha.-6.alpha.-epoxycholesterol,
7.quadrature.-hydroperoxy-choles-5-en-3.quadrature.-ol,
4-hydroxynonenal (4-HNE), 9-HODE, 13-HODE and cholesterol-9-HODE)
29. OxyLDL by products (e.g. lysolecithin, lysophosphatidylcholine,
malondialdehyde, 4-hydroxynonenal) 30 LDL & oxyLDL receptors
(e.g., LDL oxyLDL, acetyl-LDL, VLDL, LRP, CD36, SREC, LOX-1,
macrophage scavenger receptors)
[1130] Vaccine Use
[1131] For use as a vaccine, the constructs are administered
subcutaneously, intramuscularly intradermally or intraperitoneally
in doses ranging from 50 to 500 ng in various vehicles such as
Freund's adjuvant, aluminum hydroxide, pluruonic acid triblock and
liposomes as described in the art. Doses may be repeated every 10
days. Tumors are implanted after the last dose. A control group
does not receive the vaccine.
[1132] Use in Established Tumors
[1133] For proteins or nucleic acid constructs, treatment consists
of injecting animals iv or ip with 50, 500 1000 or 5,000 ng of in
0.1-0.5 ml of normal saline. Unless indicated otherwise above,
treatments are given one to three times per week for two to five
weeks. Phage displays are administered as 10.sup.9 transducing
units (TU) and irradiated bacterial cells as 10.sup.5 cells iv into
the tail vein one to three times per week for two to five weeks.
Exosomes or vesicles, harvested from transfected, transformed or
fusion tumor cells or sickled cells are given i.v. into the tail
vein in a dose of 0.25-1 g per animal one to three times per week
for two to five weeks. The results shown in Table VI are for each
composition and dose tested. The results are statistically
significant by the Wilcoxon rank sum test.
[1134] Treatment regimens for SAg activated effector T or NKT cells
are in Example 16, 18, 19. The preferred animal model for
evaluation of the adoptively transferred T or NKT effector cells is
the MCA 205/207 fibrosarcoma with pulmonary metastases (Shu S. et
al., J. Immunol. 152: 1277-1288 (1994)). The other models given in
Example 20 are also suitable for evaluation of the therapeutic
effectiveness of the effector T cells.
17TABLE VI Tumor Model Parameter % of Control Response L1210 Mean
survival time >130% P388 Mean survival time >130% B16 Mean
survival time >130% B16 metastasis Median number of metastases
<70% 3LL Mean survival time >130% Mean tumor weight <40%
3LL metastasis Median survival time >130% Mean lung weight
<60 Median number of metastases <60% Median volume of
metastases <60% Medial volume of metastases <60% Median
uptake of IdUrd <60% Walker carcinoma Median survival time
>130% Mean tumor weight <40% A20 Mean survival time >130%
Mean tumor volume <40%
EXAMPLE 22
Antitumor Effects of Therapeutic Constructs and Effector T, NKT
Cells or Sickled Erythrocytes in Human Patients
[1135] All patients treated have histologically confirmed malignant
disease including carcinomas, sarcomas, melanomas, lymphomas and
leukemia and have failed conventional therapy. Patients may be
diagnosed as having any stage of metastatic disease involving any
organ system. Staging describes both tumor and host, including
organ of origin of the tumor, histologic type and histologic grade,
extent of tumor size, site of metastases and functional status of
the patient. A general classification includes the known ranges of
Stage I (localized disease) to Stage 4(widespread metastases).
Patient history is obtained and physical examination performed
along with conventional tests of cardiovascular and pulmonary
function and appropriate radiologic procedures. Histopathology is
obtained to verify malignant disease.
EXAMPLE 23
Treatment Procedures
[1136] Constructs (or Preparations)
[1137] Doses of the constructs are determined as described above
using, inter alia, appropriate animal models of tumors. Two classes
of therapeutic compositions are administered namely SAg proteins or
SAg conjugates as described above for animal models.
[1138] A treatment consists of injecting the patient with 0.5-500
mg of Construct intravenously in 200 ml of normal saline over a one
hour period. Treatments are given 3.times./week for a total of 12
treatments. Patients with stable or regressing disease are treated
beyond the 12.sup.th treatment. Treatment is given on either an
outpatient or inpatient basis as needed.
[1139] Effector T or NKT Cells
[1140] Eligible patients are treated with tumor antigens such as
irradiated tumor cells or GM-CSF transduced tumor cells injected
approximately 10 centimeters from a draining lymph node site. Ten
days post injection, draining lymph nodes are obtained in a limited
surgical procedure at the site draining the injection. The lymph
nodes are converted to a single cell suspension of lymphocytes and
these are incubated with various SAg preparations for two days
followed by Il-2 for an additional 72 hours. These lymphocytes now
called effector T cells or NKT cell are used for adoptive
immunotherapy.
[1141] Effector T or NKT cells harvested by centrifugation at
500.times.g for 15 min and the cell pellets are pooled. After
washing the cells in HBSS, the cell are resuspended in 200 ml of
normal saline containing 5% human serum albumin and 450,000 IU of
IL-2 for transfer. Each recipient will receive four escalating
doses or 33 million, 100 million, 330 million and 1 billion cells
per square meter of body surface area each given one week apart.
Cells are infused through a subclavian central venous catheter over
a 30-minute interval. IL-2 administration i.v. is commenced
immediately after completion of cell infusion at a dose and
schedule of 180,000 IU/ml every 8 h. for 5 days. All patients
receive indomethacin (50 mg P.O.) every 8 h, acetaminophen (650 mg
P.O.) every 6 h. and ranitidine (150 mg P.O.) every 12 h while
receiving IL-2 in order to reduce febrile and gastric side effects.
As controls, a cohort of patients is treated with the in vivo tumor
vaccination step and IL-2 without the tumor effector cells.
Patients will be followed for clinical response every 4 weeks for 2
months with repeat radiological examinations.
[1142] Abbreviated Exemplary Human Protocol: Sequential
Administration of GM-CSF Transduced Tumor Cells In vivo and SAg
Activated NKT and T Cells ex vivo in Patients with Metastatic Renal
Cell Carcinoma and Melanoma
[1143] In vivo Phase: Immunization with GM-CSF Transduced Tumor
Cells
[1144] Day 1: GM CSF transfected tumor cells (renal
carcinoma/melanoma) are injected as given in Phase I GM-CSF Gene
Transduction Protocol [Human Gene Therapy 6: 347-368, (1995)]
[1145] Day 7-10: Lymph Nodes draining the GM-CSF transfected tumor
cell sites are removed and placed in tissue culture OR patients are
pheresed and their peripheral blood T cells and NKT cells collected
for further treatment in tissue culture as described below.
[1146] Ex vivo Phase: Immunization with SAg
[1147] 1. The T cells are obtained from either lymph nodes draining
GM-CSF transduced tumor cell immunization or peripheral blood and
subdivided into CD4+CD8+ (T cell)and CD4-CD8- (NKT cell)
populations.
[1148] 2. SAg enterotoxin B is added to cultures of the NKT and T
cell populations for 48 hours.
[1149] 3. The NKT cells and T cells are further expanded for an
additional 72 hours (optional).
[1150] SAg Activated NKT and/or T Cell Administration
[1151] 1. The CD4+CD8+ (T cell) and CD4-CD8- (NKT) populations are
harvested for injection into patients.
[1152] 2. T cells or NKT cells are administered with a mean 1011
cells per patient.
[1153]
[1154] Assessment:
[1155]
[1156] 1. T cells phenotypes for NKT cell markers, V expression,
CD44, CD62 are carried out on lymph node and peripheral blood T
cells or NKT cells immediately after their removal and at various
intervals after ex vivo SAg stimulation and expansion.
[1157] 2. Tumor and DTH assessment are as described in the Phase I
Protocol on GM-CSF Transduction [Human Gene Therapy 6: 347-368
(1995)].
[1158] Patient Evaluation
[1159] Assessment of response of the tumor to the therapy is made
once per week during therapy and 30 days thereafter. Depending on
the response to treatment, side effects, and the health status of
the patient, treatment is terminated or prolonged from the standard
protocol given above. Tumor response criteria are those established
by the International Union Against Cancer and are listed in Table
VII.
18TABLE VII RESPONSE DEFINITION Complete remission Disappearance of
all evidence of disease (CR) Partial remission >50% decrease in
the product of the two greatest (PR) perpendicular tumor diameters;
no new lesions Less than partial 25-50% decrease in tumor size,
stable for at least remission (<PR) 1 month Stable disease
<25% reduction in tumor size; no progression or new lesions
Progression >25% increase in size of any one measured lesion or
appearance of new lesions despite stabilization or remission of
disease in other measured sites
[1160] The efficacy of the therapy in a population is evaluated
using conventional statistical methods including, for example, the
Chi Square test or Fisher's exact test. Long-term changes in and
short term changes in measurements can be evaluated separately.
[1161] Results
[1162] One hundred and fifty patients are treated. The results are
summarized in Table VIII. Positive tumor responses are observed in
80% of the patients as follows:
19TABLE VIII All Patients Response No. % PR 20 66% <PR 10 33%
Tumor Types Response % of Patients Breast Adenocarcinoma PR +
<PR 80% Gastrointestinal Carcinoma PR + <PR 75% Lung
Carcinoma PR + <PR 75% Prostate Carcinoma PR + <PR 75%
Lymphoma/Leukemia PR + <PR 75% Head and Neck Cancer PR + <PR
75% Renal and Bladder Cancer PR + <PR 75% Melanoma PR + <PR
75%
EXAMPLE 24
Preparation of DCs
[1163] Splenocytes obtained from naive C57BL/6 females are treated
with ammonium chloride Tris buffer for 3 min at 37.degree. C. to
deplete red blood cells. Splenocytes (3 ml) at 2.times.10.sup.7
cells/ml are layered over 2 ml metrizamide gradient column (Nycomed
Pharma AS, Oslo, Norway; analytical grade, 14.5 g added to 100 ml
PBS, pH 7.0) and centrifuged at 600 g for 10 mm. The DC-enriched
fraction from the interface is further enriched by adherence for 90
mm. Adherent cells (mostly DC and a few contaminating macrophages)
are retrieved by gentle scraping and subjected to a second round of
adherence at 37.degree. C. for 90 min to deplete the contaminating
macrophages. Non-adherent cells are pooled as splenic DC, and by
FACS.RTM. analysis are .about.80-85% DC (stainwith mAb 33D1), 1-2%
macrophages (stain with mAb F4/80), 10% T cells, and <5% B
cells. The pellet is resuspended and enriched for macrophages by
two rounds of adherence at 37.degree. C. for 90 mm each. More than
80% of the adherent population is identified as macrophages by
FACS.RTM. analysis with 5% lymphocytes and <5% DC. B cells are
separated from the non-adherent population (B and T cells) by
panning on anti-Ig-coated plates. The separated cell population
which is comprised of >80% T lymphocytes by FACS analysis is
used as responder T cells
[1164] Generation of Bone Marrow-Derived DCs.
[1165] Erythrocyte depleted mouse bone marrow cells from flushed
marrow cavities are cultured in CM with 10 ng/ml GM-CSF and 10
ng/ml IL-4 at 1.times.10.sup.6 cells/ml. On day 7, DCs are
harvested by gentle pipetting and are enriched by 14.5% (by weight)
metrizamide (Sigma) CM gradients. The low density interface
containing the DC is collected by gentle pipette aspiration. The
floating DCs express CD11b, CD11c, CD86, DEC2O5, MHC class I and II
and CD4O. They are negative or low for CD3 and B220 expression.
[1166] DC Cultures
[1167] Mouse BM-DCs are prepared in CM with IL-4 and GM-CSF (1000
IU/ml each). The DC are washed twice with CM, enumerated purity
>90% by positive coexpression of MHC class II, CD40, CD80, CD86,
and CD11c by fluorescence-activated cell sorter (ACS)], and
cultured in CM with added cytokines for further studies.
Human-monocyte-derived DCs are obtained from the adherent fraction
of mononuclear cells of healthy volunteers and are incubated 7-8
days in AIMV containing L-Glu, antibiotics and rhIL-4 and rhGM-CSF
(1000 IU/ml each, Schering Plough, Kenilworth, N.J., U.S.A). After
8 days in culture, the loosely adherent or floating cells show
typical dendritic morphology, express high levels of MHC class I
and II molecules, CD4O and CD86; most are positive for CD1a and
CD11c but low or negative for CD2, CD3, CD14, CD19 and CD83.
EXAMPLE 25
Preparation of DC/Tumor Cells Hybrids (DC/tc)
[1168] DCs derived from BM culture are fused with tumor cells at a
3:1 (DC:tumor cell) ratio using polyethylene glycol (PEG;
MW=1450)/DMSO solution (Sigma). In brief, tumor cells are cultured
in CM supplemented with 20% FCS and 1.times.OPI solution
(oxaloacetate, pyruvate, and insulin; Sigma) for 4-6 h before
fusion. Tumor cells and DCs are then mixed and washed with
serum-free medium. After removing the medium, I ml of PEG is added
to the cell pellet while resuspending the cells by stirring for 2
min. An additional 10 ml of serum-free medium is added to the cell
suspension over the next 3 min. with continued stirring. The cells
are centrifuged at 400.times.g for 5 mm. The cells are resuspended
with 20% FCS CM and cultured for 24 h before staining or being used
as targets or vaccines. Fusion preparations of DCs with B16 or
RMA-S are termed B16/DC and RMA-S/DC, respectively.
[1169] Phenotype Staining of Fused Hybrid Cells
[1170] B16, RMA-S, DCs, and their fused hybrids are analyzed by
staining with FITC- or PE-conjugated mAbs (PharMingen) against MHC
antigens (D.sup.b, K.sup.b,IA.sup.b) adhesion and costimulatory
molecules (B7.1, ICAM-1) and lymphocyte antigens (Thy-1.2, SmIg) at
4.degree. C. for 45 min. DCs were identified by labeling with mAb
against CD11c (N418). B16, B16/DC or B16/B16 fused cells are
stained with mAb against AKV Env gp85 protein (M562, provided by
Dr. Masaru Taniguchi, Chiba University, Tokyo, Japan) as a B16
tumor-specific marker. RMA-S and RMA-S/DC fused cells are stained
with Thy-1.2 or mAb against the R-MuLV-encoded Gag p12 protein
(584, provided by Dr. Bruce Chesebro, National Institute of Allergy
and Infectious Diseases, Hamilton, Mo.) as RMA-S tumor-derived
markers. The method for labeling cells with TRITC (rhodamine) is
described. Briefly, cells are resuspended in RPMI 1640 at
1.times.10.sup.6 cells/ml and incubated with TRITC (0.5 g/ml) in
37.degree. C. for 45 mm. The labeled cells are washed three times
and used for fusion studies. The phenotypes of fresh and cultured
LN T cells is determined by FACS analysis following staining with
FITC- or PE-conjugated mAbs against Thy-1.2, Lyt-2, and L3T4
(PharMingen). All cells are washed twice with HBSS and fixed with
0.2% paraformaldehyde. Fluorescence intensity and positive cell
percentage were measured on a FACScan flow microfluorometer (Becton
Dickinson, Sunnyvale, Calif.).
[1171] Additional Fusion Methods
[1172] Murine (CS 7BL16) MC38 adenocarcinoma cells are stably
transfected with the DF3/MUC1 cDNA (MC38/MUC1). MC38, MC38/MUC1 and
the syngeneic MB49 bladder cancer cells are maintained in DMEM
supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
glutamine, 100 U/ml penicillin and 100 .mu.g/ml streptomycin. DCs
are obtained as described from bone marrow culture with certain
modifications. Briefly, bone marrow is flushed from long bones, and
red cells are lysed with ammonium chloride. Lymphocytes,
granulocytes and Ia.sup.+ cells are depleted from the bone marrow
cells by incubation with the following mAbs: (1) 2.43, anti-CD8
(TIB 210; American Type Culture Collection, Rockville, Md.); (2)
GK1.5, anti-CD4 (TIB 207); (3) RA3-3A1/6.1, anti B220/CD45R (TIB
146); (4) B21-2, anti-Ia (TIB 229); and (5) RB6-8C5, anti-Gr-1
(PharMingen, San Diego, Calif.) and then rabbit complement. The
cells are plated in six-well culture plates in RPMI 1640 medium
supplemented with 5% heat-inactivated FCS, 50 M 2-mercaptoethanol,
1 mM HEPES (pH 7.4), 2 mM glutamine, 10 U/ml penicillin, 100
.mu.g/ml streptomycin and 500 U/ml recombinant murine GM-CSF
(Boehringer Mannheim, Indianapolis, Ind.). At day 7 of culture,
nonadherent and loosely adherent cells are collected and replated
in 100-mm petri dishes (10.sup.6 cells/ml; 8 nil/dish). The
nonadherent cells are washed away after 30 mm of incubation, and
GM-CSF in RPMI medium is added to the adherent cells. After 18 h,
the nonadherent cell population is removed for fusion with
MC38/MUC1 or MC38. Fusion is carried out with 50% PEG in Dulbecco's
PBS without Ca.sup.2+ or Mg.sup.2+ at pH 7.4. The fused cells are
plated in 24-well culture plates in the presence of HAT medium
(Sigma) for 10-14 days. HAT slows proliferation of MC38/MUC1 and
MC38, but not the fused cells. MC38/MUC1 and MC38 cells grow firmly
attached to the tissue culture flask, while the fused cells are
dislodged by gentle pipetting.
[1173] Flow Cytometry
[1174] Cells are washed with PBS and incubated with mAb DF3
(anti-MUC1), mAb M1/42/3.9.8 (anti-MHC class I), mAb M5/114
(anti-MHC class II), mAb 16-1OA1 (anti-B7-1), mAb GL1 (anti-B7-2)
or mAb 3E, (anti-ICAM-1) for 30 mm on ice. After washing with PBS,
the appropriate fluorescein isothiocyanate (FITC)-conjugated
anti-hamster, -rat and -mouse IgG is added for another 30 mm on
ice. Samples are then washed, fixed and analyzed in a FACScan
(Becton Dickinson, Mountain View, Calif.).
EXAMPLE 26
Transfection of Hybrid DC/tc's with SAg DNA or RNA in vivo and in
vitro
[1175] Methods of transfection of SAg-encoding nucleic acid into
tumor cell are disclosed in the Examples 1, 32. The same methods
are used for transfection of DCs or DC/tc hybrids.
EXAMPLE 27
Preparation of DCs which have Phagocytosed SAg-Transfected Tumor
Cell Lysates or Apoptotic Tumor Cells
[1176] PBMCs, DCs, macrophages, and T cells are prepared as
follows. In brief, peripheral blood is obtained from normal donors
in heparinized syringes and PBMCs are isolated by sedimentation
over Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, N.J.).
T cell-enriched and T cell-depleted fractions are prepared by
rosetting with neuraminidase-treated sheep red blood cells.
Immature DCs are prepared from the T cell-depleted fraction by
culturing cells in the presence of GM-CSF and IL-4 for 7 d. 1,000
U/ml of GM-CSF (Immunex Corp., Seattle, Wash.) and 500-1,000 U/ml
of IL-4 (Schering-Plough Corp., Kenilworth, N.J.) are added to the
cultures on days 0, 2, and 4. To generate mature DCs, the cultures
are transferred to fresh wells on day 7 and MCM is added for an
additional 3-4 d. At day 7, >95% of the cells are CD14-,CD83-,
HLA-DR.sup.lo DCs. On days 10-11, 80-100% of the cells are of the
mature CD14-, CD83+ , HLA-DR.sup.hi phenotype. FACSort.RTM. (Becton
Dickinson, San Jose, Calif.) is used to generate highly pure
populations of immature and mature DCs, based on their CD83- and
CD83+ phenotypes, respectively. Macrophages are isolated from T
cell-depleted fractions by plastic adherence for 1 h. After 24 h,
cells are removed from the plates and placed in Teflon beakers for
3-9 d. T cells are further purified from the T cell-enriched
fraction by removing contaminating monocytes, NK cells, and B
cells.
EXAMPLE 28
Induction of Apoptotic Death and Phagocytosis of Apoptotic Tumor
Cells or SAg-Transfected Tumor Cells by DCs
[1177] Monocytes are infected with influenza virus in serum-free
RPMI. These cells undergo viral-induced apoptotic death within 6-8
h. Cell death is confirmed using the Early Apoptosis Detection kit
(Kayima Biomedical Co., Seattle, Wash.). As previously described,
cells are stained with Annexin V-FITC (Ann V) and propidium iodide
(P1). Early apoptosis is defmed by Ann V+/PI staining as determined
by FACScan.RTM. (Becton Dickinson). Five to eight h after
infection, monocytes first externalize PS on the outer leaflet of
their cell membrane, as detected with Ann V. By 8-10 h, these cells
are TUNEL (Tdt-mediated dUTP-biotin nick-end labeling) positive. It
is not until 24-36 h that the majority of the monocyte population
included trypan blue into the cytoplasm, an indicator of secondary
necrosis. HeLa cells are triggered to undergo apoptosis using a 60
UV lamp (Derma Control Inc.), calibrated to provide 2
mJ/cm.sup.2/s.
[1178] Induction and Detection of Apoptosis
[1179] Monocytes are infected with influenza virus in serum-free
RPMI. Cell death is assayed using the Early Apoptosis Detection kit
(Kayima Biomedical). Briefly, cells are stained with Annexin V-FITC
(Ann V) and propidium iodide (P1). Early apoptosis is 14 defmed by
Ann V+/PI-staining as determined by FACScan (Becton Dickinson).
Cells from the 293 cell line are triggered to undergo apoptosis
using a 60 UVB amp (Derma Control Inc.), calibrated to provide 2
mJcm.sup.-2s.sup.-1.
[1180] Phagocytosis of Apoptotic Cells
[1181] Monocytes and HeLa cells are dyed red using PKH.sub.26-GL
(Sigma Biosciences, St. Louis, Mo.), and induced to undergo
apoptosis by influenza infection and UV irradiation, respectively.
After 6-8 h, allowing time for the cells to undergo apoptosis, they
are cocultured with phagocytic cells that were dyed green using
PKH67-GL (Sigma Biosciences), at a ratio of 1:1. Macrophages are
used 3-6 d after isolation from peripheral blood; immature DCs are
used on days 6-7 of culture; and mature DCs are used on days 10-11.
Where direct comparison of cells is needed, cells are prepared from
the same donor on different days. In blocking experiments, the
immature DCs are preincubated in the presence of 50 .mu.g/ml of
various mAbs for 30 mm before the establishment of cocultures.
After 451 20 mm, FACScan.RTM. analysis is performed and double
positive cells were enumerated.
[1182] Coculture of DCs with Apoptotic Cells
[1183] Monocytes from HLA-A2.1-donors are infected with live or
heat-inactivated influenza virus. Live influenza virus (Spafas
Inc.) is added at a final concentration of 250 HAU ml-1 (MOI of
0.5) for 1 h at 37.degree. C. Virus is heat-inactivated by
treatment for 30 min at 56.degree. C. before use. After washing,
cells are added to 24-well plates in varying doses. After 1 h,
contaminating non-adherent cells are removed and fresh media is
added. Following a 10 h incubation at 37.degree. C.,
3.3.times.10.sup.3 uninfected DCs and 1.times.10.sup.6 T cells are
added to the wells.
[1184] Antigen Pulsing of DC
[1185] Day 7 DC are incubated with freeze-thawed tumor lysates at a
ratio of three tumor cell equivalent to one DC (ie., 3:1) in CM.
After 18 hr of incubation, DC are harvested, irradiated with rad
(Gamma Cell 1000; Nordion, Kanata, Canada), washed twice in Hank's
balanced salt solution (GIBCO), and in Hank's balanced salt
solution.
EXAMPLE 29
Treatment of Tumor Bearing Animals with SAg-Transfected or
SAg-Expressing DCs, Accessory Cells or S/D/t Cells: Vaccination
Protocols and Treatment of Established Tumor
[1186] Immunotherapy
[1187] C57BL/6 mice are immunized once with irradiated, S/D/t cells
(2.times.10.sup.6 cells/mouse) 10-14 d post-immunization mice are
challenged with 2.times.10.sup.7 live tumor cell subcutaneously in
the scapular region. Mice are monitored on a regular basis for
tumor growth and size. Mice with tumor sizes >3.5 cm were
killed. All survivors were killed 40 d post-challenge.
[1188] P10.9-B 16 Melanoma Model.
[1189] Mice are injected intra-footpad with 2.times.10.sup.5 F10.9
cells. Legs are amputated when the local tumor in the footpad is
7-8 mm in diameter. Post-amputation mortality is less than 5%. 2 d
post-amputation mice are immunized intraperitoneally with S/D/t
cells followed by weekly vaccinations twice, for a total of three
vaccinations. Mice are killed based on the metastatic death in the
non-immunized or control groups (28-32 d post-amputation).
Metastatic loads are assayed by weighing the lungs.
[1190] S/D/t cells: In Vivo Immunization and Tumor Challenge
[1191] B6 or BALB/c mice are immunized s.c. in the right flank with
1.times.10.sup.6 MCA-207 or 1.times.10.sup.6 S/D/t cells,
respectively, twice at 7-day intervals. Mice then are rechallenged
7 days after the last immunization with a lethal dose of
1.times.10.sup.5 MCA-207 (for B6 mice) or 3.times.10.sup.5 MT-901
(for BALB/c mice) viable tumor cells by s.c. injections into the
left flank. The size of the tumors is assessed in a blinded, coded
fashion twice weekly and recorded as tumor area (in square mm) by
measuring the largest perpendicular diameters with calipers. Data
are reported as the average tumor area SEM (five or more mice per
group).
[1192] Vaccination Protocol
[1193] B6 mice are s.c. immunized twice in a 2-wk interval with
10.sup.6 irradiated (15,000 rad) B16, B16 mixed with DCs (1/1:
unfractionated cells from overnight culture), or S/D/t cells or
recombinant formalin fixed bacteria (10.sup.6 -10.sup.8). Ten days
following the final immunization, each group of mice is injected
s.c. with varying doses (10.sup.4, 10.sup.5, or 10.sup.6
cells/mouse) of viable B16. Tumor growth and survival time of each
group of mice are recorded. The size of the tumor in each mouse is
measured in two perpendicular dimensions with a Vernier caliper
twice weekly after tumor challenge. Tumor incidence is considered
positive when the average diameters of the tumor exceeded 3 mm.
[1194] In Vivo Immunization for Treatment of Pulmonary
Metastases
[1195] B6 or BALB/c mice receive 1.5.times.10.sup.5 MCA-207 or
2.times.10.sup.5 MT-901 viable tumor cells, respectively, i.v. in
the lateral tail vein to establish pulmonary metastases, as
described. The mice then are immunized s.c. with, respectively,
1.times.10.sup.6 MCA-207 tumor lysate-pulsed S/D/t cells three
times on days 3, 7, and 11 or 1.times.10.sup.6 MT-901 tumor
lysate-pulsed S/D/t cells twice on days 3 and 7 after tumor
injection and are killed on days 14 and 17, respectively. Pulmonary
metastases are enumerated on day 15 (MCA-207) or 14 (MT-901). Data
are reported as the mean number of metastases .+-.SEM (five or more
mice per group).
[1196] In vitro Activation of LN T cells
[1197] B6 mice are immunized s.c. twice in a 2-wk interval on the
flanks with 2.times.10.sup.6 (10.sup.6/side) irradiated (15,000
rad) tumor, S/D/t cell preparation, or tumor mixed with DCs (1/1)
suspended in 0.1 ml of HBSS. One week after the final immunization,
inguinal LNs from each group of mice are harvested. LN cells from
each group of mice are activated and expended in culture using
anti-CD3 plus IL-2. In brief, LN cells (3-4.times.10.sup.6
cells/well) are activated on 24-well plates coated with anti-CD3
mAb (145-2C11) and incubated at 37.degree. C. for 2 days.
Alternatively, S/D/t cells (10.sup.4-10.sup.5/well) or exosomes
(3-5 g) or recombinant bacteria (10.sup.6-10.sup.8/well) are
incubated with the LN cells for 2 days and optionally with low dose
IL-2 for an additional 2 days. The activated cells are suspended at
1-2.times.10.sup.5 cells/ml in CM containing IL-2 (4 U/ml) and
incubated in gas-permeable culture bags (Baxter Healthcare,
Deerfield, Ill.) for an additional 3 days. The derived LN T cells
are harvested and used as effector cells for adoptive
immunotherapy.
[1198] Adoptive Immunotherapy Models
[1199] For therapy of B 16 pulmonary metastases. B6 mice are
injected i.v. with 105 live B16 tumor cells in 1 ml of PBS to
initiate pulmonary metastases. Three days after tumor inoculation,
mice are randomly divided into several groups to receive treatments
by i.v. injection of 5.times.10.sup.7 cultured LN T cells suspended
in 1 ml of PBS. On day 21 after tumor inoculation, mice from each
group are killed, and lungs are insufflated with Fekete's solution.
Lung metastases are counted. In some experiments. tumor-bearing
mice are i.p. administered IL-2 (15,000 U. twice/day for 5 days)
following the adoptive transfer of cultured LN T cells. For therapy
of FBL-3 tumor. B6 mice are inoculated i.p. with 5.times.10.sup.6
viable FBL-3 tumor cells on day 0. By day 5, the tumor is
disseminated, and mice are treated with cyclophosphamide (CY) at a
dose of 180 mg/kg followed in 6 h by i.p. injection of cultured LN
T cells (5.times.10.sup.7 cells/mouse) suspended in 0.5 ml of PBS.
The tumor growth and the survival time of each group of mice are
monitored and recorded on a regular basis
[1200] Induction of anti-tumor activity by FC/MUC1.
[1201] Groups of 1 mice are immunized twice at 14-day intervals by
subcutaneous injection of 3.times.10.sup.5 DCs (0) or S/D/t cells
represented by FC/MUC1cells. PBS is injected as a control (0).
After 14 days, mice are challenged subcutaneously with
2.5.times.10.sup.5 MC38/MUC1 cells. Tumors of 3 mm in diameter are
scored as positive.
[1202] Immunization with FC/MUC1 for Prevention and Treatment of
Pulmonary Metastases
[1203] Groups of 10 mice are injected twice with S/D/t cells
represented by FC/MUC1cells or PBS and then challenged after 14
days with intravenous administration of 1.times.10.sup.6 MC38/MUC1
cells. The mice are killed 28 days after challenge. Pulmonary
metastases are enumerated after staining the lungs with India ink.
Groups of 10 mice are injected intravenously with 1.times.10.sup.6
MC38/MUC1 or MC38 cells. The mice are immunized with
1.times.10.sup.6 S/D/t cells representing FC/MUC1 cells or FC/MC38
at 4 and 18 days after tumor challenge and then killed after an
additional 10 days. Pulmonary metastases are enumerated for each
mouse.
[1204] Protection Assays
[1205] C57BL/6 mice are immunized with the indicated antigen-gene
construct. Animals are challenged with tumors and evaluated for
tumor survival as described. Briefly, 7 days after the final
immunization (day 0), immunized animals are challenged by
intradermal injection in the mid-flanks bilaterally with melanoma
cells (2.times.10.sup.4) at two times the dose lethal to 50% of the
animals tested (LD50). Survival is recorded as the percentage of
surviving animals. Melanoma cells for injection are washed three
times in PBS. Injected cells were greater than 95% viable by trypan
blue exclusion. All experiments include five mice per group and
were repeated at least three times. Mice that became moribund were
killed according to animal care guidelines
EXAMPLE 30
DNA or RNA from SAg Transfected Tumor Cells, SAg Transfected DCs
and SAg Transfected DC/tc Hybrids for In Vivo Vaccination and
Transfection of Naive DCs to Produce a DC Expressing SAgs and Tumor
Associated Antigens
[1206] Plasmid DNA Vector
[1207] 1. Genes from SAg Transfected Tumor Cells, SAg transfected
DCs and S/D/t cells are cloned by PCR to contain a partial or
entire coding region. In most cases, it is desirable to not include
any sequence 5' to the ATG or 3' to the termination codon. PCR
primers are designed to contain a restriction site, such as BglII
or BamHI.
[1208] 2. The PCR fragments are separated from unreacted oligomers
and template and then the fragment is cut with an excess of BglII
for at least 5 h. The DNA is Phenol extracted and
ethanol-precipitated. The purified cut fragment is resuspended in
TE, pH 8.0 and ligated. to BglII-digested V1J, which has been
gel-purified and dephosphorylated with calf intestinal alkaline
phosphatase (CLAP), phenol-extracted, ethanol-precipitated, and
resuspended in TB, pH 8.0. A 6:1 molar ratio of insert:vector in
the ligation reaction is used.
[1209] 3. Competent E. coli cells (e.g., DH5, DH5a) are transformed
with the ligation reaction, plated on L-ampicillin plates and grown
overnight at 37.degree. C. Colonies are screened by hybridization
of plate lifts to kinase-labeled PCR primer. Several
hybridization-positive colonies are selected and grown in overnight
cultures for miniprep purification.
[1210] 4. Miniprep DNAs, are prepared and cut with the appropriate
restriction enzymes to determine correct orientation of the gene in
the vector. At least three DNAs with the gene in the correct
orientation are selected to confirm by sequencing across the
ligation junctions. Sequencing primers are designed from the vector
sequence. Each primer is 30-50 bp from the restriction site (BglII
in the example), so that 10-20 bases within the vector can be read
as well as 150-200 bases within the gene. This amount of sequence
verifies orientation and give a reasonable estimate of the quality
of the PCR-generated gene.
[1211] 5. DNA preparations that have been sequence-verified 1/1000
in TB, pH 8.0, are diluted and use to retransform competent E.
Coli. Three isolated colonies from the transformation plates are
grown overnight at 37.degree. C., and used to make a -70.degree. C.
cell stock by adding 0.8 ml fresh overnight growth to 0.2 ml
sterile 80% (v/v) glycerol, mixing well, and freezing on dry ice.
The -70.degree. C. stocks are used to isolate plasmid DNA from
remaining cells by miniprep procedures. Miniprep DNA is cut again
with the appropriate restriction enzymes, and visualized on a gel
to verify the construct. All subsequent growth of cells for plasmid
production are made from the -70.degree. C. frozen stock.
[1212] All constructs are tested in vitro to validate their ability
to express the desired gene product. Plasmids purified by column
(Wizard preps, Promega, Madison, Wis.) or by cesium chloride
banding are used to transfect tissue-culture cells transiently.
Protein expression is detected by immunoblot. This check not only
verifies expression but can validate the size and immunoreactivity
of the gene product.
[1213] Characterization of Plasmid DNA Vectors
[1214] All constructs are tested in vitro to validate their ability
to express the desired gene product. Plasmids purified by column
(Wizard preps, Promega, Madison. Wis.) or by cesium chloride
banding are used to transfect tissue-culture cells transiently.
Protein expression is detected by immunoblot. This check not only
verifies expression but can validate the size and immunoreactivity
of the gene product.
[1215] Cell Growth and Transfection
[1216] 1. DC /tumor cell hybrids, at 0.8-1.5.times.10.sup.6
cells/100 mm plate in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum, 20 mM
HEPES, 4 mM L-glutamine, and 100 .mu.g/ml each of penicillin and
streptomycin, and incubate at 37.degree. C. in 5% CO.sub.2 for 18
h.
[1217] 2. The construct to be tested is cotransfected with 10
.mu.g/plate and 10 g of V1J-CAT using a calcium phosphate procedure
or other methods given in Example 1.
[1218] 3. Five hours after transfection, the cells are shocked in
15% (v/v) glycerol in PBS, pH 7.2, for 2.5 mm.
[1219] 4. Cultures are harvested 72 h after transfection by washing
the plates twice with 10 ml of cold PBS, pH 7.2, then adding 5 ml
of cold TEN buffer and scraping.
[1220] 5. Pellet cells and use immediately or store at -70.degree.
C. for subsequent analysis.
[1221] Immunoblot Analysis
[1222] 1. Cell pellets are lysed in Single Detergent Lysis Buffer,
and sonicate on ice (2-15 s bursts) to reduce viscosity.
[1223] 2. Cell debris is removed by sedimentation and determine
soluble protein concentrations of the supernatants by the Bradford
method.
[1224] 3. Equal loadings of soluble cell protein per lane are run
on SDS-polyacrylamide gel and transfer the proteins to Immobilon P
(Millipore, Bedford, Mass.) membrane.
[1225] 4. Western blots are incubated overnight with an appropriate
dilution of the antibody to the gene product being tested, followed
by a 1.5-h reaction with a 1:1000 dilution of peroxidase-conjugated
secondary antibody. Develop blots using the ECL kit (Amersham,
Arlington Heights, Ill.).
[1226] Large-Scale DNA Preparations
[1227] 1. Expression vectors are grown in E. coli strain DH5 with
vigorous aeration in 500 ml growth medium/1-L shake flask. V1J
constructs are grown overnight to saturation.
[1228] 2. Cells are harvested and lysed by a modification of the
alkaline SDS procedure. The modification consists of increasing the
volumes threefold for cell lysis and DNA extraction.
[1229] 3. DNA is purified by double banding on CsC1/ethidium
bromide gradients.
[1230] 4. The ethidium bromide is removed by 1-butanol extraction,
and the resulting DNA is extracted with phenol/chloroform and
precipitated with ethanol.
[1231] 5. DNA in TE for transfections is resuspended and in 0.9%
NaCl for injection into mice.
[1232] 6. The concentration and purity of each DNA preparation is
determined by A 260/280 readings. The 260/280 ratios are
>1.8.
[1233] 7. DNA is stored in small aliquots at -20.degree. C.
EXAMPLE 31
DNA Immunization in vivo
[1234] 1. Animals are housed in an American Association for the
Accreditation of Laboratory Animal Care (AAALAC) accredited
facility or other national facility and cared for in accordance
with the Guide for the Care and Use of Laboratory Animals. Prior to
bleeding, or administration of anesthetic or inoculation, animals
are in good physical condition and free from stress.
[1235] 2. For administration of DNA vaccines, animals are
anesthetized by ip injection of a solution containing ketamine and
xylazine (50 and 20 .mu.g/g body wt, respectively) in a total
volume of 0.3 ml of saline. Alternatively, transiently immobilize
mice for a sufficient period of time to administer an im injection
by allowing inhalation of metophane. Larger animals, such as
ferrets or nonhuman primates, are anesthetized using ketamine (30
mg/kg)/xylazine. (2 mg/kg)/atropine (1 mg/kg) or ketamine (10
mg/kg), respectively.
[1236] 3. Fully anesthetized animals are prepared for injection by
flooding and swabbing the injection site with ethanol (70%). This
provides sterilization and, for small animals, such as mice,
facilitates visualization of the muscle groups. To visualize small
muscles further, fur around the injection site is shaved followed
by ethanol swabbing, or a short incision can be made to permit
direct observation of the muscle. In the latter case, the incision
is sutured after inoculation.
[1237] 4. DNA vaccines are administered in saline solution alone or
together with a facilitator that induces muscle generation or
regeneration. Facilitators are used in animals that may not
necessarily be used in humans. For mice, volumes of up to about 50
.mu.L are injected into each quadriceps muscle using a disposable
insulin syringe equipped with a 27-gauge needle and having a
capacity of 0.3 ml.
[1238] 5. DNA vaccines are also administered using particle
bombardment technology. Plasmid DNA is coated onto gold beads and
propelled directly into tissue. Genetic immunization is
accomplished by biolistic bombardment using methods similar to
those recently described. Briefly, DNA-coated gold particles are
prepared by combining 50 mg of 0.95 um gold beads and 100 1 of 0.1
M
[1239] spermidine and sonicating for 5 s. Plasmid DNA (100 .mu.g)
and CaCl (200 .mu.l) are added sequentially to the beads spinning
in a vortex; mixer. This mixture is allowed to precipitate at room
temperature for 5-10 mm. The bead preparation is then centrifuged
(10,000 r.p.m. for 30 s) and washed 3 times in cold ethanol before
resuspension in 7 ml of ethanol to give a final concentration of 7
mg gold per milliliter. The solution is then loaded into Tefzel
tubing (Agracetus, Middleton, Wis.) and allowed to settle for 5 mm.
The ethanol is removed and the beads are attached to the side of
the tubing by rotation at 20 r.p.m. for 30 s and N.sub.2 dried. The
dried tubing lined with beads is then cut into 0.5-inch sections
and stored for use with desiccant in parafilm-sealed vials. Animals
are vaccinated by delivery of two shots (each shot consisted of 0.5
m4j gold beads in 0.5 inch of tubing) to the shaved abdominal
region using the Accell gene delivery device (Agracetus) at a
discharge pressure of 400 p.s.i. This delivers approximately
1.00.mu.g/DNA per shot. Animals are immunized with various plasmids
In some experiments, particles are coated with the pGREEN LANTERN-1
plasmid (Gibco BRL, Gaithersburg, Md.), which contains the
"humanized" reporter gene encoding GFP from the Aequorecia Victoria
jellyfish. This gene encodes a naturally fluorescent protein
requiring no substrates for visualization.
[1240] Formulation of DNA Vaccine:
[1241] Saline is the preferred solvent. However, plasmid DNA may
also be administered in various other buffer formulations and
cationic lipid formulations. Facilitators include anesthetics, such
as bupivacaine, and toxins, which are used in conjunction with DNA
vaccines. Conventional delivery vehicles are used which facilitate
internalization of DNA by cells, protect DNA from digestion by
extracellular nucleases, or effect a slow release of DNA; adjuvants
are coadministered to provide an additional stimulus for the immune
system.
[1242] Dosage and Injection Regimen:
[1243] DNA vaccines are effective across a broad dosage range.
Protective efficacy is achieved with submicrogram amounts of DNA.
With respect to humoral immune responses against HA, there is a
direct correlation between magnitude of antibody responses and dose
of DNA between 10 ng and at least 100 g. However, perhaps owing to
viscosity of the solution and/or distribution of the inoculum in
the muscle, administration of DNA at concentrations in excess of
2-4 mg/ml results in decreased immunogenicity with some antigens.
Therefore, in mice, doses in excess of 200 g are not practical by
im injection. The number of injections also directly correlates
with magnitude of immune responses (up to at least three). For the
influenza model in mice, we have found that three injections given
at 3-wk intervals yield optimal protection. It is likely, however,
that dosing and regimen will need to be optimized for each gene and
challenge model.
[1244] Site of injection:
[1245] Injection of plasmid DNA into muscle cells is far superior
to other cell types in their capacity to internalize DNA and/or
express reporter proteins in vivo. However, immune responses also
have been generated after id and iv routes of DNA injection. In
addition, particle bombardment of DNA results in the transfection
of dermal and epidermal cells leading to the generation of immune
responses. The relative effectiveness of these different routes of
delivery has yet to be tested rigorously. However, direct im
injection generates a protective immune responses at doses (100 ng
to 1 g) and is preferred in the range used by particle
bombardment.
EXAMPLE 32
Pulsing DCs with RNA from SAg Producing Bacteria or S/D/t Cells
[1246] Total RNA is isolated from SAg producing bacteria or S/D/t
cells by standard methods. Pulsing DCs with RNA from SAg producing
bacteria, S/D/t cells or SAg transfected tumor cells is performed
in serum-free Opti-MEM medium (GIBCO BRL) for tumor extracts with
the following modification RNA (25 g in 250 1 Opti-MEM medium) and
DOTAP (50 g in 250 1 Opti-MEM medium) are mixed in 12.times.75 mm
polystyrene tubes at room temperature for 20 mm. The complex is
added to the DCs (25.times.10.sup.6 cells/ml) and incubated
37.degree. C. in a water bath with occasional agitation for 25 mm.
The cells are washed twice and resuspended in PBS (10.sup.5 RNA
pulsed DCs in 500 l PBS/mouse) for intraperitoneal immunizations.
PBS, B16 extract from 10.sup.5 cells in PBS, or DCs prepared as
described above are injected intraperitoneally in a volume of 500
l.
EXAMPLE 33
PolyA-Cellular RNA from S/D/t cells or DCs Transfected with SAg:
Preparation and Immunization Protocols
[1247] Total RNA is isolated from actively S/D/t cells given above
as follows. Briefly, 10.sup.7 cells are lysed in 1 ml of
guanidinium isothiocyanate (CT) buffer (4 M guanidinium
isothiocyanate, 25 mM sodium citrate, pH 7.0; 0.5% sarcosyl, 20 mM
EDTA, 0.1M 2-mercaptoethanol). Samples are vortexed followed by
sequential addition of 100 l 3M sodium acetate, 1 ml water
saturated phenol and 200 l chloroform/isoamyl alcohol (49:1).
Suspensions are vortexed and placed on ice for 15 mm. The tubes are
centrifuged at 10,000 g, 4.degree. C. for 20 min and the
supernatant is carefully transferred to a fresh tube. An equal
volume of isopropanol is added and the samples are placed at
-20.degree. C. for at least 1 h. RNA is pelleted by centrifugation
as above. The pellet is resuspended in 300 l GT buffer which is
then transferred to a microcentrifuge tube. RNA is re-precipitated
by adding an equal volume of isopropanol and placing the tube at
-20.degree. C. for at least 1 h. Tubes are microcentrifuged at high
speed at 4.degree. C. for 20 mm. Supernatants are decanted and
pellets are washed once with 70% ethanol. Pellets are allowed to
dry at RT and then resuspended in TB (10 mM Tris-HCl, 1 mM EDTA, pH
7.4). Possible contaminating DNA is removed by incubating RNA in 10
mM MgCl.sub.2, 1 mM DTT and 50 U/ml RNase free DNase
(Boehringer-Mannheim, Indianapolis, Ind.) for 15 min at 37.degree.
C. The solution is adjusted to 10 mM Tris, 10 mM EDTA, 0.5% SDS and
1 mg/ml Pronase (Boehringer-Mannheim) followed by incubation at
37.degree. C. for 30 mm. Samples are extracted once with
phenol-chloroform and once with chloroform, and RNA was then
re-precipitated in isopropanol at -20.degree. C. After
centrifugation the pellets are washed with 70% ethanol, air dried,
and resuspended in sterile water. Total RNA is quantitated by
measuring OD at 260 and 280 nm. OD 260/280 ratios are typically
1.65-2.0. RNA is stored at -70.degree. C. PolyA+ RNA is either
isolated from total RNA using Oligotex (Qiagen, Chatsworth, Calif.)
or directly from tissue culture cells using the Messenger RNA
Isolation kit (Stratagene, La Jolla, Calif.) as per manufacturer's
protocols.
[1248] Production of In vitro Transcribed RNA
[1249] The 1.9-kb EcoR1 fragment containing the coding region and
3' un-translated region is cloned into the EcoR1 site of pGEM4Z
(Promega, Madison, Wis.). Clones containing the insert in both the
sense and anti-sense orientations are isolated and large scale
plasmid preparations are made using Maxi Prep Kits (Qiagen).
Plasmids are linearized with BamHl for use as templates for in
vitro transcription. Transcription is carried out at 37.degree. C.
for 34 h using the 5P6 MEGAscript In vitro Transcription Kit
(Ambion, Austin, Tex.) per manufacturer's protocol and adjusting
the GTP concentration to 1.5 mM and including 6 mM m7G(5')ppp(5')G
cap analogue (Ambion). Template DNA is digested with RNase free
DNase I and RNA is recovered by phenol/chloroform and chloroform
extraction followed by isopropanol precipitation. RNA is pelleted
by microcentrifugation and the pellet is washed once with 70%
ethanol. The pellet is air-dried and resuspended in sterile water.
RNA is incubated for 30 mm at 30.degree. C. in 20 mM Tris-HCl, pH
7.0, 50 mM KCl, 0.7 mM MnCl.sub.2, 0.2 mM EDTA, 100 .mu.g/ml
acetylated BSA, 10% glycerol, 1 mM ATP and 5,000 U/ml yeast poly(A)
polymerase (United States Biochemical, Cleveland, Ohio). The
capped, polyadenylated RNA is recovered by phenol/chloroform and
chloroform extraction followed by isopropanol precipitation. RNA is
pelleted by microcentrifugation and the pellet is washed once with
70% ethanol. The pellet is air-dried and resuspended in sterile
water. RNA is quantitated by measuring OD at 260 and 280 nm and
stored at -70.degree. C.
[1250] Pulsing of Antigen-Presenting Cells, Accessory Cells DCs.
Tumor Cells or DC/Tumor Cell Hybrids with RNA Derived from S/D/t
cells
[1251] Pulsing of cells with RNA is routinely performed in
serum-free Opti-MEM medium (GIBCO BRL). Cells are washed twice in
Opti-MEM medium. Cells are resuspended in Opti-MEM medium at
25.times.10.sup.6 cells/nil and added to 15 ml polypropylene tubes
(Falcon). The cationic lipid, DOTAP, (Boehringer Mannheim) is used
to deliver RNA into cells. RNA (in 250-500 l Opti-MEM medium) and
DOTAP (in 250-500 p. 1 Opti-MEM medium) are mixed in 12.times.75-mm
polystyrene tubes at room temperature (RT) for 20 mm. The amount of
polyA+ RNA or IVT RNA used is 5 g and the amount of total RNA used
is 25 g. The RNA to DOTAP ratio is 1:2. The complex is added to the
APC (2-5.times.10.sup.6 cells) in a total volume of 2 ml and
incubated at 37.degree. C. in a water-bath with occasional
agitation for 2-4 h.
EXAMPLE 34
In vivo Immunization with RNA derived from "S/D/t cells" or
SAg-Transfected Tumor Cells
[1252] Preparation of mRNA for Transfection
[1253] DNA is linearized downstream of the poly A tail with a
5-fold excess of PstI. The linearized DNA is then purified with two
phenol/chloroform extractions, followed by two chloroform
extractions. DNA is then precipitated with NaOAc (0.3M) and 2
volumes of EtOH. The pellet is resuspended at about 1 mg/ml in
DEP-treated deionized water.
[1254] A transcription buffer is prepared, comprising 400 mM Tris.
HCl (pH 8.0), 80 mM MgCl.sub.2, 50 mM DTT, and 40 mM spermidine.
The following materials are added in order to one volume of
DEP-treated water at room temperature: 1 volume T7 transcription
buffer; rATP, RCTP, and rUTP to 1 mM concentration; rGTP to 0.5 mM
concentration; 7 g(5')ppp(5')G cap analog (New England Biolabs,
Beverly, Mass.) to 0.5 mM concentration; the linearized DNA
template to 0.5 mg/ml concentration; RNAsin (Promega, Madison,
Wis.) to 2000 U/ml concentration; and T7 RNA polymerase (N.E.
Biolabs) to 4000 U/ml concentration.
[1255] This mixture is incubated for 1 hour at 37.degree. C. The
successful transcription reaction is indicated by increasing
cloudiness of the reaction mixture.
[1256] Following generation of the mRNA, 2U RQ1 DNAse (Promega) per
microgram of DNA template used is added and was permitted to digest
the template for 15 minutes. Then, the RNA is extracted twice with
chloroform/phenol and twice with chloroform. The supernatant is
precipitated with 0.3M NaOAc in 2 volumes of EtOH, and the pellet
is resuspended in 100 mu 1 DEP-treated deionized water per 500 l
transcription product. This solution is passed over an RNAse-free
Sephadex G50 column (Boehringer Mannheim #100 411). The resultant
mRNA is sufficiently pure to be used in transfection of vertebrates
in vivo.
[1257] mRNA Vaccination in vivo
[1258] A liposomal formulation containing mRNA coding for the
SAg/tumor associated antigen protein prepared and is inserted into
the plasmid pXBG in A volume of 200 l of a formulation is prepared
containing 200 .mu.g/ml of S/D/t cell-derived mRNA and 500 .mu.g/ml
1:1 DOTAP/PE in 10% sucrose is injected into the tail vein of mice
3 times in one day. At about 12 to 14 h after the last injection, a
segment of muscle is removed from the injection site, and prepared
as a cell lysate according to Example 7. The S/D/t cell-derived
specific protein is identified in the lysate.
[1259] Severe combined immunodeficient (SCID) mice (Molecular
Biology Institute, (MBI), La Jolla, Calif.) were reconstituted with
adult human peripheral blood lymphocytes by injection into the
peritoneal cavity according to the method of Mosier (Mosier et al.,
Nature 335:256 (1988)). The mice were maintained in a P3 level
animal containment facility in sealed glove boxes. mRNA coding for
the S/D/t cell-derived proteins is prepared by obtaining the S/D/t
cell gene in the form of a plasmid removing the gene from the
plasmid; inserting the gene into the pXBG plasmid for
transcription; and purifying the transcription product S/D/t
cell-derived mRNA. The S/D/t cells mRNA is then incorporated into a
formulation and 200 l tail vein injections of a 10% sucrose
solution containing 200 .mu.g/ml S/D/t cell RNA and 500 .mu.g/ml
1:1 DOTAP:DOPE (in RNA/liposome complex form) were performed daily
on experimental animals, while control animals were likewise
injected with RNA/liposome complexes containing 200 .mu.g/ml yeast
tRNA and 500 .mu.g/ml 1:1 DOTAP/DOPE liposomes. At 2, 4 and 8 weeks
post injection, biopsy specimens are obtained from injected
lymphoid organs and prepared for immunohistochemistry.
[1260] A volume of 200 l of the formulation, containing 200
.mu.g/ml MRNA from S/D/t cells, and 500 .mu.g/ml 1:1 DOTAP:DOPE in
10% sucrose is injected into the tail vein of the human stem
cell-containing SCID mice 3 times in one day. Following
immunization, the mice are challenged by tumor inoculation.
[1261] The full-length sequence for the cDNA of the S/D/t-derived
gene is obtained and ligated to BgIII linkers and then digested
with BgIII. The modified fragment is inserted into the BgIII site
of pXBG. S/D/t-derived protein is transcribed and purified mRNA is
incorporated into a formulation. Balb 3T3 mice are injected
directly in the tail vein with 200 l of this formulation,
containing 200 .mu.g/ml of S/D/t-derived mRNA, and 500 .mu.g/ml
DOTAP in 10% sucrose.
EXAMPLE 35
Preparation of "String of Beads" Tumor Antigens for Transfection of
SAg-Transfected DCs, Other Accessory Cells, or Tumor Cells
[1262] Generation of rAd
[1263] All cell lines were maintained in Iscove's modified
Dulbecco's medium (IMDM) (Scromed, Berlin) supplemented with 4%
fetal calf serum (FlyClone), penicillin (110 international
units/ml; Brocades Pharma, Leiderdorp, The Netherlands). and
2-mercaptoethanol (20 .mu.M) at 37.degree. C. in a 5% CO.sub.2
atmosphere. The adenoviral vector construction adapter plasmid
pMad5 is derived from plasmid pMLPI0 as follows. pMLPI0-lin is
constructed by insertion of a synthetic DNA fragment with unique
sites for the restriction endonucleases MluI, SplI, SnaBI, SpeI,
Asull, and MunI into the Hindlll site of pMLP10. Subsequently, the
adenovirus BglII fragment spanning nucleotides 3328 8914 of the AdS
genome is inserted into the Munl site of pMLP-lin. Finally, the
Sall-BamH1 fragment is deleted to inactivate the tetracycline
resistance gene, resulting in plasmid pMad5. A mini-gene cassette
vector, pMad5-0. is generated by ligation of the annealed and
phosphorylated double-stranded oligonucleotides 1a/b and 2a/b into
the MluI and SpeI sites of pMad5. This cloning step leads to
elimination of the original MluI and SpeI sites and to creation of
a small ORF, which essentially consists of a start codon, the
sequence SEOKLISEEDLNN, a human c-Myc-derived sequence, which is
recognized by mAb 9E10 and a stop codon. A small "stuffer"
sequence. flanked by newly generated MluI and SpeI sites, is
present between the start codon and the c-Myc sequence.
[1264] pMad5-1 and -2, each of which harbor a multi-epitope
encoding minigene. are constructed by unidirectional cloning of the
following double-stranded **oligonucleotides into pMad5-0, which
had been cleaved with MluI and SpeI. pMad5-I. After each cloning
step, the sequence of the inserts is verified by DNA sequencing.
Expression of these minigenes is driven by the Ad5 major late
promoter, which in this configuration is linked to the AdS
immediate early enhancer, resulting in immediate early expression
of the minigenes. rAds are generated through in vivo homologous
recombination in the Ad5E1-transformed helper cell line 911 between
plasmid pJMI7. containing the sequence of the AdS mutant d1309, and
either of the plasmids pMad5-1 or pMad5-2. 911 cells are
transfected with 10 g of plasmid pJMI7 in combination with 10 g of
either pMad5-1 or pMad5-2. The rAds are plaque-purified three
times, after which the clonal rAds are propagated in 911 cells,
purified by double cesium chloride density gradient centrifugation.
and extensively dialyzed. The presence of replication-competent
adenoviruses is routinely checked by infection of Hep-G2 cells. The
viral stocks were stored in aliquots with 10% glycerol at
-80.degree. C. and titered by plaque assay using 911 cells.
[1265] Further Transfection of SAg-Transfected DCs, Accessory
Cells, or Tumor Cells
[1266] In short, 100 ng of plasmid DNA encoding Ad5LI, HPV 16 E7,
murine p53 or the influenza-matrix protein are transfected into
1.times.10.sup.4 SAg-transfected DCs, accessory cells or tumor
cells. The transfected cells are incubated in 100 .mu.l of IMDM
containing 8% fetal calf serum for 48 h at 37.degree. C., after
which 1500-500 CTL ??? in 25 .mu.l of IMDM containing 50 Cetus
units (=300 international units) of recombinant interleukin-2
(Cetus) are added. After 24 h, the supernatant is collected, and
its tumor necrosis factor (TNF) content is determined by measuring
its cytotoxic effect on WEHI-164 clone 13 cells.
EXAMPLE 36
Production of Exosomes from DCs Expressing SAg and Tumor Associated
Antigens and Normal Hepatocytes
[1267] Exosome Isolation
[1268] SAgs or tumor associated antigens are transfected into tumor
cells, DCs, or DC/tc hybrids by methods disclosed herein.. The
SAg-encoding nucleic acid is provided with sorting sequences which
route the translated protein to the endoplasmic reticulum and
thereupon to secretory vesicles or exosomes. Alternatively, tumor
cells, DCs or DC/tc are incubated 18-20 hours with tumor peptides
or SAgs. DCs supernatants are harvested, centrifuged (at 4.degree.
C.) at 300 g for 20 mm and then at 10,000 g for 30 min (to
eliminate cell debris). Exosomes are then pelleted at 100,000 g for
one hour, and washed once in a large volume of PBS (over 100-fold
the final volume of resuspension of the exosomes). The protein
concentrations in exosome preparations is measured by Bradford
assay (BioRad). The slightly acidic pH transiently induced by the
acid peptide elution increases the amounts of exosomes produced by
DCs. Three to five g of exosomes are routinely obtained from
5-10.times.10.sup.5 DCs in 18-20 hours. Exosomes containing LDL,
oxyLDL, apolipoproteins, LDL receptors and oxyLDL receptors are
obtained from normal hepatocytes by a method similar to that
described above for dendritic cells and sickled erythrocytes as in
Example 6.
[1269] Mice and Tumor Cell Lines for Exosome Trials
[1270] DBA/2J (H-2.sup.d) and BALB/c (H-2.sup.d) female mice 6-8
weeks of age are raised in pathogen-free conditions. P815
(H-2.sup.d) is a methylcholanthrene induced mastocytoma, syngeneic
with DBA/2. TS/A (H-2.sup.d) is a spontaneously-arising
undifferentiated mammary adenocarcinoma, syngeneic with BALB/c. All
tumor cell lines are maintained in RPMI 1 640 supplemented with 10%
endotoxin-free fetal calf serum (Gibco BRL), 2 mM L-Glutamine, 100
U/ml penicillin, 100 .mu.g/ml streptomycin, essential amino acids
and pyruvate.
[1271] Experimental Mouse Models for Exosome Trials
[1272] Twice the minimal tumorigenic dose of tumor cells
(5.times.10.sup.5 P815, 10.sup.5 TS/A) is inoculated intradermally
in the upper right flank of DBA/2 and BALB/c mice, respectively.
Animals with established tumors at days 3-4 for TS/A, or days 8-10
for P815, are immunized with a single intradermal injection of 3-5
g of exosomes per mouse in the lower ipsilateral flank. The tumor
size is monitored biweekly and mice are sacrificed when bearing
ulcerated or huge tumor burdens. All experiments are performed two
to three times using individual treatment groups of five mice per
group.
EXAMPLE 37
Bacterial Constructs for the Expression of SAgs Linked to
Galactosylceramides, .alpha.-Gal Epitope, Peptidoglycans,
Lipopolysaccharides and .quadrature.1,3-Glucans
[1273] Nucleic acids encoding SAgs may be transfected into bacteria
which naturally synthesize and express fundamental recognition
units for innate immunity. Some of these moieties such as
monogalactosylceramides and .alpha.-galactosylceramides are potent
immunogens and induce anti-tumor activity. The addition of the SAg
and a dominant tumor associated epitope coexpressed with these
natural bacterial constructs and administered to a tumor bearing
host would promote a potent tumor specific response. The system
described uses S. carnosus as a model bacterial system to express a
SAg peptide and dominant tumor epitope.
[1274] Expression Vectors for Surface Display.
[1275] The shuttle vector constructed pSPPmABPXM consists of the
following parts: (i) the origin of replication for E. coli and the
13-lactamase gene giving ampicillin resistance for transformed E.
coli cells; (ii) the origin of replication for phage f1; (iii) the
origin of replication from S. aureus and the chloramphenicol
acetyltransferase gene for staphylococcus expression; (iv) the
promoter, signal sequence, and propeptide sequences from the S.
hyicus lipase gene construct, optimized for expression in S.
carnosus; (v) a multicloning site containing three unique
recognition sites for restriction endonucleases; (vi) a gene
fragment encoding a serum ABP from streptococcal protein G; and
(vii) gene fragments encoding the cell wall-anchoring regions X and
M from staphylococcal protein A.
[1276] As a model system, the surface display of SAg staphylococcal
enterotoxin B. substitutes for place the 80 amino acid malaria
peptide M3 from falciparum blood stage antigen Pfl55/RESA.. A
plasmid vector, pSPPM3ABPXM is constructed, in which a gene
fragment encoding SEB instead of M3 is introduced between the
propeptide region and the ABP sequence of plasmid pSPPmABPXM. An
oligonucleotide linker (5'AGCTTGGCTGTTCCGCCATGGCTC- GAG-3' with
complementary sequence) is inserted into the HindIII site of
plasmid pSZZmpISX thus creating additional NcoI and XhoI
recognition sites downstream of the HindIII site in the resulting
vector, pSZZmpI8XhoXM. A gene fragment encoding a 198-amino-acid
ABP from the serum albumin binding region of streptococcal protein
G is generated by a PCR
20 (primers respectively) 5'-CCGAATTCAAGCTTAGATGCTCTAGCA-
AAAGCCAAG-3' and 5'-CCCCTGCAGTTAGGATCCCTCGAGAGGT-
AAAATTTCATC-3'
[1277] with plasmid pSPGI as template sequenced in plasmid pRIT28
by solid-phase DNA sequencing and HindIII-XhoI subcloned in frame
downstream of the mp18 multilinker of pSZZmp18XhoXM. yielding
plasmid pSZZmpI8ABPXM. An M3-encoding gene fragment was
BamHI-HindIII subcloned from plasmid pRIT28EM3DAStop into
pSZZmpI8ABPXM, yielding plasmid pSZZM3ABPXM. Plasmid pLipPS17 is
constructed from pLipPSlk the introduction of a BsmI recognition
site in the beginning of the lipase signal sequence. a Bc/I site at
the end of the signal sequence and a BglII site at the end of the
propeptide-encoding region by site-directed in vitro mutagenesis. A
gene fragment constituting almost the entire S. carnosus vector
pLipPSI except for a fragment encoding the C terminus of the
propeptide and the majority of the mature lipase from S. hyicus is
isolated by SalI-Hind III digestion and ligated to the E. Co/i
plasmid pRIT28. which had previously been cut with the same
restriction endonucleases. The resulting plasmid. designated
pSDLip. contained the origin of replication for both E. coli and S.
aureus. To restore the C-terminal region of the lipase propeptide,
a gene fragment encoding the C-terminal part is generated by PCR
amplification with the oligonucleotides
21 5-CCGAATTCTCGAGGCTCCTAAAGAAAATAC-3' and
5'-CCAAGCTTGGATCCTGCGCAGATCTTGGTGTTGGTTTTTTG-3'
[1278] as upstream and downstream primers. respectively, with
plasmid pLipPS17 as template. This amplification introduced
upstream EcoRI and XhoI sites and downstream FspI. BamHI. and
HindIII recognition sequences by noncomplementary sequences in the
PCR primers. The gene fragment encoding the C-terminal propeptide
region was EcoRI-HindIII suncloned to pRIT28 to verify a correct
sequence by solid-phase DNA sequencing and thereafter XhoI-BamHI
transferred to SalI-BaniHI-restricted pSDLip. The resulting
plasmid. pSPP is HindIII restricted, filled in with Klenow
polymerase. and religated to yield plasmid pSPPDHind. which encodes
the signal peptide and the complete propeptide of the S. hyicus
lipase with transcription from a promoter region suitable for
overproduction in S. carnosus.
EXAMPLE 38
Gene Transfer for Expression of an Mono or Digalactosylceramide by
Transfection with a Cosmid Genomic Library Prepared from a Cell
Line in which the Specific Glycosylceramide is Highly Expressed
[1279] The deliberate transfer of mono or digalactosylceramide
expression in tumor cells is achieved by transfection with a cosmid
DNA library prepared from Fabry's cells in which the mono or
digalactosylceramide is highly expressed. This model demonstrates a
general method for transferring glycosyltransferase genes and other
factors necessary for the expression of glycosphingolipid antigens.
The recipient tumor cells contain mono or digalactosylceramide and
the direct precursor, lactosylceramide. The transfected cells
express mono or digalactosylceramide detected both chemically and
immunologically and contained human DNA detected by an Alti
sequence probe.
[1280] Cells and antibodies: Fabry's cells or normal cells with an
.alpha.-galactosidase deficiency and tumor cells including but not
limited to neuroblastoma cells are used. Anti-galactosyl ceramide
monoclonal antibody is prepared. Total DNA is prepared from Fabry's
cells is excised by MboI and ligated by Bam HI-treated cosmid
vector PCV 108, which has the SV40 promotor fused to the neomycin
phosphotransferase gene. The target DNA for cosmid cloning is
purified by gel electrophoresis between 30-40 KB size. In vitro
packaging is made with an extract of lysogenic bacteria and
propagated in E. coli. as described elsewhere. Transfection and
Selection of Galactosylceramide Expression: Cosmid library DNAs are
transfected into various cells using the calcium phosphate DNA
precipitation technique with the addition of a glycerol shock after
a 6 hour incubation. Galactosylceramide selection is started 2 days
later at 400 .mu.g/ml concentration. The expression of
galactosylceramide in the original Fabry's cell and the transfected
tumor cells was determined by cytofluorometry (FACS II), in which
FITC-conjugated anti- mono or digalactosylceramide antibody is
used. Glycolipids in transfected cells are analyzed after cells
were extracted in chloroform-methanol (2:1 and 1:1 v/v). The
neutral glycolipid fraction is prepared by an acetylation
procedure. The glycolipid profile is confirmed on HPTLC, followed
by immunostaing with anti- mono or digalactosylceramide
antibody.
EXAMPLE 39
Staphylococcal Collagen Binding Adhesin Nucleic Acids Transfected
into SAg Transfected Tumor Cells, SAg Transfected DCs or Accessory
Cells and S/D/t Cells
[1281] Collagen gene fragments from S. aureus strain FDA 574 are
overexpressed in E. coli using the vector pQE-30 (QIAGEN inc.
Chatworth, Calif.). Recombinant proteins expressed from this vector
contain an NH.sub.2-terminal tail of six histidine residues. The
gene named cna encoding a S.aureus collagen adhesin is isolated
from a S. aureus genomic library cloned and sequenced. The cna gene
encodes a 1185 amino acid polypeptide. The deduced amino acid
sequence reveals several structural characteristics similar to
previously described Gram-positive bacterial cell surface
proteins.
[1282] Plasmids expressing cna gene fragments are produced as
follows. Recombinant S. aureus collagen adhesin fragments are
overexpressed in E. coli using three different prokaryotic
expression systems. The amino terminus including the entire A
domain is amplified from S. aureus FDA 574 chromosomal DNA using
PCR together with primers CNA 20 and CNA 21. The amplified 1.6-kb
cna gene fragment is cleaved with EcoRI and PstI, gel purified and
ligated to the prokaryotic expression vector pKK223-3 obtained from
Pharmacia LKB Biotechnology to create plasmid pKK1.5. Expression
vector pKK223-3 contains an IPTG-inducible tac promoter adjacent to
a consnesus Shine-Dalgarno ribosomal binding site. However, this
vector lacks an initiation codon; therefore, the DNA to be
expressed must contain an appropriate start codon. In order to
express an internal cna fragment, a DNA linker sequence containing
an ATG start codon is synthesized. Two partially complementary
ologonucletides, JPI (5'AATTACCATGGAATTCCTGCA-3') and JP2
(5'-TGGTACCTTAAGG-3'), are heated to 70.degree. C. and slowly
cooled to allow annealing. Once annealed, the double-stranded
linker is phosphorylated by the addition of ATP and T4
polynucleotide kinase. The DNA linker contained EcoRI and PstI
restriction sites at the 5'- and 3'-termini, respectively. These
sites are used to insert the linker onto pKK223-3. A 2.9-kb
EcoRI/PstI DNA fragment, originally isolated from lambdaGT11 clone
pCOL11 was ligated to vector pKK223-3 to create plasmid pKK2.9. The
collagen adhesin fragment encoded by pKK2.9 contains three repeated
domains (B1, B2, and B3), the carboxyl terminus and downstream
sequences. The plamid containing the collagen adhesin is
transfected into DTES by methods in Example 1 and 3 and expression
of the transduced gene is monitored by Immunoblots (Example
33).
EXAMPLE 40
Transfection of Nucleic Acids Encoding SAgs in Combination with
Nucleic Acids the Promote Apoptosis Induction or Predispose to
Apoptosis
[1283] SAgs expressed in apoptotic tumor cells or tumor cell/DC
hybrids are ingested by DCs which present them to the immune system
in more which evokes a potent immune response to the tumor
associated antigens. The apoptotic cell is also one which is
overexpresses a GalCer such as one with a natural or acquired
.alpha.-galactosidase deficiency or from a patient with Fabry's
Disease. The apoptotic stimulus can be produced by concordant
influenzal infection, radiation or chemotherapy. In addition, it
may be inducible by an exogenous source such as TNF if the cell is
predisposed by transfection of an potent inhibitor of NF-.kappa.B
such as a modified form of I.kappa.Ba. Additional stimuli to
apoptosis are provided by numerous well established activators
(caspase 9) or initiators (caspase 8) of the caspase system or the
CD95 TNFR network. Having undergone apoptosis, the SAg transfected,
GalCer overproducing cell is now ingested by DCs which are
cross-primed to present the tumor antigens and the GalCer in the
context of SAg stimulation resulting in a potent antitumor
response. Methods and protocols for SAg transfection are given in
Example 1 and for priming of DCs in Example 27-28 The apoptotic
transfectants are used as a preventative or therapeutic antitumor
vaccine by protocols in Example 15, 16, 18-23 and 29. They are also
useful ex vivo to a population of tumor specific effector T cell or
NKT cells for use in the adoptive immunotherapy of cancer (Examples
2-5, 7, 15, 16, 18-23, 29).
EXAMPLE 41
Preparation and Isolation of Glycosphingolipids and Verotoxins
Galabiosylceramide, Globotrioslceramides and
Globotetraosylceramide
[1284] Globotrioslceramides (GB3) and globotetraosylceramide (Gb4)
are purified from human renal tissue. Briefly, the
chloroform/methanol tissue extract is first applied on a Bio-Sil A
(Bio-Rad) silica column in chloroform. The column is extensively
washed with chloroform, and neutral glycolipids are eluted with
acetone/methanol, 9:1 (vol/vol). The neutral glycolipid fraction is
then applied on a second Bio-Sil A column in chloroform/methanol,
98:2 (vol/vol). Glycolipids are then resolved with a linear solvent
gradient comprising equal weights of chloroform/methanol 15:1
(vol/vol), to chloroform/methanol, 4:1 (vol/vol).
Galabiosylceramide (Gb2) or Gal(.alpha.1-4)Gal ceramide from marine
sponge may be obtained, for example, from Dr T. Matsubara
(Department of Chemistry, Kinki University, Kowakae. Japan).
[1285] VTs and Subunits
[1286] A simple method for purifying E. coli H30 verocytotoxin is
as follows. The toxin, released from the cells by exposure to
polymyxin B, is subjected to differential ammonium sulfate
precipitation and sequential chromatography on hydroxylapatite,
chromatofocussing, Cibachron blue, and Sephadex G-100 columns. The
purified toxin, 39 kDa by gel filtration and having a pI of 6.72,
resolves as a band which migrates at 32 kDa and another band of
less than 14 kDa which migrates with the buffer front on reducing
SDS-PAGE. The purified preparation is relatively heat-stable, and
has a specific activity of 3.times.10.sup.9 CD.sub.50 units/mg
protein in Vero sells, and LD.sub.50 values of 0.2, 9.0, and 40 g
protein/kg in rabbits, rats, and mice, respectively. Antiserum to
the toxin specifically neutralizes H 30 VT, Shiga toxin, and VT
activity from some clinical isolates of VT.sup.+ E. coli but not
that from a porcine edema disease strain. Verocytotoxin 2 (VT2) is
purified from E. coli strain E32511 using, as starting material,
cells harvested from a Penassay broth culture incubated for 6 h at
37.degree. C. in the presence of mitomycin C (0.2 .mu.g /ml). A
crude extract of VT2, is obtained by polymyxin B treatment of cell
pellets, is purified using differential ammonium sulphate
precipitation, and sequential column chromatography. The purified
toxin is estimated to have a pI of 6.5 by chromatofocusing and a
molecular weight of 42 kDa by gel filtration; it has a specific
activity of 1.39.times.10.sup.6 CD.sub.50 units/mg protein in Vero
cells, and resolves as a major band of Mr 35 kDa and another band
of <14 kDa which migrates with the buffer front on reducing
SDS-PAGE. The purified toxin is not neutralized by VT 1 antisera,
and antisera prepared to this toxin in rabbits did not neutralize
VT 1, but completely neutralized the activity of the homologous
toxin.
[1287] Recombinant Methods of Preparing VT's and Subunits
[1288] Recombinant VT1 is purified from pJLB28. VT2 from R82. and
VT2c from E32511. The recombinant E. coli strain pJLB28 is used as
a source of VT1 B subunit. High yields of the toxins or subunits
(10-15 mg/3 liters of broth culture) are purified by a method
involving polymyxin B extraction, ultrafiltration, hydroxylapatite
chromatography, chromatofocusing, and Cibacron Blue chromatography.
VT2 is purified by virtually the same method from an E. coli
clinical isolate, strain E325 11. The cistron encoding the B
subunit of E. coli Shiga-like toxin I (SLT-I) is cloned under
control of the tac promoter in the expression vector pKK223-3 and
the SLT-I B subunit is expressed constitutively in a wild-type
background and inducibly in a lacl.sup.q background. E. coli TB 1
lac pro rpsL ara thi .quadrature. 80d LacZ .DELTA. MI5 hsdR is
obtained from Bethesda Research Laboratories (Gaithersburg, Md.).
E. coli JM1O1 .DELTA. lacc pro supE thi (F' traD36 IacZ A MIS pro
AB IacP) is obtained from Dr. J. D. Friesen (Department of Medical
Genetics, University of Toronto, Toronto, Ontario, Canada).
Plasmids pTZ18R and pKK223-3 are obtained from Pharmacia. Plasmid
pJLB5 consists of a 3.0 kb Kpnl fragment of bacteriophage H 19B DNA
cloned in the Kpnl site of pUC18. To construct plasmid pJLB34,
pJLB5 is cut at the BglII site and digested with nuclease Bal31.
The ends are filled with Klenow fragment and dNTPs. The fragment
remaining after deletion is cleaved with EcoRI, and the piece
carrying the SLT-I B cistron is purified by agarose-gel
electrophoresis. The fragment is recovered from the gel and cloned
into pUC18 cut with EcoRI and HindII. The EcoRl-HindIII fragment is
cloned in M13mpl8 and its nucleotide sequence is determined. The B
cistron coding sequence is recovered from pJLB34 as a 1.1 kb Pstl
fragment and was then cloned in the PstI fragment and was the
cloned in the PstI site of the polylinker of pKK223-3. Clones with
the correct orientation of insertion relative to the tac promoter
are identified by restriction-endonuclease analysis. One plasmid
with the orientation is selected and designated pJLB120. pJLB120 is
transformed into E. coli TBI for constitutive expression and into
E. coli JM101 for inducible expression. Bacteria are grown in
L-broth or brain heart infusion broth (Difco Laboratories, Detroit,
Mich.) supplemented as necessary with carbenicillin at 50 .mu.g/ml
and IPTG (Bethesda Research Laboratories) at 1 mM.
[1289] Expression of Toxins
[1290] For E. coli JM 101 (pJLB 120), an overnight culture is used
to inoculate fresh L-broth supplemented with carbenicillin (50
pg/ml) and was grown to mid-exponential phase (A.sub.600=0.3-0.6)
at 37.degree. C. with shaking at 300 rev./min. IPTG is added to a
final concentration of 1 mM. and incubation is continued with
aeration. For E. coli TB I (pJLB 120), an overnight culture is used
to inoculate fresh L-broth supplemented with carbenicillin (50
.mu.g/ml), and this is grown for 12-18 h at 37.degree. C., with
shaking at 300 rev./min. In both cases the culture is harvested and
the pellet is washed once with PBS (0.15M-NaCl/10 mM sodium
phosphate buffer, pH 7.4) before extraction.
[1291] Polymyxin B extraction of Toxins
[1292] The washed pellet is resuspended in PBS containing 0.1 mg/ml
polymyxin B in one-quarter of the original culture volume and
extracted as previously described. For purification, 18 h cultures
of E. Coli TBI (pJLB 120) are extracted with polymyxin B, and the
extracts are concentrated 10-fold using a stirred-cell Amicon
concentrator with a Ym-5 membrane (Amicon Corp., Danvers, Mass.,
USA).
[1293] Quantification of Toxins
[1294] Periplasmic extracts of VT-producing clones, prepared by
polymyxin B extraction, are diluted as required and filtered onto
nitrocellulose paper in a slot-blot apparatus (Bio-Rad
Laboratories). VT is detected by using MAb 1 3C4 according to the
Western-blot procedure described above. Blots are scanned with a
Molecular Dynamics model 300A computing densitometer. VT is
quantified by comparison with a standard curve generated with
purified B subunit protein.
[1295] Purification of Toxins
[1296] The concentrated polymyxin B extract are dialysed overnight
against 50 mM-Tris/HCl buffer, pH 7.4, and then applied to a
DEAE-Sephacel column (1 cm.times.20 cm) equilibrated with 1
mM-Tris/HCL buffer, pH 7.4. Bound material is eluted by using a
linear gradient of 0-1M-NaCl in 50 mM-Tris/HCl buffer, pH 7.4, and
5 ml fractions are collected. Fractions containing VT are
identified, pooled and concentrated with Centriprep-3 concentrators
(Amicon Corp.). This pool is dialyzed overnight against 25
mM-imidazole/HCl buffer, pH 7.4, and is applied to a column (1.5
cm.times.20cm) of Polybuffer exchanger 94 (Pharmacia) equilibrated
with the same buffer. Elution is carried out with a degassed
solution of Polybuffer 74 (Pharmacia) diluted 1:8 with distilled
water and adjusted to pH 4.0 with HCl (11column volumes). Fractions
(5 ml) are collected, and the B subunit positive fractions are
pooled and concentrated with Centriprep-3 (Amicon). Ampholytes are
removed by Sephadex G-50 gel-filtration.
[1297] HPLC Purification of Toxins
[1298] Approximately 1 mg (in 1 ml) of purified toxin or subunit is
injected into a TSK-G2000SW HPLC gel filtration column previously
equilibrated with 50 mM Tris-buffered saline (TBS), pH 7.4, flow
rate of 1.0 ml/mm. Peaks, measured by absorbance at .lambda.=280
nm, are collected.
[1299] Toxin Subunit Separation
[1300] 1 mg of toxin subunit is concentrated to 30-50 .mu.l using a
Centricon 30 concentrator (Amicon). 1 ml of a subunit dissociating
solution (6 M urea, 0.1 M NaCl, 0.1 M propionic acid, pH 4, is
added dropwise, and the toxin is incubated without stirring at
4.degree. C. for 1 h. The solution is then separated by HPLC gel
filtration (as above) after previous column equilibration with the
dissociating solution. Peaks, measured by absorbance at
.lambda.=280 nm, are collected.
EXAMPLE 42
Gangliosides Shed from Tumor Cells: Isolation from Tumor Cell
Supernatants Collection of Tumor Cell Supernatant
[1301] Tumor cells are cultured in 25 ml of no serum-low protein
medium (NSLP) in an 80cm.sup.2flask for 1-5 days. Cells are
harvested by centrifugation at 400 g for 10 mm, and the supernatant
is concentrated 10-fold at 4.degree. C. in an Amicon stirred cell
with a 10-kDa cutoff ultrafilter. Concentrated supernatant and NSLP
concentrated under the same conditions are stored at -20.degree.
C., and passed through a 0.1-um sterile membrane filter.
[1302] Metabolic Labeling of Gangliosides in Tumor Cell
Supernatant
[1303] Tumor cells (1.times.10.sup.5/ml) are cultured in 10 ml of
NSLP for 2 days. After three washes with fresh medium, cells are
transferred into 10 ml of NSLP containing 1 .mu.Ci/ml
D-[1-.sup.14C]GlcNH.sub.2-HCl (50 mCi/mmol (ICN Biomedicals, St.
Laurent, Quebec, Canada) and 1 .mu.Ci/ml of D-[1-.sup.14C]Gal (56
mCi/mmol; Amersham) to label gangliosides. After 24 hr, cells are
washed with medium three times to remove unincorporated sugars,
then cultured for an additional 24-48 hr in fresh medium, before
harvesting by centrifugation at 400 g. Radioactivity in the tumor
cell supernatant and cells is quantitated by liquid scintillation
counting. The supernatant is clarified by centrifugation at 15,000
g for 10 mm, then concentrated 10-fold using a Speedvac
concentrator, before being analyzed by gel filtration
chromatography.
[1304] Gel Filtration Chromatography of .sup.14C-Labeled Tumor Cell
Supematant on Sepharose 2B-300
[1305] Concentrated .sup.14C-labeled tumor cell supernatant is
chromatographed on a Sepharose 2B-300 column (5 ml bed volume;
Sigma Chemical Go, St Louis, Mo.), equilibrated with Tris-buffered
saline (TBS; 50 mM Tris-HCl in 0.15 M NaCl, pH 7.4). The column is
eluted at a flow rate of 0.2 ml/min at 22.degree. C., and 2001
.mu.l fractions are collected and counted for .sup.14C.
Dipalmitoylphosphatidylcholine liposomes and sodium azide are used
as standards to calibrate the void and included volume of the
column, respectively.
[1306] Gel Filtration FPLC of 'P-Labeled Tumor Cell Supernatant on
Superose
[1307] FPLC is carried out on a Superose 6 column (1.times.30 cm;
Pharmacia, Dorval, Quebec, Canada) linked to a Gilson HPLC system
and a Gilson iliB ultraviolet flow detector. The column is
calibrated with a series of standard proteins of known molecular
mass, ranging from .quadrature.-galactosidase (465 kDa) to
.quadrature.-lactoglobulin (36.8 kDa) (Pharmacia, High Molecular
Weight Gel Filtration Calibration kit). The void volume and
included volume are determined using Blue Dextran (2000 kDa) and
sodium azide, respectively. .sup.3H-Labeled bovine brain
gangliosides and [.sup.14C]Gal dissolved in NSLP or TBS are also
used as standards. Concentrated YAC-1 supernatant is eluted through
the column at 22.degree. C. with TBS at a flow rate of 0.5 ml/min.
Fractions (0.5 ml) are collected and counted for .sup.14C.
EXAMPLE 43
Assessment of SAg and VT Binding to Glycosphingolipids by TLC
Overlay
[1308] Glycolipids (dissolved in chloroform/methanol (2:1 v/v), are
applied to a TLC plate and separated in choroform/methanol/water
(65:25:4, v/v). Toxin binding is determined using known methods.
Briefly, after separation of the glycolipids, the plate is air
dried, incubated overnight at 37.degree. C. in a solution of 1%
(m/v) gelatin in 50 mM Tris/HCL, 150 mM NaCl, pH 7.4 (buffer A).
The plate is washed in buffer A and incubated successively with VT
1 (0.07 .mu.g/ml in buffer A) followed by monoclonal antibody PHI
(1.5 pg/ml in buffer A), and finally with goat antimouse IgG
horseradish peroxidase conjugate (diluted 1:2000 in buffer A).
Toxin binding is visualized using 4-chloro-1-naphthol. An
equivalent plate is run and treated with 3% (m/v) orcinol spray in
3 M H.sub.2SO.sub.4 to visualize carbohydrate and ensure equal
concentrations.
[1309] Alternate Microtitre Plate Binding Assay
[1310] Quantification of toxin binding to various glycoconjugates
is performed using published methods. A methanolic solution [100 pl
containing glycolipid (300 nmol). phosphatidylcholine (0.5 .mu.g)
and cholesterol (0.25 .mu.g)] is added to microplate wells and the
methanol is allowed to evaporate overnight at room temperature. The
wells are blocked with 2% (m/v) BSA in buffer A (200 .mu.l/well)
for 2 h at room temperature and subsequently washed once with
buffer A containing 0.1% BSA (BSA/buffer A). 100 .mu.l aliquots of
dilutions of [.sup.125I]-VT-1 in BSA/buffer A are added to the
wells and incubated for 2 h at room temperature. The wells are
washed five times with BSA/buffer A. excised and the radioactivity
is measured in a .gamma. counter. Scatchard analysis was performed
using the LIGAND program.
EXAMPLE 44
Methods of Induction and Assessment of Apoptosis & Inhibition
of Protein Synthesis.
[1311] Tumor cells (5.times.10.sup.5cells/ml) are cultivated at
37.degree. C. in 96-well round-bottomed microtiter plates (Becton
Dickinson) in 200 .mu.l leucine-depleted RPMI (Eurobio, France)
containing 1 .mu.Ci of [.sup.3H] leucine. with or without 10 ng/ml
VT. After 18 hrs. cells are harvested on class fiber filters, and
radioactivity incorporated in proteins measured in a scintillation
counter.
[1312] Ultrastructural Analysis of VT-Treated Astrocytoma Cells
[1313] Cells are cultivated on a transferable 9 mm cylcopore
membrane (0.45 .mu.m pore size. Falcon) to form a confluent
monolayer and are incubated at 37.degree. C. with VTI (10 ng/ml).
Cells are fixed at room temperature by addition of 1.6%
glutaraldehyde to the wells and then incubated in 0.066 M Sorensen
buffer (pH 7.4) containing 1.5% glutaraldehyde for 1 h at 4.degree.
C. After 2 h of washing with 0.1 M phosphate buffer, cells are
post-fixed in 2% osmium tetroxide in the same buffer. After
dehydration in graded ethanols and propylene oxide, Epon embedding,
thin sectioning and uranyl-lead counterstaining on grids are
performed. Thin sections are examined in a Philips EM 400 electron
microscope and ultrastructural features of apoptosis are
analyzed
[1314] Flow Cytometry
[1315] Apoptosis of astrocytoma cells, incubated with 10 ng/ml of
VT1 for 24-36 hrs in the presence of 10% bovine fetal serum is
analyzed on an Epics Profile Analyzer (Coulter Electronics.
Pathology. University of Toronto) according to known procedures.
After treatment, cells are trypsinized and the 200.times.g
centrifuged cell pellet is suspended in 1 ml of hypotonic
fluorochrome solution of 50 .mu.g/ml propidium iodide (Sigma) and
stained for 30 min at 4.degree. C. To remove RNA prior to staining.
cells are treated with 100 .mu.l of 200 .mu.g/ml solution of
DNase-free RNase A at 37.degree. C. for 30 min. Cell cycle
distribution is determined using manual gating. Flow cytrometric
quantitation of apoptotic cells within the propidium iodide-stained
population is performed as described. Debris and dead cells are
excluded on the basis of their forward and side light-scattering
properties. Astrocytoma cells grown simultaneously in the absence
of VT1 serve as controls.
[1316] DNA Fragmentation Assays Cells:
[1317] Tumor cells are incubated in RPMI 1640 medium alone or in
the presence of intact VT or VT-B. After 18-h culture, cells are
counted and viability assessed by trypan blue exclusion. Cells are
then centrifuged and washed twice with saline buffer. The pellets
are lysed by incubation for 1 h at 50.degree. C. in 10 mM EDTA, 200
mM NaCl, 0.1 mg/ml proteinase K, 0.5% (w/v) SDS, and 50 Mm
Tris-HCL, pH 8. The DNA is extracted with phenol,
chloroform:isoamylalcohol (24:1), and then ethanol precipitated.
Unfragmented DNA is discarded, and 0.1 volume of 3 M sodium
acetate, pH 7.2, is added to the supenatant which is left at
-80.degree. C. overnight. The precipitate containing fragmented DNA
is centrifuged (1300 g, 30 mm) and dried under vacuum. DNA derived
from 5.times.10.sup.6 cells is then resuspended in 20 .mu.l RNAse
buffer containing 0.5 .mu.g/ml DNAse-free RNAse (Sigma), 15 mM
NaCl, and 10 mM Tris-HCL, pH 7.5. and incubated at 50.degree. C.
for 1 h; Electrophoresis is carried out at 70V in 2% agarose gel
containing 0.1 .mu.g/ml ethidium bromide in a buffer containing 2
mM EDTA, 80 mM Tris-phosphate. pH 8. After electrophoresis. gels
are examined under UV. Phage DNA from bacteriophage .lambda. and
.quadrature. digested by HindIII and HaeIII, respectively, provide
molecular weight standards.
[1318] Nuclear Staining with Propidium Iodide
[1319] SF-539 cells grown on the cover slips overnight are
incubated at 37.degree. C. with VT-12B subunit (50 , g/ml) for 1.5
hrs or 10 hrs and fixed (with 1% paraformaldehyde for 3 minutes).
permeabilized with 0.1% Triton X in 100 mM PBS for 5 min, and
stained with 5 .mu.g/ml propidium iodide (Sigma). After extensive
wash with 50 mM PBS, the fixed cells are mounted with DABCO
(1,4-diazabicyclo-octane (Sigma), and nuclear staining is observed
under incident UV illumination.
[1320] Proliferation Assay
[1321] Approximately 1-5.times.10.sup.4 cells are added to 24-well
plates and incubated in a-MEM in 5% CO.sub.2 at 37.degree. C. After
24 hr, the growth medium is replaced with medium containing various
concentrations of the holotoxin VT1 (0.0.1.5.50, 100 ng/ml). The
treated astrocytoma cell lines and endothehal cells are trypsinized
and counted at intervals throughout the growth curve. Cell
viability is assessed by trypan blue dye exclusion. Cell counts are
plotted against time for the various concentrations of VT1 and B
subunit. For each time point analyzed, the wells are set-up in
triplicate.
[1322] For selected cell lines, the B subunit of VT1, VT2, and VT2c
is added alone to the astrocytoma cells at same concentrations
listed above. A single dose of VT 1. VT2. and VT2c is added to
confluent astrocytoma cells in microplate wells. Cell survival at
72 hr is monitored by staining with 0.1% crystal violet, and
measuring the optical density at 590 nm using a Dynatek microtiter
plate reader.
EXAMPLE 45
Multidrug Resistant Cells: Culture and Preparation
[1323] MCF-7-wt and MCF-7-AdR (adriamycin-resistant) cells are
obtained from Drs. K. H. Cowan and M. B. Goldsmith, National Cancer
Institute. Cells are maintained in RPMI 1640 medium containing 10%
FBS (v/v), 50 units/ml penicillin, 50 .mu.g/ml streptomycin, and
584 mg/liter L-glutamine. KB-3-1 human oral epidermoid carcinoma
cells (parent, drug-sensitive) and KB-V-1 cells (highly MDR) and
subclones are obtained from the National Cancer Institute). Cells
are grown in high glucose (4.5 g/liter) Dulbecco's modified Eagle's
medium containing 10% FBS and other components described above. The
KB-V-1 cell line is maintained with vinblastine (1.0 .mu.g/ml) in
the medium. NIH:OVCAR-3 cells (human ovarian adenocarcinoma,
drug-resistant) are obtained from the American Type Culture
Collection and grown in RPMI 1640 medium containing insulin (10
.mu.g/ml), 10% PBS, and other components listed above. All cells
are cultured in a humidified, 6.5% CO.sub.2 atmosphere, tissue
culture incubator. Cells are subcultured once a week using 0.05%
trypsin and 0.53 mM EDTA solution.
[1324] Lipid Mass Analysis
[1325] Cell lipids are analyzed by TLC separation and charring of
the chromatogram. Briefly, total cellular lipids are extracted and
equal aliquots (by weight) from each sample are spotted on TLC
plates. Plates are developed in the desired solvent system (see
below), air-dried for 1 h, and sprayed using a 35% solution of
sulfuric acid in water (v/v). The lipids are charred by heating in
an oven at 180.degree. C. for 30 mm, and resulting black bands are
visualized.
[1326] Cell Radiolabeling and Analysis of Sphingolipids
[1327] MCF-7 cells grown in medium containing 10% FBS, are switched
to serum-free medium containing 0.1% fatty acid-free BSA. Cell
lipids are radiolabeled by incubating cells with [.sup.3H]serine
(2.0 .mu.Ci/ml), [.sup.3H]palmitic acid (1.0 .mu.Ci/ml, or
[.sup.3H]galactose 1.0 .mu.Ci/ml) for the indicated times. In some
instances, cells are radiolabeled in medium containing 5% PBS.
Cells are then rinsed twice with PBS, and 2 ml of ice-cold methanol
containing 2% acetic acid is added. The cells are scraped free,
transferred to glass test tubes (13.times.100 mm), and lipids are
extracted, by the addition of chloroform (2 ml) followed by water
(2 ml). The resulting organic lower phase is evaporated under a
stream of nitrogen. Lipids are resuspended in 1001 .mu.l of
chloroform'methanol (1:1, v/v) and aliquots are applied to TLC
plates. When using [.sup.3H]galactose, radiolabeled cells are
washed twice with PBS, transferred to glass tubes with methanol (2
ml, and glucosylceramides and gangliosides (2.5 pg of each) are
added to aid recovery. Lipids are extracted by the addition of
water (2 ml; and 2 ml of chloroform (three times consecutively).
The pooled organic lower phase is treated as above. Lipid analysis
is carried out by various TLC separations using solvent system I,
chloroform/methanol/ammonium hydroxide (65:25:5, v/v); solvent
system II, chloroform/methanol/ammonium hydroxide (40:10:1, v/v),
solvent system III, chloroform/methanol/water (60:40:8, v/v), or
solvent system IV, chloroform/methanol/acetic acid/water
(50:30:7:4, v/v). For determination of ceramides. an aliquot of the
chloroform-soluble lipids is base-hydrolyzed in 0.1 N KOH in
methanol for 1 h at 37 .degree. C.; lipids are re-extracted and
separated using solvent system V hexane/diethyl ether/formic acid
(60:40: 1, v/v). Galactosyl- and glucosyl-ceramides are separated
using solvent system VI, chloroform/methanol/water (60:25:4, v/v).
This separation is performed on TLC plates that are pre-run in 2.5%
borax in methanol/water (1:1) and heated at 110.degree. C. prior to
use.
[1328] Radiochromatograms are sprayed with EN.sup.3HANCE and
exposed for 3-7 days for autoradiography. TLC areas, aligned with
hands on the autoradiographs or with iodine-stained commercial
lipid standards are scraped from the plate. Water (0.5 ml) is added
to the plate scrapings, followed by 4.5 ml of EcoLume counting
fluid, and the samples are quantitated by liquid scintillation
spectrometry.
[1329] Purification of Glycosylceramides
[1330] The compounds, extracted with total lipids from MCF-7-AdrR
cells, are resolved from other lipids on preparative TLC using
silica gel H plates developed in solvent system II. The appropriate
region of the TLC plate is then scraped into test tubes, and lipids
are extracted with chloroform/methanol/acetic acid/water
(50:25:1:2, v/v). The samples are centrifuged, and the solvent
transferred to new glass tubes and evaporated to dryness under
nitrogen.
[1331] Fast-Atom Bombardment/Mass Spectrometry of TLC-isolated
Lipid-FAB/MS spectra are acquired using a VG 70 SEQ tandem hybrid
instrument of EBqQ geometry (VG analytical, Altrincham, UK.). The
instrument is equipped with a standard unheated VG FAB ion source
and a standard saddle-field gun (Ion Tech Ltd., Middlesex, UK) that
produces a beam of xenon atoms at 8 kV and 1 mA. The mass
spectrometer is adjusted to a resolving power of 1000, and spectra
are obtained at 8 kV using a scan speed of 10 s/decade.
2-Hydroxyethyl disulfide is used as matrix in the positive FAB/MS,
and triethanolamine is used as a matrix in the negative FAB/MS.
Negative FAB and positive FAB give different values for the same
compounds, due to charge (proton content) differences.
EXAMPLE 46
Incubation of Tumor Cells with Hydroxy Fatty Acids for Selective
Synthesis of Galactosphingolipids and Lipid Analysis
[1332] Tumor cells on filters are incubated for 1 hr at 37.degree.
C. in the presence of labeled and unlabelled
[.sup.3H]Cer(C.sub.6[D-20H]). After the incubation, lipids are
extracted from the cells and the combined incubation media and
analyzed Lipids are extracted from cells and media by a two-phase
extraction. The upper phase contains 20 mM acetic acid and (for
radiolabeled lipids) 120 mM KCl. After a chloroform wash. which is
added to the lower phase, lipids remaining in the upper phase
GalCer are collected on SepPak C18 cartridges (Waters, Milford,
Mass.) from which lipids are eluted with chloroform/methanol/water
1:22:0.1) and methanol. The organic (lower) phase is dried under
N.sub.2, and the lipids are applied to TLC plates that were dipped
in 2.5% boric acid in methanol, dried, and activated by heating at
110.degree. C. for 30 mm. They are developed in two dimensions:
[1333] I. chloroform/methanol/25%NH.sub.4OH/water (65:35:4:4. v/v);
and
[1334] II. chloroforrm/acetone/methanol, acetic acid/water
(50:20:10:10:5. v/v).
[1335] Fluorescent spots are detected under UV. scraped from the
TLC plates and the fluorescent lipid analogs are extracted from the
silica in 2 ml chloroform/methanol/20 mM acetic acid (1:2:2:1 v/v)
for 30 mm. After pelleting the silica for 10 min at 1,500 rpm
fluorescence in the supernatants is quantified in a fluorimeter
(Kontron. Zorich, Switzerland). Radiolabeled spots are detected by
fluorography after dipping the TLC plates in 0.4% PPO in
2-methylnaphthalene with 10% xylene. Preflashed film (Kodak X-Omat
S) is exposed to the TLC plates for 3 d at -80.degree. C. The
radioactive spots are scraped from the plates, and the
radioactivity is quantified by liquid scintillation counting in 0.3
ml Solulyte (J.T. Baker ChemicaL Deventer, The Netherlands) and 3
ml of Ultinsa Gold (Packard Instruments. Downers Grove. Ill.).
EXAMPLE 47
Conjugation of Proteins to Lipoproteins
[1336] The preferred method for coupling superantigens to
lipoproteins is to use 10 mM solution of sodium periodate for
oxidation of the carbohydrate in the lipoprotein. This will also
cleave c-c bonds in the sugars with adjacent hydroxyls and oxidize
them to reactive aldehydes. Superantigens form Schiff base linkages
with the aldehyde modified sugar groups under alkaline conditions.
the aldehyde modified sugar is then coupled to the amine containing
superantigen peptide or polypeptide. The oxidation is followed by
reductive amination using sodium cyanoborohydride to reduce the
labile Schiff base between the aldehyde on the carbohydrate and the
amine on the superantigen to form stable secondary amine covalent
linkages. An alternative procedure is to periodate oxidize the
lipoprotein as above to create reactive aldehyde groups.
Heterobifunctional cross-linking agent such as
4-(4-N-Maleimidophenyl)butryric acid hydrazide (MPBH)
4-(4-N-Maleimidophenyl)buryric acid hydrazide (MPBH), and
4-(N-Maleimidomethyl)cyclohexane-1-carboxyl-hydrazide (M2C2H) which
contain a carbonyl-reactive hydrazide group on one end and a
sulfhydryl-reactive maleimide on the other are preferred. The
hydrazide reacts specifically with aldehyde functional groups to
create a hydrazone linkage a type of Schiff base. To stabilize the
bond between the hydrazide and aldehyde, the hydrazone is reacted
with sodium cyanoborohydride to reduce the double bond and form a
secure covalent linkage. The cross-bridge between the two
functional ends provides a long, 17.9-A spacer. These agents couple
to periodate-oxidized aldehydes on the lipoportein carbohydrate via
the hydrazine and to sulfhydryl groups on the superantigen via
sulfhydryl reactive maleimide group. Superantigens without reactive
sulfhydryl groups are first thiolated with SATA or Trout's reagent
before addition to the reactive maleide. A sulfhydryl-containing
protein or molecule is is bound via the maleimide end of MPBH and
the derivative purified by gel filtration to remove excess
reactants, and then mixed with a lipoprotein (that had been
previously oxidized to provide aldehyde residues) to effect the
final conjugation. The opposite approach e.g., modification of the
glycoprotein first, purification, and subsequent mixing with a
sulfhydryl-containing molecule is also acceptable. With this second
option, however, the purification step should be done quickly to
prevent extensive hydrolysis of the maleimide group. (See Hermanson
G T Bioconjugate Techniques Academic Press, San Diego Calif.,
1996)
[1337] Protocol for Periodate Oxidation.
[1338] 1. Periodate-oxidize a liposome suspension containing
glycolipid components according to Section 2. Adjust the
concentration of total lipid to about 5 mg/ml.
[1339] 2. Dissolve the protein to be coupled in 20 mM sodium
borate, 0.15 M NaCl, pH 8.4, at a concentration of at least 10
mg/ml.
[1340] 3. Add 0.5 ml of protein solution to each milliliter of
lipoprotein suspension with stirring.
[1341] 4. Incubate for 2 h at room temperature to form Schiff base
interactions between the aldehydes on the lipoprotein and the
amines on the protein molecules.
[1342] 5. In a fume hood, dissolve 125 mg of sodium
cyanoborohydride in 1 ml water (makes a 2 M solution). This
solution may be allowed to sit for 30 mm to eliminate most of the
hydrogen-bubble evolution that could affect the lipoprotein
suspension.
[1343] 6. Add 10 ul of the cyanoborohydride solution to each
milliliter of the lipoprotein reaction.
[1344] 7. React overnight at 4.degree. C.
[1345] 8. Remove unconjugated protein and excess cyanoborohydride
by gel filtration using a column of Sephadex G-50 or G-75.
EXAMPLE 48
Isolation of Lipoproteins
[1346] Human LDL is isolated by sequential ultracentrifugation (d
1.019-1.063 g/ml) from freshly drawn, citrated normolipidemic human
plasma to which EDTA 0.1 mmol/liter is added. Freshly obtained
plasma is subjected to differential ultracentrifugation to isolate
the desired lipoprotein fractions . Typically, the following
density fractions were isolated: 1) d<1.02. to remove VLDL and
IDL; 2) d=1.02-1.05, to obtain LDL; 3) d=1.05-1.08, to obtain
Lp(a); and 4) d=1.08-1.21, to obtain Lp(a) and HDL. The
Lp(a)-containing density fractions were subjected to gel filtration
chromatography on a Bio-Gel A-15 m column (2.5.times.90 cm). This
column was eluted with 1.0 M NaCl, 10 mM Tris, 10 mM NaN3, 1 mM
EDTA, pH 7.4, and was continuously monitored at 280 nm. The LDL-
and HDL-containing density fractions are also subjected to gel
filtration chromatography to remove any contaminating species and
for uniformity of sample preparation. They are further dialyzed
against 0.01 M sodium phosphate pH 7.4, containing 0.15 M sodium
chloride and 0.01% EDTA, sterilized on 0.2-um Millipore membrane,
and stored at 4.degree. C. under nitrogen (up to 3 weeks).
[1347] Lipoprotein (a) (Lp(a))
[1348] Lp(a) is prepared from fresh human plasma by flotation
centrifugation followed by affinity chromatography on
lysine-Sepharose and CsCI density gradient centrifugation as
described. Lipoprotein preparations are dialyzed against 0.15 M
sodium chloride containing 0.01% EDTA at 0.01% sodium azide, filter
sterilized (0.45 pm) and stored at 4.degree. C. in vials filled to
allow no air space. No contamination of the preparations by
plasminogen is detected by either Coomassie Blue staining of sodium
dodecyl sulfate (SDS) gels or by treatment with streptokinase and
measuring plasmin activity with a chromogenic substrate. S2251. The
sensitivities of these assays excluded plasminogen contamination of
>1% and >0.4% respectively. Lp (a)-free LDL, HDL and
acetylated LDL are prepared as previously described. The LDL
contained no apoA-1 and the HDL contained no detectable apoB-100.
The apoprotein composition is verified by SDS polyacrylamide gel
elecrophoresis.
[1349] Lysine-Sepharose Chromatography
[1350] Lipoprotein (a) has an affinity for lysine-Sepharose by
virtue of lysine binding kringle 4 domain(s) located on apo(a). The
most important domain appears to be kringle 4.sub.37, which has the
greatest homology to kringle 4 of plasminogen, although there may
be other kringles with lesser affinity for lysine which also
contribute to the interaction of Lp(a) with lysine-Sepharose.
Plasminogen and Lp(a) have similar affinities for lysineSepharose;
however, Lp(a) species with different apo(a) isoforms may have
affinities that are significantly greater or weaker than that of
plasminogen. The buffer of choice in the isolation of plasminogen
from plasma by lysine-Sepharose affinity chromatography has been
0.1 M phosphate buffer, pH 7.4. When the same buffer system is used
in the chromatography of Lp(a), not all the lipoprotein is found to
bind to the lysine-Sepharose i.e., approximately 80% of Lp(a)
contained in the plasma had the capacity to interact with
lysine-Sepharose. The percentage of Lp(a) binding to
lysine-Sepharose is increased by lowering the ionic strength of the
buffer medium. Lipoprotein (a) species with large apo(a) isoforms
tend to self-associate in the cold therefore it is best to perform
the chromatographic isolation at room temperature.
[1351] Preparation of Lysine-Sepharose 4B
[1352] Packed Sepharose 4B (250 ml) is washed with 8 liters of
water on a coarse sintered glass funnel and activated with 25 g
CNBr dissolved in 50 ml acetonitrile. The reaction is carried out
in a well-ventilated hood, on ice, and the pH is maintained with 6
N NaOH at pH 11. After approximately 15 to 30 mm, the activated
Sepharose 4B is washed with 8 liters of 0.1 M NaHCO.sub.3 pH 8.1.
The agarose is then packed by filtration, diluted with 250 ml of
0.1 M NaHCO.sub.3 pH 8.1, containing 50 g lysine, and stirred
gently overnight at 4.degree.. The freshly conjugated
lysine-Sepharose is then washed with 6 to 10 liters of 1 mM HCl
followed by 8 liters of 0.1 M NaHCO3, pH 8.1, and an aliquot is
saved for determination of the concentration of immobilized lysine
residues using the method of Wilkie and Landry. The concentration
of coupled lysine varies from 15 to 25 umol per milliliter packed
gel
[1353] Chromatography
[1354] Bio-Rad (Richmond, Calif.) Econo-Pac columns (1.times.12 cm)
are packed with 5 ml lysine--Sepharose which is preequilibrated
with column buffer (e.g., 0.1 M phosphate, 0.01% NaN.sub.2, pH
7.4). A porous polymer filter is placed on top of the
lysine-Sepharose gel bed to prevent the column from running dry.
Plasma samples smaller than 3 ml are applied to the column and
allowed to run through by gravity at room temperature. Larger
volumes (up to 50 ml) should be applied with a pump or by gravity,
but at flow rates that should not exceed 20 ml/cm.sup.2/hr. The
samples are washed into the column with four 0.5-ml aliquots of
column buffer to be followed with four 0.5 ml aliquots, before
Lp(a) is eluted withe0.2<EACA in 10 mM phosphate, pH 7.4. One
milliliter aliquots are applied at a time, and 1 ml fractions are
collected in separate tubes. Liprotein(a)and plasminogen-containing
fractions (tubes 4 through 10) are located by their absorbance at
280 nm. The volume of applied plasma depends on the Lp(a) content
and on the sensitivity of the absorbance monitor that is part of
the density gradient fractionating system.
[1355] Density Gradient Centrifuigation of Lp(a)
[1356] Place 5 ml of 20% (w/w) NaBr into a SW-40 ultracentrifuge
tube (ultraclear). Carefully layer the eluate from the
lysine-Sepharose column (up to 8 ml) on top of the NaBr solution
and, if necessary, top off the tube with 0.2 M EACA, 10 mM
phosphate, pH 7.4. Place the tubes in the bucket of the
swinging-bucket rotor and centrifuge 64 hr at 39,000 rpm and
20.degree.. After centrifugation is completed, the tubes are
carefully removed from the buckets and placed in the density
gradient fractionating system. The tubes are pierced at the bottom,
and the gradient is pushed out the top at a flow rate of 1 ml/min
with a dense fluorocarbon oil, Fluorinert FC-40 (ISCO), that has a
density of 1.85 g/ml. The chart speed is 1 cm/min, and the fraction
collector is set to 0.5 ml/tube. The gradient is monitored at 280
nm, and the sensitivity of the chart recorder is adjusted according
to the Lp(a) content of the eluate. Densities of the various
fractions are measured with a density meter by established
techniques.
[1357] Isolation of Apolipoproteins B-48 and B-100
[1358] The following density gradient ultracentrifugation procedure
for isolating subfractions of triglyceride-rich lipoproteins is
suitable for SDS-PAGE on both slab and rod gels. Plasma is
recovered by low speed centrifugation (1750 g, 20 min, 10). To
minimize proteolytic degradation of apo B, 1.0 ul/ml plasma
phenylmethylsulfonyl fluoride (PMSF, Sigma, St. Louis, Mo.), 10 MM
dissolved in 2-propanol, and 5 ul/ml plasma aprotinin (Trasylol,
Bayer, Leverkusen, (Germany), 1400 ug/liter, are added.
Subsequently 140.4 mg solid NaCl is added per 1.0 ml plasma to
increase the density to 1.10 kg/liter. Normally, a total volume of
4.0 ml of the d 1.10 kg/liter plasma is put in the bottom of a
13.4-ml polyallomer ultracentrifuge tube (Ultra-Clear, Beckman
Instruments, Palo Alto, Calif.). Alternatively, 3.0 ml plasma can
be mixed with 1.5 mIt) 1.42 kg/liter NaUr, from which 4.0 ml is
transferred to the ubracentrifuge tube. For the rod gel method, two
such tubes are required to obtain enough material from each sample.
For the slab gel method, 1.0 ml plasma is sufficient. In the latter
case, a 1.0 ml portion of 1.10 kg/liter plasma can be mixed with
3.0 ml of 1.10 kg/liter NaCl in the tube. A density gradient
consisting of 3.0 ml each of 1.065, 1.020, and 1.006 kg/liter NaCl
solutions is then sequentially layered on top of the plasma.
Ultracentrifugation is performed in a SW4O Ti swinging bucket rotor
(Beckman) at 40,000 rpm and 15.degree. (Beckman L8-55
ultracentrifuge). Consecutive runs calculated to float Svedberg
flotation rate (Sf) >400 (32 min), SI 60-400 (3 hr 28 mm), and
Sf 20-60 (14-16 hr) particles are made. After each centrifugation,
the top 0.5 ml of the gradient containing the respective
lipoprotein subclasses is aspirated, and 0.5 ml of density 1.006
kg/liter salt solution is used to refill the tube before the next
run. The Sfl 12-20 fraction is recovered after the last
ultracentrifugal run by slicing the tube 29 mm from the top after
the Sf 20-60 lipoproteins have been aspirated. All salt solutions
should be adjusted to pH 7.4 and contain 0.02% (w/v) NaN3 and 0.01%
Na2EDTA. This method yields lipoprotein preparations almost
completely devoid of plasma albumin.
EXAMPLE 49
Preparation & Isolation of Oxidized LDL (oxyLDL
[1359] Oxidized LDL (oxyLDL)
[1360] Native LDL (200 ug protein/ml) is oxidized by exposure to 5
uM CuSO4 for 24 h at 25.degree. C. and the degree of oxidation is
assessed by the increase of mobility on 1% agarose gel (1.3-1.5
versus native LDL) and the formation of thiobarbituric
acid-reactive substances (3.41+/-0.8 mmol/L). Oxidation is
terminated by refrigeration. Different preparations of oxyLDL
display similar electrophoretic mobilities. For comparison,
commercially available preparations of native and copper-oxidized
LDLs (Sigma Chemical Co., St. Louis, Mo. and Biomedical
Technologies, Inc. Stoughton, Mass. respectively) are used. The
level of LDL oxidation is evaluated by monitoring the formation of
lipid hydroperoxides, using the FOX-2 procedure and thiobarbituric
acid-reactive substances (TBARS)). The relative electrophoretic
mobility is evaluated on Hydragel (Sebia, Paris, France) and the
level of trinitrobenzenesulfonic acid-reactive amino groups was
determined
[1361] The formation of thiobarbituric acid-reactive substances is
17.8 nanomoles of malondialdehyde/mg protein using an oxyLDL
preparation with relative electrophoretic mobility of 1.4.
[1362] Methods for Measurement of Low-Density Lipoprotein
Oxidation
[1363] Oxidation of LDL in vitro is accompanied by characteristic
changes of chemical, physicochemical, and biological properties,
and a variety of methods may therefore be used for determining the
extent and/or rate of oxidation of LDL. They include measurement of
the increase of thiobarbituric acid-reactive substances (TBARS),
total lipid hydroperoxides defmed lipid hydroperoxides, hydroxy and
hydroperoxy fatty acids, conjugated dienes, oxysterols,
lysophosphatides, aldehydes and fluorescent chromophores as well as
measurements of the disappearance of endogenous antioxidants and
polyunsaturated fatty acids, and oxygen uptake. The apolipoprotein
B (apoB) becomes progressively altered during oxidation; its loss
of reactive amino groups and fragmentation to smaller peptides is
determined and used as an index of oxidative modification. The net
increase of the negative surface charge of the whole LDL particle
is analyzed as relative electrophoretic mobility (REM) by agarose
gel electrophoresis. The biological assays used most frequently for
assessment of the extent of oxidative modification are the rate of
uptake of LDL by cultured macrophages and its cytotoxicity toward
cultured cells. Immunological assays such as enzyme-linked
immunosorbent assay (ELISA) and radioimmunoassay (RIA) employing
polyclonal or monoclonal antibodies recognizing certain
modifications in apoB characteristic for oxidative modification are
employed. The epitopes produced by covalent binding of
malonaldehyde or 4-hydroxynonenal are of particular interest.
Nuclear magnetic resonance (NMR), electron spin resonance (ESR),
circular dichrorism (CD), and fluorescence polarization have also
been applied to study certain aspects of LDL oxidation. Simple
methods, such as the measure of TBARS, conjugated dienes, or
fluorescence are preferred. Most characterize oxidized LDL by at
least two independent measurements, for example, TBARS or REM and
macrophage uptake, antioxidants and conjugated dienes.
[1364] From kinetic experiments one can conclude that both
cell-mediated oxidation of LDL and oxidation in the absence of
cells catalyzed by Cu.sup.2+ ions proceed in three consecutive time
phases: lag phase, propagation phase, and decomposition phase.
1)during the lag phase the LDL becomes depleted of antioxidants,
and during this period only minimal lipid peroxidation occurs in
LDL, as shown by measuring polyunsaturated fatty acids (PUFAs),
TBARS, lipid hydroperoxides, fluorescence, and conjugated dienes.
When LDL is depleted of its antioxidants, the rate of lipid
peroxidation rapidly accelerates and a lipid peroxide maximum is
reached after about 70-80% of the LDL, PUFAs are oxidized.
Thereafter, the peroxide content of LDL, starts to decrease again
because of decomposition reactions. During the lag and propagation
phases the time profile for TBARS, fluorescence at 430 nm, lipid
peroxides, dienes, and REM are very similar and only after the
peroxide maximum do the different indices separate and follow
different kinetics. This also indicates that all the methods will
give equivalent results for the susceptibility of LDL to oxidation
as measured by the duration of the lag time.
[1365] Preparation of Low-Density Lipoproteins for Oxidation
[1366] Isolation of Low Density Lipoproteins
[1367] After overnight fasting blood samples are withdrawn by
venipuncture and collected by free flow of blood into plastic tubes
containing the appropriate volume of an aqueous solution of 10%
EDTA (w/v) (disodium salt, pH 7.4) to obtain a final blood
concentration of 0.1% EDTA (wlv). EDTA serves as anticoagulant and
antioxidant. Blood is centrifuged at 1000 g for 10 mm; the
supernatant is then centrifuged at 10.degree. C. and 1000 g for 5
min, followed by centrifugation at 15,000 g for 10 min. This
procedure removes all cellular debris, and a completely clear
plasma is obtained. Generally plasma is not stored but is used the
same day for LDL. isolation. The most common method for isolation
of LDL is a two-step sequential ultracentrifugation with a total
run duration of about 48 hr. LDL is prepared for oxidation
experiments by a single 20-hr run with a discontinuous density
gradient. Plasma (up to 4 ml) adjusted with solid KBr to a density
of 1.22 g/liter is layered on the bottom of a centrifuge tube
(Beckman polyallomer tubes, total volume 13.2 ml) and then overlaid
by KBr density solutions of 1.08 (3 ml), 1.05 (3 ml), and 1.00
g/liter (to fill the tube) containing 1 g/liter EDTA (pH 7.4). All
density solutions are purged with nitrogen before use. The tubes
are centrifuged in a Beckman SW 41 Ti rotor at 40,000 rpm at
10.degree. for 20 hr. After centrifugation the main lipoproteins
very low-density lipoproteins (VLDL), LDL, and high-density
lipoproteins (HDL) are well separated from each other, and the LDL
band characterized by the yellow color due to the endogenous
b-carotene, is collected by aspiration with a syringe and
transferred into a polycarbonate tube.
[1368] Next, the cholesterol content of the isolated LDL sample is
determined with the CHOD-PAP enzymatic test kit (Boehringer,
Mannheimn, Germany). When 4 ml normolipidemic plasma is
centrifuged, the final LDL stock solution harvested from the
ultracentrifugation has a concentration of total cholesterol of
about 1.6 to 2.2 mg/ml. Based on the known composition of LDL the
total cholesterol values can be converted to LDL mass per
milliliter (multiply cholesterol by the factor 3.16) or LDL protein
per milliliter (multiply total cholesterol by the factor 0.63). It
is also possible to determine the LDL concentration by protein
measurement. Next EDTA is from the LDL stock solution and the
oxidation is conducted immediately after isolation of LDL. For
storage the LDL stock solution is sterile filtered through a 0.3 um
filter adapted to a syringe into a sterile, evacuated glass vial
and subsequently purged with nitrogen (Techne ViaL
Mallinckrodt-Diagnostica, Holland, or Behring, Marburg,
Germany).
[1369] Removal of EDTA
[1370] Removal of EDTA and salt from the density gradient from the
LDL stock solution is conducted with prepacked columns (Econo-Pac
10DG, Bio-Rad, Richmond, Calif.) filled with Bio-Gel P6 as
desalting gel. The bed volume is 10 ml with a void volume of 3.3
ml, and the total column volume is 30 ml. The gel is preconditioned
by passing 20 ml phosphate-buffered saline (PBS, 10 ml sodium
phosphate buffer, pH 7.4, containing 0.15 M sodium chloride)
through the column. A volume of 0.5 ml of the LDL stock solution is
then applied to the column. After the LDL solution has run into the
gel, 2.5 ml PBS is applied. The first 3 ml of eluate are
discharged. The column is then eluted with 1 ml PBS, and 1 ml
EDTA-free LDL solution is collected in a 1.5-ml Eppendorf vial. The
vial is immediately made oxygen-free by nitrogen gassing and
transferred to a refrigerator. An aliquot is removed to determine
again the concentration by the CHOD-PAP method. The LDL solution
can be rather unstable at this stage, depending on the donor, and
therefore the time elapsed between desalting and the final
oxidation experiment should not exceed 60 mm.
[1371] Thiobarbituric Acid-Reactive Substances as Index of
Low-Density Lipoprotein Oxidation
[1372] The preferred assay in LDL oxidation studies, both in
presence and absence of cells, is the determination of
thiobarbituric acid (TBA)-reactive substances (TBARS) by one of the
TBA assays developed for lipid peroxidation studies. The basal
value of TBARS in freshly prepared LDL samples is usually low (0.5
to 3 nm/mg LDL protein) or undetectable. In LDL oxidized for about
24 hr with cells or CU.sup.2+ ions, the TBARS are in the range of
30 to 100 nmol/mg protein. In copper-stimulated oxidation,
formation of TBARS shows a lag phase of about 40-150 min depending
on the LDL, temperature, medium, and Cu2+ concentration; during
this lag phase TBARS do not increase. Thereafter, TBARS rapidly
increase for about 1-2 hr to a plateau value. On prolonged
incubation TBARS remain more or less constant or increase slightly.
The reported time course studies for TBARS in cell-mediated
oxidation suggest that oxidation proceeds similarly to Cu.sup.2+
oxidation, with a lag phase followed by a rapid increase to a
plateau level. In this context, it should be noted that most
researchers only determine TBARS as an end point after about 24 hr
incubation, when LDL has reached a final stage of oxidation.
[1373] Assays Used for Measurement of TBARS
[1374] Specifically, 100 ul of an LDL preparation (50 ug LDL
cholesterin or 150 ug protein) is added to 1 ml of 20%
trichloroacetic acid (TCA). Following precipitation, 1 ml of 1%
thiobarbituric acid (TBA) is added, and the mixture is heated 45
min at 95.degree., cooled on ice, and centrifuged (20 min at 1000
g). TBARS are then determined by measuring the absorbance at 532 nm
or the emission fluorescence at 553 nm (excitation 515 nm).
Calibration is done with a malonaldehyde standard prepared from
tetramethoxypropane.
[1375] The second assay is typically as follows: LDL (25 ug
protein) is mixed with 1.5 ml of 20% TCA and 1.5 ml of 0.67% TBA.
After heating at 100.degree. for 30 mm, TBARS are determined
fluorimetrically at an emission wavelength of 553 nm with
excitation at 515 nm. The sensitivity was reported to be 0.1 nmol
TBARS/assay. This is equivalent to 4 nmol TBARS/mg protein.
Haberland a al. determined the malonaldehyde-LDL adduct using a TBA
assay. The malondialdehyde (MDA-treated LDL was precipitated with
heparin-manganese, the supernatant was discharged after
centrifugation, and the precipitate was washed with
heparin-manganese prior to the TBA test.
[1376] Minimally modified LDL (MM-LDL) is prepared by dialyzing
native LDL against 9 uM FeSO.sub.4 in PBS for 72 h at 4.degree. C.
The electrophoretic mobility increased 1.1 to 1.2 versus native
LDL. Mildly oxidized LDL was also obtained by
(UV+copper/EDTA)-mediated oxidation under mild conditions: LDL
solution (2 mg of apo/B/ml containing 2 umol/liter CuSO4) was
irradiated for 2 h. as a thin film (5 mm) in an open beaker placed
10 cm under the UV-C source (HNS 30W OFR Osram UV-C tube, 1.sub.max
254 nm 0.5 milliwatt/cm.sup.2 determined using a Scientech
thermopile Model 360001), under the standard conditions. At the end
of the irradiation, aliquots were taken up for analyses and
oxidized LDL (200 ug of apoB/ml under standard conditions or at the
indicated concentration) were immediately incorporated in the
culture medium.
[1377] Acetylation of LDL is performed with excess acetic
anhydride. Endotoxin contamination in oxyLDL is measured with the
coagulation Limulas amebocyte lysate assay using a commercially
available kit (E-TOXATE, Sigma Chemical Co.).
[1378] Induction of Apoptosis by oxyLDL
[1379] Incubation of HUVEC with oxLDL for 18 hours induced DNA
fragmentation in a concentration-dependent manner with maximal
effects at 10 ug/mL. In contrast, native LDL did not induce
apoptosis in the concentration range tested. The induction of
apoptosis by oxyLDL is confirmed by demonstrating DNA fragmentation
through agarose gel electrophoresis. LDH release did not increase
.sup.310 ug/mL oxLDL (105.+-.11% compared with control cells)
excluding the induction of necrosis
[1380] Detection of Fas and FasL Expression on Endothelial
Cells.
[1381] 90% confluent HAECs and HUVECs were incubated with oxyLDL
(150 ug protein/ml) or L-a-palmitoyl lysophosphatidyleholine (LPC,
45 uM, Sigma Chemical Co.) at 37.degree. C., 5% CO2 for 13 h, and
detached from the culture plate with 0.5% EDTA. To determine FasL
expression, endothelial cells are incubated with an anti-FasL
antibody (C-20, Santa Cruz Biotechnology, Santa Cruz, Calif.) or
with rabbit IgG followed by a FITC-conjugated antibody against
rabbit Ig (Biosource, Camarillo, Calif.). To determine Fas
expression, endothelial cells were incubated with an
FITC-conjugated anti-Fas monoclonal antibody (clone UBZ.
Immunotech. Wemtbrook. Me.) or an FITC.conjugated mouse IgG.
Immunofluorescence staining was analyzed by FACS
(fluorescence-activated cell sorter) (Becton Dickinson. Mountain
View, Calif.).
[1382] Detection of DNA Fragmentation by Agarose Gel
Electrophoresis.
[1383] HUVECs (10.sup.6) wcre incubated in the presence or absence
of native LDL (300 ug protein/ml). oxyLDL (300 ug protein/ml). LPS
(100 endotoxin U/ml), or a neutralizing anti-FasL antibody (i0
ug/ml, 4H9, MBL, Nagoya. Japan) for 36 h. Attached cells and
floating cells were combined and lysed in 0.33 ml of lysis buffer
(10 mM Tris-HCi. pH 8.0, 1 mM EDTA, 0.2% Triton X-100) followed by
incubation with 0.1 mg/ml RNAase A for 1 h at 37.degree. C. and 0.2
mg/mi proteinase K for 3 h at 50.degree. C. Ethanol-precipitated
DNA was resuspended in TE buffer, fractionated on 1.5% agarose gel
in IX THE buffer, and stained with ethidium bromide.
[1384] Detection of DNA Fragmentation by TdT-Mediated dUTP Nick-End
Labeling (TUNEL).
[1385] 70% confluent HUVECs are incubated in the presence or
absence of OxLDL (300 ug protein/ml), a neutralizing anti-FasL
antibody (10 ug/mi. 4H9). or an agonistic anti-Fas antibody (0.5
ug/ml CH11, MBL) for 16 h at 37.degree. C., 5% CO.sub.2. Attached
cells harvested by trypsinization and floating cells are combined,
fixed in 4% paraformaidehyde, permeabilized in 0.1% Triton X-100,
0.1% sodium citrate, and incubated with TUNEL solution (Boehringer
Mannheim. Indianapolis. Ind.) in the absence or in the presence of
terminal deoxynucleotidyl transferase. After washing in PBS,
fluorescence intensity was analyzed by FACS.
[1386] Cell Viability Assay.
[1387] HAECs or HUVECs are cultured in a 96-well plate at 80%
confluency and incubated in the presence or absence of oxyLDL (300
ug protein/ml), LPC-C16:0 (55 uM). a neutralizing anti-FasL
antibody (10 ug/ml. 4H9). or an agonistic anti-Fas antibody (0.5
ug/ml. CHI 1) for 18 h. Cell viability is measured by means of MTT
(dimethyithiazol-diphenyltetrazoliu- m bromide) assay and
percentage of cell death was calculated as 100.times.(1-viability
of treated endothelial cells/viability of untreated endothelial
cells).
[1388] Cell Viability Assay and Reagents--Human umbilical vein
endothelial cells (HUVECs) are isolated and cultured in endotheial
growth medium (SCM; Clonetics, San Diego, Calif.). HUVECs cultured
in a 96-well plate at 80% confluency are incubated with oyxLDL or
LPC at indicated doses for 16 h. Cell viability is measured by
means of MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) assay
EXAMPLE 50
Preparation of Vesicles Expressing Recombinant Membrane Bound
Superantigens Using the Yeast sec6 Mutant
[1389] The superantigen cDNA, or oxyLDL receptor, apoprotein
verotoxin or other polypeptide given herein corresponding to the
cDNA for protein expression in yeast is used. The length of the
5'-untranslated region is minimized. Expression of a cDNA in the
sec6-4 yeast mutant is best controlled and may be maximized with an
inducible promoter. The GALl promoter is preferred. The pYES2
expression vector (InVitrogen, San Diego, Calif.) contains the GALI
promoter followed by a multiple cloning site. Other commonly used
inducible promoters include the metallothionein CUPI promoter,
which is tightly controlled by copper; promoters activated in
response to heat shock, which are of particular interest for
expression in the temperature-sensitive sec6-4 mutant and the PH05
promoter, which is derepressed at low phosphate concentrations.
Introduction of the plasmid into yeast cells is accomplished either
by electroporation or LiCi-mediated transformation. Isolation of
transformants requires selection yeast that are ura3 auxotrophs are
able to grow on media lacking uracil when they contain the pYES2
expression vector that contains the wild-type URA3 gene. Other
selectable markers include enzymes in the adenine, histidine,
leucine, lysine, and tryptophan biosynthetic pathways. The
superantigen cDNAs are cloned into the pYES2 expression vector and
selected for transformants on plates with synthetic complete (SC)
medium lacking uracil but containing 2% raffmose as the carbon
source (SC-Ura raff medium). Single colonies are isolated and grown
overnight to saturation in 2 ml of SC-Ura raff medium at 25.degree.
with constant shaking in 2% raffinose instead of glucose. In a
subsequent step the yeast are switched to medium containing
galactose as the carbon source as the GALl promoter initiates gene
expression only when galactose is the predominant carbon source.
The 2-ml starter culture in SC-Ura raff medium is added to a
1-liter culture of the same growth medium and incubated at
25.degree. with constant shaking. When these cultures reach an
OD600 (optical density at a wavelength of 600 nm) of about 1.0
(usually about 12 hr), the cultures are centrifuged at 4000 g at
4.degree. for 5 min, resuspended in 4 liters of SC-Ura gal
induction medium (containing 2% galactose instead of 2% raffinose
as the carbon source), and shifted to 37.degree. for 2-3 hr to
induce protein expression in the sec6 vesicles.
[1390] Following growth at 37.degree. the cells are collected by
centrifugation at 4000 g at 40 for 5 mm and washed once in ice-cold
water. Pellets are resuspended in an absolute minimum volume of
water and quick frozen in liquid nitrogen. Cultures may then be
stored indefinitely at -70.degree.. Thawed cultures are resuspended
to a final concentration of 50 OD618.about.units/ml (e.g., a
1-liter culture at OD600=1.0 is resuspended in 20 ml) in 10 mM
dithiothreitol (DTF) and 100 mM Tris-CI, pH 9.4. The resuspended
culture is shaken gently at room temperature for 10 min. This step
increases the efficiency of spheroplast lysis at a later step by
reducing disulfide bonds in the yeast cell wall. We then collect
the cells by centrifugation at 4000 g at 4.degree. for 5 mm and
resuspend them in spheroplast buffer to a final concentration of 50
OD600 units/ml. Spheroplast buffer consists of 1.4 M sorbitol, 50
mM K2HPO4, pH 7.5, 10 mM NaN3, and 40 mM 2-mercaptoethanol.
Spheroplasts are generated by digesting the cell wall with lyticase
(or zymolyase) for 45 min at 37.degree., The amount of bacterially
expressed, recombinant lyticase needed to form spheroplasts is
determined empirically; after 45 min the OD.sub.600 of a 10-ul
aliquot of the yeast suspension diluted into 1 ml of 0.1% sodium
dodecyl sulfate (SDS) should be .about.20% of the OD.sub.600 of the
initial dilution measured at 0 min. The spheroplasts are then
harvested at 3000 g for 5 min at 4.degree., and the cells are
resuspended gently with a pipette or Teflon rod in spheroplast
buffer containing 10 mM MnC12 to a final concentration of 50
OD.sub.600 units/ml. Concanavalin A (Sigma, St. Louis, Mo.) is then
added to a final concentration of 0.78 to 1.25 mg/ml and incubated
with rotation or gentle shaking at 4.degree. for 15-30 mm. A
concanavalin A stock solution (25 mg/ml) is prepared in spheroplast
buffer containing 1 mM MnCl2 and 1 mM CaCl.sub.2 and is frozen in
1-mi aliquots. Lectin-coated spheroplasts are harvested at 3000 g
for 5 mm at 4.degree. and then resuspended in lysis buffer to a
final concentration of 60-70 0D.sub.600 units/mi. The suspension is
homogenized using the loose pestle of a Dounce homogenizer and
30-40 strokes of the pestle at 40 (or on ice). Lysis bufferconsists
of 0.8 M sorbitol, 10 mM triethanolamine (TEA), and 1 mM EDTA. The
pH is adjusted to 7.2 with acetic acid or TEA. Unlysed cells, cell
debris, mitochondria, and nuclei are pelleted at 20,000 g for 10 mm
at 4.degree. The supernatant is removed with a pipette and
centrifuged at 144,000 g for 1 hr at 40 to pellet the secretory
vesicles. The supernatant is decanted carefully and the pellet is
resuspended in either lysis buffer or another buffer containing
osmotic support.
[1391] Additional Documents Incorporated by Reference
[1392] This application incorporates by reference the following
patents and currently pending patent applications that disclose
inventions of the present inventor alone or with co-inventors.
[1393] 1. Patent application WO91/US342, "Tumor Killing Effects of
Enterotoxins and Related Compounds" filed 17 Jan. 1991, and
published as WO 91/10680 on 25 Jul. 1991.
[1394] 2. U.S. Ser. No. 07/891,718 "Tumor Killing Effects of
Enterotoxins and Related Compounds," filed 1 Jun. 1992.
[1395] 3. U.S. Pat. No. 5,728,388, "Method of Cancer Treatment,"
issued Mar. 17, 1998.
[1396] 4. U.S. Ser. No. 08/491,746, "Method of Cancer Treatment,"
filed 19 Jun. 1995.
[1397] 5. U.S. Ser. No. 08/898,903 "Method of Cancer Treatment,"
filed 23 Jul. 1997.
[1398] 6. U.S. Ser. No. 08/896,933 "Tumor Killing Effects of
Enterotoxins and Related Compounds," filed 18 Jul. 1997.
[1399] 7. U.S. Ser. No. 60/085,506, "Compositions and Methods for
Treatment of Cancer," filed 5 May 1998.
[1400] 8. U.S. Ser. No. 60/094,952 "Compositions and Methods for
Treatment of Cancer" filed 31 Jul. 1998.
[1401] 9. U.S. Ser. No. 60/033,172 "Superantigen-Based Methods and
Compositions for Treatment of Cancer," filed 17 Dec. 1996.
[1402] 10. U.S. Ser. No. 60/044,074 "Superantigne-Based Methods and
Compositions for Treatment of Cancer," filed 17 Apr. 1997.
[1403] 11. U.S. Ser. No. 09/061,334 "Tumor Cells with Increased
Immunogenicity and Uses Thereof," filed 17 Apr. 1998.
[1404] Moreover, all references cited herein are incorporated by
reference, whether specifically incorporated or not.
[1405] Having now fully described this invention, it will be
appreciated by those skilled in the art that the same can be
performed within a wide range of equivalent parameters,
concentrations, and conditions without departing from the spirit
and scope of the invention and without undue experimentation.
[1406] While this invention has been described in connection with
specific embodiments thereof, it will be understood that it is
capable of further modifications. This application is intended to
cover any variations, uses, or adaptations of the invention
following, in general, the principles of the invention and
including such departures from the present disclosure as come
within known or customary practice within the art to which the
invention pertains and as may be applied to the essential features
hereinbefore set forth as follows in the scope of the appended
claims.
Sequence CWU 0
0
* * * * *